Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20172022

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period fromto

Commission File Number:001-35331

 

ACADIA HEALTHCARE COMPANY, INC.

(Exact Namename of Registrantregistrant as Specifiedspecified in Its Charter)its charter)

 

Delaware

Delaware

45-2492228

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

6100 Tower Circle, Suite 1000

Franklin, Tennessee 37067

(Address, including zip code, of registrant’s principal executive offices)

(615) 861-6000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Classclass

Trading Symbol

Name of exchange on which registered

Common Stock, $.01 par value

ACHC

NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No  

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes      No  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationS-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes      No  

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of RegulationS-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form10-K or any amendment to this Form10-K.  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Emerging growth company

Non-accelerated filer

Non-accelerated filer☐  (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark ofif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).    Yes      No  

As of June 30, 2017,2022, the aggregate market value of the shares of common stock of the registrant held bynon-affiliates was approximately $3.9$6.0 billion, based on the closing price of the registrant’s common stock reported on the NASDAQ Global Select Market of $49.38$67.63 per share.

As of February 27, 2018,28, 2023, there were 87,950,96591,314,616 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 20182023 annual meeting of stockholders to be held on May 3, 201818, 2023 are incorporated by reference into Part III of this Form10-K.



Table of Contents

 

 


ACADIA HEALTHCARE COMPANY, INC.

ANNUAL REPORT ON FORM10-K

TABLE OF CONTENTS

 

PART I

Item 1. Business

1

Item 1A. Risk Factors

18

14

Item 1B. Unresolved Staff Comments

39

33

Item 2. Properties

40

34

Item 3. Legal Proceedings

41

35

Item 4. Mine Safety Disclosures

41

PART II

35

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

42

36

Item 6. Selected Financial Data[Reserved]

43

36

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

43

37

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

59

51

Item 8. Financial Statements and Supplementary Data

59

51

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

59

51

Item 9A. Controls and Procedures

59

51

Item 9B. Other Information

60

51

PART III

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

51

PART III

Item 10. Directors, Executive Officers and Corporate Governance

61

52

Item 11. Executive Compensation

61

52

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

61

53

Item 13. Certain Relationships and Related Transactions, and Director Independence

62

53

Item 14. Principal Accountant Fees and Services

62

PART IV

53

PART IV

Item 15. Exhibits and Financial Statement Schedules

63

54

Item 16. Form10-K Summary

67

57

SIGNATURES

SIGNATURES

58


Table of Contents

PART I

Unless the context otherwise requires, all references in this Annual Report on Form10-K to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries.

Item 1. Business.

Overview

Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing quality patient care,high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At December 31, 2017,2022, we operated 582250 behavioral healthcare facilities with approximately 17,80011,000 beds in 39 states the United Kingdom (“U.K.”) and Puerto Rico. During the year ended December 31, 2017,2022, we acquired one facility and added 750 new560 beds, (exclusiveconsisting of the acquisition), including 588290 added to existing facilities and 162270 added through the opening of one wholly-owned facility and two de novo facilities. For the year ending December 31, 2018,joint venture facilities, and we expect to add more than 800 total beds exclusive of acquisitions.opened seven comprehensive treatment centers (“CTCs”).

We are the leading publicly traded pure-play provider of behavioral healthcare services with operations in the United States (“U.S.(the “U.S.”) and the U.K.. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and U.K.bed additions in existing facilities.

Acadia was formed as a limited liability companyOn January 19, 2021, we completed the sale of our operations in the StateUnited Kingdom (the “U.K.”) to RemedcoUK Limited, a company organized under the laws of DelawareEngland and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allowed us to reduce our indebtedness and focus on our U.S. operations. We report, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in 2005, and converted to a corporation on May 13, 2011. the accompanying financial statements. See “U.K. Sale” below for additional details about the U.K. Sale.

Our common stock is listed for trading on The NASDAQ Global Select Market under the symbol “ACHC.” Our principal executive offices are located at 6100 Tower Circle, Suite 1000, Franklin, Tennessee 37067, and our telephone number is(615) 861-6000.

Acquisitions

2017 Acquisition

On November 13, 2017,7, 2022, we completed the acquisition of Aspire Scotland (“Aspire”), an education facility with 36 bedsacquired four CTCs located in Scotland,Georgia from Brand New Start Treatment Centers (“Brand New Start”).

On December 31, 2021, we acquired the equity of CenterPointe Behavioral Health System, LLC and certain related entities (“CenterPointe”) for cash consideration of approximately $21.3$140 million. The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility (as defined below). At the time of the acquisition, CenterPointe operated four acute inpatient hospitals with 306 beds and ten outpatient locations primarily in Missouri.

2016 U.S. AcquisitionsU.K. Sale

On June 1, 2016,January 19, 2021, we completed the acquisitionU.K. Sale pursuant to a Share Purchase Agreement in which we sold all of Pocono Mountain Recovery Centerthe securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of our U.K. operations.The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“Pocono Mountain”GBP”), an inpatient psychiatric facility with 108 beds located in Henryville, Pennsylvania, for to U.S. Dollars (“USD”) exchange rate, cash considerationretained by the buyer and transaction costs. We used the net proceeds of approximately $25.4 million.

On May 1, 2016, we completed$1,425 million (excluding cash retained by the acquisitionbuyer) along with cash from the balance sheet to reduce debt by $1,640 million during the first quarter of TrustPoint Hospital (“TrustPoint”), an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.

On April 1, 2016, we completed the acquisition of Serenity Knolls (“Serenity Knolls”), an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.

Priory

On February 16, 2016, we completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of our common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K., operating 324 facilities with approximately 7,100 beds at the acquisition date.

The Competition and Markets Authority (the “CMA”) in the U.K. reviewed our acquisition of Priory. On July 14, 2016, the CMA announced that our acquisition of Priory was referred for a phase 2 investigation unless we offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that we had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider our undertakings.

On October 18, 2016, we signed a definitive agreement with BC Partners (“BC Partners”) for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds (collectively, the “U.K. Disposal Group”). On November 10, 2016, the CMA accepted our undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concern about the impact of our acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K.2021. As a result of the CMA’s acceptanceU.K. Sale, we reported, for all periods presented, results of our undertakings, our acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, we completed the saleoperations and cash flows of the U.K. Disposal Group to BC Partners for £320 million cash (the “U.K. Divestiture”).operations as discontinued operations in the accompanying financial statements.

Our completed acquisitions1


Table of Priory, Serenity Knolls, TrustPoint, and Pocono Mountain are referred to collectively in this report as the “2016 Acquisitions”.Contents

2015 Acquisitions

During 2015, we completed the acquisition of CRC Health Group, Inc. (“CRC”), Quality Addition Management Inc., Choice Lifestyles, Pastoral Care Group, Mildmay Oaks f/k/a Vista Independent Hospital, Care UK Limited, The Manor Clinic, Belmont Behavioral Health, Southcoast Behavioral, The Danshell Group, Health and Social Care Partnerships, Manor Hall, Meadow View, Cleveland House, Duffy’s Napa Valley Rebab, Discovery House-Group Inc and MMO Behavioral Health Systems (collectively with the 2016 Acquisitions , the “2015 and 2016 Acquisitions”).

Financing Transactions

On May 10, 2017, weWe entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement, dated as of December 31, 2012 (the “Amended and Restated Credit Agreement”). The Third Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-1 Term Loancredit agreement establishing a new senior credit facility (the “TrancheB-1“New Credit Facility”) and the TrancheB-2 Term Loan facility (the “TrancheB-2 Facility”) from 3.0% to 2.75% in the case of Eurodollar Rate loans and from 2.0% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, the Company recordedon March 17, 2021. The New Credit Facility provides for a debt extinguishment charge of $0.8$600.0 million including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.

On November 30, 2016, we entered into a Refinancing Facilities Amendment (the “Refinancing Amendment”) to the Amended and Restated Credit Agreement. The Refinancing Amendment increased our line of credit on oursenior secured revolving credit facility to $500.0(the “Revolving Facility”) and a $425.0 million from $300.0 million and reduced our Term Loan Asenior secured term loan facility (the “TLA“Term Loan Facility” and, together with the Revolving Facility, the “Senior Facilities”), each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $400.0$20.0 million from $600.6 million (together, the “Refinancing Facilities”). In addition, the Refinancing Amendment extended the maturity dateto be utilized for the Refinancing Facilities to November 30, 2021 from February 13, 2019, and lowered the effective interest rate on our lineissuance of letters of credit on our revolving creditand (ii) the availability of a swingline facility and TLA Facility by 50 basis points. In connection with the Refinancing Amendment,under which we recorded a debt extinguishment charge of $0.8 million, including thewrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

On November 22, 2016, we entered into a Tenth Amendment (the “Tenth Amendment”)may borrow up to the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amended the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.

On September 21, 2016, we entered into a TrancheB-2 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-2 Repricing Amendment reduced the Applicable Rate with respect to our TrancheB-2 Facility from 3.75% to 3.00% in the case of Eurodollar Rate loans and 2.75% to 2.00% in the case of Base Rate Loans. In connection with the TrancheB-2 Repricing Amendment, we recorded a debt extinguishment charge of $3.4 million, including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

On May 26, 2016, we entered into a TrancheB-1 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-1 Repricing Amendment reduced the Applicable Rate with respect to our TrancheB-1 Facility from 3.5% to 3.0% in the case of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.

On February 16, 2016, we issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. We used the net proceeds to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions.

On February 16, 2016, we entered into a Second Incremental Facility Amendment (the “Second Incremental Amendment”) to our Amended and Restated Credit Agreement. The Second Incremental Amendment activated our TrancheB-2 Facility and added $135.0 million to the TLA Facility to our Amended and Restated Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”), subject to limited conditionality provisions. Borrowings under the TrancheB-2 Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were used to pay down the majority of our $300.0 million revolving credit facility.

On January 25, 2016, we entered into the Ninth Amendment (the “Ninth Amendment”) to the Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provided increased flexibility to us in terms of our financial covenants.$20.0 million. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—LiquidityOperations —Liquidity and Capital Resources—Amended and Restated Senior Credit Facility”Resources” for additional information.information about the New Credit Facility and the Prior Credit Facility (as defined below).

As a part of the closing of the New Credit Facility on March 17, 2021, we (i) refinanced and terminated our prior credit facilities under an amended and restated credit agreement, dated as of December 31, 2012 (the “Prior Credit Facility”) and (ii) financed the redemption of all of our outstanding 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”).

In connection with the redemption of the 5.625% Senior Notes, we satisfied and discharged the indentures governing the 5.625% Senior Notes and recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.  

On March 1, 2021, we satisfied and discharged the indentures governing the 6.500% Senior Notes due 2024 (“6.500% Senior Notes”). In connection with the redemption of the 6.500% Senior Notes, we recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.  

On January 12, 2016,5, 2021, we completed the offeringmade a voluntary payment of 11,500,000 shares of common stock (including shares sold pursuant to the exercise$105.0 million on our Term Loan B facility Tranche B-4 of the over-allotment option thatPrior Credit Facility (the “Tranche B-4 Facility”). On January 19, 2021, we granted to the underwriters as part of the offering) at a public offering price of $61.00 per share. The net proceeds to us from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering related costs of $0.7 million, were approximately $685.0 million. We used the net offering proceeds to fund a portion of the purchase price fornet proceeds from the acquisitionU.K. Sale to repay $311.7 million of Priory.the Term Loan A facility of the Prior Credit Facility (the “TLA Facility”) and $767.9 million of our Tranche B-4 Facility.

On September 21, 2015,October 14, 2020, we issued $275.0$475.0 million of additional 5.625%5.000% Senior Notes due 20332029 (the “5.625%“5.000% Senior Notes”).The 5.625%5.000% Senior Notes mature on FebruaryApril 15, 20232029 and bear interest at a rate of 5.625%5.000% per annum, payable semi-annually in arrears on FebruaryApril 15 and AugustOctober 15, commencing on April 15, 2021. We used the net proceeds of each year, beginning on August 15, 2015. The additional notes formed a single class of debt securities with the 5.625%5.000% Senior Notes issued in February 2015. Giving effect to this issuance, we have outstanding an aggregate of $650.0prepay approximately $453.3 million of 5.625% Senior Notes.

On September 21, 2015, we purchased approximately $88.3 million aggregate principal amountthe outstanding borrowings on our Term Loan B facility Tranche B-3 of 12.875% Senior Notes due 2018the Prior Credit Facility (the “12.875% Senior Notes”“Tranche B-3 Facility”) and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with a tender offer for any and all of the 12.875% Senior Notes. The notes purchased represented 90.6% of the outstanding $97.5 million principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were purchased at a price of 107.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, September 21, 2015. On September 18, 2015, we delivered a notice to redeem all $9.2 million in principal amount of the 12.875% Senior Notes remaining outstanding following the consummation of the tender offer. On November 1, 2015, we redeemed all of the outstanding $9.2 million principal amount of the 12.875% Senior Notes. As a result of this redemption, both the 12.875% Senior Notes and the indenture governing the 12.875% Senior Notes were satisfied and discharged in accordance with their terms.offering. In connection with the purchase of notes, the Company5.000% Senior Notes, we recorded a debt extinguishment charge of approximately $10.8$2.9 million, for the year ended December 31, 2015, including the premiumwrite-off of discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costscost in the consolidated statements of income.operations.

On May 11, 2015,June 24, 2020, we completed the offeringissued $450.0 million of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that we granted to the underwriters as part of the offering)5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a pricerate of $66.505.500% per share. The net proceeds to us from the saleannum, payable semi-annually in arrears on January 1 and July 1 of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.8 million, were $331.3 million. We used the net offering proceeds to repay outstanding indebtedness and fund acquisitions.

On April 22, 2015, we entered into an Eighth Amendment (the “Eighth Amendment”) to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

On February 11, 2015, we issued $375.0 million of 5.625% Senior Notes.each year, commencing on January 1, 2021. We used the net proceeds to fund a portion of the consideration for5.500% Senior Notes, together with cash on hand, to redeem in full the acquisition of CRC.

On February 11, 2015, we entered into a First Incremental Facility Amendmentoutstanding 6.125% Senior Notes due 2021 (the “First Incremental Amendment”“6.125% Senior Notes”) and the 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”) and to the Amendedpay related fees and Restated Credit Agreement. The First Incremental Amendment activated our TrancheB-1 Facility that was added to the Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-1 Facility were used to fund a portion of the consideration for the acquisition of CRC.

On February 6, 2015, we entered into a Seventh Amendment (the “Seventh Amendment”) to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreementexpenses in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.connection therewith.

Competitive Strengths

Management believes the following strengths differentiate us from other providers of behavioral healthcare services:

Premier operational management team with track record of success. Our management team has approximately 160300 combined years of experience in acquiring, integrating and operating a variety of behavioral health facilities. Following the sale of Psychiatric Solutions, Inc. (“PSI”) to Universal Health Services, Inc. (“UHS”) in November 2010, certain of PSI’s key former executive officers joined Acadia in February 2011.healthcare industry. The extensive national experience and operational expertise of our management team give us what management believes to be the premier leadership team in the behavioral healthcare industry. Our management team strives to use its years of experience operating behavioral healthcare facilities to generate strong cash flow and grow a profitable business.

Favorable industry and legislative trends. According to a 20142021 survey by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services (“SAMHSA”), 18.1% of57.8 million adults in the U.S. aged 18 years or older suffered from a mental illness in the prior year and 4.1%14.1 million suffered from a serious mental illness. In addition, 29.7 million U.S. adults with mental illness received no mental health services in the past year. Further, approximately 8.1% of43.7 million people aged 12 or older in 2014 were classified with a2021 needed substance abuse disorderuse treatment in the past year. According to the National Institutea study by The Journal of Mental Health, over 20% ofAmerican Medical Association Pediatrics, an estimated 7.7 million U.S. children either currently or at some point in their life, have hadhas a seriously debilitatingtreatable mental health disorder. Management believes the market for behavioral services will continue to grow due to increased awareness of mental health and substance abuse conditions and treatment options. According to a 2014 SAMHSA report, national expenditures at substance abuse treatment facilities are expected to reach $42.1 billion in 2020, up from $24.3 billion in 2009.

2


Table of Contents

While the growing awareness of mental health and substance abuse conditions is expected to accelerate demand for services, recent healthcare reform in the U.S. is expected to increase access to industry services as more people obtain insurance coverage. A key aspect of reform legislation is the extension of mental health parity protections established into law by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (the “MHPAEA”). The MHPAEA requires employers who provide behavioral health and addiction benefits to provide such coverage to the same extent as other medical conditions. On December 13, 2016, then President Obama signed the 21st21st Century Cures Act. The 21st21st Century Cures Act appropriates substantial resources for the treatment of behavioral health and substance abuse disorders and contains measures intended to strengthen the MHPAEA. On October 21, 2018, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the “SUPPORT Act”) was signed into law. The SUPPORT Act expands Medicare coverage to include Opioid Treatment Programs for services provided on or after January 2, 2020. It also includes Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act, which suspends the current prohibition on using federal Medicaid funds to pay for substance use disorder treatment at inpatient treatment facilities with more than 16 beds and limits beneficiaries to no more than 30 days of inpatient treatment per 12 month period.

The mental health hospitals market in the U.K. was estimated at £15.9 billion for 2014/2015. As a result of government budget constraintsNational footprint and an increased focus on quality, the independent mental health hospitals market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K. healthcare industry. Demand for independent sector beds has grown significantly as a result of the National Health Service (the “NHS”) reducing its bed capacityscale with regional density and increasing hospitalization rates. Independent sector demand is expected to further increase in light of additional bed closures and reduction in community capacity by the NHS.

Leading platform in attractive healthcare nichepresence across multiple service lines. We are a leading behavioral healthcare platform in an industry that is undergoing consolidation in an effort to reduce costs and expand programs to better serve the growing need for inpatient behavioral healthcare services. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. and U.K.count.

Diversified revenue and payor bases. As ofAt December 31, 2017,2022, we operated 582250 facilities in 39 states the U.K. and Puerto Rico. Our payor, patient and geographic diversity mitigates the potential risk associated with any single facility. For the year ended December 31, 2017,2022, we received 32%51% of our revenue from public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and Local Authorities), 28%continuing operations from Medicaid, 20%30% from commercial payors, 10%15% from Medicare and 10%4% from other payors. As we receive Medicaid payments from 4546 states, the District of Columbia and Puerto Rico, management does not believe that we are significantly affected by changes in reimbursement policies in any one state or territory. No facility accounted for more than 3%4% of revenue for the year ended December 31, 2017,2022, and no state or U.S. territory accounted for more than 8%14% of revenue for the year ended December 31, 2017. Our U.K. operations accounted for approximately 36% of our revenue for the year ended December 31, 2017.2022. We believe that our increased geographic diversity will mitigate the impact of any financial or budgetary pressure that may arise in a particular state or market where we operate.

Strong cash flow generationfinancial position to execute our strategy. Management believes we continue to be in a strong position for investments in our facilities, expansion into new and low capital requirements.existing markets and enhancement of our capabilities and infrastructure. We generate strong free cash flow by profitably operating our business and by actively managing our working capital. Moreover, as the behavioral healthcare business does not typically require the procurement and replacement of expensive medical equipment, our maintenance capital expenditure requirements are generally less than that of other facility-based healthcare providers. For the year ended December 31, 2017,2022, our maintenance capital expenditures amounted to approximately 3%2% of our revenue. In addition, our accounts receivable management is less complex than medical/surgical hospital providers because behavioral healthcare facilities have fewer billing codes and generally are paid on a per diem basis.

Business Strategy

Our strategy is to become the indispensable behavioral health provider for the high-acuity and complex needs patient population. We are committed to providing the communities we serve with high-quality, cost-effective behavioral healthcare services, while growing our business, increasing profitability and creating long-term value for our stockholders. To achieve these objectives, we have alignedThis strategy includes five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions and expansion across our activities aroundcontinuum of care. Our core strategic priorities include:

Drive organic growth of existing facilities. We seek to increase revenue at our facilities by providing a broader range of services to new and existing patients and clients. In addition, management intends to increase bed counts in our existing facilities. We added 290 beds to existing facilities during the following growth strategies:year ended December 31, 2022, and expect to add approximately 300 beds to existing facilities for the year ending December 31, 2023. Furthermore, management believes that opportunities exist to leverage out-of-state referrals to increase volume and minimize payor concentration, especially with respect to our youth and adolescent focused services and our substance abuse services.

Increase margins by enhancing programs and improving performance at existing facilities.Management believes we can improve efficiencies and increase operating margins by utilizing our management’s expertise and experience within existing programs and their expertise in improving performance at underperforming facilities. Management believes the efficiencies can be realized by investing in growth in strong markets, addressing capital-constrained facilities that have underperformed and improving management systems. Furthermore, our recent acquisitions

3


Table of additional facilities give us an opportunity to develop a marketing strategy in many markets which should help us increase the geographic footprint from which our existing facilities attract patientsContents

Fuel facility growth through accelerated joint venture partnerships and referrals.

Opportunistically pursue acquisitionsde novo builds and partnerships.pursuing programmatic mergers and acquisitions. We have positioned our companythe Company as a leading provider of mental health services in the U.S. and the U.K. The behavioral healthcare industry in the U.S. and the independent behavioral healthcare industry in the U.K. areis highly fragmented, and we selectively seek opportunities to expand and diversify our base of operations by acquiring additional facilities and entering into partnerships with healthcare providers to acquire and develop additional facilities. Acadia management believes there are a number of acquisition candidates available at attractive valuations, and weWe have a number of potential joint ventures and acquisitions in various stages of development and consideration in the U.S.

During the year ended December 31, 2022, we added 270 beds through the opening of one wholly-owned facility and two joint venture facilities, and we opened seven CTCs. For the year ending December 31, 2023, we expect to open two wholly-owned facilities, two joint venture facilities and at least six CTCs.

Management believes our focus on behavioral healthcare and history of completing acquisitions provides us with a strategic advantage in sourcing, evaluating and closing acquisitions. We leverage our management team’s expertise to identify and integrate acquisitions based on a disciplined acquisition strategy that focuses on quality of service, return on investment and strategic benefits. We also have a comprehensive post-acquisition strategic plan to facilitate the integration of acquired facilities that includes improving facility operations, retaining and recruiting psychiatrists and other healthcare professionals and expanding the breadth of services offered by the facilities.

Drive organicAccelerate expansion across the care continuum, particularly for patients with opioid use and other substance use disorders. Our growth strategy includes a patient-centric approach covering the full continuum of existing facilities.care, with deep expertise in treating high needs patients. We seekfocus on the most complex patients and are also working to increase revenue atreach underserved patient populations by expanding our facilities by providing a broader rangebreadth of services toand increasing access points within new and existing metropolitan statistical areas.

COVID-19 Impact

During March 2020, the global pandemic of the novel coronavirus known as COVID-19 (“COVID-19”) began to affect our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. and U.K. economies and financial markets. At manyof our facilities, employees and/or patients have tested positive for COVID-19. We are committed to protecting the health of our communities and have been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of our patients and clients. In addition, management intends to increase bed counts inemployees. Over the last three years, all of our existing facilities. Duringfacilities have closely followed infectious disease protocols, as well as recommendations by the year ended December 31, 2017, we added 750 new beds (exclusive of the acquisition), including 588 added to existing facilitiesCenters for Disease Control and 162 added through the opening of two de novo facilities. For the year ending December 31, 2018, we expect to add more than 800 total beds exclusive of acquisitions. Furthermore, management believes that opportunities exist to leverageout-of-state referrals to increase volumePrevention (“CDC”) and minimize payor concentration in the U.S., especially with respect to our youth and adolescent focused services and our substance abuse services.local health officials.

U.S. Operations

Our U.S. facilities and services can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers; and outpatient community-based services.centers. Outpatient programs associated with our facilities are included within each respective service line. The table below presents the percentage of our total U.S. revenue attributed to each category for the year ended December 31, 2017:2022:

 

Facility/Service

U.S. 

Revenue for the

Year Ended December 31, 20172022

Acute inpatient psychiatric facilities

43

51

%

Specialty treatment facilities

40

22

%

Comprehensive treatment centers

16

%

Residential treatment centers

15

Outpatient community-based services

11

2

%

We receive payments from the following sources for services rendered in our U.S. facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”);CMS; and (iv) individual patients and clients. For the year ended December 31, 2017 in our U.S. facilities,2022, we received 43%51% of our revenue from Medicaid, 31%30% from commercial payors, 15% from Medicare and 11%4% from other payors.

At December 31, 2017,2022, our U.S. facilities included 209250 behavioral healthcare facilities with approximately 8,90011,000 beds in 39 states and Puerto Rico. Of our U.S. facilities, excluding CTCs, approximately 40%53% are acute inpatient psychiatric facilities, approximately 41%37% are specialty treatment facilities and approximately 14%10% are residential treatment centers and approximately 5% are outpatient community-based service facilities at December 31, 2017.2022. Of the 209250 behavioral healthcare facilities, 112151 are comprehensive treatment centers (“CTCs”) which is a subset of specialty treatment facilities.CTCs. Of ourthe CTCs, 1416 are owned properties and 98135 are leased properties. Of the 97 facilities that are not CTCs, 7791% of our beds are at owned properties and 209% are at leased properties. For the years ended December 31, 20172022 and 2016,2021, our U.S.continuing operations generated revenue of $1.8 billion$2,610.4 million and $1.7 billion,$2,314.4 million, respectively.

4


Table of Contents

Acute Inpatient Psychiatric Facilities

Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides24-hour observation, daily intervention and monitoring by psychiatrists. Generally, due to shorter lengths of stay, the related higher patient turnover, and the special security and health precautions required, acute inpatient psychiatric facilities have lower average occupancy than residential treatment centers. Our facilities that offer acute care services provide evaluation and crisis stabilization of patients with severe psychiatric diagnoses through a medical delivery model that incorporates structured and intensive medical and behavioral therapies with24-hour monitoring by a psychiatrist, psychiatric trained nurses, therapists and other direct care staff. Lengths of stay for crisis stabilization and acute care range from three to five days and from five to twelve days, respectively.

Specialty Treatment Facilities

Our specialty treatment facilities include residential recovery facilities and eating disorder facilities and CTCs.facilities. We provide a comprehensive continuum of care for adults with addictive disorders andco-occurring mental disorders. Our detoxification, inpatient, partial hospitalization and outpatient treatment programs are cost-effective and give patients access to the least restrictive level of care. All programs offer individualized treatment in a supportive and nurturing environment.

The majority of our specialty treatment services are provided to patients who abuse addictive substances such as alcohol, illicit drugs or opiates, including prescription drugs. Some of our facilities also treat other addictions and behavioral disorders such as chronic pain, sexual compulsivity, compulsive gambling, mood disorders, emotional trauma and abuse. The goal of our treatment facilities is to provide the appropriate level of treatment to an individual no matter where they are in the lifecycle of their disease in order to restore the individual to a healthier, more productive life, free from dependence on illicit substances and destructive behaviors. Our treatment facilities provide a number of different treatment services such as assessment, detoxification, medication-assisted treatment, counseling, education, lectures and group therapy. We assess and evaluate the medical, psychological and emotional needs of the patient and address these needs in the treatment process. Following this assessment, an individualized treatment program is designed to provide a foundation for a lifelong recovery process. Many modalities are used in our treatment programs to support the individual, including the twelve step philosophy, cognitive/behavioral therapies, supportive therapies and continuing care.

Residential Recovery Facilities.Our inpatient facilities house and care for patients over an extended period and typically treat patients from a broadly defined regional market. We provide three basic levels of residential treatment depending on the severity of the patient’s addiction and/or behavioral disorder. Patients with the most severe dependencies are typically placed into inpatient treatment, in which the patient resides at a treatment facility. If a patient’s condition is less severe, he or she will be offered day treatment, which allows the patient to return home in the evening. The least intensive service is where the patient visits the facility for just a few hours a week to attend counseling/group sessions.

Following primary treatment, our extended care programs typically offer residential care, which allows patients to develop healthy and appropriate living skills while remaining in a safe and nurturing setting. Patients are supported in their recovery by a semi-structured living environment that allows them to begin the process of employment or to pursue educational goals and to take personal responsibility for their recovery. The structure of this treatment phase is monitored by a primary therapist who works with each patient to integrate recovery skills and build a foundation of sobriety with a strong support system. Length of stay will vary depending on the patient’s needs with a minimum stay of 30 days and could be multiple months if needed.

Our outpatient clinics serve patients that do not require inpatient treatment or are transitioning from a residential treatment program; have employment, family or school commitments; and have stabilized in their substance addiction recovery practices and are seeking ongoing continuing care.

Eating Disorder Facilities. Our eating disorder facilities provide treatment services for eating disorders and weight management, each of which may be effectively treated through a combination of medical, psychological and social treatment programs.

Our behavioral therapies are delivered in an array of treatment models that may include individual and group therapy, intensive outpatient, outpatient, partial hospitalization/day treatment, road to recovery and other programs that can be either abstinent or medication-assisted based.

Comprehensive Treatment Centers.

Our CTCs specialize in providing medication-assisted and abstinent-based treatment.treatment in an outpatient setting. Medication-assisted treatment combines behavioral therapy and medication to treat substance use disorders. CTCs utilize medication-assisted treatment to

5


Table of Contents

individuals addicted to opiates such as opioid analgesics (prescription pain medications) and heroin.. Medication is used to normalize brain chemistry to block the euphoric effects of alcohol and opioids allowing our professional staff to provide behavioral therapy. Patients begin their treatment attending the clinic almost daily. Then, through successfully progressing in treatment, patients attend less frequently depending on individual treatment plans. The length of treatment differs from patient to patient, but typically ranges fromlasts longer than one to three years.year.

Each of our CTCs provide a range of comprehensive substance abuse treatment support services that include medical, counseling, vocational, educational, and other treatment services. Our behavioral therapies are delivered in array of treatment models that may include individual and group therapy, intensive outpatient, outpatient, partial hospitalization/day treatment, road to recovery, and other programs that can be either abstinent or medication assisted based.

Residential Treatment Centers

Residential treatment centers treat patients with behavioral disorders in anon-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities. Because the setting is less intensive, demands on staffing, security and oversight are generally lower than inpatient psychiatric facilities. In contrast to acute care psychiatric facilities, occupancy in residential treatment centers can be managed more easily given a longer length of stay. Over time, however, residential treatment centers have continued to serve increasingly severe patients who would have been treated in acute care facilities in earlier years.

We provide residential treatment care through a medical model residential treatment facility, which offers intensive, medically-driven interventions and individualized treatment regimens designed to deal with moderate to high level patient acuity. Children and adolescents admitted to these facilities typically have had multiple prior failed treatment plans, severe physical, sexual and emotional abuse, termination of parental custody, substance abuse, marked deficiencies in social, interpersonal and academic skills and a wide range of psychiatric disorders. Treatment typically is provided by an interdisciplinary team coordinating psychopharmacological, individual, group and family therapy, along with specialized accredited educational programs in both secure and unlocked environments. Lengths of stay range from three months to several years.

Certain of our residential treatment centers provide group home, therapeutic group home and therapeutic foster care programs. Our group home programs provide family-style living for youths in a single house or apartment within residential communities where supervision and support are provided by24-hour staff. The goal of a group home program is to teach family living and social skills through individual and group counseling sessions within a real life environment. The residents are encouraged to take responsibility for the home and their health as well as actively take part in community functions. Most attend an accredited and licensedon-premises school or a local public school. We also operate therapeutic group homes that provide comprehensive treatment services for seriously, emotionally disturbed adolescents. The ultimate goal is to reunite or place these children with their families or prepare them, when appropriate, for permanent placement with a relative or an adoptive family. We also manage therapeutic foster care programs, which are considered the least restrictive form of therapeutic placement for children and adolescents with emotional disorders. Children and adolescents in our therapeutic foster care programs often are part of the child welfare or juvenile justice system. Care is delivered in private homes with experienced foster parents who are trained to work with children and adolescents with special needs.

Outpatient Community-Based Services

Our community-based services can be divided into two age groups: children and adolescents (seven to 18 years of age) and young children (three months to six years of age). Community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community. Many patients who participate in community-based programs have transitioned out of a residential facility or have a disorder that does not require placement in a facility that provides24-hour care.

Community-based programs developed for these age groups provide a unique array of therapeutic services to a very high-risk population of children. These children suffer from severe congenital, neurobiological, speech/motor and early onset psychiatric disorders. These services are provided in clinics and employ a treatment model that is consistent with our interdisciplinary medical treatment approach. Depending on their individual needs and treatment plan, children receive speech, physical, occupational and psychiatric interventions that are coordinated with services provided by their referring primary care physician. The children generally receive treatment during regular business hours.

U.K. Operations

Overview

WithPrior to the Priory and Partnerships in Care acquisitions,U.K. Sale, we arewere the leading independent provider of mental health services in the U.K. operating 373345 inpatient behavioral health facilities with approximately 8,9008,200 beds as ofat December 31, 2017. The2020. Our U.K. facilities arewere located in England, Wales, Scotland and Northern Ireland. For the years ended December 31, 20172021 and 2016,2020, our U.K. operations generated revenue of $1.0 billion$62.5 million and $1.1 billion,$1,119.8 million, respectively, primarily through the operation and management of inpatient behavioral health facilities. The year ended December 31, 2016 was impacted by the acquisition of Priory on February 16, 2016

Additional information about our U.K. operations and the U.K. Divestiture on November 30, 2016.

United Kingdom Healthcare and Adult Social Care Sectors

In the U.K., central government spending on health for fiscal year 2017-2018 is budgeted at approximately £149 billion, according to the U.K. government budget. This spending is primarily delivered by the NHS, which operates as three separate national public sector bodies in England, Scotland and Wales as well as the Northern Ireland Health and Social Care Board. Local Government gross spending on adult social care for the fiscal year 2017-2018 is budgeted at approximately £25 billion and is commissioned by local authorities in England, Scotland and Wales, which we refer to as Local Authorities and by the Northern Ireland Health and Social Care Board. The NHS, Local Authorities and Northern Ireland Health and Social Care Board commissioners dominate the U.K. health and social care markets in terms of the funding of care. With the exception of the elderly residential and nursing care market, private health insurance and self-payment play a minor role in these sectors.

The mental health market in the U.K. was estimated at £15.9 billion for 2014/2015. The independent mental health market accounted for roughly £1.4 billion of that amount, or approximately 9% market share. As a result of government budget constraints and an increased focus on quality, the independent mental health market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K.’s behavioral healthcare industry.

Publicly-funded healthcare services in England are commissioned at two levels as follows: (i) nationally by NHS England which, via its Local Area Teams commissions specialized healthcare services, including specialized Mental Health Secure, Eating Disorder and Children and Adolescent (CAMHS) services, and (ii) locally by over 200 local CCGs, which commission all acute, rehabilitation and community-based healthcare services. In Scotland and Wales, all healthcare services are commissioned by Local/Regional Health Boards.

The principal distinction between healthcare and social care relates to an individual’s assessed care needs. If there is a primary health need, services are commissioned by the NHS under the general NHS principle that the services are free at the point of delivery. In the case of adult social care, individuals’ healthcare-related needs have been assessed as being of secondary importance with services being means-tested. Local Authority commissioners of adult social care provided in care homes and other community settings are responsible for undertaking financial assessments to determine the level of contributions that individuals must pay towards the cost of their care. Individuals with income or capital above set statutory thresholds must fund the full cost of their care.

In recent years, the U.K. Government has placed increasing emphasis on implementing integrated care pathways across health and social care services. Integrated care pathways provide patients with highly coordinated and personalized care overseen by relevant commissioners working together to plan, arrange and monitor patient progression through each stage of the care pathway.

Additionally, mental health commissioning trends toward moving patients more quickly down care pathways, out of higher acuity, more intensive care settings towards community focused care services have increased the demand for community and rehabilitation services in the independent mental health market. The Department of Health in England recently identified priorities for essential change in mental health that include, among other things, funding providers based on the quality of their service rather than volume of patients, allocating funds to support specialized housing for people with mental health problems and adopting a new rating system and inspection process to improve the quality of care. Increasing political focus on the provision of mental health services in the U.K. and increasing support for the rights of mental health patients are expected to lead to further increases in the size of the mental health market in the U.K. In addition, rising demand for mental health services in the U.K. coupled with a constrained mental healthcare funding environment are increasing pressure to improve operational efficiency and refer patients to single provider programs with care pathways that more appropriately reflect each patient’s specific mental health needs. As a result of these pressures and an increased focus on quality, the independent mental health market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K. healthcare industry.

Description of U.K. Facilities

In the U.K., we provide inpatient services through a variety of facilities, including mental health hospitals, clinics, care homes, schools, colleges and children’s homes. In addition to these services, we also operate a U.K. division that leverages on our clinical knowledge to provide Employee Assistance Programs (“EAP”) to organizations.

Our U.K. facilities and servicesindustry can generally be classified into the following categories: healthcare facilities, education and children’s services, adult care facilities and elderly care facilities. The table below presents the percentage of our total U.K. revenue attributed to each category for the year ended December 31, 2017:

Facility/Service

U. K. Revenue for the
Year Ended December 31, 2017

Healthcare facilities

55

Education and Children’s Services

17

Adult Care facilities

18

Elderly Care facilities

10

We receive payments from approximately 500 public funded sources in the U.K. (including the NHS, CCGs and Local Authorities) and individual patients and clients. For the year ended December 31, 2017found in our U.K. facilities, we received 91% of our revenue from public funded sources inprior filings with the U.K. (including the NHS, CCGs and Local Authorities) and 9% from other payors.SEC.

At December 31, 2017, our U.K. facilities included 373 behavioral healthcare facilities with approximately 8,900 beds, including approximately 1,000non-residential education places, in the U.K. Of our U.K. facilities, approximately 22% are healthcare facilities, approximately 20% are education and children’s services facilities, approximately 47% are adult care facilities and approximately 11% are elderly care facilities at December 31, 2017. At December 31, 2017, 291 of our U.K. facilities are owned properties and 82 are leased properties.

Healthcare

In the U.K., mental health hospitals provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients detained under a section of the U.K.’s Mental Health Act of 1983, and whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient. The levels of dependency and risk stemming from the wide range of disorders treated at these hospitals determine the level of care provided, which are comprised of:

Secure Services. Medium and Low secure facilities treat patients who may present a serious danger to others and themselves but do not need the physical security arrangements of a high security hospital. The purpose of medium secure services is to provide effective care and treatment to reduce risk, promote recovery and support patients moving through the care pathway to lower levels of security or to reestablishing themselves successfully in the community. Low secure facilities provide treatment for patients whom, because of the level of risk or challenge they present, cannot be treated in open mental health settings. Low secure services deliver intensive, comprehensive and multidisciplinary treatment to patients demonstrating disturbed behavior in the context of a serious mental disorder and require the provision of security but pose a lesser risk of harm to themselves and to others.

Specialty Treatment Services. Specialty treatment services provide treatment relating to specific conditions including eating disorders and addiction. Our eating disorder facilities provide treatment services for eating disorders and weight management for both adults and adolescents. Our addiction services provide treatment for abuse of addictive substances such as alcohol and illicit drugs as well as facilities for other addictions and behavioral disorders such as compulsive gambling.

Child and Adolescent Mental Health Services. Child and adolescent mental health services provide treatment to young people in need of expert care and support for behavioral, emotional or mental health difficulties. These services are designed to enable the children and young people within our care to improve their long-term wellbeing and effectively reintegrate into the community when they are ready.

Rehabilitation Services. Both locked and open mental health rehabilitation services provide a bridge between secure hospital facilities and community living by providing relapse prevention and social integration services as well as vocational opportunities.

Acute Services. Acute services provide treatment relating to emergency admissions for patients at risk to themselves or others, as well as crisis intervention and treatment of behavioral emergencies.

Care Homes. Care homes provide long-term,non-acute care for adults suffering from a mental illness or addiction, or who have a learning disability or brain injury and are unable to cope unsupported in the community.

Other Services

Education and Children’s Services.Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require52-week residential care to support complex and challenging behavior and fostering services.

Adult Care. Adult Care focuses on care of service users with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. Care is provided in a number of settings, including in residential care homes and through supported living.

Elderly Care. Elderly care provides long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia.

Care First. Care First leverages our clinical knowledge to provide EAP to organizations. These support services are designed to help employees manage difficult issues in their professional or personal lives with services that include:

A call center for telephone counseling available24-hours a day, seven days a week;

A national network of counselors available for live,face-to-face support;

Interactive health and wellness programs;

Debt management advice services; and

Management training.

Sources of Revenue

We receiveAs of December 31, 2022, we received payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and Local Authorities); and (v)(iv) individual patients and clients. Revenue is recorded inWe determine the period in which services are provided attransaction price based on established billing rates lessreduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Revenue” Operations — Critical Accounting Policies — Revenue and Accounts Receivable”

6


Table of Contents

for additional disclosure. Other information related to our revenue, income and other operating information is provided in our Consolidated Financial Statements.

Regulation

U.S. Overview

The healthcare industry is subject to numerous laws, regulations and rules including, among others, those related to government healthcare program participation requirements, various licensure and accreditation standards, reimbursement for patient services, health information privacy and security rules, and government healthcare program fraud and abuse provisions. Providers that are found to have violated any of these laws and regulations may be excluded from participating in government healthcare programs, subjected to loss or limitation of licenses to operate, subjected to significant fines or penalties and/or required to repay amounts received from the government for previously billed patient services. Management believes that we are in substantial compliance with all applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing.

Licensing, Certification and Accreditation

All of our facilities must comply with various federal, state and local licensing and certification regulations and undergo periodic inspection by licensing agencies to certify compliance with such regulations. The initial and continued licensure of our facilities and certification to participate in government healthcare programs depends upon many factors including various state licensure regulations relating to quality of care, environment of care, equipment, services, staff training, personnel and the existence of adequate policies, procedures and controls. Federal, state and local agencies survey our facilities on a regular basis to determine whether the facilities are in compliance with regulatory operating and health standards and conditions for participating in government healthcare programs.

Most of our inpatient and residential facilities maintain accreditation from private entities, such as The Joint Commission or the Commission on Accreditation of Rehabilitation Facilities (“CARF”). The Joint Commission and CARF are private organizations that have accreditation programs for a broad spectrum of healthcare facilities. The Joint Commission accredits a broad variety of healthcare organizations, including hospitals and behavioral health organizations. CARF accredits behavioral health organizations providing mental health and alcohol and drug use and addiction services, as well as opiate treatment programs, and many other types of healthcare programs. These accreditation programs are intended generally to improve the quality, safety, outcomes and value of healthcare services provided by accredited facilities. Certain federal and state licensing agencies as well as many in government and private healthcare payment programs require that providers be accredited as a condition of licensure, certification or participation. Accreditation is typically granted for a specified period, ranging from one to three years, and renewals of accreditation generally require completion of a renewal application and anon-site renewal survey.

Certificates of Need

Many of the states in which we operate facilities have enacted certificate of need (“CON”) laws that regulate the construction or expansion of certain healthcare facilities, certain capital expenditures or changes in services or bed capacity. Failure to obtain CON approval of certain activities can result in: our inability to complete an acquisition, expansion or replacement; the imposition of civil penalties; the inability to receive Medicare or Medicaid reimbursement; or the revocation of a facility’s license, any of which could harm our business.

Quality Improvement

Services provided to Medicare beneficiaries are subject to review by Quality Improvement Organizations (“QIOs”), which aim to improve the effectiveness, efficiency, economy and quality of services furnished within the Medicare program. QIOs are independent organizations that contract with CMS to perform several functions, including reviewing the appropriateness of patient admissions and discharges, the quality of care provided, the validity of diagnosis related group classifications, and the appropriateness of length of stay, as well as investigating beneficiary complaints. QIOs may recommend the imposition of sanctions against a Medicare provider found to have, among other things, provided services deemed medically unnecessary or not of a quality that meets professionally recognized standards of care. Such sanctions may include monetary assessments and exclusion from participation in government healthcare programs.

Audits

Our healthcare facilities are also subject to federal, state and commercial payor audits to validate the accuracy of claims submitted to the government healthcare programs and commercial payors. If these audits identify overpayments, we could be required to make substantial repayments, subject to various appeal rights. Several of ourOur facilities have undergoneare routinely subjected to claims audits related to their receiptin the ordinary course of payments during the last several years withbusiness. While no such audit has identified any material overpayments identified. However,overpayment liability, should a potential material overpayment liability arise from a future audits couldaudit, such overpayment liability may ultimately exceed established reserves, and any excess could potentially be substantial. Further, Medicare and Medicaid regulations, as well as commercial payor contracts, also provide for withholding or suspending payments in certain circumstances, which could adversely affect our cash flow.

The Anti-Kickback Statute, andthe Stark Law and the Eliminating Kickbacks in Recovery Act

The Anti-Kickback Statute prohibits healthcare providers and others from directly or indirectly soliciting, receiving, offering or paying any remuneration, in cash or in kind, as an inducement or reward for using, referring, ordering, recommending or arranging for such referrals or orders of services or other items paid for by a government healthcare program. The Anti-Kickback Statute may be found to have been violated if at least one purpose of the remuneration is to induce or reward referrals. A provider is not required to have actual knowledge or specific intent to commit a violation of the Anti-Kickback Statute to be found guilty of violating the law.

7


Table of Contents

The Office of Inspector General of the Department of Health and Human Services (the “OIG”) has issued safe harbor regulations that protect certain types of common arrangements from prosecution or sanction under the Anti-Kickback Statute and there are also several statutory exceptions toward that end.Statute. The fact that conduct or a business arrangement does not fall within a safe harbor or exception does not automatically render the conduct or business arrangement illegal under the Anti-Kickback Statute. However, conduct and business arrangements falling outside the safe harbors may lead to increased scrutiny by government enforcement authorities. In December of 2020, the OIG finalized revisions to the Anti-Kickback Statute safe harbors and created new safe harbors for value-based care that became effective January 19, 2021. The new regulations are intended to improve patient care and foster innovative care models by easing regulatory burdens to coordinated and value-based care.

Although management believes that our arrangements with physicians and other referral sources comply with current law and available interpretative guidance, as a practical matter it is not always possible to structure our arrangements so as to fall squarely within an available safe harbor. Where that is the case, we cannot guarantee that applicable regulatory authorities will determine these financial arrangements do not violate the Anti-Kickback Statute or other applicable laws, including state anti-kickback laws.

In addition to the Anti-Kickback Statute, the federal Physician Self-Referral Law, also known as the Stark Law, prohibits physicians from referring Medicare patients to healthcare entities with which they or any of their immediate family members have a financial relationship for the furnishing of any “designated health services” unless certain exceptions apply. A violation of the Stark Law may result in a denial of payment; required refunds to the Medicare program; imposition of statutory civil monetary penalties of up to $24,253$15,000 for each prohibited claim up to $161,692 for circumvention schemes, and up to $19,246$100,000 for each day the entity fails to report required information;circumvention schemes; exclusion from government healthcare programs; and liability under the False Claims Act. There are ownership and compensation arrangement exceptions for many customary financial arrangements between physicians and facilities, including the employment exception, personal services exception, lease exception and certain recruitment exceptions. As part of CMS’s “regulatory sprint to coordinated care”, CMS finalized revisions to the exceptions and created new exceptions for value-based care that became effective on January 19, 2021. As with the changes made to the Anti-Kickback Statute, the new Stark exceptions are intended to improve patient care and foster innovative care models by easing regulatory burdens to coordinated and value-based care.

Management believes that our financial arrangements with physicians are structured to comply with the regulatory exceptions to the Stark Law. However, the Stark Law is a strict liability statute, meaning that no intent is required to violate the law, and even a technical violation may lead to significant penalties.

These laws and regulations are extremely complex and, in many cases, we do not have the benefit of regulatory or judicial interpretation. It is possible that different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our arrangements relating to facilities, equipment, personnel, services, capital expenditure programs and operating expenses. A determination that we have violated one or more of these laws, or the public announcement that we are being investigated for possible violations of one or more of these laws, could have a material adverse effect on our business, financial condition or results of operations. In addition, we cannot predict whether other federal or state legislation or regulations will be adopted, what form such legislation or regulations may take or what their impact on us may be.

The SUPPORT Act contains a number of provisions aimed at identifying at-risk individuals, increasing access to opioid abuse treatment, reducing overprescribing and promoting data sharing with the primary goal of reducing the use and abuse of opioids. Additionally, the SUPPORT Act attempts to address the problem of “patient brokering” in the context of addiction treatment facilities and sober living homes.

One section of the SUPPORT Act, the Eliminating Kickbacks in Recovery Act (the “EKRA”), makes it a federal crime to knowingly and willfully: (1) solicit or receive any remuneration in return for referring a patient to a recovery home, clinical treatment facility or laboratory; or (2) pay or offer any remuneration to induce such a referral or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. Each conviction under the EKRA is punishable by up to $200,000 in monetary damages, imprisonment for up to ten (10) years, or both. Unlike the Anti-Kickback Statutes, the EKRA is not limited to services reimbursable under a government healthcare program. The EKRA also contains exceptions similar to the Anti-Kickback Statute safe harbors, but those exceptions are more narrow than the Anti-Kickback Statute safe harbors such that practices that would be permissible under the Anti-Kickback Statute may violate the EKRA.

If we are deemed to have failed to comply with the Anti-Kickback Statute, the Stark Law, the EKRA or other applicable laws and regulations, we could be subjected to liabilities, including criminal penalties, civil penalties and exclusion of one or more facilities from participation in the government healthcare programs. The imposition of such penalties could have a material adverse effect on our business, financial condition or results of operations.

8


Table of Contents

Federal False Claims Act and Other Fraud and Abuse Provisions

The federal False Claims Act provides the government a tool to pursue healthcare providers for submitting false claims or requests for payment for healthcare items or services. Under the False Claims Act, the government may fine any person or entity that, among other things, knowingly submits, or causes the submission of, false or fraudulent claims for payment to the federal government or knowingly and improperly avoids or decreases an obligation to pay money to the federal government. The federal government has widely used the False Claims Act to prosecute Medicare and other federal healthcare program fraud such as coding errors, billing for services not provided, submitting false cost reports and providing care that is not medically necessary or that is substandard in quality. Claims for services or items rendered in violation of the Anti-Kickback Statute or the Stark Law can provide a basis for liability under the False Claims Act as well. The False Claims Act is also implicated by the knowing failure to report and return an overpayment within 60 days of identifying the overpayment or by the date a corresponding cost report is due, whichever is later.

Violations of the False Claims Act are punishable by significant penalties totaling $10,957$13,508 to $21,916$27,018 for each fraudulent claim plus three times the amount of damages sustained by the government. In addition, under the qui tam, or whistleblower, provisions of the False Claims Act, private parties may bring actions under the False Claims Act on behalf of the federal government. These private parties, often referred toknown as relators, are entitled to share in any amounts recovered by the government, and, as a result, whistleblower lawsuits have increased significantly in recent years. Many states have similar false claims statutes that impose liability for the types of acts prohibited by the False Claims Act or that otherwise prohibit the submission of false or fraudulent claims to the state government or Medicaid program.

In addition to the False Claims Act, the federal government may use several criminal laws, such as the federal mail fraud, wire fraud or health carehealthcare fraud statutes, to prosecute the submission of false or fraudulent claims for payment to the federal government. Most states have also adopted generally applicable insurance fraud statutes and regulations that prohibit healthcare providers from submitting inaccurate, incorrect or misleading claims to private insurance companies. Management believes our healthcare facilities have implemented appropriate safeguards and procedures to complete claim forms and requests for payment in an accurate manner and to operate in compliance with applicable laws. However, the possibility of billing or other errors can never be completely eliminated, and we cannot guarantee that the government or a qui tam plaintiff, upon audit or review, would not take the position that billing, the quality of patient care or other deficiencies or errors, should they occur, are violations of the False Claims Act.

HIPAA Administrative Simplification and Privacy and Security Requirements

The administrative simplification provisions of the Health Insurance Portability and Accountability Act (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), require the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry. HIPAA also established federal rules protecting the privacy and security of individually identifiable protected health information (“PHI”). The privacy and security regulations control the use and disclosure of PHI and the rights of patients to be informed about and control how such PHI is used and disclosed. Violations of HIPAA can result in both criminal and civil fines and penalties.

The HIPAA security regulations require healthcare providers to implement administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of PHI. HITECH has strengthened certain HIPAA rules regarding the use and disclosure of PHI, extended certain HIPAA provisions to business associates and created security breach notification requirements including notifications to the individuals affected by the breach, the Department of Health and Human Services, and in certain cases, the media. HITECH has also increased maximum penalties for violations of HIPAA privacy rules. Management believes that we have been in material compliance with the HIPAA regulations and have developed our policies and procedures to ensure ongoing compliance, although we cannot guarantee that our facilities will not be subject to security incidents or breaches which could have a material adverse effect on our business, financial condition or results of operations.

The Emergency Medical Treatment & Labor Act

The Emergency Medical Treatment & Labor Act (“EMTALA”) is intended to ensure public access to emergency services regardless of ability to pay. Section 1867 of the Social Security Act imposes specific obligations on Medicare-participating hospitals that offer emergency services to provide a medical screening examination when a request is made for examination or treatment for an emergency medical condition regardless of an individual’s ability to pay. Hospitals are then required to provide stabilizing treatment for patients with emergency medical conditions. If a hospital is unable to stabilize a patient within its capability, or if the patient requests, an appropriate transfer must be implemented. EMTALA imposes additional obligations on hospitals with specialized capabilities, such as ours, to accept the transfer of patients in need of such specialized capabilities if those patients present in the emergency room of a hospital that does not possess the specialized capabilities.

9


Table of Contents

Mental Health Parity Legislation

The MHPAEA was signed into law in October 2008 and requires health insurance plans that offer mental health and addiction coverage to provide that coverage on par with financial and treatment coverage offered for other illnesses. The MHPAEA has some limitations because health plans that do not already cover mental health treatments are not required to do so, and health plans are not required to provide coverage for every mental health condition published in the Diagnostic and Statistical Manual of Mental Disorders by the American Psychiatric Association. The MHPAEA also contains a cost exemption which operates to exempt a group health plan from the MHPAEA’s requirements if compliance with the MHPAEA becomes too costly.

On December 13, 2016, then President Obama signed the 21st Century Cures Act. The 21st Century Cures Act appropriated substantial resources for the treatment of behavioral health and substance abuse disorders and contained measures intended to strengthen the MHPAEA.

Patient Protection and Affordable Care Act

The Patient Protection and Affordable CareCARES Act and Other Regulatory Developments

On March 27, 2020, the Health CareCoronavirus Aid, Relief and Education ReconciliationEconomic Security Act of 2010 (collectively, “PPACA”(the “CARES Act”) dramatically alteredwas signed into law. The CARES Act is intended to provide over $2 trillion in stimulus benefits for the U.S. health care system. PPACA sought to provide coverage and access to substantially all Americans, to increase the quality of care provided, and to reduce the rate of growth in health care expenditures. PPACA attempted to achieve these goals by, amongeconomy. Among other things, requiring most Americansthe CARES Act includes additional support for small businesses, expands unemployment benefits, makes forgivable loans available to obtain health insurance, expanding the Medicare program’s use of value-based purchasing programs, bundling payments to hospitalssmall businesses, provides for certain federal income tax changes, and provides $500 billion for loans, loan guarantees, and other investments for or in U.S. businesses.

In addition, the CARES Act contains a number of provisions that are intended to assist healthcare providers reducing Medicare and Medicaid payments to providers, expanding Medicaid eligibility, and tying reimbursement toas they combat the satisfaction of certain quality criteria.

On January 20, 2017, Donald Trump became Presidenteffects of the United States. DuringCOVID-19 pandemic. Those provisions include, among others:

an appropriation to the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund, to reimburse, through grants or other mechanisms, eligible healthcare providers and other approved entities for COVID-19-related expenses or lost revenue;

the expansion of CMS’ Accelerated and Advance Payment Program;

the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022; and

waivers or temporary suspension of certain regulatory requirements.

The U.S. government initially announced it would offer $100 billion of relief to eligible healthcare providers through the 2016 election cycle, Republicans also assumed control of both the United States Senate and House of Representatives. Shortly after his inauguration, President Trump issued an executive order that, among other things, stated that it was the intent of his administration to repeal PPACA and, pending that repeal, instructed the executive branch of the federal government to defer or delay the implementation of any provision or requirement of PPACA that would impose a fiscal burden on any state or a cost, fee, tax, or penalty on any individual, family, health care provider, or health insurer. Several bills have been introduced and voted upon in the House of Representatives and United States Senate that would either repeal and replace or simply repeal PPACA, although none have been enactedto-date.

PHSSE Fund. On October 12, 2017,April 24, 2020, then President Trump signed an executive order intendinginto law the Paycheck Protection Program and Health Care Enhancement Act (the “PPP Act”). Among other things, the PPP Act allocates $75 billion to expandeligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the availabilityPPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. In 2020, we received approximately $34.9 million ofso-called association health plans the funds distributed from the PHSSE Fund. During the fourth quarter of 2020, we recorded approximately $32.8 million of income from provider relief fund related to PHSSE Fund funds received in 2020.

    In 2021, we received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received. During the year ended December 31, 2022, we received $7.7 million of additional funds from the PHSSE Fund
and short-term plans outside PPACA’s requirements. President Trump also announced that$14.2 million from the administration would cease making cost-sharing reduction paymentsAmerican Rescue Plan (“ARP”) Rural Payments for Hospitals. During the year ended December 31, 2022, we recorded $21.5 million of income from provider relief fund related to health insurance companies that help coverout-of-pocket costs forlow-income individuals. Finally,PHSSE Fund and ARP funds received. The remaining ARP funds of $9.0 million are included in other accrued liabilities on the Tax Act (as defined and described below) effectively eliminates PPACA’s individual health insurance mandateconsolidated balance sheet as of 2018 by reducingDecember 31, 2022. We continue to zeroevaluate our compliance with the tax penalty associated with failureterms and conditions to, maintain health insurance coverage.

It is difficult to predict whether PPACA will be repealed, replaced, or modified; whatand the effect will befinancial impact of, these additional funds received, including potential repayment of the health care-related provisions in the Tax Act; or the impact that the President’s executive actions will have on the implementation and enforcementremaining balance.

Healthcare providers were required to sign an attestation confirming receipt of the provisionsProvider Relief Fund funds and agree to the terms and conditions of PPACA orpayment. Under the regulations adopted or to be adopted to implement the law or the President’s executive orders. In addition, if PPACA is replaced or modified, it remains unclear what the replacement plan or modifications would be, when the changes would become effective, or whether anyterms and conditions for receipt of the existing provisionspayment, we were allowed to use the funds to cover lost revenues and healthcare costs related to COVID-19, and we were required to properly and fully document the use of PPACA would remain in place. Even if the current administration is not successful in its efforts to repeal and replace PPACA, there have been and likely will continue to be a number of legal challenges to various provisions of the law and President Trump’s recent executive actions. Limitations on the availability of adequate insurance coverage for patients seeking services at our facilities; any reductions in government healthcare spending; and the possible repeal, replacement or modification of PPACA could have a material adverse effect on our business, financial condition, or results of operations.

U.S. Tax Reform

On December 22, 2017, Public Law115-97, informally referred to as the Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law. The Tax Act provides for significant changesthese funds to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21% for U.S. taxable income. The Tax Act requires aone-time remeasurementDepartment of deferred taxes to reflect their value at a lower tax rate of 21%Health and Human Services (“HHS”). The Tax Act includes other changes, including, but not limited to, requiring aone-time transition tax on certain unrepatriated earnings of foreign subsidiaries that is payable over eight years, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, a new provision designed to tax global intangiblelow-taxed income, a limitationreporting of the deduction for net operating losses, elimination of net operating loss carrybacks, immediate deductions for certain new investments instead of deductions for depreciation expense for certain qualified property, additional limitations on the deductibility of executive compensation and limitations on the deductibility of interest. The effects of the Tax Act on the Company are still being evaluated.

U.K. Overview

The regulatory environment applicable to facilities in the U.K.funds is complex and multifaceted. The regulatory regime is made up of multiple statutes, regulations and minimum standards that are subject to continuous change. The laws and regulations applicable to the U.K. facilities include, without limitation, the Mental Capacity Act of 2005, Safeguarding Vulnerable Groups Act of 2006, Mental Health Act of 2007, Health and Social Care Act of 2008 and Corporate Manslaughter and Corporate Homicide Act of 2008. These laws and regulations are predominantly protective in nature and share the same general underlying purpose to protect vulnerable persons from exploitation or harm. The regulatory requirements relevant to our facilities in the U.K. cover our operations from the initial establishments of new facilities, which are subject to registration and licensing requirements, to the recruitment and appointment of staff, occupational health and safety, duty of care to service users, clinical and educational standards, conduct of our professional and support staff and other areas.

Mental Capacity Act of 2005. The Mental Capacity Act of 2005 establishes the processfuture audit for determining whether a person lacks mental capacity at a particular time and also sets out who can make decisions in those circumstances and how they should go about this. The Act sets out when liability may arise for actions in connection with the care or treatment of persons who lack capacity to consent to such actions.

Safeguarding Vulnerable Groups Act of 2006. The Safeguarding Vulnerable Groups Act of 2006 created the Independent Safeguarding Authority (“ISA”). In December 2012, the ISA merged with the Criminal Records Bureau to form the Discharge and Barring Service (“DBS”) and is required to establish and maintain lists of persons barred from working with children and adults. It is a criminal offense for a barred person to seek to work, or work in, activities from which they are barred. It is also generally a criminal offense for an employer to allow a barred person, or person who is not appropriately registered, to work in any regulated activity. The Children Act 1989 also allocates duties to Local Authorities, courts, parents, and other agencies in the U.K. to ensure children are safeguarded and their welfare is promoted.

The Mental Health Act of 2007. The Mental Health Act of 2007 regulates the manner in which an individual can be committed or detained against his or her will. The main purpose of the legislation is to ensure that people with serious mental disorders which threaten their health or safety or the safety of the public can be treated irrespective of their consent where it is necessary to prevent them from harming themselves or others. The Act places the burden on the entity detaining a person to prove that the entity has the right to hold the detainee. This places a substantial regulatory burden on service providers to ensure compliance with the law. Thereterms and conditions. We recognized Provider Relief Fund funds to the extent we had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions. The grant income associated with the COVID-19 expenses and

10


Table of Contents

lost revenues incurred during the years ended December 31, 2022, 2021 and 2020 is similar legislationreflected as income from provider relief fund in Scotland, Walesour consolidated statement of operations.

During 2020, we applied for and Northern Ireland.

received approximately $45.2 million of payments from the CMS Accelerated and Advance Payment Program. Of the $45.2 million of advance payments received in 2020, we repaid approximately $25.1 million of advance payments during 2021 and made additional repayments of approximately $20.1 million during the year ended December 31, 2022 to eliminate the liability.

The Health and Social Care Act of 2008. The Health and Social Care Act of 2008 (“HSCA”), as amended by the Care Act 2014, established the Care Quality Commission (“CQC”) as the registration and regulatory body for health and adult social care in England. Under the HSCA, service providers carrying out “regulated activities” must be registered with the CQC for each separate regulated activity provided. Where the service provider isCARES Act, we received a company, each regulated activity/location must also have an individual registered as the registered manager. Registration depends both on an assessment of the fitness of the registered provider and also the individual registered manager. Regulated activities include the provision of residential accommodation together with nursing or personal care and the provision of treatment for a disease, disorder or injury by or under the supervision of a social worker or a multidisciplinary team which includes a social worker where the treatment is for a mental disorder.

The Care Act 2014. The Care Act 2014 came into force on April 1, 2015 along with a range of supporting regulations and a single set of statutory guidance. The Care Act 2014 requires Local Authorities to set personal budgets for individuals that are appropriate to meeting those individuals’ assessed eligible care and support needs. The Care Act 2014 also imposes new statutory duties upon Local Authorities to ensure the supply of diverse, good quality, local services, including a duty to plan for future demand and to ensure that services are high quality and sustainable.

The regulated activities regulations and the registration regulations issued pursuant to the HSCA place legally binding obligations on health and social care providers. Breach of certain provisions of the HSCA or the regulations is a criminal offense. In addition, a breach may lead to the CQC taking action to suspend, cancel or vary the conditions of registration of a service provider or impose a substantial fine.

Inspections by regulators2% increase in the U.K. can be carried out on both an announced and an unannounced basis depending on the specific regulatory provisions relating to the different services provided and also depending upon whether the inspection is routine orour facilities’ Medicare reimbursement rate as a result of specific information regarding the servicetemporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provides for certain federal income and other tax changes. We received a cash benefit of approximately $39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. We repaid half of the $39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter of 2022 to eliminate the liability.

In addition to the financial and other relief that has been provided toby the regulator. Generally, however, a majority of inspections tend to be unannounced. A failure to comply with laws and regulations,federal government through the receipt of a poor inspection report rating or a lower rating, or the receipt of a negative report that leads to a determination of regulatorynon-compliance or a failure to cure any defect noted in an inspection report may result in reputational damage, fines, the revocation or suspension of the registration of any facility or a decrease in, or cessation of, the services provided at any given location.

Corporate Manslaughter and Corporate HomicideCARES Act of 2007. The Corporate Manslaughter and Corporate Homicide Act of 2007 provides liability if the way in which a provider’s activities are managed or organized causes a person’s death and amounts to a gross breach of a relevant duty of care owed to the deceased person.

Regulatory and Enforcement Bodies in the U.K.

The primary healthcare regulatory enforcement bodies in the U.K. are NHS Improvement, the CQC, Healthcare Inspectorate Wales (“HIW”), Care Inspectorate Wales (“CIW”), Healthcare Improvement Scotland (“HIS”), Social Care and Social Work Improvement Scotland (“SCSWIS”) and Regulation and Quality Improvement Authority (“RQIA”). In addition, the Office for Standards in Education, Children’s Services and Skills (“OFSTED”), Estyn, Education Scotland and other regulatory bodies regulatelegislation passed by Congress, CMS and inspect education servicesmany state governments have also issued waivers and temporary suspensions of healthcare facility licensure, certification, and reimbursement requirements in England, Walesorder to provide hospitals, physicians, and Scotland, as applicable. These enforcement bodies control and administer the registration, inspection and complaints procedures set out under the applicable laws and regulations. The enforcement bodies have the power to terminate a facility’s registration, refuse to register a facility, impose admissions holds, or impose significant fines if a service provider failsother healthcare providers with increased flexibility to meet the key minimum standardschallenges presented by the COVID-19 pandemic. For example, CMS and many state governments have temporarily eased regulatory requirements prescribedand burdens for delivering and being reimbursed for healthcare services provided remotely through telemedicine. CMS has also temporarily waived many provisions of the Stark law, including many of the provisions affecting our relationships with physicians. Many states have also suspended the enforcement of certain regulatory requirements to ensure that healthcare providers have sufficient capacity to treat COVID-19 patients. These regulatory changes are temporary, with most slated to expire at the end of the COVID-19 public health emergency, expected in May 2023.  

We are continuing to evaluate the terms and conditions and financial impact of funds received under the various lawsCARES Act and regulations. See “Riskother government relief programs.

Corporate Integrity Agreement

During the second quarter of 2019, we entered into a corporate integrity agreement (the “CIA”) with the OIG imposing certain compliance obligations on us and our subsidiary, CRC Health. For further discussion of the background of this matter and the CIA, see “Item 1A. Risk Factors— IfWe could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.”

Our primary regulators continually review their regulatory regimes and may extend their enforcement powers with the intention of holding parent companies and senior executives accountable for material breaches of regulations depending on the circumstances. Additionally, there are other regulators in the U.K. who may take enforcement action against us, including (i) the Health and Safety Executive (“HSE”) for violationsterms of the Health and Safety at Work Act in connection with patient incidents at our facilities; (ii) the Information Commissioners Office (“ICO”) for breaches of data protection legislation (and following the introduction of the General Data Protection Regulations (the “GDPR”) which come into force in May 2018, fines for material breaches may be as high as 4% of global turnover); and (iii) Her Majesty’s Revenue and Customs (“HMRC”) who in November 2017 established the Social Care Compliance Scheme (the “SCCS”) for social care providers in the U.K. with the aim of addressing the issue of potential underpayments of the National Minimum Wage (“NMW”) to workers who are paid a fixed allowance to undertake“sleep-in shifts” at care homes and other facilities at night. See “—Our operating costs are subject to increases, including due to statutorily mandated increases in the wages and salaries of our staff” for further details on U.K. staffing risks to which we are subject.

NHS Improvement.NHS Improvement now incorporates Monitor, the former economic regulator for the NHS in England. NHS Improvement is responsible for regulating the market for NHS funded services in England. It fulfills this role through licensing NHS Foundation Trusts and certain other healthcare providers and, together with the NHS England, sets the Tariff Rules for national and local pricing of NHS services. NHS Improvement’s role is to oversee the NHS healthcare market, at all times protecting and promoting patients’ interests, tackling abuses by commissioners and/or providers and dealing with unjustifiable restrictions on competition.

The CQC. The CQC is the independent regulator for health and adult social care in England. The CQC is distinct from NHS Improvement in that it focuses on quality and ensuring the maintenance of standards in health and social care practices. The CQC licenses NHS and adult social care service providers to enable it to keep a check on safety and quality standards. The CQC also carries out facility inspections. Care homes for young adults (including specialist college accommodation) are registered and inspected by the CQC. In addition, the CQC is responsible for monitoring the financial viability of corporate providers of social care.

HIWCIA”. HIW is the independent inspectorate and regulator of all health care in Wales. Certain independent healthcare services are required to register with HIW. HIW also inspects NHS and independent healthcare organizations in Wales to ensure compliance with its and the NHS’s standards, policies, guidance and regulations. The HIW Review Service for Mental Health monitors the use of the Mental Health Act 1983 to ensure that it is being used properly on behalf of Welsh Ministers.

CIW. Social care and social services in Wales are regulated by the CIW. CIW carries out unannounced inspections and measure against regulations. Children’s homes in Wales are inspected by CIW.

HIS. HIS is the independent regulator for healthcare services in Scotland. HIS inspects healthcare providers in Scotland to ensure compliance with its standards, policies, guidance and regulations.

SCSWIS. Care services in Scotland are regulated by the Care Inspectorate Scotland (also known as SCSWIS) and all care services in Scotland must be registered with them. As well as registration, SCSWIS inspects services against the National Care Standards and they can take action to force services to improve and can close services if necessary. Independent schools with boarding facilities must register their boarding provision with SCSWIS for the regulation of care as a school care accommodation service.

RQIA. In Northern Ireland, RQIA is Northern Ireland’s independent health and social care regulator. RQIA is responsible for registering, inspecting and encouraging improvement in a range of health and social care services in accordance with the Health and Personal Social Services (Quality, Improvement and Regulation) (Northern Ireland) Order 2003 and its supporting regulations. RQIA inspections are based on certain minimum care standards.

OFSTED. OFSTED was established under the Education (Schools) Act of 1992 and regulates and inspects services in England that care for children and young people, and services providing education and skills for learners of all ages. OFSTED carries out routine day school and further education college inspections to ensure compliance with inspection frameworks.

Estyn. In Wales, Estyn is led by Her Majesty’s Chief Inspector of Education and Training and inspects quality standards in all education provisions in Wales including children’s homes, independent and residential schools and colleges.

Education Scotland. In Scotland, the education provision for independent schools with boarding facilities is regulated by Education Scotland.

Risk Management and Insurance

The healthcare industry in general continues to experience an increase in the frequency and severity of litigation and claims. As is typical in the healthcare industry, we could beare subject to claims that our services have resulted in injury to our patients or clients or other adverse effects. In addition, resident, visitor and employee injuries could also subject us to the risk of litigation. While management believes that quality care is provided to patients and clients in our facilities and that we materiallysubstantially comply with all applicable regulatory requirements, an adverse settlement determination in a legal proceeding or government investigation could have a material adverse effect on our business, financial condition or results of operations.

Our statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. A portion of our professional liability risk isrisks are insured through a wholly-owned insurance subsidiary. Our wholly-owned insurance subsidiary insures usproviding coverage for professional liability losses up to $78.0$10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. We have obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. TheOur reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 millionpolicies in excess of a retention level of $3.0 million.place.

Environmental Matters

We are subject to various federal, state and local environmental laws that: (i) regulate certain activities and operations that may have environmental or health and safety effects, such as the handling, storage, transportation, treatment and disposal of medical waste

11


Table of Contents

products generated at our facilities, the identification and warning of the presence of asbestos-containing materials in buildings, as well as the removal of such materials, the presence of other hazardous substances in the indoor environment and protection of the environment and natural resources in connection with the development or construction of our facilities; (ii) impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on andoff-site, or other releases of hazardous materials or regulated substances; and (iii) regulate workplace safety. Some of our facilities generate infectious or other hazardous medical waste due to the illness or physical condition of our patients. The management of infectious medical waste is subject to regulation under various federal, state and local environmental laws, which establish management requirements for such waste. These requirements include record-keeping, notice and reporting obligations. Each of our facilities has an agreement with a waste management company for the disposal of medical waste. The use of such companies, however, does not completely protect us from violations of medical waste laws or from related third-party claims forclean-up costs.

From time to time, our operations have resulted in, or may result in,non-compliance with, or liability pursuant to, environmental or health and safety laws or regulations. Management believes that our operations are generally in compliance with environmental and health and safety regulatory requirements, including legal requirements relating to climate change, or that anynon-compliance will not result in a material liability or cost to achieve compliance. Historically, the costs of achieving and maintaining compliance with environmental laws and regulations at our facilities have not been material. However, we cannot assure you that future costs and expenses required for us to comply with any new or changes in existing environmental and health and safety laws and regulations or new or discovered environmental conditions will not have a material adverse effect on our business, financial condition or results of operations. In addition, we could be affected by climate change to the extent that climate change results in severe weather conditions or other disruptions impacting the communities in which our facilities are located. For more information regarding climate change and its possible adverse impact on us, see “Item 1A. Risk Factors — Operational Risks — Our business and operations are subject to risks related to natural disasters and climate change”.

We have not been notified of and management is otherwise currently not aware of any contamination at our currently or formerly operated facilities that could result in material liability or cost to us under environmental laws or regulations for the investigation and remediation of such contamination, and we currently are not undertaking any remediation or investigation activities in connection with any such contamination conditions. There may, however, be environmental conditions currently unknown to us relating to our prior, existing or future sites or operations or those of predecessor companies whose liabilities we may have assumed or acquired which could have a material adverse effect on our business.

New laws, regulations or policies or changes in existing laws, regulations or policies or their enforcement, future spills or accidents or the discovery of currently unknown conditions ornon-compliances may give rise to investigation and remediation liabilities, compliance costs, fines and penalties, or liability and claims for alleged personal injury or property damage due to substances or materials used in our operations, any of which may have a material adverse effect on our business, financial condition or results of operations.

Competition

The healthcare industry is highly competitive. Our principal competitors include other behavioral healthcare service companies, including UHS, private equity firms,Universal Health Services, Inc. (NYSE: UHS) and the NHS in the U.K. We also compete againstother hospitals and general healthcare facilities that provide mental health services. An important part of our business strategy is to continue making targeted acquisitions of other behavioral health facilities. However, reduced capacity, the passage of mental health parity legislation and increased demand for mental health services are likely to attract other potential buyers, including diversified healthcare companies, and possibly other pure-play behavioral healthcare companies.

The mental health services sector in the U.K. comprises hospitals or establishments that provide psychiatric treatment for illness or mental disorder at all securitycompanies and treatment levels. We operate in several highly competitive markets in the U.K. with a variety offor-profit, the NHS and othernot-for-profit groups in each of our markets. Most competition is regional or local, based on relevant catchment areas and procurement initiatives. The NHS is often the dominant provider, although the trend has been towards increased outsourcing, whereby the NHS is both a provider and customer of mental healthcare services. NHSin-house beds accounts for approximately 71% of the total mental health hospital beds providing care in the U.K., with independent providers accounting for the remaining approximately 29% of beds.private equity firms.

In addition to the competition we face for acquisitions, we must also compete for patients. Patients are referred to our behavioral healthcare facilities through a number of different sources, including healthcare practitioners, public programs, other treatment facilities, managed care organizations, unions, emergency departments, judicial officials, social workers, police departments and word of mouth from previously treated patients and their families, among others. These referral sources may instead refer patients to hospitals that are able to provide a full suite of medical services or to other behavioral healthcare centers.

Human Capital

Employees

As ofAt December 31, 2017,2022, we had approximately 40,60023,000 employees, (approximately 20,000 in the U.S. and approximately 20,600 in the U.K), of which 27,50017,000 were employed full-time. As ofAt December 31, 2017,2022, labor unions represented approximately 460350 of our U.S. employees at fivetwo of our U.S. facilities through eightfour collective bargaining agreements. Organizing activities by labor unions and certain potential changes in federal labor laws and regulations could increase the likelihood of employee unionization in the future. The Royal College of Nursing is the trade union for full and part-time nurses, nursing cadets and healthcare assistants in the U.K.

Typically, our inpatient facilities are staffed by a chief executive officer, medical director, director of nursing, chief financial officer, clinical director and director of performance improvement. Psychiatrists and other physicians working in our facilities are

12


Table of Contents

licensed medical professionals who are generally not employed by us and work in our facilities as independent contractors or medical staff members.

Diversity and Inclusion

We are committed to maintaining a welcoming and inclusive environment that treats everyone with dignity and respect. Approximately 74% of our employees are women and approximately 48% are people of color. We have policies that strictly prohibit any discrimination on the basis of race, color, national origin, age, religion, disability, gender, marital status, veteran status or any other basis prohibited by federal, state or local law.

We have also established a Diversity and Inclusion Council, a multidisciplinary group, to oversee and advance diversity and inclusion initiatives.

Talent Acquisition, Development and Retention

Our success is dependent on our ability to attract, develop and retain talented, dedicated employees. We are committed to being an employer of choice and offer a compelling total rewards program. In addition to base salaries, we offer our employees a full spectrum of benefits, including medical, dental, vision and disability plans, health savings and flexible spending accounts, a 401(k) retirement savings plan that includes a matching contribution, paid time off and employee assistance programs. We also conduct comprehensive employee satisfaction surveys to assess and ensure that we are responsive to the desires and concerns of our employees.

Like most healthcare providers, our facilities have experienced rising labor costs and turnover, and we have resorted to using more expensive contract labor at certain of our facilities. In some markets, the availability and retention of qualified medical personnel have become significant operating issues to healthcare providers, including at certain of our facilities. Shortages of nurses, qualified addiction counselors and other medical and care support personnel could result in a number of adverse impacts to our business, including capacity and growth constraints, reduced patient satisfaction, reduced employee satisfaction, impact on services offered, and increased costs, among others. For more information regarding risks of rising labor costs and its possible adverse impact on us, see “Item 1A. Risk Factors — Human Capital Risks — Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability”.

Health and Safety

We are committed to providing care to our patients in a safe, therapeutic environment. In furtherance of this commitment, we provide our employees with access to a variety of workplace safety training programs and continually evaluate our policies promoting patient safety and employee wellbeing. In response to the COVID-19 pandemic, we implemented numerous changes to our policies and procedures to ensure the health of our patients, employees, contractors and communities, including instituting social distancing practices and protective measures throughout our facilities, which included restricting or suspending visitor access, screening patients and staff who enter our facilities based on criteria established by the CDC and local health officials, and testing and isolating patients when warranted.

Seasonality of Demand for Services

Our residential recovery and other inpatient facilities typically experience lower patient volumes and revenue during the holidays, and our child and adolescent facilities typically experience lower patient volumes and revenue during the summer months, holidays and other periods when school is out of session.

Available Information

Our Internet website address is www.acadiahealthcare.com. We make available our annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form8-K and all amendments to those reports free of charge on our website on the Investors webpage under the caption “SEC Filings” as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (the “SEC”). The public may read and copy materials filed with the SEC at the Public Reference Room of the SEC at 100 F Street, NE, Washington, D. C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at1-800-732-0330.SEC. The SEC maintains a websitean internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file or furnish information electronically with the SEC at www.sec.gov.we file. Our website and the information contained therein or linked thereto are not intended to be incorporated into this Annual Report on Form10-K.

13


Table of Contents

Item 1A. Risk Factors

Risk Factors Summary

We are subject to a variety of risks and uncertainties, including financial risks, operational risks, human capital risks, legal proceedings and regulatory risks and certain general risks, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. Risks that we deem material are described under “Risk Factors” below and include, but are not limited to, the following:

Financial Risks

Our revenue and results of operations are significantly affected by payments received from the government and third-party payors.

Our debt could adversely affect our financial health and prevent us from fulfilling our obligations under our financing arrangements.

Servicing our debt will require a significant amount of cash. Our ability to generate sufficient cash to service our debt depends on many factors beyond our control.

We are subject to a number of restrictive covenants, which may restrict our business and financing activities.

Despite our current debt level, we may incur significant additional amounts of debt, which could further exacerbate the risks associated with our debt.

If we default on our obligations to pay our debt, we may not be able to make payments on our financing arrangements.

We are subject to volatility in the global capital and credit markets as well as significant developments in macroeconomic and political conditions that are out of our control.

Increases in inflation and rising interest rates may adversely impact our business, financial condition and results of operations.

The industry trend on value-based purchasing may negatively impact our revenue.

The COVID-19 global pandemic continues to impact our operations, business and financial condition, and our liquidity could be negatively impacted, particularly if the U.S. economy remains unstable for a significant amount of time or if patient volumes decline at our facilities.

An increase in uninsured or underinsured patients or the deterioration in the collectability of patient accounts receivables could harm our results of operation.

Operational Risks

An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock.

Our business growth and acquisition strategies expose us to a variety of operational and financial risks.

Joint ventures may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.

We care for a large number of vulnerable individuals with complex needs and any care quality deficiencies could adversely impact our brand, reputation and ability to market our services effectively.

Our business could be disrupted if our information systems fail or if our databases are destroyed or damaged.

A disruption to our information technology systems or a cyber security incident could have a material adverse impact on the Company, including substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to reputational harm and increased costs.

Although we have facilities in 39 states and Puerto Rico, we have substantial operations in Pennsylvania, California, Arizona and Tennessee, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those locations.

Our business and operations are subject to risks related to natural disasters and climate change.

14


Table of Contents

If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected.

We operate in a highly competitive industry, and competition may lead to declines in patient volumes.

Human Capital Risks

Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability.

Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians.

Legal Proceedings and Regulatory Risks

We are and in the future could become the subject of additional governmental investigations, regulatory actions and whistleblower lawsuits.

We could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if we fail to comply with the terms of the CIA.

We are and in the future may become involved in legal proceedings based on negligence or breach of a contractual or statutory duty from service users or their family members or from employees or former employees.

If we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.

We could face risks associated with, or arising out of, environmental, health and safety laws and regulations.

General Risk Factors

Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock.

Future sales of common stock by our existing stockholders may cause our stock price to fall.

If securities or industry analysts do not publish research or reports about our business, if they were to change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.

We incur substantial costs as a result of being a public company.

Risk Factors

Any of the following risks could materially and adversely affect our business, financial condition or results of operations. These risks should be carefully considered before making an investment decision regarding us. The risks and uncertainties described below are not the only ones we face and there may be additional risks that we are not presently aware of or that we currently consider not likely to have a significant impact. If any of the following risks actually occurred,occur, our business, financial condition and operating results could suffer, and the trading price of our common stock could decline.

Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock.Financial Risks

The stock markets experience volatility, in some cases unrelated to operating performance. These broad market fluctuations may adversely affect the trading price of our common stock and, as a result, there may be significant volatility in the market price of our common stock. If we are unable to operate our facilities as profitably as we have in the past or as our investors expect us to in the future, the market price of our common stock will likely decline when it becomes apparent that the market expectations may not be realized. In addition to our operating results, many economic and seasonal factors outside of our control could have an adverse effect on the price of our common stock and increase fluctuations in our quarterly earnings. These factors include certain of the risks discussed herein, demographic changes, operating results of other healthcare companies, changes in our financial estimates or recommendations of securities analysts, speculation in the press or investment community, the possible effects of war, terrorist and other hostilities, adverse weather conditions, the level of seasonal illnesses, managed care contract negotiations and terminations, changes in general conditions in the economy or the financial markets or other developments affecting the healthcare industry.

An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock.

Because the patients we treat suffer from severe mental health and chemical dependency disorders, patient incidents, including deaths, assaults and elopements, occur from time to time. If one or more of our facilities experiences an adverse patient incident or is found to have failed to provide appropriate patient care, an admissions hold, loss of accreditation, license revocation or other adverse regulatory action could be taken against us. Any such patient incident or adverse regulatory action could result in governmental investigations, judgments or fines and have a material adverse effect on our business, financial condition and results of operations. In addition, we have been and could become the subject of negative publicity or unfavorable media attention, whether warranted or unwarranted, that could have a significant, adverse effect on the trading price of our common stock or adversely impact our reputation and how our referral sources and payors view us.

We have been and could become the subject of governmental investigations, regulatory actions and whistleblower lawsuits.

Healthcare companies in both the U.S. and the U.K. are subject to numerous investigations by various governmental agencies. Certain of our facilities have received, and other facilities may receive, government inquiries from, and may be subject to investigation by, governmental agencies. If we incur significant costs responding to or resolving these or future inquiries or investigations, our business, financial condition and results of operations could be adversely affected.

Further, under the False Claims Act, private parties are permitted to bring qui tam or “whistleblower” lawsuits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Because qui tam lawsuits are filed under seal, we could be named in one or more such lawsuits of which we are not aware. We may also be subject to substantial reputational harm as a result of the public announcement of any investigation into such claims.

Our revenue and results of operations are significantly affected by payments received from the government and third-party payors.

A significant portion of our revenue is derived from government healthcare programs. For the year ended December 31, 2017,2022, we derived approximately 38%66% of our continuing operations revenue from the Medicare and Medicaid programs and 32% of our revenue from public funded sources in the U.K. (including the NHS, CCGs and Local Authorities). See “— Structural shifts in the U.K. behavioral healthcare market may adversely affect us” for further details on U.K. funding risks to which we are subject.programs.

Government payors in the U.S., such as Medicaid, generally reimburse us on afee-for-service basis based on predetermined reimbursement rate schedules. As a result, we are limited in the amount we can record as revenue for our services from these government programs, and if we have a cost increase, we typically will not be able to recover this increase. In addition, the federal government and many state governments, are operating under significant budgetary pressures, and they may seek to reduce payments under their Medicaid programs for services such as those we provide. Government payors also tend to pay on a slower schedule. In addition to limiting the amounts they will pay for the services we provide their members, government payors may, among other things, impose prior authorization and concurrent utilization review programs that may further limit the services for which they will pay and shift patients to lower levels of care and reimbursement. Therefore, if governmental entities reduce the amounts they will pay

15


Table of Contents

for our services, or if they elect not to continue paying for such services altogether, or if there is a total or partial repeal of PPACA results in significant contraction of the number of individuals covered by state Medicaid programs, our business, financial condition or results of operations could be adversely affected. In addition, if governmental entities slow their payment cycles further, our cash flow from operations could be negatively affected.

Commercial payors such as managed care organizations, private health insurance programs and labor unions generally reimburse us for the services rendered to insured patients based upon contractually determined rates. These commercial payors are under significant pressure to control healthcare costs. In addition to limiting the amounts they will pay for the services we provide their members, commercial payors may, among other things, impose prior authorization and concurrent utilization review programs that may further limit the services for which they will pay and shift patients to lower levels of care and reimbursement. These actions may reduce the amount of revenue we derive from commercial payors.

Changes in these government programs in recent years have resulted in limitations on reimbursement and, in some cases, reduced levels of reimbursement for healthcare services. Payments from federal and state government healthcare programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions, all of which could materially increase or decrease program payments, as well as affect the cost of providing service to patients and the timing of payments to facilities. We are unable to predict the effect of recent and future policy changes on our operations. In addition, since most states operate with balanced budgets and since the Medicaid program is often a state’s largest program, some states can be expected to enact or consider enacting legislation formulated to reduce their Medicaid expenditures. Furthermore, the potential repeal, replacement or modification of PPACA, may negatively affect the availability of taxpayer funds for Medicare and Medicaid programs. If the rates paid or the scope of services covered by government payors are reduced, there could be a material adverse effect on our business, financial condition and results of operations.

In addition to changes in government reimbursement programs, our ability to negotiate favorable contracts with private payors, including managed care providers, significantly affects the financial condition and operating results of our facilitiesfacilities. Further, we may not be able to negotiate or sustain rate increases we have experienced in the U.S.recent years, and may not be able to achieve consistent rate increases from year to year. Management expects third-party payors to aggressively manage reimbursement levels and cost controls. Reductions in reimbursement amounts received from third-party payors could have a material adverse effect on our business, financial condition and results of operations.

Our healthcare facilities are also subject to federal, state and commercial payor audits to validate the accuracy of claims submitted to government healthcare programs and commercial payors. If these audits identify overpayments, we could be required to make substantial repayments, subject to various appeal rights. Our facilities are routinely subjected to claims audits in the ordinary course of business. While no such audit has identified any material overpayment liability, should a potential material overpayment liability arise from a future audit, such overpayment liability may ultimately exceed established reserves, and any excess could potentially be substantial. Further, Medicare and Medicaid regulations, as well as commercial payor contracts, also provide for withholding or suspending payments in certain circumstances, which could adversely affect our cash flow.

Our substantial debt could adversely affect our financial health and prevent us from fulfilling our obligations under our financing arrangements.

As ofAt December 31, 2017,2022, we had approximately $3.2$1.4 billion of total debt (net of debt issuance costs, discounts and premiums of $50.4$12.6 million), which included approximately $1.8 billion of debt under our Amended and Restated Senior Credit Facility (including approximately $380.0 million of Senior Secured Term A Loans and approximately $1.4 billion of Senior Secured Term B Loans), $150.0$473.4 million of debt under our 6.125% Senior Notes (the “6.125% Senior Notes”), $300.0the New Credit Facility, $450.0 million of debt under our 5.125%the 5.500% Senior Notes (the “5.125% Senior Notes”), $650.0and $475.0 million of debt under our 5.625%the 5.000% Senior Notes, $390.0 million of debt under our 6.500% Senior Notes and $21.9 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (the “9.0% and 9.5% Revenue Bonds”).Notes. See “Item 1. Business—Financing Transactions” for additional details regarding our outstanding indebtedness.

Our substantial debt could have important consequences to our business. For example, it could:

increase our vulnerability to general adverse economic and industry conditions;

make it more difficult for us to satisfy our other financial obligations;

restrict us from making strategic acquisitions or cause us to make non-strategic divestitures;

require us to dedicate a substantial portion of our cash flow from operations to payments on our debt (including scheduled repayments on our outstanding term loan borrowings under the New Credit Facility), thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;

expose us to interest rate fluctuations because the interest on the New Credit Facility is imposed at variable rates;

make it more difficult for us to satisfy our obligations to our lenders, resulting in possible defaults on and acceleration of such debt;

16


Table of Contents

 

increase our vulnerability to general adverse economic and industry conditions;

limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;

make it more difficult for us to satisfy our other financial obligations;

place us at a competitive disadvantage compared to our competitors that have less debt;

restrict us from making strategic acquisitions or cause us to makenon-strategic divestitures;

limit our ability to borrow additional funds; and

require us to dedicate a substantial portion of our cash flow from operations to payments on our debt (including scheduled repayments on our outstanding term loan borrowings under the Amended and Restated Senior Credit Facility), thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;

expose us to interest rate fluctuations because the interest on the Amended and Restated Senior Credit Facility is imposed at variable rates;

make it more difficult for us to satisfy our obligations to our lenders, resulting in possible defaults on and acceleration of such debt;

limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;

place us at a competitive disadvantage compared to our competitors that have less debt;

limit our ability to borrow additional funds; and

limit our ability to pay dividends, redeem stock or make other distributions.

In addition, the terms of our financing arrangements contain restrictive covenants that limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default which, if not cured or waived, could result in the acceleration of all of our debts, including the Amended and Restated SeniorNew Credit Facility and the Senior Notes.

Servicing our debt will require a significant amount of cash. Our ability to generate sufficient cash to service our debt depends on many factors beyond our control.

Our ability to make payments on and to refinance our debt, to fund planned capital expenditures and to maintain sufficient working capital will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control.

We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available to us under the Amended and Restated SeniorNew Credit Facility or from other sources in an amount sufficient to enable us to service our debt or to fund our other liquidity needs. If our cash flow and capital resources are insufficient to allow us to make scheduled payments on our debt, we may need to reduce or delay capital expenditures, sell assets, seek additional capital or restructure or refinance all or a portion of our debt on or before the maturity thereof, any of which could have a material adverse effect on our business, financial condition or results of operations. We cannot assure you that we will be able to refinance any of our debt on commercially reasonable terms or at all, or that the terms of that debt will allow any of the above alternative measures or that these measures would satisfy our scheduled debt service obligations. If we are unable to generate sufficient cash flow to repay or refinance our debt on favorable terms, it could significantly adversely affect our financial condition and the value of our outstanding debt. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations.

We are subject to a number of restrictive covenants, which may restrict our business and financing activities.

Our financing arrangements impose, and the terms of any future debt may impose, operating and other restrictions on us. Such restrictions affect, and in many respects limit or prohibit, among other things, our and our subsidiaries’subsidiaries�� ability to:

incur or guarantee additional debt and issue certain preferred stock;

pay dividends on our common stock or redeem, repurchase or retire our equity interests or subordinated debt;

transfer or sell our assets;

make certain payments or investments;

make capital expenditures;

create certain liens on assets;

create restrictions on the ability of our subsidiaries to pay dividends or make other payments to us;

engage in certain transactions with our affiliates; and

merge or consolidate with other companies.

The Amended and Restated SeniorNew Credit Facility also requires us to meet certain financial ratios, including a fixed charge coverage ratio and a consolidated leverage ratio. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources —Amended and Restated Senior—New Credit Facility”.

The restrictions may prevent us from taking actions that management believes would be in the best interests of our business, and may make it difficult for us to successfully execute our business strategy or effectively compete with companies that are not similarly restricted. We also may incur future debt obligations that might subject us to additional restrictive covenants that could affect our financial and operational flexibility. Our ability to comply with these covenants in future periods will largely depend on the pricing of

17


Table of Contents

our products and services, our success at implementing cost reduction initiatives and our ability to successfully implement our overall business strategy. We cannot assure you that we will be granted waivers or amendments to our financing arrangements if for any reason we are unable to comply with our financial covenants. The breach of any of these covenants and restrictions could result in a default under the indentures governing the Senior Notes or under the Amended and Restated SeniorNew Credit Facility, which could result in an acceleration of our debt.

Despite our current debt level, we may incur significant additional amounts of debt, which could further exacerbate the risks associated with our substantial debt.

We may incur substantial additional debt, including additional notes and other debt, in the future. Although the indentures governing our outstanding Senior Notes and our Amended and Restated Seniorthe New Credit Facility contain restrictions on the incurrence of additional debt, these restrictions are subject to a number of significant qualifications and exceptions, and under certain circumstances, the amount of debt that could be incurred in compliance with these restrictions could be substantial. If new debt is added to our existing debt levels, the related risks that we now face would intensify and we may not be able to meet all our debt obligations.

If we default on our obligations to pay our debt, we may not be able to make payments on our financing arrangements.

Any default under the agreements governing our debt, including a default under the Amended and Restated SeniorNew Credit Facility or the indentures governing our Senior Notes, and the remedies sought by the holders of such debt, could adversely affect our ability to pay the principal, premium, if any, and interest on the Senior Notes and substantially decrease the market value of the Senior Notes. If we are unable to generate sufficient cash flows and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our debt, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our debt (including the Amended and Restated SeniorNew Credit Facility and the indentures governing the Senior Notes), we would be in default under the terms of the agreements governing such debt. In the event of such default, the holders of such debt could elect to declare all the funds borrowed thereunder to be due and payable, the lenders under the Amended and Restated SeniorNew Credit Facility could elect to terminate their commitments or cease making further loans and institute foreclosure proceedings against our assets, or we could be forced to apply all available cash flows to repay such debt, and, in any such case, we could ultimately be forced into bankruptcy or liquidation. Because the indentures governing the Senior Notes and the agreement governing the Amended and Restated SeniorNew Credit Facility have customary cross-default provisions, if the debt under the Senior Notes or the Amended and Restated SeniorNew Credit Facility is accelerated, we may be unable to repay or refinance the amounts due.

Expanding our international operations poses additional risks to our business.

Our business or financial performanceWe may be adversely affected duerequired to record additional charges to future earnings if our goodwill, intangible assets and property and equipment become impaired.

We are required under U.S. generally accepted accounting principles (“GAAP”) to review annually, or more frequently if events indicate the riskscarrying value of operating internationally, including buta reporting unit may not limited to the following: economicbe recoverable, our goodwill and political instability, failure to comply with foreign laws and regulations and adverse changes in the health care policy of the U.K. (including decreases in fundingindefinite-lived intangible assets for impairment. Although there were no impairment charges recorded for the services provided by our U.K. facilities), adverse changes2022 annual impairment review, we may be required to record charges to earnings during any period in law and regulations affecting our operations in the U.K., difficulties and costs of staffing and managing our operations in the U.K. If any of these events were to materialize, they could lead to disruptionwhich an impairment of our business, significant expenditures and/or damages to our reputation, which could have a material adverse effect on our results of operations, financial condition or prospects.

As a company based outside of the U.K., we need to take certain actions to be more easily accepted in the U.K. For example, we may need to engage in a public relations campaign to emphasize service qualitygoodwill, intangible assets and company philosophy, preserve local management continuityproperty and business practices and be transparent in our dealings with local governments and taxing authorities. Such efforts require significant time and effort on the part of our management team. Our results of operation could suffer if these efforts are not successful.

With significant operations in the U.K., our business and operations may be adversely affected by economic and political conditions in the U.K.

The global financial markets continue to experience significant volatility as a result of, among other things, economic and political instability in the wake of the referendum in the U.K. on June 23, 2016, in which the voters approved an exit from the European Union, or Brexit. Following the vote on Brexit, stock markets worldwide experienced significant declines and certain currency exchange rates fluctuated substantially, and the outlook for the global economy in 2018 and beyond remains uncertain as negotiations commence to determine the future terms of the U.K.’s relationship with the European Union. Such global market instability may hinder future economic growth,equipment is determined which could adversely affect our assets, business, cash flow, condition (financial or otherwise), liquidity, prospects and results of operations.

Our facilities face competitionevaluation of goodwill and the need for staffing that may increaseany further impairment in subsequent periods is sensitive to revisions to our labor costscurrent projections. See “Item 7. Management’s Discussion and reduce our profitability.Analysis of Financial Condition and Results of Operations— Critical Accounting Policies — Property and Equipment and other Long-Lived Assets” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies — Goodwill and Indefinite-Lived Intangible Assets” for additional information.

Our operations depend on the efforts, abilities, and experience of our management and medical support personnel, including our addiction counselors, therapists, nurses, pharmacists, licensed counselors, clinical technicians, and mental health technicians, as well as our psychiatrists and other professionals. We compete with other healthcare providers in recruiting and retaining qualified management, program directors, physicians (including psychiatrists) and support personnel responsible for the daily operations of our business, financial condition or results of operations.

With respect to our facilities in the U.K., we compete with various providers, including the NHS, staffing agencies and other employers, in attracting and retaining qualified management, medical, nursing, care and teaching personnel. Competition for such employees is growing and could leadoperating costs are subject to increases in the wages and salaries of our personnel and recruiting costs, which would in turn adversely impact our operating costs and margins. Competitors, in particular the NHS, may offer more attractive wages, pension plans or other benefits than us and we may not be able to provide similar offerings to our prospective employees as a result of cost or other reasons.staff.

A shortage of nurses, qualified addiction counselors, and other medical support personnel has been aThe most significant operating issue facing us and other healthcare providers, particularlyexpense for our facilities is wage costs, which represent the staff costs incurred in providing our services and running our facilities, and which are primarily driven by the U.K. Such shortages may requirenumber of employees and pay rates. The number of employees employed by us is primarily linked to enhance wagesthe number of facilities we operate and benefitsthe number of individuals cared for by us. While we can reduce the number of employees should occupancy rates decrease at our facilities, there is a limit on the extent to recruit and retain nurses, qualified addiction counselors, and other medical support personnel or require us to hire more expensive temporary or contract personnel. The use of temporary or contract personnel could also heighten the risk onewhich this can be done without impacting quality of our facilities experiences an adverse patient incident. Further, because we generally recruit our personnel from the local area where the relevant facility is located, the availability in certain areasservices.

We also have a number of suitably qualified personnelrecurring costs including insurance, utilities and rental costs, and may face increases to other recurring costs such as regulatory compliance costs. There can be limited, particularly care home management, qualified teaching personnel and nurses. In addition, certainno assurance that any of our facilities are required to maintain specified staffing levels. To the extent we cannot meet those levels, we may be required to limit the services provided by these facilities, which would haverecurring costs will not grow at a corresponding adverse effect onfaster rate than our netrevenue. As a result, any increase in our operating revenue. Certain of our treatment facilities are located in remote geographical areas, far from population centers, which increases this risk.

We cannot predict the degree to which we will be affected by the future availability or cost of attracting and retaining talented medical support staff. If our general labor and related expenses increase, we may not be able to raise our rates correspondingly. Our failure either to recruit and retain qualified management, psychiatrists, therapists, counselors, nurses and other medical support personnel or control our labor costs could have a material adverse effect on our business, results of operations and financial condition.

18


Table of Contents

We are subject to volatility in the global capital and credit markets as well as significant developments in macroeconomic and political conditions that are out of our control.

Our business can be affected by a number of factors that are beyond our control, such as general macroeconomic conditions, conditions in the financial services markets, geopolitical conditions and other general political and economic developments. In particular, we have historically financed acquisitions, the development of de novo and joint venture facilities and the modification of our existing facilities through a variety of sources, including our own cash reserves and debt financing. While we intend to seek to finance acquisitions and new and existing developments from similar sources in the future, there may be insufficient cash reserves to fund the budgeted capital expenditure and market conditions and other factors may prevent us from obtaining debt financing on appropriate terms or at all. In addition, market conditions may limit the number of financial institutions that are willing to provide financing to landlords with whom we wish to contract to build new healthcare facilities which can then be made available to us under a long-term operating lease. If conditions in the global economy remain uncertain or weaken further, this could materially adversely impact our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.

A worsening of the economic and employment conditions in the geographies in which we operate could materially affect our business and future results of operations.

During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at the federal, state and local levels have decreased, and may continue to decrease, spending for health and human service programs, including Medicare and Medicaid, which are significant payor sources for our facilities. In periods of high unemployment, we also face the risk of potential declines in the population covered under private insurance, patient decisions to postpone or decide against receiving behavioral healthcare services, potential increases in the uninsured and underinsured populations we serve and further difficulties in collecting patient co-payment and deductible receivables.

A sizable portion of our revenue from certain residential recovery, eating disorder facilities, CTCs and youth programs is from self-payors. Accordingly, a sustained downturn in the U.S. economy could restrain the ability of our patients and the families of our students to pay for services.

Furthermore, the availability of liquidity and capital resources to fund the continuation and expansion of many business operations worldwide has been limited in recent years. Our ability to access the capital markets on acceptable terms may be severely restricted at a time when we would like, or need, access to those markets, which could have a negative impact on our growth plans, our flexibility to react to changing economic and business conditions and our ability to refinance existing debt (including debt under the New Credit Facility and the Senior Notes). A sustained economic downturn or other economic conditions could also adversely affect the counterparties to our agreements, including the lenders under the New Credit Facility, causing them to fail to meet their obligations to us.

Increases in inflation and rising interest rates may adversely impact our business, financial condition and results of operations.

Inflation in the U.S. has recently accelerated and is currently expected to continue at an elevated level in the near-term. Current and future inflationary effects may be driven by, among other things, supply chain disruptions and governmental stimulus or fiscal policies, and geopolitical instability, including the ongoing conflict between the Ukraine and Russia. Continuing increases in inflation, have in the past, and could in the future, impact our costs of labor and services and the margins we are able to realize on the operation of our facilities and services, all of which could have an adverse impact on our business, financial position, results of operations and cash flows. Inflation has also resulted in higher interest rates, which in turn will result in higher costs of debt borrowing and could limit our growth strategy.

The industry trend on value-based purchasing may negatively impact our revenue.

There is a trend in the healthcare industry toward value-based purchasing of healthcare services, rather than per diem charges. These value-based purchasing programs include both public reporting of quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for care related to certain preventable adverse events. Many large commercial payors currently require hospitals to report quality data, and several commercial payors do not reimburse hospitals for certain preventable adverse events.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. We are unable at this time to predict how this trend will affect our results of operations, but it could negatively impact our revenue if we are unable to meet quality standards established by both governmental and private payers.

19


Table of Contents

The trend by insurance companies and managed care organizations to enter into sole-source contracts may limit our ability to obtain patients.

Insurance companies and managed care organizations are entering into sole-source contracts with healthcare providers, which could limit our ability to obtain patients since we do not offer the range of services required for these contracts. Moreover, private insurers, managed care organizations and, to a lesser extent, Medicaid and Medicare, are beginning to carve-out specific services, including mental health and substance abuse services, and establish small, specialized networks of providers for such services at fixed reimbursement rates. Continued growth in the use of carve-out arrangements could materially adversely affect our business to the extent we are not selected to participate in such networks or if the reimbursement rate in such networks is not adequate to cover the cost of providing the service.

The COVID-19 global pandemic continues to impact our operations, business and financial condition, and our liquidity could be negatively impacted, particularly if the U.S. economy remains unstable for a significant amount of time or if patient volumes decline at our facilities.

The global pandemic of COVID-19 is affecting our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. economy and financial markets. During 2020, 2021 and 2022 COVID-19 resulted in fewer referrals to our facilities and lower voluntary admissions as individuals were less inclined to leave their homes and seek treatment. When employees and/or patients at a facility are infected with COVID-19, there is a risk that the virus will spread to others at the facility and impact the operations of such facility. COVID-19 is continuing to evolve and its full impact remains unknown and difficult to predict; however, it has adversely affected our business operations in 2020, 2021 and 2022 and could negatively impact our financial performance for 2023 or longer.

We could experience supply chain disruptions and significant price increases in equipment, pharmaceuticals and medical supplies, which could cause delays in our ability to develop a de novo or joint venture facility or modify an existing facility. Pandemic-related staffing difficulties and equipment, pharmaceutical and medical supplies shortages may impact our ability to treat patients at our facilities. Such shortages could lead to us paying higher prices for supplies, equipment and labor and an increase in overtime hours paid to our employees.

The steps we have taken to mitigate the financial impact of COVID-19, see “Item 1. Business — COVID-19 Impact,” may not be successful, and we could experience material decreases in Adjusted EBITDA in 2023 or longer. In addition, we may need to take further steps to mitigate the financial impact of COVID-19, which actions could adversely affect our financial condition and results of operations.

Broad economic factors resulting from COVID-19, including reduced consumer spending, could also negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Business closings and layoffs in the areas in which we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services as rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions continue to deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be adversely affected.

In addition, our results and financial condition may be further adversely affected by future federal or state laws, regulations, orders, or other governmental or regulatory actions addressing the current COVID-19 pandemic or the U.S. healthcare system, which, if adopted, could result in direct or indirect restrictions to our business. We may also be subject to negative press and/or lawsuits from patients, employees and others exposed to COVID-19 at our facilities. Such actions may involve large demands, as well as substantial costs to resolve. Our professional and general liability insurance may not cover all claims against us.

The foregoing and other continued disruptions to our business as a result of the COVID-19 pandemic have impacted our business and may have a material adverse effect on our business, results of operations, financial condition, cash flows and our ability to service our indebtedness. Additionally, the COVID-19 pandemic (including governmental responses, broad economic impacts and market disruptions) has heightened the materiality of certain other risk factors described herein.

An increase in uninsured or underinsured patients or the deterioration in the collectability of patient accounts receivables could harm our results of operation.

Collection of receivables from third-party payors and patients is critical to our operating performance. Our primary collection risks relate to uninsured patients and the portion of the bill that is the patient’s responsibility, which primarily includes co-payments and deductibles. We determine the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical

20


Table of Contents

collection experience. At December 31, 2022, our estimated implicit price concessions represented approximately 15% of our accounts receivable balance as of such date.

Significant changes in business office operations, payor mix, economic conditions or trends in federal and state governmental health coverage could affect our collection of accounts receivable, cash flow and results of operations. If we experience unexpected increases in the growth of uninsured and underinsured patients or in bad debt expenses, our results of operations will be harmed.

Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), could have a material adverse effect on our business.

We are required to maintain internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act. If we are unable to maintain adequate internal control over financial reporting, we may be unable to report our financial information on a timely basis, may suffer adverse regulatory consequences or violations of NASDAQ listing rules and may breach the covenants under our financing arrangements. There could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements. If we or our independent registered public accounting firm identify any material weakness in our internal control over financial reporting in the future (including any material weakness in the controls of businesses we have acquired), their correction could require additional remedial measures which could be costly, time-consuming and could have a material adverse effect on our business.

We do not anticipate paying any cash dividends in the foreseeable future.

We intend to retain our future earnings, if any, for use in our business or for other corporate purposes and do not anticipate that cash dividends with respect to common stock will be paid in the foreseeable future. Any decision as to the future payment of dividends will depend on our results of operations, financial position and such other factors as our board of directors, in its discretion, deems relevant. In addition, the terms of our debt substantially limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain for the foreseeable future.

Operational Risks

An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock.

Because many of the patients we treat suffer from severe mental health and chemical dependency disorders, patient incidents, including deaths, sexual abuse, assaults and elopements, occur from time to time. If one or more of our facilities experiences an adverse patient incident or is found to have failed to provide appropriate patient care, an admissions hold, loss of accreditation, license revocation or other adverse regulatory action could be taken against us. Any such patient incident or adverse regulatory action could result in governmental investigations, judgments or fines and have a material adverse effect on our business, financial condition and results of operations. In addition, we have been and could become the subject of negative publicity or unfavorable media attention, whether warranted or unwarranted, that could have a significant, adverse effect on the trading price of our common stock or adversely impact our reputation and how our referral sources and payors view us.

Our business growth and acquisition strategy exposesstrategies expose us to a variety of operational and financial risks.

A principal element of our business strategy is to grow by acquiring other companies and assets in the behavioral healthcare industry. Growth especially rapid growth, through acquisitions exposes us to a variety of operational and financial risks. We summarize the most significant of these risks below.

Integration risks

We must integrate our acquisitions with our existing operations. This process includes the integration of the various components of our business and of the businesses we have acquired or may acquire in the future, including the following:

additional psychiatrists, other physicians and employees who are not familiar with our operations;

patients who may elect to switch to another behavioral healthcare provider;

regulatory compliance programs; and

disparate operating, information and record keeping systems and technology platforms.

21


Table of Contents

 

additional psychiatrists, other physicians and employees who are not familiar with our operations;

 

patients who may elect to switch to another behavioral healthcare provider;

regulatory compliance programs; and

disparate operating, information and record keeping systems and technology platforms.

Integrating a newnewly acquired facility could be expensive and time consuming and could disrupt our ongoing business, negatively affect cash flow and distract management and other key personnel fromday-to-day operations.

We may not be able to successfully combine the operations of acquired facilities with our operations, and even if such integration is accomplished, we may never realize the potential benefits of the acquisition. The integration of acquisitions with our operations requires significant attention from management, may impose substantial demands on our operations or other projects and may impose challenges on the combined business including, but not limited to, consistencies in business standards, procedures, policies, business cultures and internal controls and compliance. Certain acquisitions involve a capital outlay, and the return that we achieve on any capital invested may be less than the return that we would achieve on our other projects or investments. If we fail to complete the integration of acquired facilities, we may never fully realize the potential benefits of the related acquisitions.

Successful integration depends on the ability to effect any required changes in operations or personnel, which may entail unforeseen liabilities. The integration of acquired businesses may expose us to certain risks, including the following: difficulty in integrating these businesses in a cost-effective manner, including the establishment of effective management information and financial control systems; unforeseen legal, regulatory, contractual, employment or other issues arising out of the combination; combining corporate cultures; maintaining employee morale and retaining key employees; potential disruptions to ouron-going business caused by our senior management’s focus on integrating these businesses; and performance of the combined assets not meeting our expectations or plans. A failure to properly integrate these businesses could have a corresponding material adverse effect on our business, results of operations, financial condition or prospects.

Benefits may not materialize

When evaluating potential acquisition targets, we identify potential synergies and cost savings that we expect to realize upon the successful completion of the acquisition and the integration of the related operations. We may, however, be unable to achieve or may otherwise never realize the expected benefits. Our ability to realize the expected benefits from potential cost savings and revenue improvement opportunities is subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control, such as changes to government regulation governing or otherwise impacting the behavioral healthcare industry, reductions in reimbursement rates from third-party payors, reductions in service levels under our contracts, operating difficulties, client preferences, changes in competition and general economic or industry conditions. If we are unsuccessful in implementing these improvements or if we do not achieve our expected results, it may adversely impact our business, financial condition or results of operations.

Assumptions of unknown liabilities

Facilities that we acquire may have unknown or contingent liabilities, including, but not limited to, liabilities for uncertain tax positions, liabilities for failure to comply with healthcare laws and regulations and liabilities for unresolved litigation or regulatory reviews. Although we typically attempt to exclude significant liabilities from our acquisition transactions and seek indemnification from the sellers of such facilities, the purchase agreement with Priory containedfor some of our significant acquisitions contain minimal representations and warranties about the entities and business that we acquired. In addition, we have no indemnification rights against the sellers under the Priorysome purchase agreementagreements and all of the purchase price consideration was paid at closing of the Priory acquisition.closing. Therefore, we may incur material liabilities for the past activities of acquired entities and facilities. Even in those acquisitions in which we have such rights, we may experience difficulty enforcing the sellers’ obligations, or we may incur material liabilities for the past activities of acquired facilities. Such liabilities and related legal or other costs and/or resulting damage to a facility’s reputation could negatively impact our business, financial condition or results of operations.

Competing for acquisitions

We face competition for acquisition candidates primarily from otherfor-profit healthcare companies, as well as fromnot-for-profit entities. Some of our competitors may have greater resources than we do. As a result, we may pay more to acquire a target business or may agree to less favorable deal terms than we would have otherwise. Our principal competitors for acquisitions have included Universal Health ServicesUHS and private equity firms. Also, suitable acquisitions may not be accomplished due to unfavorable terms. Further, the cost of an acquisition could result in a dilutive effect on our results of operations, depending on various factors, including the amount paid for an acquired facility, the acquired facility’s results of operations, the fair value of assets acquired and liabilities assumed, effects of subsequent legislation and limits on rate increases. In addition, we may have to pay cash, incur debt, or issue equity securities to pay for any such acquisition, which could adversely affect our financial results, result in dilution to our stockholders, result in increased fixed obligations or impede our ability to manage our operations. There can be no assurances that we will be able to acquire facilities at historical or expected rates or on favorable terms.

22


Table of Contents

Antitrust and other legal challenges

We may face antitrust and other legal challenges when acquiring facilities or other businesses, which could negatively impact our ability to close acquisition transactions. Antitrust enforcement in the healthcare industry is currently a priority of the Federal Trade Commission, the Department of Justice and many state agencies, including with respect to hospital acquisitions. Additionally, many states require CONs in order to acquire a hospital or other healthcare facility. The acquisition of hospitals and other healthcare facilities also often requires licensure approvals or reviews and complex change of ownership processes for Medicare and other payers. The increasingly challenging antitrust enforcement environment and other regulatory review or approval processes could significantly delay or even prevent our ability to acquire facilities and other businesses and increase our acquisition costs, which could adversely affect our overall growth strategy.

Managing growth

Some of the facilities we have acquired or may acquire in the future may have had significantly lower operating margins prior to the time of our acquisition or may have had operating losses prior to such acquisition. If we fail to improve the operating margins of the facilities we acquire, operate such facilities profitably or effectively integrate the operations of the acquired facilities, our results of operations could be negatively impacted.

Joint ventures may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.

As part of our growth strategy, we have completed, orand have announced plans to complete, a number of joint ventures and strategic alliances. These joint ventures may involve significant cash expenditures, debt incurrence, additional operating losses and expenses, and compliance risks that could negatively impact our business, financial condition or results of operations. Further, there is often a significant delay between our formation of a joint venture and the time that a de novo facility can be constructed and have a positive financial impact on our results of operations.

The nature of a joint venture requires us to consult with and share certain decision-making powers with unaffiliated third parties, some of which may benot-for-profit healthcare systems. If our joint venture partners do not fulfill their obligations, the affected joint venture may not be able to operate according to its business or strategic plans. In that case, our financial condition and results of operations may be materially adversely affected or we may be required to increase our level of financial commitment to the joint venture. Moreover, differences in economic or business interests or goals among joint venture participants could result in delayed decisions, failures to agree on major issues and even litigation. If these differences cause the joint ventures to deviate from their business or strategic plans, or if our joint venture partners take actions contrary to our policies, objectives or the best interests of the joint venture, our business, financial condition and results of operationoperations could be negatively impacted. In addition, our relationships withnot-for-profit healthcare systems and the joint venture agreements that govern these relationships are intended to be structured to comply with current revenue rulings published by the Internal Revenue Service (“IRS”), as well as case law relevant to joint ventures betweenfor-profit andnot-for-profit healthcare entities. Material changes in these authorities could adversely affect our relationships withnot-for-profit healthcare systems and related joint venture arrangements.

The majority of our revenue from our operationsWe incur significant transaction-related costs in the U.K. is not guaranteedconnection with acquisitions and is being generated either from spot purchasing or under framework agreements where no volume commitments are given.other strategic transactions.

We incur substantial costs in connection with acquisitions and other strategic transactions, including transaction-related expenses. In addition, there can be no assurancewe may incur additional costs to maintain employee morale, retain key employees, and to formulate and execute integration plans. Although we expect that we can achieve any fee rate increases in the future or will not suffer any fee rate decreases.

Any decline in demand for our services inelimination of duplicative costs, as well as the U.K. from publicly funded entities or private payers or any failure by us to extend current agreements or enter into alternative agreements on comparable terms with such entities could have an adverse effect on our average daily census (“ADC”), which would have a corresponding negative impact on our business, resultsrealization of operations and financial condition. Further, there can be no assurances that we will be able to implement fee rate increases, which are a driver of our revenue from our operations, or not suffer from any decline in fee rates in the future. Should the effect of any increase in annual wages or other operating costs of the business exceed the effect of any increase in our fee rates or should our fee rates suffer a decline, we would have to absorb any costs that cannot be offset by our fees, which could have a negative impact on our business, results of operations and financial condition.

Publicly funded entities

A significant portion of our services funded by U.K. publicly funded entities are commissioned on a spot-purchase basis at prices determined by prevailing market conditions. It is generally a matter for the relevant commissioner to determine whether to use our services, and there is no guarantee that previous spot market purchasing activity by a commissioner will continue in the future or at all. We also have a number of fixed-term framework agreements which grant us preferred provider status with Local Authorities or the NHS typically lasting between one to three years. While we and the commissioners typically agree on pricing for 12 months, at times with discountsefficiencies related to the numberintegration of beds purchased, the commissioners do not make minimum purchasing commitments under such agreements. As such, commissioners may decideacquired businesses, should allow us to place existingmore than offset incremental transaction and new service users with our competitors, including their ownin-house service providers, on short notice. We also have a small number of fixed-period block contracts, where a set number of beds are paid for at a discount to spot prices regardless of occupancy. While we may have flexibility to increase spot rates for new admissions, any fee increases under our block contracts are restricted by the terms and conditions of those block contracts.

The rates that we charge publicly-funded entities for our services are negotiated individually with commissioners and historically have been subject to annual review on April 1 of each year, with customary adjustments based on the Retail Prices Index (“RPI”), Consumer Price Index (“CPI”) or sector specificacquisition-related costs indices. However, the current economic climate and the U.K. government’s overriding economic policy to reduce the budget deficit means that, in the short term at least, commissioners are resistant to fee increases, often expecting that efficiency savings be made to offset inflationary cost increases in accordance with national policy. As a result, there can be no assurance that we can maintain the payment terms of our arrangements with publicly funded entities, including with respect to the timing of payments.

Further, following expiration of contracts there can be no assurance that negotiations with commissioners will result in the extension or renewal of existing arrangements or the entering into of alternative arrangements for those services. Commissioners may also require that following the expiration date of current agreements with us, they contract with us on a spot basis rather than through a block arrangement or reduce the number of beds subject to block arrangements. Even if we are successful in extending current agreements or in entering into alternative arrangements, the duration of such extensions or arrangements is uncertain, and we may be unsuccessful in implementing rate increases under such agreements.

In addition, changing commissioning structures and practices, such as those under the Health and Social Care Act 2012, involve tendering processes that could result in failing to remain or become an approved provider. There are currently a number of commissioning initiatives involving public and independent providers that could change the distribution ofin-patient beds in the U.K. Certain services that were historically commissioned centrally by NHS England are moving towards more local commissioning to better meet patient needs and to enhance local care pathways. These initiatives could cause our ADC to decrease in areas where there is surplus capacity or more focus on community-based treatment. Further, if we are not invited to participate in initiatives or do not meet the local commissioning standards, our ADC could be adversely affected.

Private payers

Although we have agreements in place with a number of private medical insurance (“PMI”) plans where pricing is generally agreed annually, there is no obligation on the PMI plans to refer its members to us or to pay for its members to use our services. Further, weover time, this net benefit may not be able to renew our existing arrangements with PMI plans on terms comparable to what it has achieved in the past. Fee rates for self-paying individuals are adjusted on January 1 of each year depending on capacity and demand in the relevant service markets. Fees paidnear term, or reimbursed by PMI plans are typically adjusted in line with specific contract terms and are generally based on RPI and specific wage indices. Demand in both the PMI market and theself-pay is dependent on economic conditions, which impacts the number of people with sufficient income or capital to pay for insurance coverage or treatment themselves.at all.

Structural shifts in the U.K. behavioral healthcare market may adversely affect us.

Publicly funded entities

Payments for our services by publicly funded entities in the U.K., particularly the NHS and Local Authorities, account for the vast majority of our U.K. revenue. We expect publicly funded entities in the U.K. to continue to generate the significant majority of our revenue from our operations in the U.K. Budget constraints, public spending cuts or other financial pressures could cause such publicly funded entities to spend less money on the type of services that we provide, or political or U.K. government policy changes could mean that fewer of such services are purchased by publicly funded entities from independent sector providers in favor of protecting NHS and Local Authorityin-house services.

While the outsourcing by the NHS in England of healthcare services has been increasing in recent years, the need of the NHS in England to achieve substantial efficiency savings is likely to result in continued funding pressure in the pricing of such services. For instance, Monitor (now part of NHS Improvement), the NHS economic regulator, has, under NHS Tariff Rules, determined national prices across a range of NHS services and has issued extensive guidance on how they are to be applied, including provision for local variations to national tariffs, subject to approval by Monitor. While none of our services are currently subject to national prices, the future application of any national prices regime upon our services could have a material adverse impact on our revenue.

In addition, the allocation of funding responsibility for adult social care may be subject to change at some time in the future under the provisions of the Care Act 2014 under which individuals identified as being required to pay for their own care under the relevant means test will be required to take funding responsibility up to a specified lifetime monetary cap, with Local Authorities responsible for the remainder of expenses for personal care, excluding “daily living” expenses. This would potentially place greater funding responsibility with public sector bodies over the longer term, which would potentially exacerbate the current funding challenges faced by such bodies.

Private payers

Payments for our services in the U.K. by PMI plans account for a small portion of our U.K. revenue. In addition, payments for our services in the U.K. byself-pay patients, who purchase treatment on a spot basis account for a small portion of our U.K. revenue. Many of the patients who use our acute healthcare services in the U.K. do so because their PMI plan recognizes our facilities as being an appropriate provider of the psychiatric treatment services required by the patient. Our ability to attract patients who are funded by PMI plans could be adversely impacted if one or more PMI plans withdraws recognition status from our facilities, for example, as a result of a change in a PMI plan’s recognition status standards. In addition, many PMI plans have been changing the terms of their policies and shortening the length of time they will cover a stay at one of our U.K. facilities.

There can be no assurance that the entities or individuals who fund our services will not reduce or cease spending on the types of services that we provide or that alternative service or funding models for mental healthcare, learning disabilities care, specialist education or elderly care will not emerge. Any such funding or structural change in the markets where we operate could have a material adverse effect on our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.

We are reliant upon maintaining strong relationships with commissioners employed by publicly funded entities, psychiatric and other medical consultants, and any reorganization of such publicly funded entities may result in the loss of those relationships.

The relationships that we have with commissioners is a key driver of referrals for our facilities in the U.K. Referrals to our U.K. business by the NHS accounted for a significant percentage of our revenue for the year ended December 31, 2017. Should there be a major reorganization of publicly funded entities, such as the NHS reorganization announced in 2010 and implemented between 2012 and 2013, we may need to rebuild such relationships which could result in a decrease in the number of referrals made to our facilities, which could have a corresponding material adverse effect on our business, results of operations, financial condition or prospects. Any actual or perceived deterioration in service quality, any serious incidents at our facilities or any other event that could cause commissioners to prefer other service providers over us could also adversely impact referrals from commissioners. Further, our business also depends, in part, on psychiatric and other medical consultants referring their patients to us for treatment either asin-patients or day patients. From time to time, consultants may decide to relocate or reposition their practices, retire or refer patients elsewhere with the result that there is a decrease in the number of referrals made to our facilities. A deterioration in relationships with commissioners or consultants or the decision by one or more commissioners or consultants to refer patients to our competitors or to stop all referrals would have an adverse effect on the ADC at our facilities in the U.K., which would have a corresponding negative impact on our business, results of operations and financial condition.

Our operating costs are subject to increases, including due to statutorily mandated increases in the wages and salaries of our staff.

The most significant operating expense for our facilities is wage costs, which represent the staff costs incurred in providing our services and running our facilities, and which are primarily driven by the number of employees and pay rates. The number of employees employed by us is primarily linked to the number of facilities we operate and the number of individuals cared for by us. While we can reduce the number of employees should occupancy rates decrease at our facilities, there is a limit on the extent to which this can be done without impacting quality of our services.

Furthermore, in April 2016, a new “National Living Wage” was introduced across the U.K. which was increased in April 2017 and is scheduled to increase again in April 2018 with further annual increases expected until at least 2020. These changes to the National Living Wage have and will increase our operating costs and, unless we can increase revenue or reduce other costs, will reduce our margins.

In the U.K., there has been an increase in enforcement action by HMRC against employers who do not pay the NMW, particularly for fixed allowance payments forsleep-in shifts in the care sector. The industry standard practice has been to pay a fixed allowance to employees who sleep at sites at night with a“top-up” if an employee is woken and provides care to residents during the

night. Our U.K. facilities have elected to join the SCCS established by HMRC to mitigate our exposure to potentialback-pay liability. Nevertheless, we may be subject to (i) increased payments to employees forsleep-in shifts on anon-going basis; (ii) payments of up to 6 years of arrears to employees or former employees who have carried outsleep-in shifts at our U.K. facilities; and (iii) payments of interest and penalties to HMRC, all of which would have a corresponding negative impact on our business, results of operations and financial condition.

We also have a number of recurring costs including insurance, utilities and rental costs, and may face increases to other recurring costs such as regulatory compliance costs. There can be no assurance that any of our recurring costs will not grow at a faster rate than our revenue. As a result, any increase in our operating costs could have a material adverse effect on our business, results of operations and financial condition.

We care for a large number of vulnerable individuals with complex needs and any care quality deficiencies could adversely impact our brand, reputation and ability to market our services effectively.

Our future growth will partly depend on our ability to maintain our reputation for providing quality patient care and, through successful salesnew programs and marketing activities, increased demand for our services. Factors such as increased acuity of our patients, health and safety incidents problems at our facilities, regulatory enforcement actions, negative press or general customer dissatisfaction could lead to deterioration in the level of our quality ratings or the public perception of the quality of our services (including as a result of negative publicity about our industry generally), which in turn could lead to a loss of patient placements, referrals andself-pay patients or service users. Any impairment of our reputation, loss of goodwill or damage to the value of our brand name could have a material

23


Table of Contents

adverse effect on our business, results of operations and financial condition.

Many of our service users have complex medical conditions or special needs, are vulnerable and often require a substantial level of care and supervision. There is a risk that one or more service users could be harmed by one or more of our employees, either intentionally, through negligence or by accident. Further, individuals cared for by us have in the past engaged, and may in the future engage, in behavior that results in harm to themselves, our employees or to one or more other individuals, including members of the public. A serious incident involving harm to one or more service users or other individuals could result in negative publicity. Such negative publicity could have a material adverse effect on our brand, reputation and ADC, which would have a corresponding negative impact on our business, results of operations and financial condition. Furthermore, the damage to our reputation or to the reputation of the relevant facility from any such incident could be exacerbated by any failure on our part to respond effectively to such incident.

We are and in the future may become involved in legal proceedings based on negligence or breach of a contractual or statutory duty from service users or their family members or from employees or former employees.

From time to time, we are subject to complaints and claims from service users and their family members alleging professional negligence, medical malpractice or mistreatment. We are also subject to claims for unlawful detention from time to time when patients allege they should not have been detained under the Mental Health Act or where the appropriate procedures were not correctly followed.

Similarly, there may be substantial claims from employees in respect of personal injuries sustained in the performance of their duties, particularly in respect of incidents involving patients detained under the Mental Health Act and where future employment prospects are impaired. Current or former employees may also make claims against us in relation to breaches of employment legislation.

We may also be involved in coroner’s inquests (or the Scottish equivalent) where there is a fatality at one of our facilities in the U.K. resulting in an adverse coroner’s verdict or civil claims by individuals or criminal prosecutions by regulatory authorities. Any fines imposed by the courts are likely to be substantial in view of the Sentencing Council guidelines published in November 2015, which materially increase fines for corporate manslaughter and certain health and safety offenses. There may also be safeguarding incidents at our facilities which, depending on the circumstances, may result in custodial sentences or other criminal sanctions for the member of staff involved.

The incurrence of any legal fees, damage awards or other fines as summarized above as well as any impact on our brand or reputation as a result of being involved in any legal proceedings are likely to have a material adverse impact on our business, results of operations and financial condition.

We handle sensitive personal data which are protected by numerous U.S. and U.K. laws in the ordinary course of business and any failure to maintain the confidentiality of such data could result in legal liability and reputational harm.

We process and store sensitive personal data as part of our business. In the event of a security breach, sensitive personal data could become public. We are currently not aware of any material incidences of potential data breach; however, there can be no assurance that such breaches will not arise in future. Although we have in place policies and procedures to prevent such breaches, breaches could occur either as a result of a breach by us or as a result of a breach by a third party to whom we have provided sensitive personal data, and as a result, we could face liability under data protection laws.

In addition to U.S. data protection laws, we are subject to similar, and in some cases more restrictive, U.K. data protection laws. For example, the GDPR will provide heightened data protection requirements once effective in May 2018, including more stringent consent requirements, data protection and security measures and requirements to appoint a data protection officer. While we are taking appropriate steps to ensure compliance with U.K. data protection laws and regulations, we cannot guarantee that our facilities will not be subject to data breaches which could have a material adverse effect on our business, financial condition, or results of operations.

Liability under data protection laws may result in sanctions, including substantial fines and/or may cause us to suffer damage to our brand and reputation, which could have a material adverse effect on our business, results of operations and financial condition.

We may be subject to liabilities from claims brought against us or our facilities.

We are subject to medical malpractice lawsuits and other legal actions in the ordinary course of business. Some of these actions may involve large claims, as well as significant defense costs. We cannot predict the outcome of these lawsuits or the effect that findings in such lawsuits may have on us. All professional and general liability insurance we purchase is subject to policy limitations and in some cases, an insurance company may defend us subject to a reservation of rights. Management believes that, based on our past experience and actuarial estimates, our insurance coverage is adequate considering the claims arising from the operations of our facilities. While we continuously monitor our coverage, our ultimate liability for professional and general liability claims could change materially from our current estimates. If such policy limitations should be partially or fully exhausted in the future, or payments of claims exceed our estimates or are not covered by our insurance, it could have a material adverse effect on our business, financial condition or results of operations. Further, insurance premiums have increased year over year and insurance coverage may not be available at a reasonable cost, especially given the significant increase in insurance premiums generally experienced in the healthcare industry.

We carry a large self-insured retention and may be responsible for significant amounts not covered by insurance. In addition, our insurance may be inadequate, premiums may increase and, if there is a significant deterioration in our claims experience, insurance may not be available on acceptable terms.

We maintain liability insurance intended to cover service user, third-party and employee personal injury claims. Due to the structure of our insurance program under which we carry a large self-insured retention, there may be substantial claims in respect of which the liability for damages and costs falls to us before being met by any insurance underwriter. There may also be claims in excess of our insurance coverage or claims which are not covered by our insurance due to other policy limitations or exclusions or where we have failed to comply with the terms of the policy. Furthermore, there can be no assurance that we will be able to obtain liability insurance coverage in the future on acceptable terms, or without substantial premium increases or at all, particularly if there is a deterioration in our claim experience history. A successful claim against us not covered by or in excess of our insurance coverage could have a material adverse effect on our business, results of operations and financial condition.

Foreign currency exchange rate fluctuations could materially impact our consolidated financial position and results of operations.

We have significant U.K. operations. Accordingly, we translate revenue and other results denominated in a foreign currency into U.S. dollars (“USD”) for our consolidated financial statements. During periods of a strengthening USD or weakening British pound (“GBP”), our reported international revenue and expenses could be reduced because foreign currencies may translate into fewer USD. Following the Brexit vote and subsequent developments, the GBP dropped to its lowest level against the USD in more than 30 years. If the exchange rate further declines, our results of operations will be negatively impacted in future periods.

In all jurisdictions in which we operate, we are also subject to laws and regulations that govern foreign investment, foreign trade and currency exchange transactions. These laws and regulations may limit our ability to repatriate cash as dividends or otherwise to the U.S. and may limit our ability to convert foreign currency cash flows into USD.

We incur significant transaction related costs in connection with acquisitions.

We incur substantial costs in connection with acquisitions, including transaction-related expenses. In addition, we may incur additional costs to maintain employee morale, retain key employees, and to formulate and execute integration plans. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of acquired businesses, should allow us to more than offset incremental transaction and acquisition-related costs over time, this net benefit may not be achieved in the near term, or at all.

Our ability to grow our business through organic expansion either by developing newde novo or joint venture facilities or by modifying existing facilities is dependent upon many factors.

Our ability to grow our business through organic expansion is dependent on capacity and occupancy at our facilities. Should our facilities reach maximum occupancy, we may need to implement other growth strategies either by developing newde novo or joint venture facilities or by modifying existing facilities.

Our facilities typically need to be purpose-designed in order to enable the type and quality of service that we provide. Consequently, we must either develop sites to create facilities or purchase or lease existing facilities, which may require substantial modification. We must be able to identify suitable sites and there is no guarantee that such sites will be available at all, or at an economically viable cost or in areas of sufficient demand for our services. The subsequent successful development and construction of a newde novo or joint venture facility is contingent upon, among other things, negotiation of construction contracts, regulatory permits and planning consents and satisfactory completion of construction. Similarly, our ability to expand existing facilities is also dependent upon various factors, including identification of appropriate expansion projects, permitting, licensure, financing, integration into our relationships with payors and referral sources, and margin pressure as newde novo and joint venture facilities are filled with patients.

Delays caused by difficulties in respect of any of the above factors may lead to cost overruns and longer periods before a return is generated on an investment, if at all. We may incur significant capital expenditure but due to a regulatory, planning or other reason, may find that we are prevented from opening a newde novo or joint venture facility or modifying an existing facility. Moreover, even when incurring such development capital expenditure, there is no guarantee that we can fill beds when they become available. Upon operational commencement of a newde novo or joint venture facility, we typically expect that it will take approximately12-1810 to 12 months, on average, to reach our targeted occupancy level.break-even results. Any delays or stoppages in our projects, the unsatisfactory completion or construction of such projects or the failure of such projects to increase our occupancy levels could have a material adverse effect on our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.

The cost of construction materials and labor has significantly increased, and we continue to grow our business through expansion of existing facilities and development of de novo and joint venture facilities.

      Although we evaluate the financial feasibility of construction projects by determining whether the projected cash flow return on investment exceeds our cost of capital and have implemented efforts to realize efficiencies in our design and construction processes, such returns may not be achieved if the cost of construction continues to rise significantly or the expected patient volumes are not attained.

Our business could be disrupted if our information systems fail or if our databases are destroyed or damaged.

Our information technology (“IT”) platforms support, among other things, management control of patient administration, billing and financial information and reporting processes. For example, patients in some of our facilities have an electronic patient record that allows our caregivers and nurses to see information about a patient’s care and treatment. Our IT systems are subject to damage or interruption from power outages, facility damage, computer and telecommunications failures, computer viruses, security breaches including credit card or personally identifiable information breaches, vandalism, theft, natural disasters, catastrophic events, human error and potential cyber threats, including malicious codes, worms, phishing attacks, denial of service attacks, ransomware and other sophisticated cyber-attacks, and our disaster recovery planning cannot account for all eventualities. Any failure in or breach of our IT systems could adversely impact our business, results of operations and financial condition.

24


Table of Contents

If we do not continually enhance our facilities with the most recent technological advances, our ability to maintain and expand our markets will be adversely affected.

As healthcare technology continues to advance, we expect information technology to play a greater role in our marketing and admissions processes and the operation of our facilities. To compete effectively, we must continually assess our automation needs and upgrade when significant technological advances occur. If our facilities do not stay current with technological advances in the healthcare industry, patients may seek treatment from other providers and/or physicians may refer their patients to alternate sources, which could adversely affect our results of operations and harm our business.

A cyber security incident could have a material adverse impact on the Company, including substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to reputational harm and increased costs.

We have experienced adverse IT events in the past including a criminal ransomware attack on our computer network which resulted in a temporary systems outage, as well as attempts of computer hacking, vandalism and theft, malware, computer viruses, malicious codes, worms, phishing and other cyber-attacks. To date, we have seen no material impact on our business or operations from these attacks or events. However, it is widely reported that healthcare companies are increasingly prime targets for cyber-attacks and we expect our systems to continue to be subject to attack on a regular basis.

The proliferation of ever-evolving cyber threats mean that we and our third-party service providers and vendors must continually evaluate and adapt our respective systems and processes and overall security environment, as well as those of any operations we acquire. As cyber criminals continue to become more sophisticated through evolution of their tactics, techniques and procedures, we have taken, and will continue to take, additional preventive measures to strengthen the cyber defenses of our networks and data. There is no guarantee that these measures will be adequate to safeguard against all data security breaches, system compromises, or misuses of data.  

We may be required to expend significant capital and other resources to protect against the threat of security breaches or to alleviate problems caused by breaches, including unauthorized access to patient data and personally identifiable information stored in our IT systems, and the introduction of computer viruses or other malicious software programs to our systems, and cyber-attacks, email phishing schemes, malware, and ransomware. Moreover, a security breach, or threat thereof, could require that we expend significant resources to repair or improve our information systems and infrastructure and could distract management and other key personnel from performing their primary operational duties. In the event of a material breach or cyber-attack, the associated expenses and losses may exceed our current insurance coverage for such events. In addition, some adverse consequences are not insurable, such as reputational harm and third-party business interruption.

A cyber-attack that bypasses our IT security systems, or other adverse IT event, resulting in an IT security breach, loss of PHI or other data subject to privacy laws, loss of proprietary business information, or a material disruption of our IT business systems, could have a material adverse impact on our business, financial condition or results of operations. Any successful cybersecurity attack or other unauthorized attempt to access our systems or facilities could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors, or other third parties and could subject us to substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to litigation with those affected.

We may fail to deal with clinical waste in accordance with applicable regulations or otherwise be in breach of relevant medical, health and safety or environmental laws and regulations.

As part of our normal business activities, we produce and store clinical waste which may produce effects harmful to the environment or human health. The storage and transportation of such waste is strictly regulated. Our waste disposal services are outsourced and should the relevant service provider fail to comply with relevant regulations, we could face sanctions or fines which could adversely affect our brand, reputation, business or financial condition. Health and safety risks are inherent in the services that we provide and are constantly present in our facilities, primarily in respect of food and water quality, as well as fire safety and the risk that service users may cause harm to themselves, other service users or employees. From time to time, we have experienced, like other providers of similar services, undesirable health and safety incidents. Some of our activities are particularly exposed to significant medical risks relating to the transmission of infections or the prescription and administration of drugs for residents and patients. If any of the above medical or health and safety risks were to materialize, we may be held liable, fined and any registration certificate could be suspended or withdrawn for failure to comply with applicable regulations, which may have a material adverse impact on our business, results of operations and financial condition.

The value25


Table of Contents

Although we have facilities in 39 states and Puerto Rico, we have substantial operations in Pennsylvania, California, Arizona and Tennessee, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those states.

Revenue from Pennsylvania, California, Arizona and Tennessee represented approximately 13%, 8%, 6% and 6% of our real estate assets willtotal revenue for the year ended December 31, 2022, respectively. This concentration makes us particularly sensitive to legislative, regulatory, economic, environmental and competition changes in those states. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these locations could have a disproportionate effect on our overall business results. If our facilities in these locations are adversely affected by changes in regulatory and economic conditions, our business, financial condition or results of operations could be adversely affected.

Our business and operations are subject to fluctuationsrisks related to natural disasters and climate change.

Some of our facilities are located in areas prone to hurricanes or wildfires. Natural disasters have historically had a disruptive effect on the operations of facilities and the patient populations in such areas. Our business activities could be significantly disrupted by wildfires, hurricanes or other natural disasters, and our property insurance may not be adequate to cover losses from such wildfires, storms or other natural disasters. Even if our facilities are not directly damaged, we may experience considerable disruptions in our operations due to property damage or electrical outages experienced in storm-affected areas by our personnel, payors, vendors and others. Additionally, long-term adverse weather conditions, whether caused by global climate change or otherwise, could cause an outmigration of people from the communities where our facilities are located. If any of the circumstances described above occur, our business, financial condition or results of operations could be adversely affected.

A pandemic, epidemic or outbreak of an infectious disease in the U.K. real estate market.markets in which we operate or that otherwise impacts our facilities could adversely impact our business.

If a pandemic, epidemic, outbreak of an infectious disease, such as COVID-19, or other public health crisis were to occur in an area in which we operate, our operations could be adversely affected. Such a crisis could diminish the public trust in healthcare facilities, especially facilities with patients affected by infectious diseases. If any of our facilities were involved, or perceived as being involved, in treating such patients, other patients might fail to seek care at our facilities, and our reputation may be negatively affected. Further, a pandemic, epidemic or outbreak might adversely impact our business by causing a temporary shutdown or diversion of patients, by disrupting or delaying production and delivery of pharmaceuticals and other medical supplies or by causing staffing shortages in our facilities. Although we have disaster plans in place and operate pursuant to infectious disease protocols, the potential impact of a pandemic, epidemic or outbreak of an infectious disease with respect to our markets or our facilities is difficult to predict and could adversely impact our business, financial condition or results of operations.

If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected.

Our ability to grow or even to maintain our existing level of business depends significantly on our ability to establish and maintain close working relationships with physicians, managed care companies, insurance companies, educational consultants and other referral sources. We may not be able to maintain our existing referral source relationships or develop and maintain new relationships in existing or new markets. If we lose existing relationships with our referral sources, the number of people to whom we provide services may decline, which may adversely affect our revenue. If we fail to develop new referral relationships, our growth may be restrained.

We holdoperate in a highly competitive industry, and competition may lead to declines in patient volumes.

The healthcare industry is highly competitive, and competition among healthcare providers (including hospitals) for patients, physicians and other healthcare professionals has intensified in recent years. There are other healthcare facilities that provide behavioral and other mental health services comparable to those offered by our facilities in each of the geographical areas in which we operate. Some of our competitors are owned by tax-supported governmental agencies or by non-profit corporations and may have certain financial advantages not available to us, including endowments, charitable contributions, tax-exempt financing and exemptions from sales, property and income taxes. Some of our for-profit competitors are local, independent operators or physician groups with strong established reputations within the surrounding communities, which may adversely affect our ability to attract a sufficiently large portfolionumber of patients in markets where we compete with such providers. We also face competition from other for-profit entities, who may possess greater financial, marketing or research and development resources than us or may invest more funds in renovating their facilities or developing technology.

If our competitors are better able to attract patients, recruit and retain physicians and other healthcare professionals, expand services or obtain favorable managed care contracts at their facilities, we may experience a decline in patient volume and our results of operations may be adversely affected.

26


Table of Contents

We may be unable to extend leases at expiration, which could harm our business, financial condition or results of operations.

We lease the real estate assets, including significantproperty on which a number of our facilities are located. Our lease agreements generally give us the right to renew or extend the term of the leases and, in certain cases, purchase the real estate assetsproperty. These renewal and purchase rights generally are based upon either prescribed formulas or fair market value. Management expects to renew, extend or exercise purchase options with respect to our leases in the U.K. The valuenormal course of our U.K. property portfolio is subject to, among other things, the conditions of the real estate market in the U.K. The average values of real estate in the U.K., as in other European countries, experienced sharp declines from 2007 as a result of the credit crisis, economic recession and reduced confidence in global financial markets. Although real estate asset values have recovered and stabilized in recent years in the U.K.,business; however, there can be no assurance that this improvementthese rights will continuebe exercised in the future or that we will be sustainable. Real estate asset valuesable to satisfy the conditions precedent to exercising any such renewal, extension or purchase options. Furthermore, the terms of any such options that are based on fair market value are inherently uncertain and could decline substantially, particularlybe unacceptable or unfavorable to us depending on the circumstances at the time of exercise. If we are not able to renew or extend our existing leases, or purchase the real property subject to such leases, at or prior to the end of the existing lease terms, or if the U.K. economyterms of such options are unfavorable or unacceptable to us, our business, financial condition or results of operations could be adversely affected.

Controls designed to reduce inpatient services may reduce our revenue.

Controls imposed by Medicare, Medicaid and commercial third-party payors designed to reduce admissions and lengths of stay, commonly referred to as “utilization review,” have affected and are expected to continue to affect our facilities. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required preadmission authorization and utilization review and by payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Efforts to impose more stringent cost controls are expected to continue. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, expanded the potential use of prepayment review by Medicare contractors by eliminating certain statutory restrictions on its use. Utilization review is also a requirement of most non-governmental managed-care organizations and other third-party payors. Although we are unable to predict the effect these controls and changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on our financial condition and results of operations.

Human Capital Risks

Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability.

Our operations depend on the efforts, abilities and experience of our management and medical support personnel, including our addiction counselors, therapists, nurses, pharmacists, licensed counselors, clinical technicians, and mental health technicians, as well as our psychiatrists and other professionals. We compete with other healthcare providers in recruiting and retaining qualified management, program directors, physicians (including psychiatrists) and support personnel responsible for the daily operations of our business, financial condition or results of operations.

A shortage of nurses, qualified addiction counselors and other medical and care support personnel, combined with low unemployment rates for such personnel and intense competition from other healthcare facilities, has been a significant operating issue facing us and other healthcare providers. We may be required to enhance wages and benefits to hire nurses, qualified addiction counselors and other medical and care support personnel, hire more expensive temporary personnel or increase our recruiting and marketing costs relating to labor. We have resorted to using more expensive contract labor at certain of our facilities, and the use of temporary or agency staff could heighten the risk one of our facilities experiences an adverse patient incident. Further, because we generally recruit our personnel from the local area where the relevant facility is located, the availability in certain areas of suitably qualified personnel can be limited, particularly care home management, qualified teaching personnel and nurses. In addition, certain of our facilities are required to maintain specified staffing levels. To the extent we cannot meet those levels, we may be required to limit the services provided by these facilities, which would have a corresponding adverse effect on our net operating revenue. Certain of our treatment facilities are located in remote geographical areas, far from population centers, which increases this risk.

We cannot predict the degree to which we will be affected by the future availability or cost of attracting and retaining talented medical support staff. If our general labor and related expenses increase, we may not be able to raise our rates correspondingly. Increased turnover rates within our employee base can lead to decreased efficiency and increased costs, such as increased overtime and use of contract labor to meet demand and increased wage rates to attract and retain employees. Our failure either to recruit and retain qualified management, psychiatrists, therapists, counselors, nurses and other medical support personnel or control our labor costs could have a material adverse effect on our results of operations.

Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians.

The success and competitive advantage of our facilities depends, in part, on the number and quality of the psychiatrists and other physicians on the medical staffs of our facilities and our maintenance of good relations with those medical professionals. Although we

27


Table of Contents

employ psychiatrists and other physicians at many of our facilities, psychiatrists and other physicians generally are not employees of our facilities, and, in a number of our markets, they have admitting privileges at competing hospitals providing acute or inpatient behavioral healthcare services. Such physicians (including psychiatrists) may terminate their affiliation with us at any time or admit their patients to competing healthcare facilities or hospitals. If we are unable to attract and retain sufficient numbers of quality psychiatrists and other physicians by providing adequate support personnel and facilities that meet the needs of those psychiatrists and other physicians, they may stop referring patients to our facilities and our results of operations may decline.

It may become difficult for us to attract and retain an adequate number of psychiatrists and other physicians to practice in certain of the communities in which our facilities are located. Our failure to recruit psychiatrists and other physicians to these communities or the Eurozone economyloss of such medical professionals in these communities could make it more difficult to attract patients to our facilities and thereby may have a material adverse effect on our business, financial condition or results of operations. Additionally, our ability to recruit psychiatrists and other physicians is closely regulated. The form, amount and duration of assistance we can provide to recruited psychiatrists and other physicians is limited by the Stark Law, the Anti-Kickback Statute, state anti-kickback statutes, and related regulations.

Some of our employees are represented by labor unions and any work stoppage could adversely affect our business.

Increased labor union activity could adversely affect our labor costs. At December 31, 2022, labor unions represented approximately 350 of our employees at two of our facilities through four collective bargaining agreements. We cannot assure you that employee relations will remain stable. Furthermore, there is a possibility that work stoppages could occur as a whole were to sufferresult of union activity, which could increase our labor costs and adversely affect our business, financial condition or results of operations. To the extent that a further recession or debt crisis, and could result in declines in the carrying valuesgreater portion of our real estate assets (andemployee base unionizes and the value at which weterms of any collective bargaining agreements are significantly different from our current compensation arrangements, it is possible that our labor costs could disposeincrease materially and our business, financial condition or results of such assets). Anyoperations could be adversely affected.

We depend on key management personnel, and the departure of one or more of our key executives or a significant portion of our local facility management personnel could harm our business.

The expertise and efforts of our senior executives and the chief executive officer, chief financial officer, medical directors, physicians and other key members of our facility management personnel are important to the success of our business. The loss of the above mayservices of one or more of our senior executives or our facility management personnel could significantly undermine our management expertise and our ability to provide efficient, quality healthcare services at our facilities, which could have a material adverse effect on our business, results of operations and financial condition.

OurLegal Proceedings and Regulatory Risks

We are and in the future could become the subject of additional governmental investigations, regulatory actions and whistleblower lawsuits.

Healthcare companies in the U.S. may be subject to investigations by various governmental agencies. Certain of our individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit reports and other inquiries from, and may be subject to investigation by, federal and state agencies. See Note 20— Commitments and Contingencies in the accompanying notes to our consolidated financial statements beginning on Page F-1 of this Annual Report on Form 10-K for additional information about pending investigations. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. If we incur significant costs responding to or resolving these or future inquiries or investigations, our business, financial condition and results of operations could be disruptedmaterially adversely affected.

Further, under the False Claims Act, private parties are permitted to bring qui tam or “whistleblower” lawsuits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Because qui tam lawsuits are filed under seal, we could be named in one or more such lawsuits of which we are not aware. We may also be subject to substantial reputational harm as a result of the public announcement of any investigation into such claims.

We could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if our information systemswe fail or if our databases are destroyed or damaged.to comply with the terms of the CIA.

Our information technology platform supports, among other things, management controlDuring the second quarter of patient administration, billing and financial information and reporting processes. For example, patients2019, we reached a settlement with the U.S. Attorney’s Office for the Southern District of West Virginia relating to the manner in our U.K. facilities and somewhich seven of our U.S. facilities have an Electronic Patient Record that allowsCTCs in West Virginia had historically billed lab claims to the West Virginia

28


Table of Contents

Medicaid Program. During the three months ended June 30, 2019, we entered into the CIA with the OIG imposing certain compliance obligations on us and our caregiverssubsidiary, CRC Health, in connection with such settlement. Material, uncorrected violations of the CIA could lead to our suspension or exclusion from participation in Medicare, Medicaid and nursesother federal and state healthcare programs and repayment obligations. In addition, we are subject to see all information aboutpossible civil penalties for failure to substantially comply with the terms of the CIA, including stipulated penalties ranging between $1,000 to $2,500 per day. We are also subject to a patient’s care and treatment. Although

we have taken measuresstipulated penalty of $50,000 for each false certification made by us or on our behalf, pursuant to mitigate potential information technology security risks and have information technology continuity plans across our business intended to minimize the impactreporting provisions of the CIA. The CIA increases the amount of information technology failures, there can be no assurance that such measureswe must provide to the federal government regarding our healthcare practices and plans will be effective. Any failureour compliance with federal regulations. The reports we provide in connection with the CIA could result in greater scrutiny by regulatory authorities.

We are and in the future may become involved in legal proceedings based on negligence or breach of our information technology systems could adversely impact our business, results of operations and financial condition.a contractual or statutory duty from service users or their family members or from employees or former employees.

WeFrom time to time, we are subject to volatilitycomplaints and claims from service users and their family members alleging professional negligence, medical malpractice or mistreatment. We are also subject to claims for unlawful detention from time to time when patients allege they should not have been detained under applicable laws and regulations or where the appropriate procedures were not correctly followed.

Similarly, there may be substantial claims from employees in respect of personal injuries sustained in the global capital and credit marketsperformance of their duties. Current or former employees may also make claims against us in relation to breaches of employment laws.There may also be safeguarding incidents at our facilities which, depending on the circumstances, may result in custodial sentences or other criminal sanctions for the member of staff involved.

The incurrence of substantial legal fees, damage awards or other fines as well as significant developmentsthe potential impact on our brand or reputation as a result of being involved in macroeconomic and political conditions that are out of our control.

Our business can be affected by a number of factors that are beyond our control, such as general macroeconomic conditions, conditions in the financial services markets, geopolitical conditions and other general political and economic developments. These conditions and developments may continue to put pressure on the economy in the U.K., whichany legal proceedings could have a negative effect on our business. There may be a shortage of liquidity and credit in the U.K. or worldwide and this can be exacerbated bymaterial adverse developments in global or national political and/or macroeconomic conditions. In particular, we have historically financed the development of new facilities and the modification of our existing facilities through a variety of sources, including our own cash reserves and debt financing. While we intend to seek to finance new and existing developments from similar sources in the future, there may be insufficient cash reserves to fund the budgeted capital expenditure and market conditions and other factors may prevent us from obtaining debt financing on appropriate terms or at all. In addition, market conditions may limit the number of financial institutions that are willing to provide financing to landlords with whom we wish to contract to build homes for learning disability services, new schools or new mental health facilities which can then be made available to us under a long-term operating lease. If conditions in the U.K. or the global economy remain uncertain or weaken further, this could materially adversely impact our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.

Failure to comply with the international andWe handle sensitive personal data which are protected by numerous U.S. laws in the ordinary course of business and regulations applicable to our international operations could subject us to penalties and other adverse consequences.

We face several risks inherent in conducting business internationally, including compliance with international and U.S. laws and regulations that apply to our international operations. These laws and regulations include U.S. laws such as the Foreign Corrupt Practices Act and other U.S. federal laws and regulations established by the Office of Foreign Asset Control, local laws such as the U.K. Bribery Act 2010 or other local laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. Given the high level of complexity of these laws, however, there is a risk that some provisions may be inadvertently breached by us, for example through fraudulent or negligent behavior of individual employees, ourany failure to comply with certain formal documentation requirements, or otherwise. Violationsmaintain the confidentiality of these laws and regulationssuch data could result in fines, criminal sanctions against us, our officers or our employees, implementation of compliance programs,legal liability and prohibitions on the conductreputational harm.

We collect, process and store sensitive personal data as part of our business. AnyIn the event of a security breach, sensitive personal data could become public. We are currently not aware of any material incidences of potential data breach; however, there can be no assurance that such violationsbreaches will not arise in future. Although we have in place policies and procedures to prevent such breaches, breaches could include prohibitions onoccur either as a result of a breach by our abilityemployees or as a result of a breach by a third party to conduct businesswhom we have provided sensitive personal data, and we could face liability under data protection laws.

Liability under data protection laws may result in the U.K. and could materiallysanctions, including substantial fines and/or compensation to those affected. Additionally, liability may cause us to suffer damage our reputation,to our brand our international expansion efforts, our ability to attract and retain employees, our business and our operating results. Our success depends, in part, on our ability to anticipate these risks and manage these challenges.

We are subject to taxation in the U.S. and certain foreign jurisdictions. Any adverse development in the tax laws of such jurisdictions or any disagreement with our tax positionsreputation, which could have a material adverse effect on our business, financial condition or results of operations.operations and financial condition.

We carry a large self-insured retention and may be responsible for significant amounts not covered by insurance. In addition, our effective tax rate could change materially asinsurance may be inadequate, premiums may increase and, if there is a result of certain changessignificant deterioration in our mix of U.S. and foreign earnings and other factors, including changes in tax laws.claims experience, insurance may not be available on acceptable terms.

We are subject to taxationmedical malpractice lawsuits and other legal actions in the ordinary course of business. Some of these actions may involve large claims, as well as significant defense costs. We cannot predict the outcome of these lawsuits or the effect that findings in such lawsuits may have on us. We maintain liability insurance intended to cover service user, third-party and employee personal injury claims. Due to the tax lawsstructure of our insurance program under which we carry a large self-insured retention, there may be substantial claims in respect of which the liability for damages and regulationscosts falls to us before being met by any insurance underwriter. There may also be claims in excess of our insurance coverage or claims which are not covered by our insurance due to other policy limitations or exclusions or where we have failed to comply with the terms of the U.S. and certain foreign jurisdictions aspolicy. Furthermore, there can be no assurance that we will be able to obtain liability insurance coverage in the future on acceptable terms, or without substantial premium increases or at all, particularly if there is a resultdeterioration in our claim experience history. A successful claim against us not covered by or in excess of our operations and our corporate and financing structure. Adverse developments in these tax laws or regulations, or any change in position regarding the application, administration or interpretation thereof, in any applicable jurisdiction,insurance coverage could have a material adverse effect on our business, financial condition or results of operations. In addition, the tax authorities in any applicable jurisdiction may disagree with the tax treatment or characterization of any of our transactions, which, if successfully challenged by such tax authorities, could have a material adverse effect on our business, financial condition or results of operations. Certain changes in the mix of our earnings between jurisdictions and assumptions used in the calculation of income taxes, among other factors, could have a material adverse effect on our overall effective tax rate. In addition, the Tax Act makes significant changes to the rules applicable to the taxation of corporations. The Company is currently in the process of analyzing the effects of the Tax Act on the Company. It is uncertain at this time whether the application of these new rules will have any material and adverse impact on our operating results, cash flowsoperations and financial condition.

A worsening of the economic and employment conditions in the geographies in which we operate could materially affect our business and future results of operations.

During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at the federal, state and local levels have decreased, and may continue to decrease, spending for health and human service programs, including Medicare and Medicaid in the U.S., which are significant payor sources for our facilities. In periods of high unemployment, we also face the risk of potential declines in the population covered under private insurance, patient decisions to postpone or decide against receiving behavioral healthcare services, potential increases in the uninsured and underinsured populations we serve and further difficulties in collecting patientco-payment and deductible receivables.

A sizable portion of our revenue from certain residential recovery, eating disorder facilities, comprehensive treatment centers and youth programs is from self-payors. Accordingly, a sustained downturn in the U.S. economy could restrain the ability of our patients and the families of our students to pay for services.

Furthermore, the availability of liquidity and capital resources to fund the continuation and expansion of many business operations worldwide has been limited in recent years. Our ability to access the capital markets on acceptable terms may be severely restricted at a time when we would like, or need, access to those markets, which could have a negative impact on our growth plans, our flexibility to react to changing economic and business conditions and our ability to refinance existing debt (including debt under our Amended and Restated Senior Credit Facility and the Senior Notes). A sustained economic downturn or other economic conditions could also adversely affect the counterparties to our agreements, including the lenders under the Amended and Restated Senior Credit Facility, causing them to fail to meet their obligations to us.

Our reimbursement may be adversely affected by the repeal, replacement or modification of PPACA.

On January 20, 2017, Donald Trump became President of the United States. During the 2016 election cycle, Republicans also assumed control of both the United States Senate and House of Representatives. Shortly after his inauguration, President Trump issued an executive order that, among other things, stated that it was the intent of his administration to repeal PPACA. Several bills have been introduced and voted upon in the House of Representatives and United States Senate that would either repeal and replace or simply repeal PPACA, although no such comprehensive legislation has been enactedto-date. The Tax Act does, however, effectively repeal the individual mandate to obtain and maintain health insurance by eliminating the tax penalty associated with failing to do so.    

If PPACA is repealed, with or without a replacement, we may experience a significant decrease in reimbursement from state Medicaid programs. We may also experience a significant increase in uncompensated care if many of our patients who currently obtain private health insurance coverage or Medicaid coverage under the provisions of PPACA are no longer able to maintain that coverage. Finally, PPACA currently works in conjunction with MHPAEA to require that third-party payors reimburse providers of certain mental health and substance abuse treatment services on anout-of-network basis. If PPACA or this particular provision thereof is repealed, we may experience a significant decrease inout-of-network reimbursement at certain of our facilities.

If we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.

Companies operating in the behavioral healthcare industry in the U.S. are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things: billing practices and prices for services; relationships with physicians and other referral sources; necessity and quality of medical care; condition and adequacy of facilities; qualifications of medical and support personnel; confidentiality, privacy and security issues associated with health-related

29


Table of Contents

information and PHI; EMTALA compliance; handling of controlled substances; certification, licensure and accreditation of our facilities; operating policies and procedures; activities regarding competitors; state and local land use and zoning requirements; and addition or expansion of facilities and services.

Among the laws applicable to our operations are the federal Anti-Kickback Statute, the Stark Law, the federal False Claims Act, the EKRA, and similar state laws. These laws impact the relationships that we may have with physicians and other potential referral sources. We have a variety of financial relationships with physicians and other professionals who refer patients to our facilities, including employment contracts, leases and professional service agreements. The OIG has issued certain safe harbor regulations that outline practices that are deemed acceptable under the Anti-Kickback Statute, and similar regulatory exceptions have been promulgated by CMS under the Stark Law. While we endeavor to ensure that our arrangements with referral sources comply with an applicable safe harbor to the Anti-Kickback Statute where possible, certain of our current arrangements with physicians and other potential referral sources may not qualify for such protection. Failure to meet a safe harbor does not mean that the arrangement automatically violates the Anti-Kickback Statute, but may subject the arrangement to greater scrutiny. Even if our arrangements are found to be in compliance with the Anti-Kickback Statute, they may still face scrutiny under the newly enacted EKRA law. Moreover, while we believe that our arrangements with physicians comply with applicable Stark Law exceptions, the Stark Law is a strict liability statute for which no intent to violate the law is required.

Effective January 1, 2022, the No Surprises Act, enacted as part of the Consolidated Appropriations Act (the “CAA”), creates price transparency requirements, including (i) requiring providers to send to patients or their health plan a good faith estimate of the expected charges and diagnostic codes prior to furnishing scheduled items or services and (ii) prohibiting providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to limited exceptions. Price transparency initiatives like the No Surprises Act may impact our ability to obtain or maintain favorable contract terms, and may impact our competitive position and our relationships with patients and insurers.

These laws and regulations are extremely complex, and, in many cases, we do not have the benefit of regulatory or judicial interpretation. In the future, it is possible that different interpretations of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our arrangements for facilities, equipment,

personnel, services, capital expenditure programs and operating expenses. A determination that we have violated one or more of these laws could subject us to liabilities, including civil penalties, exclusion of one or more facilities from participation in the government healthcare programs and, for violations of certain laws and regulations, criminal penalties. Even the public announcement that we are being investigated for possible violations of these laws could cause our reputation to suffer and have a material adverse effect on our business, financial condition or results of operations. In addition, we cannot predict whether other similar legislation or regulations at the federal or state level will be adopted, what form such legislation or regulations may take or what their impact on us may be.

The construction and operation of healthcare facilities in the U.S. are subject to extensive federal, state and local regulation relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, fire prevention, rate-setting, compliance with building codes and environmental protection. Additionally, such facilities are subject to periodic inspection by government authorities to assure their continued compliance with these various standards. If we fail to adhere to these standards, we could be subject to monetary penalties or restrictions on our ability to operate.

All of our facilities that handle and dispense controlled substances must comply with strict federal and state regulations regarding the purchase, storage, distribution and disposal of such controlled substances. The potential for theft or diversion of such controlled substances for illegal uses has led the federal government as well as a number of states and localities to adopt stringent regulations not applicable to many other types of healthcare providers. Compliance with these regulations is expensive and these costs may increase in the future.

Property owners and local authorities have attempted, and may in the future attempt, to use or enact zoning ordinances to eliminate our ability to operate a given treatment facility or program. Local governmental authorities in some cases also have attempted to use litigation and the threat of prosecution to force the closure of certain comprehensive treatment facilities. If any of these attempts were to succeed or if their frequency were to increase, our revenue would be adversely affected and our operating results might be harmed. In addition, such actions may require us to litigate which would increase our costs.

Many of our U.S. facilities are also accredited by third-party accreditation agencies such as The Joint Commission or CARF. If any of our existing healthcare facilities lose their accreditation or any of our newde novo or joint venture facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid.

Federal, state and local regulations determine the capacity at which many of our U.S. facilities may be operated. State licensing standards require many of our U.S. facilities to have minimum staffing levels; minimum amounts of residential space per student or patient

30


Table of Contents

and adhere to other minimum standards. Local regulations require us to follow land use guidelines at many of our U.S. facilities, including those pertaining to fire safety, sewer capacity and other physical plant matters.

Similarly, providers of behavioral healthcare services in the U.K. are also subject to a highly regulated business environment. Failure to comply with regulations, lapses in the standards of care, the receipt of poor ratings or lower ratings, the receipt of a negative report that leads to a determination of regulatory noncompliance, or the failure to cure any defect noted in an inspection report could lead to substantial penalties, including the loss of registration or closure of one or more facilities as well as damage to reputation.

Our operations in the U.K. are subject to a high level of regulation and supervision, ranging from the initial establishment of new facilities, which are subject to registration and licensing requirements, to the recruitment and appointment of staff, occupational health and safety, duty of care to service users, clinical and educational standards, conduct of our professional and support staff, the environment, public health and other areas. The regulatory requirements differ across our divisions, though almost all of our activity in England in relation to mental healthcare, elderly care and learning disability care are regulated by the CQC and in Scotland, Wales and Northern Ireland, its local equivalent. In addition, our children’s homes, residential schools and colleges in England are regulated by OFSTED, and in Scotland and Wales by their local equivalent, and all of our schools must be licensed by the Department for Education. See “Item 1. Business—Regulation—U.K. Overview” for further details on the key U.K. regulations to which we are subject.

Inspections by CQC, OFSTED, and other regulators can be carried out on both an announced and unannounced basis depending on the specific regulatory provisions relating to the different healthcare, social care and specialist education services we provide.

A failure to comply with regulations, the receipt of a poor rating or a lower rating, or the receipt of a negative report that leads to a determination of regulatorynon-compliance or our failure to cure any defect noted in an inspection report could result in reputational damage, fines, the revocation or suspension of the registration of any facility or service or a decrease in, or cessation of, the services provided by us at any given facility. Additionally, where placements are funded by Local Authorities, most Local Authorities monitor performance and where there are shortcomings may impose punitive measures. These can, for example, include the suspension of new placements (known in the industry as “embargoes”) and, in extreme cases, removal of all residents placed by that authority, which in turn may affect the level of referrals from other publicly funded entities and our occupancy levels.

Furthermore, new regulations or regulatory bodies may be introduced in the future or existing regulations and regulatory bodies may be amended or replaced and we may not adapt to such changes quickly enough, or in a cost-efficient manner. For example, the U.K. government appointed Monitor (now part of NHS Improvement) as the market regulator for healthcare providers in 2012 by way of a licensing regime. Any failure by us to comply with the licensing regime could result in Monitor revoking our license, which would mean we would be unable to operate. In addition, such regulatory changes may preclude management from executing its business plan as intended, including the timing for new developments and openings.

We cannot guarantee that current laws, regulations and regulatory assessment methodologies will not be modified or replaced in the future. There can be no assurance that our business, results of operations and financial condition will not be adversely affected by any future regulatory developments or that the cost of compliance with new regulations will not be material.

If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected.

Our ability to grow or even to maintain our existing level of business depends significantly on our ability to establish and maintain close working relationships with physicians, managed care companies, insurance companies, educational consultants and other referral sources. We may not be able to maintain our existing referral source relationships or develop and maintain new relationships in existing or new markets. If we lose existing relationships with our referral sources, the number of people to whom we provide services may decline, which may adversely affect our revenue. If we fail to develop new referral relationships, our growth may be restrained.

We may be required to spend substantial amounts to comply with statutes and regulations relating to privacy and security of PHI.

There are currently numerous legislative and regulatory initiatives in both the U.S. and the U.K. addressing patient privacy and information security concerns. In particular, federal regulations issued under HIPAA require our U.S. facilities to comply with standards to protect the privacy, security and integrity of PHI. These requirements include the adoption of certain administrative, physical, and technical safeguards; development of adequate policies and procedures, training programs and other initiatives to ensure the privacy of PHI is maintained; entry into appropriate agreements withso-called business associates; and affording patients certain rights with respect to their PHI, including notification of any breaches. Compliance with these regulations requires substantial expenditures, which could negatively impact our business, financial condition or results of operations. In addition, our management has spent, and may spend in the future, substantial time and effort on compliance measures.

In addition to HIPAA, we are subject to similar, and in some cases more restrictive, state and federal privacy regulations. For example, the federal government and some states impose laws governing the use and disclosure of health information pertaining to mental health and/or substance abuse treatment that are more stringent than the rules that apply to healthcare information generally. As public attention is drawn to the issues of the privacy and security of medical information, states may revise or expand their laws concerning the use and disclosure of health information, or may adopt new laws addressing these subjects.

Violations of the privacy and security regulations could subject our operations to substantial civil monetary penalties and substantial other costs and penalties associated with a breach of data security, including criminal penalties. We may also be subject to substantial reputational harm if we experience a substantial security breach involving PHI.

We are subject to uncertainties regarding recent health reform and budget legislation.

Recent developments with respect to the implementation of PPACA have created uncertainty for many healthcare providers. For example, the Tax Act will effectively repeal the individual health insurance mandate imposed under PPACA by eliminating the tax penalty associated with failure to obtain and maintain coverage. Additionally, President Trump’s administration has taken certain executive actions that may promote the availability of alternative forms of health insurance outside PPACA’s requirements and otherwise affect the implementation of PPACA. We cannot predict how these changes to, or the potential repeal, replacement or further modification of, PPACA will affect our business, results of operations, cash flow, capital resources and liquidity, or whether we will be able to adapt successfully thereto.

We are similarly unable to guarantee that current U.K. laws, regulations and regulatory assessment methodologies will not be modified or replaced in the future. Additionally, there is a risk that budget constraints, public spending cuts (such as the cuts announced by the U.K. government in the 2010 Comprehensive Spending Review and implemented in the 2011 and 2012 government budgets) or other financial pressures could cause the NHS to reduce funding for the types of services that we provide. Such policy changes in the U.K. could lead to fewer services being purchased by publicly funded entities or material changes being made to their procurement practices, any of which could materially reduce our revenue. These and other future developments and amendments may negatively impact our operations, which could have a material adverse effect on our business, financial condition or results of operations. See “—Expanding our operations internationally poses additional risks to our business.”

Finally, the allocation of funding responsibility for adult social care will be subject to change over the next few years under the provisions of the Care Act 2014 with individuals identified as being required to pay for their own care under the relevant means test being required to take funding responsibility up to a specified lifetime monetary cap, with Local Authorities then becoming responsible for the continued funding of personal care, but not ‘daily living’ expenses. This will potentially place greater funding responsibility with public sector bodies over the longer term, which will potentially exacerbate the current funding challenges faced by such bodies.

The industry trend on value-based purchasing may negatively impact our revenue.

There is a trend in the healthcare industry toward value-based purchasing of healthcare services. These value-based purchasing programs include both public reporting of quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for care related to certain preventable adverse events. Many large commercial payors currently require hospitals to report quality data, and several commercial payors do not reimburse hospitals for certain preventable adverse events.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. We are unable at this time to predict how this trend will affect our results of operations, but it could negatively impact our revenue if we are unable to meet quality standards established by both governmental and private payers.

We operate in a highly competitive industry, and competition may lead to declines in patient volumes.

The healthcare industry is highly competitive, and competition among healthcare providers (including hospitals) for patients, physicians and other healthcare professionals has intensified in recent years. There are other healthcare facilities that provide behavioral and other mental health services comparable to those offered by our facilities in each of the geographical areas in which we operate. Some of our competitors are owned bytax-supported governmental agencies or bynon-profit corporations and may have certain financial advantages not available to us, including endowments, charitable contributions,tax-exempt financing and exemptions from sales, property and income taxes. Some of ourfor-profit competitors are local, independent operators or physician groups with strong established reputations within the surrounding communities, which may adversely affect our ability to attract a sufficiently large number of patients in markets where we compete with such providers. We also face competition from otherfor-profit entities, who may possess greater financial, marketing or research and development resources than us or may invest more funds in renovating their facilities or developing technology.

If our competitors are better able to attract patients, recruit and retain physicians and other healthcare professionals, expand services or obtain favorable managed care contracts at their facilities, we may experience a decline in patient volume and our results of operations may be adversely affected.

The NHS is the principal provider of secure mental healthcare services in the U.K., with approximately 70% of the total beds in secure mental healthcare services in the U.K. As the preferred provider, there is often a bias toward referrals to NHS, and therefore NHS facilities have maintained high occupancy rates. As a result of budget constraints, independent operators have emerged to satisfy the demand for mental health services not supplied by the NHS. In addition to the NHS, we face competition in the U.K. from independent sector providers and other publicly funded entities for individuals requiring care and for appropriate sites on which to develop or expand facilities in the U.K. Should we fail to compete effectively with our peers and competitors in the industry, or if the competitive environment intensifies, individuals may be referred elsewhere for services that we provide, negatively impacting our ability to secure referrals and limiting the expansion of our business.

The trend by insurance companies and managed care organizations to enter into sole-source contracts may limit our ability to obtain patients.

Insurance companies and managed care organizations in the U.S. are entering into sole-source contracts with healthcare providers, which could limit our ability to obtain patients since we do not offer the range of services required for these contracts. Moreover, private insurers, managed care organizations and, to a lesser extent, Medicaid and Medicare, are beginning tocarve-out specific services, including mental health and substance abuse services, and establish small, specialized networks of providers for such services at fixed reimbursement rates. Continued growth in the use ofcarve-out arrangements could materially adversely affect our business to the extent we are not selected to participate in such networks or if the reimbursement rate in such networks is not adequate to cover the cost of providing the service.

Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians.

The success and competitive advantage of our facilities depends, in part, on the number and quality of the psychiatrists and other physicians on the medical staffs of our facilities and our maintenance of good relations with those medical professionals. Although we employ psychiatrists and other physicians at many of our facilities, psychiatrists and other physicians generally are not employees of our facilities, and, in a number of our markets, they have admitting privileges at competing hospitals providing acute or inpatient behavioral healthcare services. Such physicians (including psychiatrists) may terminate their affiliation with us at any time or admit their patients to competing healthcare facilities or hospitals. If we are unable to attract and retain sufficient numbers of quality psychiatrists and other physicians by providing adequate support personnel and facilities that meet the needs of those psychiatrists and other physicians, they may stop referring patients to our facilities and our results of operations may decline.

It may become difficult for us to attract and retain an adequate number of psychiatrists and other physicians to practice in certain of the communities in which our facilities are located. Our failure to recruit psychiatrists and other physicians to these communities or the loss of such medical professionals in these communities could make it more difficult to attract patients to our facilities and thereby may have a material adverse effect on our business, financial condition or results of operations. Additionally, our ability to recruit psychiatrists and other physicians is closely regulated. The form, amount and duration of assistance we can provide to recruited psychiatrists and other physicians is limited by the Stark Law, the Anti-Kickback Statute, state anti-kickback statutes, and related regulations.

Some of our employees are represented by labor unions and any work stoppage could adversely affect our business.

Increased labor union activity could adversely affect our labor costs. As of December 31, 2017, labor unions represented approximately 460 of our employees at five of our U.S. facilities through eight collective bargaining agreements. The Royal College of Nursing represents nursing employees at our facilities in the U.K. We cannot assure you that employee relations will remain stable. Furthermore, there is a possibility that work stoppages could occur as a result of union activity, which could increase our labor costs and adversely affect our business, financial condition or results of operations. To the extent that a greater portion of our employee base unionizes and the terms of any collective bargaining agreements are significantly different from our current compensation arrangements, it is possible that our labor costs could increase materially and our business, financial condition or results of operations could be adversely affected.

We depend on key management personnel, and the departure of one or more of our key executives or a significant portion of our local facility management personnel could harm our business.

The expertise and efforts of our senior executives and the chief executive officer, chief financial officer, medical directors, physicians and other key members of our facility management personnel are important to the success of our business. The loss of the services of one or more of our senior executives, including our U.K. senior management team, or of a significant portion of our facility management personnel could significantly undermine our management expertise and our ability to provide efficient, quality healthcare services at our facilities, which could harm our business.

We could face risks associated with, or arising out of, environmental, health and safety laws and regulations.

We are subject to various federal, foreign, state and local laws and regulations that:

regulate certain activities and operations that may have environmental or health and safety effects, such as the generation, handling and disposal of medical wastes;

impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and damages to natural resources from, past spills, waste disposals on andoff-site, or other releases of hazardous materials or regulated substances; and

regulate workplace safety.

Compliance with these laws and regulations could increase our costs of operation. Violation of these laws may subject us to significant fines, penalties or disposal costs, which could negatively impact our results of operations, financial condition or cash flows. We could be responsible for the investigation and remediation of environmental conditions at currently or formerly owned, operated or leased sites, as well as for associated liabilities, including liabilities for natural resource damages, third-party property damage or personal injury resulting from lawsuits that could be brought by the government or private litigants, relating to our operations, the operations of facilities or the land on which our facilities are located. We may be subject to these liabilities regardless of whether we operate, lease or own the facility, and regardless of whether such environmental conditions were created by us or by a prior owner or tenant, or by a third party or a neighboring facility whose operations may have affected such facility or land. That is because liability for contamination under certain environmental laws can be imposed on current or past owners, lessors or operators of a site without regard to fault. We cannot assure you that environmental conditions relating to our prior, existing or future sites or those of predecessor companies whose liabilities we may have assumed or acquired will not have a material adverse effect on our business, financial condition or results of operations.

State efforts to regulate the construction or expansion of healthcare facilities in the U.S. could impair our ability to operate and expand our operations.

A majority of the states in which we operate facilities in the U.S. have enacted certificate of need (“CON”)CON laws that regulate the construction or expansion of healthcare facilities, certain capital expenditures or changes in services or bed capacity. In giving approval for these actions, these states consider the need for additional or expanded healthcare facilities or services. Our failure to obtain necessary state approval could (i) result in our inability to acquire a targeted facility, complete a desired expansion or make a desired replacement, (ii) make a

31


Table of Contents

facility ineligible to receive reimbursement under the Medicare or Medicaid programs or (iii) result in the revocation of a facility’s license or imposition of civil or criminal penalties, any of which could harm our business.

In addition, significant CON reforms have been proposed in a number of states that would increase the capital spending thresholds and provide exemptions of various services from review requirements. In the past, we have not experienced any material adverse effects from such requirements, but we cannot predict the impact of these changes upon our operations.

We may be unable to extend leases at expiration, which could harm our business, financial condition or results of operations.

We lease the real property on which a number of our facilities are located. Our lease agreements generally give us the right to renew or extend the term of the leases and, in certain cases, purchase the real property. These renewal and purchase rights generally are based upon either prescribed formulas or fair market value. Management expects to renew, extend or exercise purchase options with respect to our leases in the normal course of business; however, there can be no assurance that these rights will be exercised in the future or that we will be able to satisfy the conditions precedent to exercising any such renewal, extension or purchase options. Furthermore, the terms of any such options that are based on fair market value are inherently uncertain and could be unacceptable or unfavorable to us depending on the circumstances at the time of exercise. If we are not able to renew or extend our existing leases, or purchase the real property subject to such leases, at or prior to the end of the existing lease terms, or if the terms of such options are unfavorable or unacceptable to us, our business, financial condition or results of operations could be adversely affected.

Controls designed to reduce inpatient services may reduce our revenue.

Controls imposed by Medicare, Medicaid and commercial third-party payors designed to reduce admissions and lengths of stay, commonly referred to as “utilization review,” have affected and are expected to continue to affect our facilities. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required preadmission authorization and utilization review and by payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Efforts to impose more stringent cost controls are expected to continue. For example, PPACA expanded the potential use of prepayment review by Medicare contractors by eliminating certain statutory restrictions on its use. Utilization review is also a requirement of mostnon-governmental managed-care organizations and other third-party payors. Although we are

unable to predict the effect these controls and changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on our financial condition and results of operations.

Additionally, the outsourcing of behavioral healthcare to the private sector is a relatively recent development in the U.K. There has been some opposition to outsourcing. While we anticipate that the NHS will continue to rely increasingly upon outsourcing, we cannot assure you that the outsourcing trend will continue. The absence of future growth in the outsourcing of behavioral healthcare services could have a material adverse impact on our business, financial condition and results of operations.

Although we have facilities in 39 states, the U.K. and Puerto Rico, we have substantial operations in the U.K., Pennsylvania, California and Arkansas, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those locations.

For the year ended December 31, 2017, our revenue in the U.K. represented approximately 36% of our total revenue. Revenue from Pennsylvania, California and Arkansas represented approximately 7%, 5% and 5% of our total revenue for the year ended December 31, 2017, respectively. This concentration makes us particularly sensitive to legislative, regulatory, economic, environmental and competition changes in those locations. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these locations could have a disproportionate effect on our overall business results. If our facilities in these locations are adversely affected by changes in regulatory and economic conditions, our business, financial condition or results of operations could be adversely affected.

In addition, some of our facilities are located in hurricane-prone areas. In 2017 and at other times in the past, hurricanes have had a disruptive effect on the operations of facilities and the patient populations in hurricane-prone areas. Our business activities could be significantly disrupted by a particularly active hurricane season or even a single storm, and our property insurance may not be adequate to cover losses from such storms or other natural disasters.

We are required to treat patients with emergency medical conditions regardless of ability to pay.

In accordance with our internal policies and procedures, as well as EMTALA, we provide a medical screening examination to any individual who comes to one of our hospitals seeking medical treatment (whether or not such individual is eligible for insurance benefits and regardless of ability to pay) to determine if such individual has an emergency medical condition. If it is determined that such person has an emergency medical condition, we provide such further medical examination and treatment as is required to stabilize the patient’s medical condition, within the facility’s capability, or arrange for the transfer of the individual to another medical facility in accordance with applicable law and the treating hospital’s written procedures. Our hospitals may face substantial civil penalties if we fail to provide appropriate screening and stabilizing treatment or fail to facilitate other appropriate transfers as required by EMTALA.

An increase in uninsured or underinsured patients or the deteriorationWe are subject to taxation in the collectability ofU.S., Puerto Rico and various state jurisdictions. Any adverse development in the accountstax laws of such patients could harmjurisdictions or any disagreement with our results of operations.

Collection of receivables from third-party payors and patients is critical to our operating performance. Our primary collection risks relate to uninsured patients and the portion of the bill that is the patient’s responsibility, which primarily includesco-payments and deductibles. We estimate our provisions for doubtful accounts based on general factors such as payor source, the aging of the receivables and historical collection experience. At December 31, 2017, our allowance for doubtful accounts represented approximately 12% of our accounts receivable balance as of such date. We routinely review accounts receivable balances in conjunction with these factors and other economic conditions that might ultimately affect the collectability of the patient accounts and make adjustments to our allowances as warranted. Significant changes in business office operations, payor mix, economic conditions or trends in federal and state governmental health coverage (including the repeal, replacement or modification of PPACA) could affect our collection of accounts receivable, cash flow and results of operations. If we experience unexpected increases in the growth of uninsured and underinsured patients or in bad debt expenses, our results of operations will be harmed.

A cyber security incident could cause a violation of HIPAA and other privacy laws and regulations or result in a loss of confidential data.

A cyber-attack that bypasses our information technology (“IT”) security systems causing an IT security breach, loss of PHI or other data subject to privacy laws, loss of proprietary business information, or a material disruption of our IT business systems,tax positions could have a material adverse impacteffect on our business, financial condition or results of operations. In addition, our future resultseffective tax rate could change materially as a result of operations, as well as our reputation, could be adversely impacted by theft, destruction, loss, or misappropriation of PHI, other confidential data or proprietary business information.changes in tax laws.

FailureWe are subject to maintain effective internal control over financial reportingtaxation in, accordance with Section 404and to the tax laws and regulations of, the Sarbanes-Oxley ActU.S., Puerto Rico and various state jurisdictions as a result of 2002 (the “Sarbanes-Oxley Act”),our operations and our corporate and financing structure. Adverse developments in these tax laws or regulations, or any change in position regarding the application, administration or interpretation thereof, in any applicable jurisdiction, could have a material adverse effect on our business.

We are required to maintain internal control overbusiness, financial reporting under Section 404condition or results of operations. In addition, the Sarbanes-Oxley Act. If we are unable to maintain adequate internal control over financial reporting, wetax authorities in any applicable jurisdiction may be unable to report our financial information on a timely basis, may suffer adverse regulatory consequencesdisagree with the tax treatment or violationscharacterization of NASDAQ listing rules and may breach the covenants under our financing arrangements. There could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliabilityany of our financial statements. If we or our independent registered public accounting firm identify any material weakness in our internal control over financial reporting in the future (including any material weakness in the controls of businesses we have acquired), their correction could require additional remedial measurestransactions, which, could be costly, time-consuming andif successfully challenged by such tax authorities, could have a material adverse effect on our business.business, financial condition or results of operations. Certain changes in the mix of our earnings between jurisdictions and assumptions used in the calculation of income taxes, among other factors, could have a material adverse effect on our overall effective tax rate.

We are responsible forGeneral Risk Factors

Provisions of our charter documents or Delaware law could delay or prevent an underfunded pension liability relatedacquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for stockholders to change management.

Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition of Partnershipsor other change in Care. In addition, wecontrol that stockholders may be requiredconsider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. This is because these provisions may prevent or frustrate attempts by stockholders to increase fundingreplace or remove our management. These provisions include:

a classified board of directors;

a prohibition on stockholder action through written consent;

a requirement that special meetings of stockholders be called only upon a resolution approved by a majority of our directors then in office;

advance notice requirements for stockholder proposals and nominations; and

the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine.

Section 203 of the pension plans and/Delaware General Corporation Law (the “DGCL”) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns or within the last three years has owned 15% of voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Although we have elected not to be subject to Section 203 of the DGCL, our amended and restated certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that Waud Capital Partners, L.L.C. (“WCP”), its affiliates and any investment fund managed by WCP will be deemed to have been approved by our board of directors, and thereby not subject to the restrictions set forth in our amended and restated certificate of incorporation that have the same effect as Section 203 of the DGCL. Accordingly, the

32


Table of Contents

provision in our amended and restated certificate of incorporation that adopts a modified version of Section 203 of the DGCL may discourage, delay or prevent a change in control of us.

As a result of these provisions in our charter documents and Delaware law, the price investors may be willing to pay in the future for shares of our common stock may be limited.

Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock.

The stock markets experience volatility, in some cases unrelated to operating performance. These broad market fluctuations may adversely affect the trading price of our common stock and, as a result, there may be significant volatility in the market price of our common stock. If we are unable to operate our facilities as profitably as we have in the past or as our investors expect us to in the future, the market price of our common stock will likely decline when it becomes apparent that the market expectations may not be realized. In addition to our operating results, many economic and other factors outside of our control could have an adverse effect on the useprice of excess cash.

Partnershipsour common stock and increase fluctuations in Care isour quarterly earnings. These factors include certain of the sponsorrisks discussed herein, outcomes of political elections, demographic changes, operating results of other healthcare companies, changes in our financial estimates or recommendations of securities analysts, speculation in the press or investment community, the possible effects of war, terrorist and other hostilities, adverse weather conditions, climate change, the impact of a defined benefit pension plan (the Partnershipspandemic, epidemic, or outbreak of an infectious disease, managed care contract negotiations and terminations, changes in Care Limited Pension and Life Assurance Plan) that covers approximately 180 membersgeneral conditions in the U.K., most of whom are inactive and retired former employees. As of May 1, 2005, this plan was closed to new participants but then-current participants continue to accrue benefits, and effective May 2015, active participants no longer accrued benefits. As of December 31, 2017,economy or the net deficit recognized under U.S. GAAP in respect of this plan was £6.5 million.

financial markets or other developments affecting the healthcare industry.

Future sales of common stock by our existing stockholders may cause our stock price to fall.

The market price of our common stock could decline as a result of sales by us or our existing stockholders, particularly our largest stockholders, our directors and executive officers, in the market, or the perception that these sales could occur. These sales might also make it more difficult for us to sell equity securities at a time and price that we deem appropriate. Certain current and former members of our management and stockholders have demand and piggyback registration rights with respect to shares of our common stock beneficially owned by them. The presence of additional shares of our common stock trading in the public market, as a result of the exercise of such registration rights, may have an adverse effect on the market price of our securities.

If securities or industry analysts do not publish research or reports about our business, if they were to change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us. If one or more of these analysts cease coverage of us or fail to publish regular reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet their expectations, our stock price could decline.

We incur substantial costs as a result of being a public company.

As a public company, we incur significant legal, accounting, insurance and other expenses, including costs associated with public company reporting requirements. We incur costs associated with complying with the requirements of the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), and related rules implemented by the SEC and NASDAQ. Enacted in July 2010, the Dodd-Frank Act contains significant corporate governance and executive compensation-related provisions, some of which the SEC has implemented by adopting additional rules and regulations in areas such as executive compensation. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. Management expects these laws and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although management is currently unable to estimate these costs with any degree of certainty. These laws and regulations could make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for stockholders to change management.

Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. This is because these provisions may prevent or frustrate attempts by stockholders to replace or remove our management. These provisions include:

a classified board of directors;

a prohibition on stockholder action through written consent;

a requirement that special meetings of stockholders be called only upon a resolution approved by a majority of our directors then in office;

advance notice requirements for stockholder proposals and nominations; and

the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine.

Section 203 of the Delaware General Corporation Law (“DGCL”) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns or within the last three years has owned 15% of voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Although we have elected not to be subject to Section 203 of the DGCL, our amended and restated certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that Waud Capital Partners, L.L.C. (“WCP”), its affiliates and any investment fund managed by WCP and any persons to whom WCP sells at least five percent (5%) of our outstanding voting stock will be deemed to have been approved by our board of directors, and thereby not subject to the restrictions set forth in our amended and restated certificate of incorporation that have the same effect as Section 203 of the DGCL. Accordingly, the provision in our amended and restated certificate of incorporation that adopts a modified version of Section 203 of the DGCL may discourage, delay or prevent a change in control of us.

As a result of these provisions in our charter documents and Delaware law, the price investors may be willing to pay in the future for shares of our common stock may be limited.

We do not anticipate paying any cash dividends in the foreseeable future.

We intend to retain our future earnings, if any, for use in our business or for other corporate purposes and do not anticipate that cash dividends with respect to common stock will be paid in the foreseeable future. Any decision as to the future payment of dividends will depend on our results of operations, financial position and such other factors as our board of directors, in its discretion, deems relevant. In addition, the terms of our debt substantially limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain for the foreseeable future.

Item 1B. Unresolved Staff Comments.

None.


33


Table of Contents

Item 2. Properties.

The following table lists, by state or country, the number of behavioral healthcare facilities directly or indirectly owned and operated by us as ofat December 31, 2017:2022:

 

State

  Facilities   Operated Beds 

 

Facilities

 

 

Operated Beds

 

Alaska

   1    —   

 

 

1

 

 

 

 

Arizona

   3    425 

 

 

4

 

 

 

481

 

Arkansas

   7    713 

 

 

6

 

 

 

785

 

California

   22    462 

 

 

25

 

 

 

496

 

Delaware

   2    93 

 

 

3

 

 

 

130

 

Florida

   6    482 

 

 

12

 

 

 

481

 

Georgia

   5    332 

 

 

9

 

 

 

390

 

Illinois

   1    164 

 

 

2

 

 

 

252

 

Indiana

   8    303 

 

 

10

 

 

 

337

 

Iowa

   1    —   

 

 

2

 

 

 

 

Kansas

   1    —   

 

 

1

 

 

 

 

Kentucky

 

 

1

 

 

 

 

Louisiana

   6    372 

 

 

6

 

 

 

467

 

Maine

   4    —   

 

 

5

 

 

 

 

Maryland

   3    —   

 

 

3

 

 

 

 

Massachusetts

   13    120 

 

 

14

 

 

 

263

 

Michigan

   6    343 

 

 

4

 

 

 

346

 

Mississippi

   3    412 

 

 

3

 

 

 

496

 

Missouri

   2    313 

 

 

6

 

 

 

580

 

Montana

   1    108 

Nevada

   4    144 

 

 

3

 

 

 

134

 

New Hampshire

   2    —   

 

 

2

 

 

 

 

New Jersey

   1    —   

 

 

1

 

 

 

 

New Mexico

   2    207 

 

 

1

 

 

 

46

 

North Carolina

   11    477 

 

 

10

 

 

 

503

 

Ohio

   2    146 

 

 

6

 

 

 

290

 

Oklahoma

   1    108 

 

 

4

 

 

 

108

 

Oregon

   6    —   

 

 

7

 

 

 

 

Pennsylvania

   31    1,413 

 

 

29

 

 

 

1,729

 

Rhode Island

   2    —   

 

 

2

 

 

 

 

South Carolina

   1    42 

 

 

1

 

 

 

63

 

South Dakota

   1    126 

 

 

1

 

 

 

126

 

Tennessee

   6    533 

 

 

14

 

 

 

985

 

Texas

   4    397 

 

 

5

 

 

 

567

 

Utah

   6    147 

 

 

6

 

 

 

147

 

Vermont

   1    —   

 

 

1

 

 

 

 

Virginia

   6    215 

 

 

9

 

 

 

442

 

Washington

   6    135 

 

 

9

 

 

 

137

 

West Virginia

   7    —   

 

 

7

 

 

 

 

Wisconsin

   13    35 

 

 

14

 

 

 

35

 

Puerto Rico

 

 

1

 

 

 

172

 

 

 

250

 

 

 

10,988

 

International

        

Puerto Rico

   1    172 

United Kingdom

   373    8,865 
  

 

   

 

 
          582           17,804 
  

 

   

 

 

See “Business—“Item 1. Business— U.S. Operations” and “Business— U.K. Operations— Description of U.K. Facilities” for a summary description of our U.S. and U.K.the facilities that we own and lease. WeIn addition, we currently lease approximately 61,000 square feet of office space at 6100 Tower Circle, Franklin, Tennessee, for our corporate headquarters. Our headquarters and facilities are generally well maintained and in good operating condition.

34


Table of Contents

We are, from timeInformation with respect to time, subject to various claimsthis item may be found in Note 20—Commitments and legal actions that ariseContingencies in the ordinary courseaccompanying notes to our consolidated financial statements beginning on Page F-1 of our business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be coveredthis Annual Report on Form 10-K, which information is incorporated herein by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bringqui tam,or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. In the opinion of management, we are not currently a party to any proceeding that would have a material adverse effect on our business, financial condition or results of operations.reference.

Item 4. Mine Safety Disclosures

Not applicable.

35


Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Price Range of Common Stock

Our common stock is listed for trading on The NASDAQ Global Select Market under the symbol “ACHC.” The following table sets forth the high and low sales prices per share of our common stock as reported on The NASDAQ Global Select Market for the two most recent fiscal years:

   High   Low 

Year ended December 31, 2016:

    

First Quarter

  $65.89   $49.77 

Second Quarter

  $65.00   $50.30 

Third Quarter

  $57.29   $46.99 

Fourth Quarter

  $50.18   $32.54 

Year ended December 31, 2017:

    

First Quarter

  $47.39   $32.69 

Second Quarter

  $49.99   $40.37 

Third Quarter

  $54.34   $44.26 

Fourth Quarter

  $48.35   $26.92 

Stockholders

As of February 27, 2018,28, 2023, there were approximately 495541 holders of record of our common stock.

Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

During the three months ended December 31, 2017,2022, the Company withheld shares of Company common stock to satisfy employee minimum statutory tax withholding obligations payable upon the vesting of restricted stock, as follows:

 

Period

  Total Number
of Shares
Purchased
   Average Price
Paid per Share
   Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
   Maximum Number of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
 

 

Total Number

of Shares

Purchased

 

 

Average Price

Paid per Share

 

 

Total Number

of Shares

Purchased

as Part of

Publicly

Announced

Plans or

Programs

 

 

Maximum

Number of

Shares that

May Yet Be

Purchased

Under the

Plans or

Programs

 

October 1 – October 31

   590   $33.25    —      —   

 

 

2,502

 

 

$

82.34

 

 

 

 

 

 

 

November 1 – November 30

   4,670   $29.42    —      —   

 

 

1,151

 

 

$

79.40

 

 

 

 

 

 

 

December 1 – December 31

   893    31.83    —      —   

 

 

 

 

 

 

 

 

 

 

 

 

  

 

       

Total

   6,153       

 

 

3,653

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

       

Dividends

We have never declared or paid dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore we do not anticipate paying any cash dividends in the foreseeable future. Additionally, because we are a holding company, our ability to pay dividends on our common stock is limited by restrictions on the ability of our subsidiaries to pay dividends or make distributions to us, including restrictions under the terms of the agreements governing our indebtedness. Any future determination to pay dividends will be at the discretion of our board of directors, subject to compliance with covenants in current and future agreements governing our indebtedness (including our Amended and Restated SeniorNew Credit Facility and the indenture governing our Senior Notes), and will depend upon our results of operations, financial condition, capital requirements and other factors that our board of directors deems relevant.

Item 6. Selected Financial Data.[Reserved]

The selected financial data presented below for the years ended December 31, 2017, 2016 and 2015, and as36


Table of December 31, 2017 and 2016, is derived from our audited consolidated financial statements included elsewhere in this Annual Report on Form10-K. The selected financial data for the years ended December 31, 2014 and 2013, and as of December 31, 2015, 2014 and 2013, is derived from our audited consolidated financial statements not included herein. The selected consolidated financial data below should be read in conjunction with the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and with our consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form10-K. The selected financial data presented below does not give effect to our acquisitions prior to the respective date of such acquisitions.Contents

 

   Year Ended December 31, 
   2017  2016  2015  2014  2013 
   (In thousands, except per share data) 

Income Statement Data:

      

Revenue before provision for doubtful accounts

  $2,877,234  $2,852,823  $1,829,619  $1,030,784  $735,109 

Provision for doubtful accounts

   (40,918  (41,909  (35,127  (26,183  (21,701
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Revenue

   2,836,316   2,810,914   1,794,492   1,004,601   713,408 

Salaries, wages and benefits(1)

   1,536,160   1,541,854   973,732   575,412   407,962 

Professional fees

   196,223   185,486   116,463   52,482   37,171 

Supplies

   114,439   117,425   80,663   48,422   37,569 

Rents and leases

   76,775   73,348   32,528   12,201   10,049 

Other operating expenses

   331,827   312,556   206,746   110,654   80,572 

Depreciation and amortization

   143,010   135,103   63,550   32,667   17,090 

Interest expense, net

   176,007   181,325   106,742   48,221   37,250 

Debt extinguishment costs

   810   4,253   10,818   —     9,350 

Loss on divestiture

   —     178,809   —     —     —   

(Gain) loss on foreign currency derivatives

   —     (523  1,926   (15,262  —   

Transaction-related expenses

   24,267   48,323   36,571   13,650   7,150 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income from continuing operations, before income taxes

   236,798   32,955   164,753   126,154   69,245 

Provision for income taxes

   37,209   28,779   53,388   42,922   25,975 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income from continuing operations

   199,589   4,176   111,365   83,232   43,270 

Income (loss) from discontinued operations, net of income taxes

   —     —     111   (192  (691
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income

   199,589   4,176   111,476   83,040   42,579 

Net loss attributable to noncontrolling interests

   246   1,967   1,078   —     —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $199,835  $6,143  $112,554  $83,040  $42,579 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income from continuing operations per share basic

  $2.30  $0.07  $1.65  $1.51  $0.87 

Income from continuing operations per share diluted

  $2.30  $0.07  $1.64  $1.50  $0.86 

Balance Sheet Data (as of end of period):

      

Cash and cash equivalents

  $67,290  $57,063  $11,215  $94,040  $4,569 

Total assets

   6,424,502   6,024,726   4,279,208   2,206,955   1,213,623 

Total debt

   3,239,888   3,287,809   2,240,744   1,079,635   606,100 

Total equity

   2,572,871   2,167,724   1,683,028   880,965   480,710 

(1)Salaries, wages and benefits for the years ended December 31, 2017, 2016, 2015, 2014 and 2013 include $23.5 million, $28.3 million, $20.5 million, $10.1 million and $5.2 million, respectively, of equity-based compensation expense.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations with our audited consolidated financial statements and notes thereto included elsewhere in this Annual Report onForm 10-K.

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form10-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “would,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contained are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to:to, the following:

the impact of competition for staffing, labor shortages and higher turnover rates on our labor costs and profitability;

the impact of increases in inflation and rising interest rates;

compliance with laws and government regulations;

our indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt;

the impact of payments received from the government and third-party payors on our revenue and results of operations;

the impact of volatility in the global capital and credit markets, as well as significant developments in macroeconomic and political conditions that are out of our control;

the impact of general economic and employment conditions, including increased construction and other costs due to inflation, on our business and future results of operations;

difficulties in successfully integrating the operations of acquired facilities or realizing the potential benefits and synergies of our acquisitions and joint ventures;

our ability to recruit and retain quality psychiatrists and other physicians, nurses, counselors and other medical support personnel;

the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations;

the impact of claims brought against us or our facilities including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employee related claims;

the impact of governmental investigations, regulatory actions and whistleblower lawsuits;

any failure to comply with the terms of the Company’s corporate integrity agreement with the OIG;

the impact of healthcare reform in the U.S.;

our acquisition, joint venture and wholly-owned de novo strategies, which expose us to a variety of operational and financial risks, as well as legal and regulatory risks;

the impact of state efforts to regulate the construction or expansion of healthcare facilities on our ability to operate and expand our operations;

our ability to implement our business strategies;

the impact of disruptions on our inpatient and outpatient volumes caused by pandemics, epidemics or outbreaks of infectious diseases, such as the COVID-19 pandemic;

37


Table of Contents

 

our significant indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt;

our dependence on key management personnel, key executives and local facility management personnel;

difficulties in successfully integrating the operations of acquired facilities or realizing the potential benefits and synergies of our acquisitions and joint ventures;

our restrictive covenants, which may restrict our business and financing activities;

our ability to implement our business strategies in the U.S. and the U.K. and adapt to the regulatory and business environment in the U.K.;

the impact of adverse weather conditions and climate change, including the effects of hurricanes, wildfires and other natural disasters, and any resulting outmigration;

potential difficulties operating our business in light of political and economic instability in the U.K. and globally following the referendum in the U.K. on June 23, 2016, in which voters approved an exit from the European Union, or Brexit;

the risk of a cyber-security incident and any resulting adverse impact on our operations or violation of laws and regulations regarding information privacy;

the impact of fluctuations in foreign exchange rates, including the devaluations of the GBP relative to the USD following the Brexit vote;

our future cash flow and earnings;

the impact of payments received from the government and third-party payors on our revenue and results of operations including the significant dependence of our U.K. facilities on payments received from the NHS;

the impact of our highly competitive industry on patient volumes;

our ability to recruit and retain quality psychiatrists and other physicians;

our ability to cultivate and maintain relationships with referral sources;

the impact of competition for staffing on our labor costs and profitability;

the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts on our ability to obtain patients;

the impact of increases to our labor costs;

the impact of value-based purchasing programs on our revenue;

the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations;

our potential inability to extend leases at expiration;

our future cash flow and earnings;

the impact of controls designed to reduce inpatient services on our revenue;

our restrictive covenants, which may restrict our business and financing activities;

the impact of different interpretations of accounting principles on our results of operations or financial condition;

our ability to make payments on our financing arrangements;

the impact of environmental, health and safety laws and regulations, especially in locations where we have concentrated operations;

the impact of the economic and employment conditions in the U.S. and the U.K. on our business and future results of operations;

the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions;

compliance with laws and government regulations;

the impact of a change in the mix of our earnings, adverse changes in our effective tax rate and adverse developments in tax laws generally;

the impact of claims brought against us or our facilities;

changes in interpretations, assumptions and expectations regarding recent tax legislation, including provisions of the CARES Act and additional guidance that may be issued by federal and state taxing authorities;

the impact of governmental investigations, regulatory actions and whistleblower lawsuits;

failure to maintain effective internal control over financial reporting;

the impact of healthcare reform in the U.S. and abroad, including the potential repeal, replacement or modification of PPACA;

the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities; and

the impact of our highly competitive industry on patient volumes;

our dependence on key management personnel, key executives and local facility management personnel;

our acquisition, joint venture and de novo strategies, which expose us to a variety of operational and financial risks, as well as legal and regulatory risks;

the impact of state efforts to regulate the construction or expansion of healthcare facilities on our ability to operate and expand our operations;

our potential inability to extend leases at expiration;

the impact of controls designed to reduce inpatient services on our revenue;

the impact of different interpretations of accounting principles on our results of operations or financial condition;

the impact of environmental, health and safety laws and regulations, especially in locations where we have concentrated operations;

the impact of an increase in uninsured and underinsured patients or the deterioration in the collectability of the accounts of such patients on our results of operations;

the risk of a cyber-security incident and any resulting violation of laws and regulations regarding information privacy or other negative impact;

the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions;

our ability to cultivate and maintain relationships with referral sources;

the impact of a change in the mix of our U.S. and U.K. earnings, adverse changes in our effective tax rate and adverse developments in tax laws generally;

changes in interpretations, assumptions and expectations regarding the Tax Act, including additional guidance that may be issued by federal and state taxing authorities;

failure to maintain effective internal control over financial reporting;

the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities;

the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts on our ability to obtain patients;

the impact of value-based purchasing programs on our revenue; and

those risks and uncertainties described from time to time in our filings with the SEC.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date of this Annual Report on Form10-K. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Overview

Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At December 31, 2017,2022, we operated 582250 behavioral healthcare facilities with approximately 17,80011,000 beds in 39 states the U.K. and Puerto Rico. During the year ended December 31, 2017,2022, we acquired one facility and added 750 new560 beds, (exclusiveconsisting of the acquisition), including 588290 added to existing facilities and 162270 added through the opening of one wholly-owned facility and two de novo facilities.joint venture facilities, and we opened seven CTCs. For the year ending December 31, 2018,2023, we expect to add more than 800 totalapproximately 300 beds exclusive of acquisitions.through additions to existing facilities, and we expect to open two wholly-owned facilities, two joint venture facilities and at least six CTCs.

We are the leading publicly traded pure-play provider of behavioral healthcare services with operations in the U.S. and the U.K. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of

38


Table of Contents

our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and U.K.

bed additions in existing facilities.

On January 19, 2021, we completed the U.K. Sale pursuant to a Share Purchase Agreement in which we sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of our U.K. operations.The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current GBP to USD exchange rate, cash retained by the buyer and transaction costs. We used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash from the balance sheet to reduce debt by $1,640 million during the first quarter of 2021. As a result of the U.K. Sale, we reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements.

Acquisitions

2017 Acquisition

On November 13, 2017,7, 2022, we completed the acquisition of Aspire, an education facility with 36 bedsacquired four CTCs located in Scotland,Georgia from Brand New Start.

On December 31, 2021, we acquired the equity of CenterPointe for cash consideration of approximately $21.3$140 million.

2016 U.S. Acquisitions

On June 1, 2016, we completed The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility. At the time of the acquisition, of Pocono Mountain, anCenterPointe operated four acute inpatient psychiatric facilityhospitals with 108306 beds locatedand ten outpatient locations primarily in Henryville, Pennsylvania, for cash consideration of approximately $25.4 million.Missouri.

On May 1, 2016, we completed the acquisition of TrustPoint, an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.

On April 1, 2016, we completed the acquisition of Serenity Knolls, an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.

Priory

On February 16, 2016, we completed the acquisition of Priory for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of our common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K. operating 324 facilities with approximately 7,100 beds at the acquisition date.

The CMA in the U.K. reviewed our acquisition of Priory. On July 14, 2016, the CMA announced that our acquisition of Priory was referred for a phase 2 investigation unless we offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that we had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider our undertakings.

On October 18, 2016, we signed a definitive agreement with BC Partners for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds. On November 10, 2016, the CMA accepted our undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concerns about the impact of our acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K. As a result of the CMA’s acceptance of our undertakings, our acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, we completed the sale of the U.K. Disposal Group to BC Partners for £320 million cash.

Revenue

Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and Local Authorities in England, Scotland and Wales); and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.

Results of Operations

The following table illustrates our consolidated results of operations from continuing operations for the respective periods shown (dollars in thousands):

 

 

Year Ended December 31,

 

  Year Ended December 31, 

 

2022

 

 

2021

 

 

2020

 

  2017 2016 2015 
  Amount % Amount % Amount % 

Revenue before provision for doubtful accounts

  $2,877,234   $2,852,823   $1,829,619  

Provision for doubtful accounts

   (40,918  (41,909  (35,127 
  

 

   

 

   

 

  

 

Amount

 

 

%

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

Revenue

   2,836,316  100.0 2,810,914  100.0 1,794,492  100.0

 

 

2,610,399

 

 

 

100.0

%

 

 

2,314,394

 

 

 

100.0

%

 

 

2,089,929

 

 

 

100.0

%

Salaries, wages and benefits

   1,536,160  54.2 1,541,854  54.9 973,732  54.3

 

 

1,393,434

 

 

 

53.4

%

 

 

1,243,804

 

 

 

53.7

%

 

 

1,154,522

 

 

 

55.2

%

Professional fees

   196,223  6.9 185,486  6.6 116,463  6.5

 

 

158,013

 

 

 

6.1

%

 

 

136,739

 

 

 

5.9

%

 

 

120,489

 

 

 

5.8

%

Supplies

   114,439  4.0 117,425  4.2 80,663  4.5

 

 

100,200

 

 

 

3.8

%

 

 

90,702

 

 

 

3.9

%

 

 

87,241

 

 

 

4.2

%

Rents and leases

   76,775  2.7 73,348  2.6 32,528  1.8

 

 

45,462

 

 

 

1.7

%

 

 

38,519

 

 

 

1.7

%

 

 

37,362

 

 

 

1.8

%

Other operating expenses

   331,827  11.7 312,556  11.1 206,746  11.5

 

 

349,277

 

 

 

13.4

%

 

 

301,339

 

 

 

13.0

%

 

 

262,272

 

 

 

12.5

%

Income from provider relief fund

 

 

(21,451

)

 

 

(0.8

)%

 

 

(17,900

)

 

 

(0.8

)%

 

 

(32,819

)

 

 

(1.6

)%

Depreciation and amortization

   143,010  5.0 135,103  4.8 63,550  3.5

 

 

117,769

 

 

 

4.5

%

 

 

106,717

 

 

 

4.6

%

 

 

95,256

 

 

 

4.6

%

Interest expense, net

   176,007  6.2 181,325  6.4 106,742  6.0

 

 

69,760

 

 

 

2.7

%

 

 

76,993

 

 

 

3.3

%

 

 

158,105

 

 

 

7.6

%

Debt extinguishment costs

   810  0.0 4,253  0.1 10,818  0.6

 

 

 

 

 

0.0

%

 

 

24,650

 

 

 

1.1

%

 

 

7,233

 

 

 

0.3

%

Loss on divestiture

   —    —   178,809  6.4  —    —  

(Gain) loss on foreign currency derivatives

   —    —   (523 —   1,926  0.1

Transaction related expenses

   24,267  0.9 48,323  1.7 36,571  2.0

Loss on impairment

 

 

 

 

 

0.0

%

 

 

24,293

 

 

 

1.0

%

 

 

4,751

 

 

 

0.2

%

Transaction-related expenses

 

 

23,792

 

 

 

0.9

%

 

 

12,778

 

 

 

0.6

%

 

 

11,720

 

 

 

0.6

%

  

 

  

 

  

 

  

 

  

 

  

 

 

 

 

2,236,256

 

 

 

85.7

%

 

 

2,038,634

 

 

 

88.0

%

 

 

1,906,132

 

 

 

91.2

%

   2,599,518  91.6 2,777,959  98.8 1,629,739  90.8

Income from continuing operations, before income taxes

   236,798  8.4 32,955  1.2 164,753  9.2

Income from continuing operations

before income taxes

 

 

374,143

 

 

 

14.3

%

 

 

275,760

 

 

 

12.0

%

 

 

183,797

 

 

 

8.8

%

Provision for income taxes

   37,209  1.3 28,779  1.0 53,388  3.0

 

 

94,110

 

 

 

3.6

%

 

 

67,557

 

 

 

2.9

%

 

 

40,606

 

 

 

1.9

%

  

 

  

 

  

 

  

 

  

 

  

 

 

Income from continuing operations

  $199,589  7.1 $4,176  0.2 $111,365  6.2

 

 

280,033

 

 

 

10.7

%

 

 

208,203

 

 

 

8.9

%

 

 

143,191

 

 

 

6.8

%

  

 

  

 

  

 

  

 

  

 

  

 

 

Loss from discontinued

operations, net of taxes

 

 

 

 

 

0.0

%

 

 

(12,641

)

 

 

(0.5

)%

 

 

(812,390

)

 

 

(38.9

)%

Net income (loss)

 

 

280,033

 

 

 

10.7

%

 

 

195,562

 

 

 

8.4

%

 

 

(669,199

)

 

 

(32.0

)%

Net income attributable to

noncontrolling interests

 

 

(6,894

)

 

 

(0.3

)%

 

 

(4,927

)

 

 

(0.2

)%

 

 

(2,933

)

 

 

(0.1

)%

Net income (loss) attributable to Acadia

Healthcare Company, Inc.

 

 

273,139

 

 

 

10.4

%

 

 

190,635

 

 

 

8.2

%

 

 

(672,132

)

 

 

(32.2

)%

We are encouraged by the favorable trends in our business and believe we are well positioned to capitalize on the expected growth in demand for behavioral health services. As with many other healthcare providers and other industries across the country, we are currently dealing with a tight labor market. While we experienced higher wage inflation in 2022 compared to previous years, we believe the diversity of our markets and service lines and our proactive focus helps us manage through this environment. We remain focused on ensuring that we have the level of staff to meet the demand in our markets across our 39 states and Puerto Rico.

39


Table of Contents

The following table sets forth percent changes in same facility operating data for our continuing operations for the years ended December 31, 2022 and 2021 compared to the previous years:

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

U.S. Same Facility Results (a)

 

 

 

 

 

 

 

 

Revenue growth

 

9.2%

 

 

10.9%

 

Patient days growth

 

2.5%

 

 

4.3%

 

Admissions growth

 

(1.0)%

 

 

3.5%

 

Average length of stay change (b)

 

3.6%

 

 

0.8%

 

Revenue per patient day growth

 

6.5%

 

 

6.3%

 

Adjusted EBITDA margin change (c)

 

70 bps

 

 

150 bps

 

Adjusted EBITDA margin excluding income

    from provider relief fund (d)

 

60 bps

 

 

220 bps

 

(a)

Results for the periods presented include facilities we have operated more than one year and exclude certain closed services.

(b)

Average length of stay is defined as patient days divided by admissions.

(c)

Adjusted EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, loss on impairment, transaction-related expenses, interest expense and depreciation and amortization. Management uses Adjusted EBITDA as an analytical indicator to measure performance and to develop strategic objectives and operating plans. Adjusted EBITDA is commonly used as an analytical indicator within the healthcare industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(d)

For the years ended December 31, 2022, 2021 and 2020, excludes income from provider relief fund of $21.5 million, $17.9 million and $32.8 million, respectively.

Year Ended December 31, 2017 Compared2022 compared to the Year Ended December 31, 20162021

Revenue.Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $24.4$296.0 million, or 0.9%12.8%, to $2.9 billion$2,610.4 million for the year ended December 31, 20172022 from $2.9 billion$2,314.4 million for the year ended December 31, 2016. The increase related primarily to2021. Same facility revenue generated during the year ended December 31, 2017 from the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory, offset by the reduction in revenue before provision for doubtful accounts related to the U.K. Divestiture of $154.7 million and the decline in the exchange rate between USD and GBP of $45.5 million. Same-facility revenue before provision for doubtful accounts increased by $138.2$210.9 million, or 5.5%9.2%, for the year ended December 31, 20172022 compared to the year ended December 31, 2016,2021, resulting from same-facilitysame facility growth in patient days of 3.6%2.5%, an increase in same facility revenue per day of 6.5% and an increase in same-facility revenue per daythe average length of 1.9%stay of 3.6%. Consistent with the same-facilitysame facility patient day growth in 2016,2021, the growth in same-facilitysame facility patient days for the year ended December 31, 20172022 compared to the year ended December 31, 20162021 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

Provision for doubtful accounts. The provision for doubtful accounts was $40.9 million for the year ended December 31, 2017, or 1.4% of revenue before provision for doubtful accounts, compared to $41.9 million for the year ended December 31, 2016, or 1.5% of revenue before provision for doubtful accounts.

Salaries, wages and benefits. Salaries, wages and benefits (“SWB”) expense was $1.5 billion$1,393.4 million for the year ended December 31, 20172022 compared to $1.5 billion$1,243.8 million for the year ended December 31, 2016, a decrease2021, an increase of $5.7$149.6 million. SWB expense included $23.5$29.6 million and $28.3$37.5 million of equity-based compensation expense for the years ended December 31, 20172022 and 2016,2021, respectively. Excluding equity-based compensation expense, SWB expense was $1.5 billion,$1,363.8 million, or 53.3%52.2% of revenue, for the year ended December 31, 2017,2022, compared to $1.5 billion,$1,206.3 million, or 53.8%52.1% of revenue, for the year ended December 31, 2016. The slight decrease in SWB expense, excluding equity-based compensation expense, was primarily attributable to the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP offset by SWB expense incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory. Same-facility2021. Same facility SWB expense was $1.3 billion for the year ended December 31, 2017, or 50.9% of revenue compared to $1.3 billion for the year ended December 31, 2016, or 51.0% of revenue.

Professional fees. Professional fees were $196.2$1,208.4 million for the year ended December 31, 2017,2022, or 6.9%48.3% of revenue, compared to $185.5$1,112.4 million for the year ended December 31, 2016,2021, or 6.6%48.5% of revenue. The $10.7 million increase was primarily attributable professional fees incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory, and higher contract labor costs in our U.K. Facilities offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facility professional

Professional fees. Professional fees were $160.1$158.0 million for the year ended December 31, 2017,2022, or 6.2%6.1% of revenue, compared to $145.0$136.7 million for the year ended December 31, 2016,2021, or 5.9% of revenue.

Supplies.Supplies expense was $114.4 Same facility professional fees were $132.6 million for the year ended December 31, 2017,2022, or 4.0%5.3% of revenue, compared to $117.4$124.1 million, for the year ended December 31, 2016,2021, or 4.2%5.4% of revenue. The $3.0 million decrease was primarily attributable to the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP offset by supplies expense incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory. Same-facility supplies

Supplies. Supplies expense was $103.5 million for the year ended December 31, 2017, or 4.0% of revenue, compared to $100.2 million for the year ended December 31, 2016,2022, or 4.1%3.8% of revenue.

Rents and leases. Rents and leases were $76.8revenue, compared to $90.7 million for the year ended December 31, 2017,2021, or 2.7%3.9% of revenue, compared to $73.3revenue. Same facility supplies expense was $94.7 million for the year ended December 31, 2016,2022, or 2.6%3.8% of revenue. The $3.4 million increase was primarily attributablerevenue, compared to rents and leases incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory slightly offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facility rents and leases were $58.0$89.8 million for the year ended December 31, 2017,2021, or 2.2%3.9% of revenue, compared to $57.5revenue.

40


Table of Contents

Rents and leases. Rents and leases were $45.5 million for the year ended December 31, 2016,2022, or 2.3%1.7% of revenue, compared to $38.5 million for the year ended December 31, 2021, or 1.7% of revenue. Same facility rents and leases were $37.0 million for the year ended December 31, 2022, or 1.5% of revenue, compared to $35.0 million for the year ended December 31, 2021, or 1.5% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $331.8$349.3 million for the year ended December 31, 2017,2022, or 11.7%13.4% of revenue, compared to $312.6$301.3 million for the year ended December 31, 2016,2021, or 11.1%13.0% of revenue. The $19.2 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory slightly offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facilitySame facility other operating expenses were $297.8$314.9 million for the year ended December 31, 2017,2022, or 11.4%12.6% of revenue, compared to $273.3$290.0 million for the year ended December 31, 2016,2021, or 11.1%12.6% of revenue.

Income from provider relief fund. For the year ended December 31, 2022, we recorded $21.5 million of income from provider relief fund related to PHSSE Fund and ARP funds received in 2021 and 2022. For the year ended December 31, 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received in 2021 and 2020.

Depreciation and amortization. Depreciation and amortization expense was $143.0$117.8 million for the year ended December 31, 2017,2022, or 5.0%4.5% of revenue, compared to $135.1$106.7 million for the year ended December 31, 2016,2021, or 4.8%4.6% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2016 and 2017 and real estate acquired as part of the 2016 Acquisitions, particularly the acquisition of Priory, offset by reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP.

Interest expense. Interest expense was $176.0$69.8 million for the year ended December 31, 20162022 compared to $181.3$77.0 million for the year ended December 31, 2016.2021. The decrease in interest expense was primarily athe result of the lower interest rates in connection with amendmentsa significant reduction to the Amended and Restated Senior Credit Facility and theoutstanding debt paydown on November 30, 2016 using proceeds from the U.K. Divestiture. Interest expense was also impacted by higher interest rates applicable to our variable rate debt, borrowings under the Amended and Restated Senior Credit Facility and the issuance of the 6.500% Senior Notes on February 16, 2016.

Debt extinguishment costs. Debt extinguishment costs for the year ended December 30, 2017 represent $0.5 million of charges and $0.3 ofnon-cash charges recorded in connection with the Third Repricing Amendment to the Amended and Restated Senior Credit Facility.U.K. Sale.

Debt extinguishment costs. Debt extinguishment costs for the year ended December 31, 2016 represent $1.1 million of cash charges and $3.2 million ofnon-cash charges recorded in connection with the TrancheB-2 Repricing Amendment and the Refinancing Amendment.

Loss on divestiture.As part of our divestitures in the U.K. and U.S., we recorded $178.8 million of loss on divestiture for the year ended December 31, 2016, which included an allocation of goodwill to the disposal groups of approximately $106.9 million, loss on the sale of properties of approximately $45.0 million, transaction-related expenses of approximately $26.8 million andwrite-off of intangible assets of approximately $0.1 million.

Gain on foreign currency derivatives. We entered into foreign currency forward contracts during the year ended December 31, 2016 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and the U.K. under our cash management and foreign currency risk management programs. Exchange rate changes between the contract date and the settlement date resulted in a gain on foreign currency derivatives of $0.5were $24.7 million for the year ended December 31, 2016.

2021 and represented $6.3 million of cash charges and $18.4 million of non-cash charges in connection with the redemption of the 5.625% Senior Notes and the 6.500% Senior Notes and the termination of the Prior Credit Facility.

Transaction-related expenses. Transaction-related expenses wereLoss on impairment. Loss on impairment was $24.3 million for the year ended December 31, 2017 compared to $48.32021. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

Transaction-related expenses. Transaction-related expenses were $23.8 million for the year ended December 31, 2016.2022 compared to $12.8 million for the year ended December 31, 2021. Transaction-related expenses represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective periods, primarily related to the 2016 Acquisitions, the U.K. Divestiture and the related integration efforts, as summarized below (in thousands):

 

   Year Ended December 31, 
   2017   2016 

Severance and contract termination costs

  $14,709   $12,415 

Legal, accounting and other fees

   9,558    21,058 

Advisory and financing commitment fees

   —      14,850 
  

 

 

   

 

 

 
  $24,267   $48,323 
  

 

 

   

 

 

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Management transition costs

 

$

11,575

 

 

$

 

Termination and restructuring costs

 

 

6,476

 

 

 

5,343

 

Legal, accounting and other acquisition-related costs

 

 

5,741

 

 

 

7,435

 

 

 

$

23,792

 

 

$

12,778

 

Discontinued Operations. Loss from discontinued operations for the year ended December 31, 2021 was $12.6 million.

Provision for income taxes. For the year ended December 31, 2017,2022, the provision for income taxes was $37.2$94.1 million, reflecting an effective tax rate of 15.7%25.2%, compared to $28.8$67.6 million, reflecting an effective tax rate of 87.3%24.5%, for 2016. The decrease in the effective tax rate for the year ended December 31, 2017 was primarily attributable to the Company’s estimate of theone-time tax benefit on revaluation of deferred tax items pursuant to the enactment of the Tax Act as well as changes in the foreign exchange rate between USD and GBP in 2017 and the disparity between the accounting treatment and the tax treatment of the U.K. Divestiture on November 30, 2016. The Company will continue to analyze the effects of the Tax Act on its financial statements and operations. Additional impacts from the enactment of the Tax Act will be recorded as they are identified during the measurement period as provided for in Staff Accounting Bulletin 118 (“SAB 118”).2021.

Year Ended December 31, 2016 Compared2021 compared to the Year Ended December 31, 20152020

Revenue.Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $1.0 billion,$224.5 million, or 55.9%10.7%, to $2.9 billion for the year ended December 31, 2016 from $1.8 billion for the year ended December 31, 2015. The increase related primarily to revenue generated during the year ended December 31, 2016 from the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. The decrease in the GBP to USD exchange rate had an unfavorable impact on revenue before provision for doubtful accounts of $35.6$2,314.4 million for the year ended December 31, 2016. Same-facility2021 from $2,089.9 million for the year ended December 31, 2020. Same facility revenue before provision for doubtful accounts increased by $127.2$225.6 million, or 7.5%10.9%, for the year ended December 31, 20162021 compared to the year ended December 31, 2015, primarily2020, resulting from same-facilitysame facility growth in patient days of 7.2%4.3% and an increase in same facility revenue per day of 6.3%. Consistent with the same-facilitysame facility patient day growth in 2015,2020, the growth in same-facilitysame

41


Table of Contents

facility patient days for the year ended December 31, 20162021 compared to the year ended December 31, 20152020 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

Provision for doubtful accounts. The provision for doubtful accountsSalaries, wages and benefits. SWB expense was $41.9$1,243.8 million for the year ended December 31, 2016, or 1.5 % of revenue before provision for doubtful accounts,2021 compared to $35.1$1,154.5 million for the year ended December 31, 2015, or 1.9% of revenue before provision for doubtful accounts. The same-facility provision for doubtful accounts was $35.3 million for the year ended December 31, 2016, or 1.9% of revenue before provision for doubtful accounts, compared to $31.5 million for the year ended December 31, 2015, or 1.9% of revenue before provision for doubtful accounts.

Salaries, wages and benefits. Salaries, wages and benefits expense was $1.5 billion for the year ended December 31, 2016 compared to $973.7 million for the year ended December 31, 2015,2020, an increase of $568.1$89.3 million. SWB expense included $28.3$37.5 million and $20.5$22.5 million of equity-based compensation expense for the years ended December 31, 20162021 and 2015,2020, respectively. Excluding equity-based compensation expense, SWB expense was $1.5 billion,$1,206.3 million, or 53.8%52.1% of revenue, for the year ended December 31, 2016,2021, compared to $953.3$1,132.0 million, or 53.1%54.2% of revenue, for the year ended December 31, 2015. The $560.3 million increase in SWB expense, excluding equity-based compensation expense, was primarily attributable to SWB expense incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facility2020. Same facility SWB expense was $895.0$1,115.0 million for the year ended December 31, 2016,2021, or 50.2%48.5% of revenue, compared to $830.8$1,049.0 million for the year ended December 31, 2015,2020, or 50.0%50.6% of revenue.

Professional fees. Professional fees were $185.5$136.7 million for the year ended December 31, 2016,2021, or 6.6 %5.9% of revenue, compared to $116.5$120.5 million for the year ended December 31, 2015,2020, or 6.5%5.8% of revenue. The $69.0 million increase was primarily attributable to professional fees incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility professional fees were $92.8$123.3 million for the year ended December 31, 2016,2021, or 5.2%5.4% of revenue, compared to $95.0$108.0 million, for the year ended December 31, 2015,2020, or 5.7%5.2% of revenue.

Supplies.Supplies expense was $117.4$90.7 million for the year ended December 31, 2016,2021, or 4.2%3.9% of revenue, compared to $80.7$87.2 million for the year ended December 31, 2015,2020, or 4.5%4.2% of revenue. The $36.7 million increase was primarily attributable to supplies expense incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility supplies expense was $79.5$89.7 million for the year ended December 31, 2016,2021, or 4.5%3.9% of revenue, compared to $74.2$86.6 million for the year ended December 31, 2015,2020, or 4.5%4.2% of revenue.

Rents and leases. Rents and leases were $73.3$38.5 million for the year ended December 31, 2016,2021, or 2.6%1.7% of revenue, compared to $32.5$37.4 million for the year ended December 31, 2015,2020, or 1.8% of revenue. The $40.8 million increase was primarily attributable to rents and leases incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility rents and leases were $31.5$34.5 million for the year ended December 31, 2016,2021, or 1.8%1.5% of revenue, compared to $29.6$34.1 million for the year ended December 31, 2015,2020, or 1.8%1.6% of revenue.

Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $312.6$301.3 million for the year ended December 31, 2016,2021, or 11.1%13.0% of revenue, compared to $206.7$262.3 million for the year ended December 31, 2015,2020, or 11.5%12.5% of revenue. The $105.9 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility other operating expenses were $202.6$286.2 million for the year ended December 31, 2016,2021, or 11.4%12.4% of revenue, compared to $188.4$256.0 million for the year ended December 31, 2015,2020, or 11.3%12.3% of revenue.

Income from provider relief fund. For the year ended December 31, 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received in 2021 and 2020. For the year ended December 31, 2020, we recorded $32.8 million of income from provider relief fund related to $34.9 million of PHSSE Fund funds received from April through December 2020. Our recognition of this income in the fourth quarter of 2020 was based on revised guidance in the CAA enacted in December 2020.

Depreciation and amortization. Depreciation and amortization expense was $135.1 million for the year ended December 31, 2016, or 4.8% of revenue, compared to $63.6 million for the year ended December 31, 2015, or 3.5% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2015 and 2016 and real estate acquired as part of the 2015 and 2016 Acquisitions, particularly the acquisition of Priory.

Interest expense. Interest expense was $181.3 million for the year ended December 31, 2016 compared to $106.7 million for the year ended December 31, 2015. The increase in interest expense was primarily a result2021, or 4.6% of borrowings under the Amended and Restated Senior Credit Facility, the issuance of the 5.625% Senior Notes on February 11, 2015 and September 21, 2015 and the issuance of the 6.500% Senior Notes on February 16, 2016.

Debt extinguishment costs. Debt extinguishment costs for the year ended December 31, 2016 represent $1.1 million of cash charges and $3.2 million ofnon-cash charges recorded in connection with the TrancheB-2 Repricing Amendment and the Refinancing Amendment. Debt extinguishment costs for the year ended December 31, 2015 represent $7.5 million of cash charges and $3.3 million ofnon-cash charges recorded in connection with the repayment of $97.5 million of 12.875% Senior Notes.

Loss on divestiture.As part of our divestitures in the U.K. and U.S., we recorded $178.8 million of loss on divestiture for the year ended December 31, 2016, which included an allocation of goodwillrevenue, compared to the disposal groups of approximately $106.9 million, loss on the sale of properties of approximately $45.0 million, transaction-related expenses of approximately $26.8 million andwrite-off of intangible assets of approximately $0.1 million.

(Gain) loss on foreign currency derivatives. We entered into foreign currency forward contracts during the years ended December 31, 2016 and 2015 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and the U.K. under our cash management and foreign currency risk management programs. Exchange rate changes between the contract date and the settlement date resulted in a gain on foreign currency derivatives of $0.5$95.3 million for the year ended December 31, 2016, compared to a loss2020, or 4.6% of $1.9revenue.

Interest expense. Interest expense was $77.0 million for the year ended December 31, 2015.

Transaction-related expenses. Transaction-related expenses were $48.32021 compared to $158.1 million for the year ended December 31, 2016 compared2020. The decrease in interest expense was primarily the result of a significant reduction to $36.6outstanding debt in connection with the U.K. Sale.

Debt extinguishment costs. Debt extinguishment costs were $24.7 million for the year ended December 31, 2015.2021 and represented $6.3 million of cash charges and $18.4 million of non-cash charges in connection with the redemption of the 5.625% Senior Notes and the 6.500% Senior Notes and the termination of the Prior Credit Facility. Debt extinguishment costs were $7.2 million for the year ended December 31, 2020 and represented $1.4 million of cash charges and $5.8 million of non-cash charges recorded in connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the issuance of the 5.000% Senior Notes and the Fourth Repricing Facilities Amendment.

Loss on impairment. Loss on impairment was $24.3 million for the year ended December 31, 2021. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage. Loss on impairment of $4.8 million for the year end December

42


Table of Contents

31, 2020 represents a non-cash long-lived asset impairment charge of $4.2 million and $0.6 million related to indefinite-lived asset impairment related to closed facilities in the U.S.

Transaction-related expenses. Transaction-related expenses were $12.8 million for the year ended December 31, 2021 compared to $11.7 million for the year ended December 31, 2020. Transaction-related expenses represent legal, accounting, termination, restructuring, strategic review and other similar costs incurred in the respective periods, primarily related to the 2015 and 2016 Acquisitions, as summarized below (in thousands):

 

   Year Ended December 31, 
   2016   2015 

Legal, accounting and other fees

  $21,058   $17,768 

Advisory and financing commitment fees

   14,850    10,337 

Severance and contract termination costs

   12,415    8,466 
  

 

 

   

 

 

 
  $48,323   $36,571 
  

 

 

   

 

 

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Legal, accounting and other acquisition-related costs

 

$

7,435

 

 

$

8,252

 

Termination and restructuring costs

 

 

5,343

 

 

 

3,468

 

 

 

$

12,778

 

 

$

11,720

 

Discontinued Operations. Loss from discontinued operations for the year ended December 31, 2021 was $12.6 million compared to loss from discontinued operations of $812.4 million for the year ended December 31, 2020. The year ended December 31, 2020 included a loss on sale of $867.3 million related to the U.K. operations and a non-cash long-lived asset impairment charge of $20.2 million related to the decision to close certain U.K. elderly care facilities.

Provision for income taxes. For the year ended December 31, 2016,2021, the provision for income taxes was $28.8$67.6 million, reflecting an effective tax rate of 87.3%24.5%, compared to $53.4$40.6 million, reflecting an effective tax rate of 32.4%22.1%, for 2015.the year ended December 31, 2020. The changeincrease in the effective tax rate for the year ended December 31, 2016 is2021 was primarily attributable to the disparity between the accounting treatmentour recognition of a deferred tax liability as a result of a change in our previous permanent reinvestment assertion and thenon-recurring impacts of U.S. and U.K. tax treatment of the U.K. Divestiture on November 30, 2016.

legislation enacted in 2020.

Liquidity and Capital Resources

Cash provided by continuing operating activities for the year ended December 31, 20172022 was $401.3$380.6 million compared to $371.7$374.2 million for the year ended December 31, 2016. The2021. Operating cash flows for the year ended December 31, 2022 included net government relief funds paid of approximately $39.1 million, which consisted of $19.4 million of payroll tax deferral payments and repayment of $20.1 million of Medicare advance payments offset by net receipts of $0.4 million of provider relief fund payments. Operating cash flows were impacted by an increase in earnings, a reduction in cash provided by continuing operating activities was primarily attributable topaid for interest and an increase in tax payments during the year ended December 31, 2022. Operating cash provided by continuing operating activities from our 2016 Acquisitionsflows for the year ended December 31, 2021 included government relief funds paid of approximately $38.1 million, which consisted of $19.4 million of payroll tax deferral payments and repayment of $25.1 million of Medicare advance payments, offset by the U.K. Divestiture and the decline in the exchange rate between USD and GBP.net receipts of $6.4 million of provider relief fund payments. Days sales outstanding as ofat December 31, 20172022 was 3844 compared to 34 as of42 at December 31, 2016. As of December 31, 2017 and December 31, 2016, we had working capital of $94.2 million and $85.1 million, respectively.2021.

Cash used in continuing investing activities for the year ended December 31, 20172022 was $336.5$305.8 million compared to $660.4cash provided by continuing investing activities of $1,013.1 million for the year ended December 31, 2016.2021. Cash used in continuing investing activities for the year ended December 31, 20172022 primarily consisted of $274.2payments of $296.1 million of cash paid for capital expenditures, and $41.1$9.5 million of cash paid for real estate.acquisitions and $7.2 million of cash paid for other, offset by proceeds from the sale of property and equipment of $7.1 million. Cash paid for capital expenditures for the year ended December 31, 2017 consisted of $70.82022 was $296.1 million, consisting of routine or maintenance capital expenditures and $203.4of $60.5 million ofand expansion capital expenditures.expenditures of $235.6 million. We define expansion capital expenditures as those that increase the capacity of our facilities or otherwise enhance revenue. Routine or maintenance capital expenditures, including information technology capital expenditures, were approximately 2.5%2% of revenue for the year ended December 31, 2017.2022. Cash used inprovided by continuing investing activities for the year ended December 31, 20162021 primarily consisted of $683.5proceeds from the U.K. Sale of $1,511.0 million, proceeds from the sale of cash paid for acquisitions, $307.5property and equipment of $3.5 million offset by $244.8 million of cash paid for capital expenditures, and $40.8$139.0 million of cash paid for real estate acquisitions, partially offset by$84.8 million of settlement of foreign currency derivatives, $31.4 million of cash received on divestiturespaid for purchase of $373.3finance lease and $1.4 million of cash paid for other. Cash paid for capital expenditures for the year ended December 31, 2021 was $244.8 million, consisting of routine or maintenance capital expenditures of $41.8 million and expansion capital expenditures of $203.0 million.

Cash used in continuing financing activities for the year ended December 31, 20172022 was $60.1$110.9 million compared to cash provided by financing activities of $358.8$1,636.5 million for the year ended December 31, 2016.2021. Cash used in continuing financing activities for the year ended December 31, 20172022 primarily consisted of principal payments on revolving credit facility of $95.0 million, principal payments on long-term debt of $34.8$18.6 million, repaymentrepurchase of long-term debtshares for payroll tax witholdings, net of $22.5proceeds from stock option exercises of $6.2 million, acquisition of ownership interests from noncontrolling partners of $5.5 million and common stock withheld for minimum statutory taxesdistributions to noncontrolling partners in joint ventures of $3.5$1.0 million, offset by contributions from noncontrolling partners in joint ventures of $15.4 million and other of $0.1 million. Cash provided by

43


Table of Contents

used in continuing financing activities for the year ended December 31, 20162021 primarily consisted of repayment of long-term debt borrowings of $1.5 billion, borrowings on our revolving credit facility of $179.0$2,227.9 million, and an issuance of common stock of $685.1 million, partially offset by repayment of assumed Priory debt of $1.4 billion, paymentprincipal payments on revolving credit facility of $337.0 million, repayment of long-term debt of $200.6$330.0 million, principal payments on long-term debt of $49.9$8.0 million, payment of debt issuance costs of $36.6$8.0 million, other of $6.9 million and commondistributions to noncontrolling partners in joint ventures of $1.6 million, offset by borrowing on long-term debt of $425.0 million, borrowings on revolving credit facility of $500.0 million, repurchase of shares for payroll tax withholdings, net of proceeds from stock withheld for minimum statutory taxesoption exercises of $8.8$16.3 million and contributions from noncontrolling partners in joint ventures of $4.5 million.

We had total available cash and cash equivalents of $67.3$97.6 million, $57.1$133.8 million and $11.2$378.7 million as ofat December 31, 2017, 20162022, 2021 and 2015,2020, respectively, of which approximately $20.4$3.7 million, $41.4$20.1 million and $9.2$17.0 million was held by our foreign subsidiaries, respectively. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to permanently reinvest our foreign cash and cash equivalents outside of the U.S. On December 22, 2017, the Tax Act was enacted into law. The Tax Act provides for significant changes to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21% for U.S. taxable income and requires aone-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. While we are still evaluating the full impact of the legislation, we expect the substantial reduction of the federal corporate tax rate to benefit our financial results and cash flow in future periods. We believe the change will not result in a U.S. tax liability on those foreign earnings which have not previously been repatriated to the U.S., with future foreign earnings potentially not subject to U.S. income taxes when repatriated.

Amended and Restated SeniorNew Credit Facility

We entered into a credit agreement establishing the New Credit Facility on March 17, 2021. The New Credit Facility provides for a $600.0 million Revolving Facility and a $425.0 million Term Loan Facility with each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which we may borrow up to $20.0 million.  

As a part of the closing of the New Credit Facility on March 17, 2021, we (i) refinanced and terminated the Prior Credit Facility and (ii) financed the redemption of all of the outstanding 5.625% Senior Notes.

We had $521.6 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.4 million related to security for the payment of claims required by our workers’ compensation insurance program at December 31, 2022.

During the third quarter of 2021, we repaid $60.0 million of the initial $160.0 million balance outstanding on the Revolving Facility. During the fourth quarter of 2021, we had a draw of $70.0 million on the Revolving Facility related to the CenterPointe acquisition. During the year ended December 31, 2022, we repaid $95.0 million of the balance outstanding on the Revolving Facility.

The New Credit Facility requires quarterly principal repayments for the Term Loan Facility of $5.3 million for March 31, 2023 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.

We have the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of the Consolidated EBITDA (as defined in the New Credit Facility) of the Company and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.

Subject to certain exceptions, substantially all of our existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of our obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at our option, either (i) adjusted LIBOR plus 1.375% or (ii) an alternative base rate plus 0.375% (in each case, subject to adjustment based on the Company’s consolidated total net leverage ratio). An unused fee initially set at 0.20% per annum (subject to adjustment based on the Company’s consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.

The interest rates and the unused line fee on unused commitments related to the Senior Facilities are based upon the following pricing tiers:

Pricing Tier

 

Consolidated

Leverage Ratio

 

Eurodollar

Rate Loans

 

 

Base Rate

Loans

 

 

Commitment

Fee

 

1

 

4.50:1.0

 

 

2.250

%

 

 

1.250

%

 

 

0.350

%

2

 

<4.50:1.0 but 3.75:1.0

 

 

2.000

%

 

 

1.000

%

 

 

0.300

%

3

 

<3.75:1.0 but ≥ 3.00:1.0

 

 

1.750

%

 

 

0.750

%

 

 

0.250

%

4

 

<3.00:1.0 but ≥ 2.25:1.0

 

 

1.500

%

 

 

0.500

%

 

 

0.200

%

5

 

<2.25:1.0

 

 

1.375

%

 

 

0.375

%

 

 

0.200

%

44


Table of Contents

The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At December 31, 2022, the Company was in compliance with such covenants.

Prior Credit Facility

We entered into a credit agreement establishing a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, we entered into an amended and restated credit agreement establishing the Amended and RestatedPrior Credit AgreementFacility, which amended and restated the Senior Secured Credit Facility. We have amended the Amended and RestatedPrior Credit AgreementFacility from time to time as described in our prior filings with the SEC.

On February 6, 2015,April 21, 2020, we entered into the SeventhThirteenth Amendment to our Amended and Restatedthe Prior Credit Agreement.Facility. The SeventhThirteenth Amendment added Citibank, N.A. as an “L/C Issuer” underamended the Amended and Restated Credit AgreementConsolidated Leverage Ratio in orderthe prior covenant to permitincrease such leverage ratio for the rolloverrest of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.2020.

On February 11, 2015,November 13, 2020, we entered into the First IncrementalFourth Repricing Facilities Amendment to our Amended and Restatedthe Prior Credit Agreement.Facility. The First IncrementalFourth Repricing Facilities Amendment activated a new $500.0 million incremental TrancheB-1 Facility that was added toextended the Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-1 Facility were used to fund a portionmaturity date of each of the purchase price for our acquisitionprior revolving line of CRC.

On April 22, 2015, we entered into an Eighth Amendment to our Amendedcredit and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.

On January 25, 2016, we entered into the Ninth Amendment to our Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provides increased flexibility to us in terms of our financial covenants. Our baskets for permitted investments were also increased to provide increased flexibility for us to invest innon-wholly owned subsidiaries, joint ventures and foreign subsidiaries. As a result of the Ninth Amendment, we may invest innon-wholly owned subsidiaries and joint ventures up to 10.0% of our and our subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 12.5% of our and our subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. We may also invest in foreign subsidiaries that are not loan parties up to 10% of our and our subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of our and our subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of our and our subsidiaries’ total assets in any fiscal year.

On February 16, 2016, we entered into the Second Incremental Facility Amendment to our Amended and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility and added $135.0 million to the Term Loan A facility to our Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-2 Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were usedfrom November 30, 2021 to pay downNovember 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the majorityrevolving line of our $300.0credit in an aggregate committed amount of $500.0 million revolving credit facility.

On May 26, 2016, we entered into a TrancheB-1 Repricing Amendmentwith an aggregate committed amount of approximately $459.0 million and (2) replaced the TLA Facility aggregate outstanding principal amount of approximately $352.4 million with an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to both facilities remained unchanged from the prior facilities, and the commitment fee applicable to the Amended and Restated Credit Agreement. The TrancheB-1 Repricing Amendment reducednew revolving line of credit also remained unchanged from the Applicable Rate with respect to the TrancheB-1 Facility from 3.5% to 3.0% in the caseprior revolving line of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.

On September 21, 2016, we entered into a TrancheB-2 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-2 Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-2 Facility from 3.75% to 3.00% in the case of Eurodollar Rate loans and 2.75% to 2.00% in the case of Base Rate Loans.credit. In connection with the TrancheB-2Fourth Repricing Facilities Amendment, we recorded a debt extinguishment charge of $3.4$1.0 million, including the write-off of discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of income.operations at December 31, 2020.

On November 22, 2016,January 5, 2021, we entered intomade a Tenth Amendmentvoluntary payment of $105.0 million on the Tranche B-4 Facility. On January 19, 2021, we used a portion of the net proceeds from the U.K. Sale to repay the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amendedoutstanding balances of $311.7 million of the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.

On November 30, 2016, we entered into a Refinancing Facilities Amendment to the Amended and Restated Credit Agreement. The Refinancing Amendment increased our line of credit on our revolving credit facility to $500.0 million from $300.0 million and reduced our TLA Facility to $400.0and $767.9 million from $600.6 million. In addition,of the Refinancing Amendment extendedTranche B-4 Facility. As a part of the maturity date forclosing of the Refinancing Facilities to November 30,New Credit Facility on March 17, 2021, from February 13, 2019,we refinanced and lowered our effective interest rate on our line of credit on our revolving credit facility and TLAterminated the Prior Credit Facility by 50 basis points. In. At March 31, 2021, in connection with the Refinancing Amendment,termination of the Prior Credit Facility, we recorded a debt extinguishment charge of $0.8$10.9 million, including thewrite-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.

On May 10, 2017, we entered into the Third Repricing Amendment to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-1 Facility and the TrancheB-2 Facility from 3.0% to 2.75% in the case of Eurodollar Rate loans and 2.0% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, we recorded a debt extinguishment charge of $0.8 million, including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of operations.

We had $493.4 million of availability under the revolving line of credit and had standby letters of credit outstanding of $6.6 million related to security for the payment of claims required by our workers’ compensation insurance program as of December 31, 2017. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $5.0 million for March 31, 2018 to December 31, 2019, $7.5 million for March 31, 2020 to December 31, 2020, and $10.0 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. We are required to repay the TrancheB-1 Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-1 Facility due on February 11, 2022. We are required to repay the TrancheB-2 Facility in equal quarterly installments of approximately $2.4 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-2 Facility due on February 16, 2023. On December 29, 2017, the Company made an additional payment of $22.5 million, including $7.7 million on the TrancheB-1 Facility and $14.8 million on the TrancheB-2 Facility.

Borrowings under the Amended and Restated Credit Agreement are guaranteed by each of our wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of our and such subsidiaries’ assets. Borrowings with respect to the TLA Facility and our revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.75% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.75% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2017. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of December 31, 2017, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.75%. In addition, we are required to pay a commitment fee on undrawn amounts under our revolving credit facility.

The interest rates and the unused line fee on unused commitments related to the Pro Rata Facilities are based upon the following pricing tiers:

Pricing Tier

  Consolidated Leverage Ratio  Eurodollar Rate
Loans
  Base Rate
Loans
  Commitment
Fee
 

1

  < 3.50:1.0   1.75  0.75  0.20

2

  >3.50:1.0 but < 4.00:1.0   2.00  1.00  0.25

3

  >4.00:1.0 but < 4.50:1.0   2.25  1.25  0.30

4

  >4.50:1.0 but < 5.25:1.0   2.50  1.50  0.35

5

  >5.25:1.0   2.75  1.75  0.40

Eurodollar Rate Loans with respect to the TrancheB-1 Facility bear interest at the TrancheB-1 Facility Applicable Rate (as defined below) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans bear interest at the TrancheB-1 Facility Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “TrancheB-1 Facility Applicable Rate” means, with respect to Eurodollar Rate Loans, 3.0%, and with respect to Base Rate Loans, 2.0%. The TrancheB-2 Facility bears interest as follows: Eurodollar Rate Loans bear interest at the Applicable Rate (as defined in the Amended and Restated Credit Agreement) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period) and Base Rate Loans bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Applicable Rate” means, with respect to Eurodollar Rate Loans, 3.0%, and with respect to Base Rate Loans, 2.0%.

The lenders who provided the TrancheB-1 Facility and TrancheB-2 Facility are not entitled to benefit from the Company’s maintenance of its financial covenants under the Amended and Restated Credit Agreement. Accordingly, if we fail to maintain its financial covenants, such failure shall not constitute an event of default under the Amended and Restated Credit Agreement with respect to the TrancheB-1 Facility or the TrancheB-2 Facility until and unless the Amended and Restated Senior Credit Facility is accelerated or the commitment of the lenders to make further loans is terminated.

The Amended and Restated Credit Agreement requires us and our subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and consolidated senior secured leverage ratio. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of our material debt agreements. Set forth below is a brief description of such covenants, all of which are subject to customary exceptions, materiality thresholds and qualifications:

a)the affirmative covenants include the following: (i) delivery of financial statements and other customary financial information; (ii) notices of events of default and other material events; (iii) maintenance of existence, ability to conduct business, properties, insurance and books and records; (iv) payment of taxes; (v) lender inspection rights; (vi) compliance with laws; (vii) use of proceeds; (viii) further assurances; and (ix) additional collateral and guarantor requirements.

b)

the negative covenants include limitations on the following: (i) liens; (ii) debt (including guaranties); (iii) investments; (iv) fundamental changes (including mergers, consolidations and liquidations); (v) dispositions; (vi) sale leasebacks; (vii) affiliate transactions; (viii) burdensome agreements; (ix) restricted payments; (x) use of proceeds; (xi) ownership of subsidiaries; (xii) changes to line of business; (xiii) changes to organizational documents, legal name, state of formation,

form of entity and fiscal year; (xiv) prepayment or redemption of certain senior unsecured debt; and (xv) amendments to certain material agreements. The Company is generally not permitted to issue dividends or distributions other than with respect to the following: (w) certain tax distributions; (x) the repurchase of equity held by employees, officers or directors upon the occurrence of death, disability or termination subject to cap of $500,000 in any fiscal year and compliance with certain other conditions; (y) in the form of capital stock; and (z) scheduled payments of deferred purchase price, working capital adjustments and similar payments pursuant to the merger agreement or any permitted acquisition.

c)The financial covenants include maintenance of the following:

the fixed charge coverage ratio may not be less than 1.25:1.00 as of the end of any fiscal quarter;

the total leverage ratio may not be greater than the following levels as of the end of each fiscal quarter listed below:

March 31June 30September 30December 31
20176.75x6.75x6.50x6.50x
20186.50x6.25x6.00x6.00x
20195.75x5.75x5.50x5.50x
20205.25x5.25x5.25x5.00x

the secured leverage ratio may not be greater than the following levels as of the end of each fiscal quarter listed below:

December 31, 2017- June 30, 2018

3.75x

September 30, 2018 and each fiscal quarter thereafter

3.50x

As of December 31, 2017, the Company was in compliance with all of the above covenants.

Senior Notes

6.125% Senior Notes Due 2021

On March 12, 2013, we issued $150.0 million of 6.125%5.500% Senior Notes due 2021.2028

On June 24, 2020, we issued $450.0 million of the 5.500% Senior Notes due 2028. The 6.125%5.500% Senior Notes mature on March 15, 2021July 1, 2028 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, we issued $300.0 million of 5.125% Senior Notes due 2022. The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125%5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.year, commencing on January 1, 2021.

5.625%5.000% Senior Notes due 20232029

On February 11, 2015,October 14, 2020, we issued $375.0$475.0 million of 5.625% Senior Notes due 2023. On September 21, 2015, we issued $275.0 million of additional 5.625%the 5.000% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, we have outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625%5.000% Senior Notes mature on FebruaryApril 15, 20232029 and bear interest at a rate of 5.625%5.000% per annum, payable semi-annually in arrears on FebruaryApril 15 and AugustOctober 15 of each year.

6.500%year, commencing on April 15, 2021. We used the net proceeds of the 5.000% Senior Notes due 2024

On February 16, 2016, we issued $390.0to prepay approximately $453.3 million of 6.500%the outstanding borrowings on the Tranche B-3 Facility and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, due 2024. The 6.500% Senior Notes mature on March 1, 2024we recorded a debt extinguishment charge of $2.9 million, including the write-off of discount and bear interest at a ratedeferred financing costs of 6.500% per annum, payable semi-annuallythe Tranche B-3 Facility, which was recorded in arrears on March 1 and September 1debt extinguishment costs in the consolidated statement of eachoperations for the year beginning on September 1, 2016.ended December 31, 2020.

The indentures governing the Senior Notes contain covenants that, among other things, limit the Company’sour ability and the ability of itsour restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’sour assets; and (vii) create liens on assets.

45


Table of Contents

The Senior Notes issued by the Companyus are guaranteed by each of the Company’sour subsidiaries that guarantee the Company’sguaranteed our obligations under the Amended and Restated SeniorNew Credit Facility. The guarantees are full and unconditional and joint and several.

The CompanyWe may redeem the Senior Notes at itsour option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds5.625% Senior Notes due 2023

On NovemberFebruary 11, 2012,2015, we issued $375.0 million of the 5.625% Senior Notes. On September 21, 2015, we issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, we had outstanding an aggregate of $650.0 million of the 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, we redeemed the 5.625% Senior Notes.

6.500% Senior Notes due 2024

On February 16, 2016, we issued $390.0 million of the 6.500% Senior Notes. The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, we redeemed the 6.500% Senior Notes.

Redemption of 5.625% Senior Notes and 6.500% Senior Notes

On January 29, 2021, we issued conditional notices of full redemption providing for the redemption in full of $650 million of the 5.625% Senior Notes and $390 million of the 6.500% Senior Notes to the holders of such notes.

On March 1, 2021, we satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the acquisitionredemption of the 6.500% Senior Notes, we recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.  

On March 17, 2021, we satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, we recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.  

6.125% Senior Notes due 2021

On March 12, 2013, we issued $150.0 million of the 6.125% Senior Notes. The Pavilion6.125% Senior Notes were to mature on March 15, 2021 and bear interest at HealthPark, LLC (“Park Royal”),a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. On June 24, 2020, we assumedredeemed the 6.125% Senior Notes.

5.125% Senior Notes due 2022

On July 1, 2014, we issued $300.0 million of the 5.125% Senior Notes. The 5.125% Senior Notes were to mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. On June 24, 2020, we redeemed the 5.125% Senior Notes.

Redemption of 6.125% Senior Notes and 5.125% Senior Notes

On June 10, 2020, we issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and the 5.125% Senior Notes on the Redemption Date, in each case at the Redemption Price. On June 24, 2020, we satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, we recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statement of operations for the year ended December 31, 2020.

Other long-term debt

During the year ended December 31, 2021, we repaid other long-term debt of $23.0 million. The fair market value of the debt assumed was $25.6$3.3 million, and resultedwhich is reflected in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5%, respectively. The 9.0% bondsfinancing activities in the amountconsolidated statement of $7.5 million have a maturity datecash flows.

46


Table of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond-sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of December 31, 2017 and 2016, $2.3 million was recorded within other assets on the consolidated balance sheets related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the 9.0% and 9.5% Revenue Bonds using the effective interest method.Contents

Contractual Obligations

The following table presents a summary of contractual obligations (dollars in thousands):

 

   Payments Due by Period 
   Less Than
1 Year
   1-3 Years   3-5 Years   More Than
5 Years
   Total 

Long-term debt(1)

  $199,973   $405,354   $1,508,021   $2,006,944   $4,120,292 

Operating leases

   69,613    124,712    107,691    835,369    1,137,385 

Purchase and other obligations(2)

   4,307    7,404    33,899    27,085    72,695 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total obligations and commitments

  $273,893   $537,470   $1,649,611   $2,869,398   $5,330,372 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

 

Payments Due by Period

 

 

 

Less Than

1 Year

 

 

1-3 Years

 

 

3-5 Years

 

 

More Than

5 Years

 

 

Total

 

Long-term debt (a)

 

$

97,302

 

 

$

216,197

 

 

$

481,468

 

 

$

973,000

 

 

$

1,767,967

 

Operating lease liabilities (b)

 

 

32,818

 

 

 

54,714

 

 

 

31,631

 

 

 

62,653

 

 

 

181,816

 

Finance lease liabilities

 

 

990

 

 

 

2,096

 

 

 

2,269

 

 

 

21,821

 

 

 

27,176

 

Total obligations and commitments

 

$

131,110

 

 

$

273,007

 

 

$

515,368

 

 

$

1,057,474

 

 

$

1,976,959

 

 

(1)

(a)

Amounts include required principal and interest payments. The projected interest payments reflect interest rates in place on our variable-rate debt as ofat December 31, 2017.2022.

(2)

(b)

Amounts relate to purchase obligations, including capitalexclude variable components of lease payments.

Off-Balance Sheet Arrangements

As ofAt December 31, 2017,2022, we had standby letters of credit outstanding of $6.6$3.4 million related to security for the payment of claims as required by our workers’ compensation insurance program.

Market Risk

Interest Rate Risk

Our interest expense is sensitive to changes in market interest rates. Our long-term debt outstanding at December 31, 20172022 was composed of $1.5 billion$914.3 million of fixed-rate debt and $1.7 billion$450.2 million of variable-rate debt with interest based on LIBOR plus an applicable margin. A hypothetical 10% increase in interest rates (which would equate to a 0.42% higher rateBased on our variable rate debt) would decrease our net income and cash flows by $5.0 million on an annual basis based upon our borrowing level at December 31, 2017.2022, a hypothetical 1% increase in interest rates would decrease our pretax income on an annual basis by approximately $4.5 million.

Foreign Currency Risk

The functional currency forWe expect our U.K. facilities is the British pound or GBP. Our revenue and earnings are sensitivevariable-rate debt to changes in the GBP to USD exchange ratetransition from the translation of our earnings into USD at exchange rates that may fluctuate. Based upon the level of our U.K. operations relativeLIBOR plus an appliable margin to the CompanySecured Overnight Financing Rate (“SOFR”) during 2023. SOFR was chosen as the recommended risk-free reference rate by the Alternative Reference Rates Committee and is a whole, a hypothetical 10% change (which would equatebroad measure of the cost of borrowing cash overnight collateralized by U.S. Treasury securities. The Federal Reserve Bank of New York started to an increase or decreasepublish SOFR in the exchange rate of 0.13) would cause a change in our net income of $10.1 million for the year ended December 31, 2017.

In May 2016, we entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency exchange risk by effectively converting a portion of our fixed-rate USD denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate,GBP-denominated debt of £449.3 million. The cross currency swap agreements limit the impact of changes in the exchange rate on our cash flows and leverage. Following the Brexit vote, the GBP dropped to its lowest level against the USD in more than 30 years. If the exchange rate remains low, our results of operations will be negatively impacted in future periods.April 2018. 

Critical Accounting Policies

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses included in the financial statements. Estimates are based on historical experience and other available information, the results of which form the basis of such estimates. While management believes our estimation processes are reasonable, actual results could differ from our estimates. The following accounting policies are considered critical to the portrayal of our financial condition and operating performance and involve highly subjective and complex assumptions and assessments:

Revenue and Accounts Receivable

Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and local authorities in England, Scotland and Wales); and (v)(iv) individual patients and clients. Revenue is recorded inWe determine the period in which services are provided attransaction price based on established billing rates lessreduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.

The following table presents revenue by payor typecontractual agreements, discount policies and as a percentage of revenue before provision for doubtful accounts for the years ended December 31, 2017, 2016 and 2015 (in thousands):

   Year Ended December 31, 
   2017  2016  2015 
   Amount  %  Amount  %  Amount  % 

Commercial

  $569,242   19.8 $534,468   18.7 $423,077   23.1

Medicare

   281,270   9.8  266,868   9.4  214,125   11.7

Medicaid

   796,375   27.7  725,508   25.4  609,805   33.3

NHS

   937,595   32.6  1,021,888   35.8  356,965   19.5

Self-Pay

   249,978   8.7  268,160   9.4  174,850   9.6

Other

   42,774   1.4  35,931   1.3  50,797   2.8
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Revenue before provision for doubtful accounts

   2,877,234   100.0  2,852,823   100.0  1,829,619   100.0

Provision for doubtful accounts

   (40,918   (41,909   (35,127 
  

 

 

   

 

 

   

 

 

  

Revenue

  $2,836,316   $2,810,914   $1,794,492  
  

 

 

   

 

 

   

 

 

  

The following tables present a summary of our aging of accounts receivable as of December 31, 2017 and 2016:

December 31, 2017

   Current  30-90  90-150  >150  Total 

Commercial

   15.3  8.7  3.2  6.9  34.1

Medicare

   9.4  1.6  0.5  1.1  12.6

Medicaid

   19.8  6.4  2.5  5.2  33.9

NHS

   7.0  3.4  0.2  0.0  10.6

Self-Pay

   1.8  1.4  1.4  3.2  7.8

Other

   0.3  0.3  0.2  0.2  1.0
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

   53.6  21.8  8.0  16.6  100.0

December 31, 2016

   Current  30-90  90-150  >150  Total 

Commercial

   15.8  8.5  3.0  5.3  32.6

Medicare

   12.0  1.6  0.8  1.2  15.6

Medicaid

   18.7  6.5  2.9  5.5  33.6

NHS

   5.1  3.4  0.6  0.4  9.5

Self-Pay

   1.8  1.5  1.5  3.3  8.1

Other

   0.1  0.1  0.1  0.3  0.6
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total

   53.5  21.6  8.9  16.0  100.0

Medicaid accounts receivable as of December 31, 2017 and 2016 included approximately $0.9 million and $1.2 million, respectively, of accounts pending Medicaid approval.

Allowance for Contractual Discountshistorical experience. Implicit price concessions are based on historical collection experience.

We derive a significant portion of our revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in ourthe Company’s inpatient facilities and cost settlement provisions. Management estimates the allowance for contractual discountstransaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from our estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

47


Table of Contents

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on ourthe Company’s financial condition or results of operations. Our cost report receivablespayables were $9.0$13.7 million and $7.4$6.5 million atas of December 31, 20172022 and 2016,2021, respectively, and were included in other current assets inliabilities on the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.sheet. The net adjustments to estimated cost report settlements resulted in increasesan increase to revenue of $0.2$0.1 million $0.7for the year ended December 31, 2022, compared to decreases to revenue of $5.4 million and $1.9$1.3 million for the years ended December 31, 2017, 20162021 and 2015,2020, respectively.

Management believes that we are in substantial compliance with all applicable lawsThe following table presents revenue by payor type and regulationsas a percentage of revenue for continuing operations for the years ended December 31, 2022, 2021 and is not aware2020 (in thousands):

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

Commercial

 

$

788,895

 

 

 

30.2

%

 

$

684,292

 

 

 

29.6

%

 

$

596,698

 

 

 

28.5

%

Medicare

 

 

394,227

 

 

 

15.1

%

 

 

364,598

 

 

 

15.8

%

 

 

330,070

 

 

 

15.8

%

Medicaid

 

 

1,319,600

 

 

 

50.6

%

 

 

1,147,884

 

 

 

49.6

%

 

 

1,037,852

 

 

 

49.7

%

Self-Pay

 

 

76,050

 

 

 

2.9

%

 

 

93,425

 

 

 

4.0

%

 

 

98,302

 

 

 

4.7

%

Other

 

 

31,627

 

 

 

1.2

%

 

 

24,195

 

 

 

1.0

%

 

 

27,007

 

 

 

1.3

%

Revenue

 

$

2,610,399

 

 

 

100.0

%

 

$

2,314,394

 

 

 

100.0

%

 

$

2,089,929

 

 

 

100.0

%

The following tables present a summary of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.

Allowance for Doubtful Accounts

Our ability to collect outstanding patient receivables from third-party payors is critical to our operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. We estimate uncollectible accounts and establish an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectabilityaging of accounts receivable we consider a number of factors, including the age of the accounts, historical collection experience, current economic conditions,at December 31, 2022 and other relevant factors. Accounts receivable that2021:

December 31, 2022

 

 

Current

 

 

30-90

 

 

90-150

 

 

>150

 

 

Total

 

Commercial

 

 

18.0

%

 

 

5.3

%

 

 

2.8

%

 

 

8.4

%

 

 

34.5

%

Medicare

 

 

11.5

%

 

 

1.7

%

 

 

0.7

%

 

 

1.4

%

 

 

15.3

%

Medicaid

 

 

31.7

%

 

 

4.5

%

 

 

2.6

%

 

 

4.7

%

 

 

43.5

%

Self-Pay

 

 

1.2

%

 

 

1.4

%

 

 

1.2

%

 

 

2.6

%

 

 

6.4

%

Other

 

 

0.2

%

 

 

0.0

%

 

 

0.0

%

 

 

0.1

%

 

 

0.3

%

Total

 

 

62.6

%

 

 

12.9

%

 

 

7.3

%

 

 

17.2

%

 

 

100.0

%

December 31, 2021

 

 

Current

 

 

30-90

 

 

90-150

 

 

>150

 

 

Total

 

Commercial

 

 

20.1

%

 

 

6.2

%

 

 

2.6

%

 

 

8.2

%

 

 

37.1

%

Medicare

 

 

11.3

%

 

 

1.7

%

 

 

0.5

%

 

 

2.0

%

 

 

15.5

%

Medicaid

 

 

28.6

%

 

 

3.5

%

 

 

2.0

%

 

 

5.6

%

 

 

39.7

%

Self-Pay

 

 

1.3

%

 

 

1.4

%

 

 

1.4

%

 

 

3.0

%

 

 

7.1

%

Other

 

 

0.1

%

 

 

0.1

%

 

 

0.2

%

 

 

0.2

%

 

 

0.6

%

Total

 

 

61.4

%

 

 

12.9

%

 

 

6.7

%

 

 

19.0

%

 

 

100.0

%

Insurance

We are determined to be uncollectible based on our policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on our results of operations and cash flows.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides.we provide. A portion of the Company’sour professional liability risk isrisks are insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Companyproviding coverage for professional liability losses up to $78.0$10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. We have obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. TheOur reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 millionpolicies in excess of a retention level of $3.0 million.place. The reserve for professional and general liability risks was estimated based on historical claims, prior settlements and judgments, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and

48


Table of Contents

expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. We recorded an unfavorable adjustment of $5.9 million to our estimated liability for self-insured professional and general liability claims during the year ended December 31, 2022, relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period. The professional and general liability reserve was $55.0$103.6 million as ofat December 31, 2017,2022, of which $22.8$12.1 million was included in other accrued liabilities and $32.2$91.5 million was included in other long-term liabilities. The professional and general liability reserve was $52.3$87.8 million as ofat December 31, 2016,2021, of which $11.7$11.9 million was included in other accrued liabilities and $40.6$75.9 million was included in other long-term liabilities. The Company estimatesWe estimate receivables for the portion of professional and general liability reserves that are recoverable under the Company’sour insurance policies. Such receivable was $22.7$37.8 million as ofat December 31, 2017,2022, of which $17.6$10.2 million was included in other current assets and $5.1$27.6 million was included in other assets, and such receivable was $25.9$37.9 million as ofat December 31, 2016,2021, of which $6.5$10.8 million was included in other current assets and $19.4$27.1 million was included in other assets.

The Company’sOur statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $18.5$24.2 million as ofat December 31, 2017,2022, of which $10.0$12.0 million was included in accrued salaries and benefits and $8.5$12.2 million was included in other long-term liabilities, and such liability was $16.6$23.6 million as ofat December 31, 2016,2021, of which $10.0$12.0 million was included in accrued salaries and benefits and $6.6$11.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $143.0$117.8 million, $134.8$106.7 million and $63.0$95.3 million for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives,life, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

We performed an impairment review of long-lived assets in the fourth quarter of 2022 and 2021 and recorded no impairment. The impairment review of long-lived assets in the fourth quarter of 2020 indicated the carrying amounts of certain of our long-lived assets may not be recoverable. This created a non-cash impairment of $4.2 million for the year ended December 31, 2020, which was recorded in loss on impairment on our consolidated statements of operations.

Goodwill and Indefinite-Lived Intangible Assets

Our goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. We have

As of our annual impairment tests on October 1, 2022 and October 1, 2021, we had one reporting unit, behavioral health services. The fair value of our behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded.

During the second quarter of 2021, we sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, we sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition.

49


Table of Contents

As of our annual impairment test on October 1, 2020, we had two operating segments U.S. Facilities and U.K. Facilities, for segment reporting purposes, U.S. facilities and U.K. facilities, each of which representsrepresented a reporting unit for purposes of the Company’sour goodwill impairment test.  Potential

Our annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. facilities of $356.2 million. The non-cash loss on impairment is noted for a reporting unit if its carrying value exceedsincluded in loss on sale within discontinued operations in the consolidated statement of operations. As of our impairment test on October 1, 2020, the fair value of the reporting unit. For aour U.S facilities reporting unit with potential impairment of goodwill, we determine the implied fair value of goodwill. If thesubstantially exceeded its carrying value, of goodwill exceeds its implied fair value, an impairment loss is recorded. Our annual impairment tests of goodwill and other indefinite-lived intangibles in 2017, 2016 and 2015 resulted intherefore no impairment charges.

was recorded. Additionally, for the year ended December 31, 2020, we recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statement of operations.

Income Taxes

We use the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

We review our deferred tax assets for recoverability and establish a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

We report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

We also haveestablished accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. We accrue for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Although weWe believe that the positions taken on previously filed tax returns are reasonable we neverthelessand have not established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by us resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect our potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

Financial Accounting Standards Board Accounting Standards Codification 740 requires us to recognize the effect

50


Table of tax law changes in the period of enactment. However, the SEC staff issued SAB 118 which will allow us to record provisional amounts during a measurement period similarly to the measurement period used when accounting for business combinations. We will continue to assess the impact of the recently enacted tax law on our business and consolidated financial statements.Contents

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.Risk

Information with respect to this Item is provided under the caption “Market Risk” under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Item 8. Financial Statements and Supplementary Data.Data

Information with respect to this Item is contained in our consolidated financial statements beginning on PageF-1 of this Annual Report onForm 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.Disclosure

None.

Item 9A. Controls and Procedures.Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management conducted an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined inRules 13a-15(e) and15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Reports on Internal Control Over Financial Reporting

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we have included a report of management’s assessment of the design and operating effectiveness of our internal controls as part of this report. Our independent registered public accounting firm also reported on the effectiveness of internal control over financial reporting. Management’s report and the independent registered public accounting firm’s report are included in our consolidated financial statements beginning on pageF-1 of this report under the captions entitled “Management’s Report on Internal Control Over Financial Reporting” and “Report of Independent Registered Public Accounting Firm.”

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 20172022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

51


Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Directors

The information with respect to our directors set forth under the caption “Election of Directors” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Audit and Risk Committee

The information with respect to our Audit and Risk Committee and our audit committee financial experts serving on the Audit and Risk Committee is set forth under the caption “Corporate Governance – Committees of the Board of Directors – Audit and Risk Committee” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Executive Officers

The information with respect to our executive officers set forth under the caption “Management – Executive Officers” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Section 16(a) Compliance

The information with respect to compliance with Section 16(a) of the Exchange Act set forth under the caption “Security Ownership of Certain Beneficial Owners and Management—Delinquent Section 16(a) Beneficial Ownership Reporting Compliance”Reports” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Stockholder Nominees

The information with respect to the procedures by which stockholders may recommend nominees to the Boardboard of Directorsdirectors set forth under the caption “Corporate Governance – Nomination of Directors – Nominations by Our Stockholders” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Corporate Governance Documents

We have adopted a Code of Conduct that applies to all of our directors, officers and employees and a Code of Ethics for Senior Financial Officers. These documents, as well as the charters of the Audit and Risk Committee, Compensation Committee, Compliance Committee, and Nominating and Governance Committee, are available on our website at www.acadiahealthcare.com on the Investors webpage under the caption “Corporate Governance.” Upon the written request of any person, we will furnish, without charge, a copy of any of these documents. Requests should be directed to Acadia Healthcare Company, Inc., 6100 Tower Circle, Suite 1000, Franklin, Tennessee 37067, Attention: Christopher L. Howard, Esq. We intend to disclose any amendments to our Code of Ethics and any waiver from a provision of our code, as required by the SEC, on our website.

Item 11. Executive Compensation

The information with respect to the compensation of our executive officers set forth under the captions “Executive Compensation” and “Compensation Discussion and Analysis” and the information set forth under the captions “Director Compensation,” “Corporate Governance – Compensation Committee Interlocks and Insider Participation,” and “Compensation Committee Report” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

52


Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information with respect to security ownership of certain beneficial owners and management and related stockholder matters set forth under the caption “Security Ownership of Certain Beneficial Owners and Management” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Equity Compensation Plan Information

The following table provides information as ofat December 31, 20172022 with respect to compensation plans (including individual compensation arrangements) under which shares of Common Stock are authorized for issuance:

 

Plan Category

  Number of Securities
to be Issued upon
Exercise of
Outstanding  Options,
Warrants and Rights
 Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights
   Number of Securities
Remaining Available for
Future Issuance under
Equity  Compensation
Plans(1)
 

Number of Securities

to be Issued upon

Exercise of

Outstanding Options,

Warrants and Rights

 

 

Weighted-Average

Exercise Price of

Outstanding Options,

Warrants and Rights

 

 

Number of Securities

Remaining Available for

Future Issuance under

Equity Compensation

Plans (a)

 

Equity Compensation Plans Approved by Stockholders(2)

   2,491,252(3)  $53.44    4,498,687 

Equity Compensation Plans Not Approved by Stockholders(4)

   15,000  $5.64    —   
  

 

    

 

 

Equity Compensation Plans Approved by

Stockholders (b)

 

3,298,279

 

(c)

 

 

$

46.27

 

 

 

3,133,811

 

Equity Compensation Plans Not Approved by

Stockholders

 

 

 

 

$

 

 

 

 

Total

   2,506,252  $47.89    4,498,687 

 

3,298,279

 

 

 

 

 

 

 

 

3,133,811

 

  

 

    

 

 

 

(1)

(a)

Excludes shares to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units.

(2)

(b)

Represents securities issued or available for issuance under the Acadia Healthcare Company, Inc. Incentive Compensation Plan.

(3)

(c)

Includes 721,8181,273,800 shares that may be issued upon vesting of outstanding restricted stock units that vest over three years, assuming that maximum performance goals are attained in all three years.

(4)Includes stock options issued pursuant to the PHC, Inc. 2004Non-Employee Director Stock Option Plan. On November 1, 2011, we issued options to purchase shares of our Common Stock as replacements for PHC, Inc. options.

The information with respect to certain relationships and related transactions and director independence set forth under the captions “Certain Relationships and Related Transactions” and “Corporate Governance – Independence of the Board of Directors” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

The information with respect to the fees paid to and services provided by our principal accountants set forth under the caption “Ratification of Appointment of Independent Registered Public Accounting Firm” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.

53


Table of Contents

PART IV

Item 15. Exhibits and Financial Statement Schedules.

(a) The following documents are filed as part of this Annual Report on Form10-K:

 

1.

Consolidated Financial Statements:

The consolidated financial statements required to be included in Part II, Item 8, Financial Statements and Supplementary Data, begin on PageF-1 and are submitted as a separate section of this report.

 

2.

Financial Statement Schedules:

All schedules are omitted because they are not applicable or are not required, or because the required information is included in the consolidated financial statements or notes in this report.

 

3.

Exhibits :

3.Exhibits:

 

Exhibit

No.

Exhibit Description

    2.1

AgreementPut and Plan Call Option Deed, dated as of Merger, dated May 23,  2011, December 30, 2020, by and among Acadia Healthcare Company, Inc.
( between RemedcoUK Limited and the “Company”), Acadia Merger  Sub, LLC and PHC, Inc. Company. (a)

    2.2

Agreement and Plan of Merger, dated February  17, 2011, by and among the Company (f/k/a Acadia Healthcare Company, LLC), Acadia—YFCS Acquisition Company, Inc., Acadia—YFCS Holdings, Inc., Youth  & Family Centered Services, Inc., each of the stockholders who are signatories thereto, and TA Associates, Inc., solely in the capacity as Stockholders’ Representative. (b)

    2.3AssetShare Purchase Agreement, dated as of March  15, 2011, between Universal Health Services, Inc. and PHC, Inc. for the acquisition of MeadowWood Behavioral Health System. (c)
    2.4Membership Interest Purchase Agreement, dated December  30, 2011, by and among Hermitage Behavioral, LLC, Haven Behavioral Healthcare Holdings, LLC and Haven Behavioral Healthcare, Inc. (d)
    2.5Asset Purchase Agreement, dated August 28, 2012,January 7, 2021, by and between Timberline Knolls, LLC, and TK Behavioral, LLC. (e)
    2.6Acquisition Agreement, dated November 21, 2012, by and among (i)  Behavioral Centers of America, LLC, (ii) Behavioral Centers of America Holdings, LLC, (iii) Linden BCA Blocker Corp., (iv)SBOF-BCA Holdings Corporation, (v)  HEP BCA Holdings Corp. (vi) Siguler Guff Small Buyout Opportunities Fund, LP, and Siguler Guff Small Buyout Opportunities Fund (F), LP, (vii)  Health Enterprise Partners, L.P., HEP BCACo-Investors, LLC, (viii) Linden Capital Partners A, LP, (ix) Commodore Acquisition Sub, LLC, and (x)  the Company (the “BCA Purchase Agreement”). (f)
    2.7Amendment No. 1, dated as of December 31, 2012, to the BCA Purchase Agreement. (g)
    2.8Membership Interest Purchase Agreement, dated November  23, 2012 by and among 2C4K, L.P., ARTC Acquisitions, Inc., Acadia Vista, LLCRemedcoUK Limited and the Company. (f)(a)
    2.9Amendment, dated as of December  31, 2012, to Membership Interest Purchase Agreement by and among 2C4K, LP, ARTC Acquisitions, Inc., Acadia Vista, LLC and the Company. (g)
    2.10Stock Purchase Agreement, dated as of March  29, 2013, by and among First Ten Broeck Tampa, Inc., UMC Ten Broeck, Inc., Capestrano Holding 12, Inc., Donald R. Dizney, David A. Dizney and Acadia Merger Sub, LLC. (h)
    2.11Agreement, dated June  3, 2014, by and among Partnerships in Care Holdings Limited, The Royal Bank of Scotland plc, Piper Holdco 2, Ltd. and the Company. (i)
    2.12Agreement and Plan of Merger, dated as of October  29, 2014, by and among the Company, Copper Acquisition Co., Inc. and CRC Health Group, Inc. (j)
    2.13Sale and Purchase Deed, dated as of December  31, 2015, by and among Whitewell UK Investments 1 Limited, the institutional sellers named therein, Appleby Trust (Jersey) Limited, the management sellers named therein, and the Company. (cc)

Exhibit
No.

Exhibit Description

    2.14

    3.1

Amendment to Sale and Purchase Deed, by and among Whitewell UK Investments 1 Limited, the institutional sellers named therein, Appleby Trust (Jersey) Limited, the management sellers named therein, and the Company. (dd)

    3.1Amended and Restated Certificate of Incorporation, as filed on October 28, 2011 with the Secretary of State of the State of Delaware, as amended by the Certificate of Amendment filed on May 25, 2017. (kk)(b)

    3.2

Amended and Restated Bylaws of the Company, as amended May 25, 2017. (kk)(b)

    4.1

Indenture, dated as of March  12, 2013,June 24, 2020, by and among the Company, the Guarantors named thereinguarantors party thereto and U.S. Bank National Association, as Trustee. (l)(c)

    4.2

Form of 6.125%5.500% Senior Note due 2021. (Included2028 (included as Exhibit A1 in Exhibit 4.1).

    4.3

Registration Rights Agreement,Indenture, dated March  12, 2013,October 14, 2020, by and among the Company, the Guarantors named therein and
Merrill Lynch, Pierce, Fenner & Smith Incorporated. (l)

    4.4Indenture, dated as of July  1, 2014, among the Company, the Guarantors named thereinguarantors party thereto and U.S. Bank National Association, as Trustee. (m)(d)

    4.5

    4.4

Supplemental Indenture, dated as of August 4, 2014, to the Indenture, dated as of July  1, 2014, among the Company, the Guarantors named therein and U.S. Bank National Association, as Trustee. (n)

    4.6Form of 5.125%5.000% Senior Note due 2022. (Included2029 (included as Exhibit A1 in Exhibit 4.4)4.3).

    4.7

    4.5

Registration Rights Agreement, dated July  1, 2014, among the Company, the Guarantors named therein and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC. (m)

    4.8Indenture, dated February  11, 2015, by and among the Company, the Guarantors named therein and U.S. Bank National Association, as Trustee. (o)
    4.9Form of 5.625% Senior Note due 2023. (Included in Exhibit 4.8)
    4.10Registration Rights Agreement, dated February  11, 2015, by and among the Company, the Guarantors named therein and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC, as Representatives of the Initial Purchasers. (o)
    4.11Registration Rights Agreement, dated September  21, 2015, by and among the Company, the Guarantors named therein and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC, as Representatives of the Initial Purchasers. (bb)
    4.12Indenture, dated February  16, 2016, by and among the Company, the Guarantors named therein and U.S. Bank National Association, as Trustee. (ff)
    4.13Form of 6.500% Senior Note due 2024. (Included in Exhibit 4.12)
    4.14Registration Rights Agreement, dated February  16, 2016, by and among the Company, the Guarantors named therein and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC, as Representatives of the Initial Purchasers. (ff)
    4.15Amended and Restated Stockholders Agreement, dated as of October 29, 2014, by and among the Company and each of the stockholders named therein. (j)(e)

    4.16

    4.6

Specimen Acadia Healthcare Company, Inc. Common Stock Certificate to be issued to holders of Acadia Healthcare Company, Inc.the Company’s Common Stock. (p)(f)

    4.17

    4.7

Third Amended and Restated Registration Rights Agreement, dated as of December 31, 2015, by and among the Company and each of the parties named therein. (cc)(g)

    4.18

    4.8

Joinder, dated February 16, 2016, to the Third Amended and Restated Registration Rights Agreement dated as of December 31, 2015, by and among the Company and each of the parties named therein. (ff)(h)

    4.9

Description of the Company’s Securities (i).

    10.1

Amended and Restated Credit Agreement, dated December  31, 2012, byas of March 17, 2021, among the Company, certain subsidiaries of the Company, as guarantors, the several banks and amongother financial institutions as may from time to time become parties thereunder as lenders, and Bank of America, NA (AdministrativeN.A., as Administrative Agent Swing Line Lender and L/C Issuer)Swingline Lender. (j)

    10.2

Security and Pledge Agreement, dated as of March 17, 2021, among the Company, (f/k/a Acadia Healthcare Company, LLC), the guarantors listed on the signature pagesother obligors party thereto and the lenders listed on the signature pages thereto
(the “Credit Agreement”). (g)Bank of America, N.A., as Administrative Agent. (j)

  10.2First Amendment, dated March 11, 2013, to the Credit Agreement. (l)
  10.3Second Amendment, dated June 28, 2013, to the Credit Agreement. (q)

Exhibit
No.

Exhibit Description

  10.4

  †10.3

Third Amendment, dated September 30, 2013, to the Credit Agreement. (r)

  10.5Fourth Amendment, dated February 13, 2014, to the Credit Agreement. (s)
  10.6Fifth Amendment, dated June 16, 2014, to the Credit Agreement. (t)
  10.7Sixth Amendment, dated December 15, 2014, to the Credit Agreement. (u)
  10.8Seventh Amendment, dated February 6, 2015, to the Credit Agreement. (o)
  10.9First Incremental Facility Amendment, dated February 11, 2015, to the Credit Agreement. (o)
  10.10Eighth Amendment, dated April 22, 2015, to the Credit Agreement. (aa)
  10.11Ninth Amendment, dated January 25, 2016, to the Credit Agreement. (ee)
  10.12Second Incremental Facility Amendment, dated February 16, 2016, to the Credit Agreement. (ff)
  10.13TrancheB-1 Repricing Amendment, dated May 26, 2016, to the Credit Agreement. (gg)
  10.14TrancheB-2 Repricing Amendment, dated September  21, 2016, to the Credit Agreement. (hh)
  10.15Tenth Amendment, dated November 22, 2016, to the Credit Agreement. (ii)
  10.16Refinancing Facilities Amendment, dated November 30, 2016, to the Credit Agreement. (ii)
  10.17Third Repricing Amendment, dated May 10, 2017, to the Amended and Restated Credit Agreement. (jj)
†10.18Amended and Restated Employment Agreement, dated as of January 19, 2021, by and between Acadia Management Company, Inc. and Debra K. Osteen. (k)

54


Table of Contents

  †10.4

Amendment to Employment Agreement, dated December 22, 2021, by and between Acadia Management Company, Inc. and Debra K. Osteen. (l)

  †10.5

Side Letter to Employment Agreement, dated January 31, 2022, by and between Acadia Management Company, Inc. and Debra K. Osteen. (l)

  †10.6

Consultant Services Agreement, dated April  7, 2014, 11, 2022 by and between Acadia Management Company, Inc. and Debra K. Osteen. (m)

  †10.7

Employment Agreement, dated March 31, 2022, among the Company, Acadia Management Company, Inc. and Joey A. Jacobs. (v)Christopher H. Hunter. (m)

  †10.8

†10.19

Amended and Restated Employment Agreement, dated April  7, 2014, among the Company, Acadia Management Company, Inc. and Brent Turner. (v)

†10.20Amended and Restated Employment Agreement, dated April  7, 2014, among the Company, Acadia Management Company, Inc. and Ronald M. Fincher. (v)
†10.21Amended and Restated Employment Agreement, dated April 7, 2014, among the Company, Acadia Management Company, Inc. and Christopher L. Howard. (v)(n)

†10.22

  †10.9

Employment Agreement, dated April 7, 2014, by and among the Company, Acadia Management Company, Inc. and David M. Duckworth. (v)(n)

†10.23

  †10.10

Employment Agreement, dated as of May 23, 2011,July 31, 2019, by and between theAcadia Management Company, Inc. and Bruce A. Shear. (b)John S. Hollinsworth. (o)

†10.24

  †10.11

PHC,Employment Agreement, dated August 6, 2019, by and between Acadia Management Company, Inc.’s 2004Non-Employee Director Stock Option Plan. (w) and Laurence L. Harrod. (p)

†10.25

  †10.12

Acadia Healthcare Company, Inc. Incentive Compensation Plan, effective May 23, 2013. (x)(q)

†10.26

  †10.13

First Amendment, effective May 19, 2016, to the Acadia Healthcare Company, Inc. Incentive Compensation Plan. (y)(r)

†10.27

  †10.14

Second Amendment, effective May 6, 2021, to the Acadia Healthcare Company, Inc. Incentive Compensation Plan. (s)

  †10.15

Form of Restricted Stock Unit Agreement. (b)(t)

†10.28

  †10.16

Form of Incentive Stock Option Agreement. (b)(u)

†10.29

  †10.17

Form ofNon-Qualified Stock Option Agreement. (b)(u)

†10.30

  †10.18

Form of Restricted Stock Agreement. (b)(t)

†10.31

  †10.19

Form of Stock Appreciation Rights Agreement. (b)(u)

†10.32

  †10.20

Acadia Healthcare Company, Inc. Nonqualified Deferred Compensation Plan, effective February 1, 2013. (z)(v)

†10.33

  †10.21

Nonmanagement Director Compensation Program, effective January 1, 2013. (z)(v)

  10.34

    10.22

Form of Indemnification Agreement (for directors and officers affiliated with Waud Capital Partners or Bain
Capital). (k)(w)

  10.35

    10.23

Form of Indemnification Agreement (for directors and officers not affiliated with Waud Capital Partners or Bain Capital). (k)(w)

    21*

Subsidiaries of the Company.

Exhibit
No.

Exhibit Description

    22*

List of Subsidiary Guarantors and Issuers of Guaranteed Securities.

    23*

Consent of Independent Registered Public Accounting Firm.

    31.1*

Rule13a-14(a) Certification of the Chief Executive Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2*

Rule13a-14(a) Certification of the Chief Financial Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    32.1*

Section 1350 Certification of Chairman of the Board and Chief Executive Officer of the Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

55


Table of Contents

    32.2*

Section 1350 Certification of Chief Financial Officer of the Company pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**

Inline XBRL Instance Document.Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH**

Inline XBRL Taxonomy Extension Schema Document.

101.CAL**

Inline XBRL Taxonomy Calculation Linkbase Document.

101.DEF**

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB**

Inline XBRL Taxonomy Labels Linkbase Document.

101.PRE**

Inline XBRL Taxonomy Presentation Linkbase Document.

 

104

The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, has been formatted in Inline XBRL.

Indicates management contract or compensatory plan or arrangement.

*

Filed herewith.

**

The XBRL related information in Exhibit 101 to this Annual Report on Form10-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

(a)

Incorporated by reference to exhibits filed with PHC, Inc.’sthe Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (File No. 001-35331).

(b)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed May 25, 20112017 (FileNo. 001-33323)001-35331).

(b)

(c)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed June 24, 2020 (File No. 001-35331).

(d)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed October 14, 2020 (File No. 001-35331).

(e)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form 8-K filed October 30, 2014 (File No. 001-35331).

(f)

Incorporated by reference to exhibits filed with the Company’s registration statement on FormS-4, S-1, as amended (FileNo. 333-175523), originally filed with the SEC on July 13,November 23, 2011.

(c)

(g)

Incorporated by reference to exhibits filed with PHC, Inc.’s Current Report on Form8-K filed March 18, 2011 (FileNo. 001-33323).
(d)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed January 5, 20124, 2016 (FileNo. 001-35331).

(e)

(h)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed September 4, 2012February 16, 2016 (FileNo. 001-35331).

(f)

(i)

Incorporated by reference to exhibits filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (File No. 001-35331).

(j)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed November 27, 2012 10-Q for the three months ended March 31, 2021 (FileNo. 001-35331).

(g)

(k)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed January 2, 201322, 2021 (FileNo. 001-35331).

(h)

(l)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed April 4, 2013February 1, 2022 (FileNo. 001-35331).

(i)

(m)

Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022 (File No. 001-35331).

(n)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed June 6,April 11, 2014 (FileNo. 001-35331).

(j)

(o)

Incorporated by reference to exhibits filed with the Company’s Amendment No. 1 to the Current Report on Form 8-K filed August 6, 2019 (File No. 001-35331).

(p)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed October 30, 2014August 6, 2019 (FileNo. 001-35331).

(q)

Incorporated by reference to exhibits filed with the Company’s registration statement on Form S-8 filed July 30, 2013 (File No. 333-190232).

(r)

Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2016 (File No. 001-35331).

56


Table of Contents

(k)

(s)

Incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement filed March 24, 2021 (File No. 001-35331).

(t)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed November 1, 2011 10-Q for the three months ended March 31, 2018 (FileNo. 001-35331).

(l)

(u)

Incorporated by reference to exhibits filed with the Company’s registration statement on Form S-4, as amended (File No. 333-175523), originally filed with the SEC on July 13, 2011.

(v)

Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2013 (File No. 001-35331).

(w)

Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed March 12, 2013November 1, 2011 (FileNo. 001-35331).

(m)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed July 2, 2014 (FileNo. 001-35331).
(n)Incorporated by reference to exhibits filed with the Company’s registration statement on FormS-4 filed August 8, 2014 (FileNo. 333-198004).
(o)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed February 12, 2015 (FileNo. 001-35331).
(p)Incorporated by reference to exhibits filed with the Company’s registration statement on FormS-1, as amended (FileNo. 333-175523), originally filed with the SEC on November 23, 2011.

(q)Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form10-Q for the three months ended June 30, 2013 (FileNo. 001-35331).
(r)Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form10-Q for the three months ended September 30, 2013 (FileNo. 001-35331).
(s)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed February 19, 2014 (FileNo. 001-35331).
(t)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed June 17, 2014 (FileNo. 001-35331).
(u)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed December 15, 2014 (FileNo. 001-35331).
(v)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed April 11, 2014 (FileNo. 001-35331).
(w)Incorporated by reference to exhibits filed with PHC, Inc.’s registration statement on FormS-8 filed April 5, 2005 (FileNo. 333-123842).
(x)Incorporated by reference to exhibits filed with the Company’s registration statement on FormS-8 filed July 30, 2013 (FileNo. 333-190232).
(y)Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form10-Q for the three months ended June 30, 2016 (FileNo. 001-35331).
(z)Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form10-Q for the three months ended March 31, 2013 (FileNo. 001-35331).
(aa)Incorporated by reference to exhibits filed with the Company’s Quarterly Report on Form10-Q for the three months ended March 31, 2015 (FileNo. 001-35331).
(bb)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed September 21, 2015 (FileNo. 001-35331).
(cc)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed January 4, 2016 (FileNo. 001-35331).
(dd)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed January 8, 2016 (FileNo. 001-35331).
(ee)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed January 27, 2016 (FileNo. 001-35331).
(ff)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed February 16, 2016 (FileNo. 001-35331).
(gg)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed May 26, 2016 (FileNo. 001-35331).
(hh)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed September 21, 2016 (FileNo. 001-35331).
(ii)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed November 30, 2016 (FileNo. 001-35331).
(jj)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed May 10, 2017 (FileNo. 001-35331).
(kk)Incorporated by reference to exhibits filed with the Company’s Current Report on Form8-K filed May 25, 2017 (FileNo. 001-35331).

Item 16. Form10-K Summary.

None.

57


Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Acadia Healthcare Company, Inc.

By:

/s/ CHRISTOPHER H. HUNTER

Christopher H. Hunter

Chief Executive Officer and Director

Dated: February 28, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature

Title

Date

/s/ CHRISTOPHER H. HUNTER

Christopher H. Hunter

Chief Executive Officer and Director (Principal Executive Officer)

February 28, 2023

/s/ DAVID M. DUCKWORTH

David M. Duckworth

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

February 28, 2023

/s/ REEVE B. WAUD

Reeve B. Waud

Chairman of the Board

February 28, 2023

/s/JASON R. BERNHARD

Jason R. Bernhard

Director

February 28, 2023

/s/ E. PEROT BISSELL

E. Perot Bissell

Director

February 28, 2023

/s/ MICHAEL J. FUCCI

Michael J. Fucci

Director

February 28, 2023

/s/ VICKY B. GREGG

Vicky B. Gregg

Director

February 28, 2023

/s/ WILLIAM F. GRIECO

William F. Grieco

Director

February 28, 2023

/s/ DAVID R. KELLY

David R. Kelly

Director

February 28, 2023

/s/ WADE D. MIQUELON

Wade D. Miquelon

Director

February 28, 2023

/s/ DEBRA K. OSTEEN

Debra K. Osteen

Director

February 28, 2023

/s/ WILLIAM M. PETRIE

William M. Petrie

Director

February 28, 2023

58


Table of Contents

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

F-1


Table of Contents

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules13a-15(f) and15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as ofat December 31, 20172022 based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as ofat December 31, 2017.2022.

Our accompanying consolidated financial statements have been audited by the independent registered public accounting firm of Ernst & Young LLP. Reports of the independent registered public accounting firm, including the independent registered public accounting firm’s report on our internal control over financial reporting, are included in this report.

F-2


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

TheTo the Stockholders and the Board of Directors and Stockholdersof

Acadia Healthcare Company, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Acadia Healthcare Company, Inc.’s internal control over financial reporting as of December 31, 2017,2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Acadia Healthcare Company, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017,2022, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Acadia Healthcare Company, Inc. as of December 31, 20172022 and 2016,2021, and the related consolidated statements of income,operations, comprehensive income shareholders’(loss), equity and cash flows for each of the three years in the period ended December 31, 2017,2022, and the related notes and our report dated February 27, 201828, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

/s/ Ernst & Young LLP

Nashville, Tennessee

February 27, 2018

28, 2023


F-3


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The

To the Stockholders and the Board of Directors and Stockholders

of Acadia Healthcare Company, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Acadia Healthcare Company, Inc. (the Company) as of December 31, 20172022 and 2016,2021, the related consolidated statements of income,operations, comprehensive income shareholders’(loss), equity and cash flows for each of the three years in the period ended December 31, 2017,2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 20172022 and 2016,2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017,2022, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’sCompany's internal control over financial reporting as of December 31, 2017,2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 27, 201828, 2023, expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’sCompany's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

/s/ Ernst & Young LLP

Revenue Recognition

Description of the Matter

For the year ended December 31, 2022, the Company recognized $2.6 billion of revenue from continuing operations. As discussed in Note 3 of the consolidated financial statements, the Company determines the transaction price for services to patients based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based primarily on historical collection experience.

How We Addressed the Matter in Our Audit

Auditing the Company’s revenue recognition and its estimates of contractual adjustments, discounts and implicit price concessions was complex and judgmental due to the significant data inputs and subjective assumptions utilized in estimating the related amounts. Various reimbursement programs under which these amounts must be estimated are complex and subject to interpretation and adjustment. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s revenue recognition, including controls over key data inputs to the contractual adjustment, discount and implicit price concession estimates and management’s review and consideration of retrospective analyses of historical expected cash collections compared to subsequent actual collections.

To test the revenue recognized, we performed audit procedures that included, among others, testing the validity of a sample of revenue transactions and the completeness and accuracy of data inputs to the estimates of contractual adjustments, discounts and implicit price concessions, including payor contractual terms and historical collection experience. We assessed the historical accuracy of management’s estimates based on subsequent collection experience and used the assessment as a source of potential corroborative or contrary evidence supporting management’s assumptions of future collections of existing accounts receivable.  

F-4


Table of Contents

/s/ Ernst & Young LLP

We have served as the Company’sCompany's auditor since 2006.

Nashville, Tennessee

February 27, 2018

28, 2023

F-5


Table of Contents

Acadia Healthcare Company, Inc.

Consolidated Balance Sheets

 

  December 31, 

 

December 31,

 

  2017 2016 

 

2022

 

 

2021

 

  

(In thousands, except share and per

share amounts)

 

 

(In thousands, except share and per

share amounts)

 

ASSETS

   

 

 

 

 

 

 

 

 

Current assets:

   

 

 

 

 

 

 

 

 

Cash and cash equivalents

  $67,290  $57,063 

 

$

97,649

 

 

$

133,813

 

Accounts receivable, net of allowance for doubtful accounts of $39,803 and $38,916, respectively

   296,925  263,327 

Accounts receivable, net

 

 

322,439

 

 

 

281,332

 

Other current assets

   107,335  107,537 

 

 

86,037

 

 

 

79,886

 

  

 

  

 

 

Total current assets

   471,550  427,927 

 

 

506,125

 

 

 

495,031

 

Property and equipment:

   

Land

   450,342  411,331 

Building and improvements

   2,370,918  2,031,819 

Equipment

   400,596  318,020 

Construction in progress

   173,693  157,114 

Less accumulated depreciation

   (347,419 (214,589
  

 

  

 

 

Property and equipment, net

   3,048,130  2,703,695 

 

 

1,952,045

 

 

 

1,771,159

 

Goodwill

   2,751,174  2,681,188 

 

 

2,222,805

 

 

 

2,199,937

 

Intangible assets, net

   87,348  83,310 

 

 

76,041

 

 

 

70,145

 

Deferred tax assets – noncurrent

   3,731  3,780 

Derivative instruments

   12,997  73,509 

Deferred tax assets

 

 

2,950

 

 

 

3,080

 

Operating lease right-of-use assets

 

 

135,238

 

 

 

133,761

 

Other assets

   49,572  51,317 

 

 

92,697

 

 

 

94,965

 

  

 

  

 

 

Total assets

  $6,424,502  $6,024,726 

 

$

4,987,901

 

 

$

4,768,078

 

  

 

  

 

 

LIABILITIES AND EQUITY

   

 

 

 

 

 

 

 

 

Current liabilities:

   

 

 

 

 

 

 

 

 

Current portion of long-term debt

  $34,830  $34,805 

 

$

21,250

 

 

$

18,594

 

Accounts payable

   102,299  80,034 

 

 

104,723

 

 

 

98,575

 

Accrued salaries and benefits

   99,047  105,068 

 

 

125,298

 

 

 

137,845

 

Current portion of operating lease liabilities

 

 

26,463

 

 

 

23,348

 

Other accrued liabilities

   141,213  122,958 

 

 

110,592

 

 

 

126,499

 

  

 

  

 

 

Total current liabilities

   377,389  342,865 

 

 

388,326

 

 

 

404,861

 

Long-term debt

   3,205,058  3,253,004 

 

 

1,364,541

 

 

 

1,478,626

 

Deferred tax liabilities – noncurrent

   80,333  78,520 

Deferred tax liabilities

 

 

92,588

 

 

 

74,368

 

Operating lease liabilities

 

 

116,429

 

 

 

116,841

 

Other liabilities

   166,434  164,859 

 

 

125,033

 

 

 

110,505

 

  

 

  

 

 

Total liabilities

   3,829,214  3,839,248 

 

 

2,086,917

 

 

 

2,185,201

 

Redeemable noncontrolling interests

   22,417  17,754 

 

 

88,257

 

 

 

65,388

 

Equity:

   

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued

   —     —   

 

 

 

 

 

 

Common stock, $0.01 par value; 180,000,000 shares authorized; 87,060,114 and 86,688,199 issued and outstanding as of December 31, 2017 and 2016, respectively

   871  867 

Common stock, $0.01 par value; 180,000,000 shares authorized;

89,913,659 and 89,028,158 issued and outstanding as of

December 31, 2022 and 2021, respectively

 

 

899

 

 

 

890

 

Additionalpaid-in capital

   2,517,545  2,496,288 

 

 

2,658,440

 

 

 

2,636,350

 

Accumulated other comprehensive loss

   (374,118 (549,570

Retained earnings

   428,573  220,139 
  

 

  

 

 

Retained earnings (accumulated deficit)

 

 

153,388

 

 

 

(119,751

)

Total equity

   2,572,871  2,167,724 

 

 

2,812,727

 

 

 

2,517,489

 

  

 

  

 

 

Total liabilities and equity

  $6,424,502  $6,024,726 

 

$

4,987,901

 

 

$

4,768,078

 

  

 

  

 

 

See accompanying notes.

F-6


Table of Contents

Acadia Healthcare Company, Inc.

Consolidated Statements of IncomeOperations

 

 

Year Ended December 31,

 

  Year Ended December 31, 

 

2022

 

 

2021

 

 

2020

 

  2017 2016 2015 

 

(In thousands, except per share amounts)

 

  (In thousands, except per share amounts) 

Revenue before provision for doubtful accounts

  $2,877,234  $2,852,823  $1,829,619 

Provision for doubtful accounts

   (40,918 (41,909 (35,127
  

 

  

 

  

 

 

Revenue

   2,836,316  2,810,914  1,794,492 

 

$

2,610,399

 

 

$

2,314,394

 

 

$

2,089,929

 

Salaries, wages and benefits (including equity-based compensation expense of $23,467, $28,345 and $20,472, respectively)

   1,536,160  1,541,854  973,732 

Salaries, wages and benefits (including equity-based compensation

expense of $29,635, $37,530 and $22,504, respectively)

 

 

1,393,434

 

 

 

1,243,804

 

 

 

1,154,522

 

Professional fees

   196,223  185,486  116,463 

 

 

158,013

 

 

 

136,739

 

 

 

120,489

 

Supplies

   114,439  117,425  80,663 

 

 

100,200

 

 

 

90,702

 

 

 

87,241

 

Rents and leases

   76,775  73,348  32,528 

 

 

45,462

 

 

 

38,519

 

 

 

37,362

 

Other operating expenses

   331,827  312,556  206,746 

 

 

349,277

 

 

 

301,339

 

 

 

262,272

 

Income from provider relief fund

 

 

(21,451

)

 

 

(17,900

)

 

 

(32,819

)

Depreciation and amortization

   143,010  135,103  63,550 

 

 

117,769

 

 

 

106,717

 

 

 

95,256

 

Interest expense, net

   176,007  181,325  106,742 

 

 

69,760

 

 

 

76,993

 

 

 

158,105

 

Debt extinguishment costs

   810  4,253  10,818 

 

 

 

 

 

24,650

 

 

 

7,233

 

Loss on divestiture

   —    178,809   —   

(Gain) loss on foreign currency derivatives

   —    (523 1,926 

Loss on impairment

 

 

 

 

 

24,293

 

 

 

4,751

 

Transaction-related expenses

   24,267  48,323  36,571 

 

 

23,792

 

 

 

12,778

 

 

 

11,720

 

  

 

  

 

  

 

 

Total expenses

   2,599,518  2,777,959  1,629,739 

 

 

2,236,256

 

 

 

2,038,634

 

 

 

1,906,132

 

  

 

  

 

  

 

 

Income from continuing operations before income taxes

   236,798  32,955  164,753 

 

 

374,143

 

 

 

275,760

 

 

 

183,797

 

Provision for income taxes

   37,209  28,779  53,388 

 

 

94,110

 

 

 

67,557

 

 

 

40,606

 

Income from continuing operations

 

 

280,033

 

 

 

208,203

 

 

 

143,191

 

Loss from discontinued operations, net of taxes

 

 

 

 

 

(12,641

)

 

 

(812,390

)

Net income (loss)

 

 

280,033

 

 

 

195,562

 

 

 

(669,199

)

Net income attributable to noncontrolling interests

 

 

(6,894

)

 

 

(4,927

)

 

 

(2,933

)

Net income (loss) attributable to Acadia Healthcare Company, Inc.

 

$

273,139

 

 

$

190,635

 

 

$

(672,132

)

Basic earnings (loss) per share attributable to Acadia Healthcare Company,

Inc. stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations attributable to Acadia Healthcare Company, Inc.

 

$

3.05

 

 

$

2.29

 

 

$

1.60

 

Loss from discontinued operations

 

 

 

 

 

(0.14

)

 

 

(9.25

)

Net income (loss) attributable to Acadia Healthcare Company, Inc.

 

$

3.05

 

 

$

2.15

 

 

$

(7.65

)

  

 

  

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations

   199,589  4,176  111,365 

Income from discontinued operations, net of income taxes

   —     —    111 
  

 

  

 

  

 

 

Net income

   199,589  4,176  111,476 

Net loss attributable to noncontrolling interests

   246  1,967  1,078 
  

 

  

 

  

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $199,835  $6,143  $112,554 
  

 

  

 

  

 

 

Basic earnings attributable to Acadia Healthcare Company, Inc. stockholders:

    

Income from continuing operations

  $2.30  $0.07  $1.65 

Income from discontinued operations

   —     —     —   
  

 

  

 

  

 

 

Net income

  $2.30  $0.07  $1.65 
  

 

  

 

  

 

 

Diluted earnings attributable to Acadia Healthcare Company, Inc. stockholders:

    

Income from continuing operations

  $2.30  $0.07  $1.64 

Income from discontinued operations

   —     —     —   
  

 

  

 

  

 

 

Net income

  $2.30  $0.07  $1.64 
  

 

  

 

  

 

 

Diluted earnings (loss) per share attributable to Acadia Healthcare

Company, Inc. stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations attributable to Acadia Healthcare Company, Inc.

 

$

2.98

 

 

$

2.24

 

 

$

1.58

 

Loss from discontinued operations

 

 

 

 

 

(0.14

)

 

 

(9.17

)

Net income (loss) attributable to Acadia Healthcare Company, Inc.

 

$

2.98

 

 

$

2.10

 

 

$

(7.59

)

Weighted-average shares outstanding:

    

 

 

 

 

 

 

 

 

 

 

 

 

Basic

   86,948  85,701  68,085 

 

 

89,680

 

 

 

88,769

 

 

 

87,875

 

Diluted

   87,060  85,972  68,391 

 

 

91,555

 

 

 

90,793

 

 

 

88,595

 

See accompanying notes.

F-7


Table of Contents

Acadia Healthcare Company, Inc.

Consolidated Statements of Comprehensive Income (Loss)

 

   Year Ended December 31, 
   2017  2016  2015 
   (In thousands) 

Net income

  $199,589  $4,176  $111,476 

Other comprehensive loss:

    

Foreign currency translation gain (loss)

   207,341   (477,772  (40,103

(Loss) gain on derivative instruments, net of tax of $(22.9) million, $29.1 million and $0, respectively

   (33,431  40,598   —   

Pension liability adjustment, net of tax of $0.4 million, $(1.3) million and $0.9 million, respectively

   1,542   (7,749  3,826 
  

 

 

  

 

 

  

 

 

 

Other comprehensive gain (loss)

   175,452   (444,923  (36,277
  

 

 

  

 

 

  

 

 

 

Comprehensive income (loss)

   375,041   (440,747  75,199 

Comprehensive loss attributable to noncontrolling interests

   246   1,967   1,078 
  

 

 

  

 

 

  

 

 

 

Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.

  $375,287  $(438,780 $76,277 
  

 

 

  

 

 

  

 

 

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

 

 

(In thousands)

 

Net income (loss)

 

$

280,033

 

 

$

195,562

 

 

$

(669,199

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation (loss) gain

 

 

 

 

 

(4,260

)

 

 

61,247

 

Gain (loss) on derivative instruments, net of tax of $0.0

   million, $0.1 million and $(3.9) million, respectively

 

 

 

 

 

19

 

 

 

(11,272

)

Pension liability adjustment, net of tax of $0.0 million, $0.0

   million and $(0.8) million, respectively

 

 

 

 

 

 

 

 

(6,456

)

U.K. Sale

 

 

 

 

 

375,606

 

 

 

 

Other comprehensive income

 

 

 

 

 

371,365

 

 

 

43,519

 

Comprehensive income (loss)

 

 

280,033

 

 

 

566,927

 

 

 

(625,680

)

Comprehensive income attributable to noncontrolling interests

 

 

(6,894

)

 

 

(4,927

)

 

 

(2,933

)

Comprehensive income (loss) attributable to Acadia Healthcare

    Company, Inc.

 

$

273,139

 

 

$

562,000

 

 

$

(628,613

)

See accompanying notes.


F-8


Table of Contents

Acadia Healthcare Company, Inc.

Consolidated Statements of Equity

(In thousands)

 

   Common Stock   Additional
Paid-
in Capital
  Other
Comprehensive
Loss
  Retained
Earnings
   Total 
   Shares   Amount       

Balance at January 1, 2015

   59,212   $592   $847,301  $(68,370 $101,442   $880,965 

Common stock issued under stock incentive plans

   384    4    1,811   —     —      1,815 

Common stock withheld for minimum statutory taxes

   —      —      (9,577  —     —      (9,577

Equity-based compensation

expense

   —      —      20,472   —     —      20,472 

Excess tax benefit from equity

awards

   —      —      309   —     —      309 

Issuance of common stock, net

   11,150    111    711,406   —     —      711,517 

Other comprehensive loss

   —      —      —     (36,277  —      (36,277

Other

   —      —      1,250   —     —      1,250 

Net income attributable to Acadia Healthcare Company, Inc. stockholders

   —      —      —     —     112,554    112,554 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

 

Balance at December 31, 2015

   70,746    707    1,572,972   (104,647  213,996    1,683,028 

Common stock issued under stock incentive plans

   408    5    1,379   —     —      1,384 

Common stock withheld for minimum statutory taxes

   —      —      (10,230  —     —      (10,230

Equity-based compensation

expense

   —      —      28,345   —     —      28,345 

Issuance of common stock, net

   15,534    155    901,824   —     —      901,979 

Other comprehensive loss

   —      —      —     (444,923  —      (444,923

Other

   —      —      1,998   —     —      1,998 

Net income attributable to Acadia Healthcare Company, Inc. stockholders

   —      —      —     —     6,143    6,143 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

 

Balance at December 31, 2016

   86,688    867    2,496,288   (549,570  220,139    2,167,724 

Common stock issued under stock incentive plans

   372    4    2,065   —     —      2,069 

Common stock withheld for minimum statutory taxes

   —      —      (5,524  —     —      (5,524

Equity-based compensation

expense

   —      —      23,467   —     —      23,467 

Cumulative effect of change in accounting principle

   —      —      —     —     8,599   8,599 

Other comprehensive gain

   —      —      —     175,452   —      175,452 

Other

   —      —      1,249   —     —      1,249 

Net income attributable to Acadia Healthcare Company, Inc. stockholders

   —      —      —     —     199,835    199,835 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

 

Balance at December 31, 2017

   87,060   $871   $2,517,545  $(374,118 $428,573   $2,572,871 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

 

 

 

Common Stock

 

 

Additional

Paid-

 

 

Accumulated

Other

Comprehensive

 

 

(Accumulated Deficit) Retained

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

in Capital

 

 

Loss

 

 

Earnings

 

 

Total

 

Balance at January 1, 2020

 

 

87,715

 

 

$

877

 

 

$

2,557,642

 

 

$

(414,884

)

 

$

361,746

 

 

$

2,505,381

 

Common stock issued under stock incentive plans

 

 

309

 

 

 

3

 

 

 

2,024

 

 

 

 

 

 

 

 

 

2,027

 

Repurchase of shares for payroll tax witholdings,

  net of proceeds from stock option exercises

 

 

 

 

 

 

 

 

(1,843

)

 

 

 

 

 

 

 

 

(1,843

)

Equity-based compensation expense

 

 

 

 

 

 

 

 

22,504

 

 

 

 

 

 

 

 

 

22,504

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

43,519

 

 

 

 

 

 

43,519

 

Net loss attributable to Acadia Healthcare

  Company, Inc. stockholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(672,132

)

 

 

(672,132

)

Balance at December 31, 2020

 

 

88,024

 

 

 

880

 

 

 

2,580,327

 

 

 

(371,365

)

 

 

(310,386

)

 

 

1,899,456

 

Common stock issued under stock incentive plans

 

 

1,004

 

 

 

10

 

 

 

22,019

 

 

 

 

 

 

 

 

 

22,029

 

Repurchase of shares for payroll tax witholdings,

  net of proceeds from stock option exercises

 

 

 

 

 

 

 

 

(5,734

)

 

 

 

 

 

 

 

 

(5,734

)

Equity-based compensation expense

 

 

 

 

 

 

 

 

37,530

 

 

 

 

 

 

 

 

 

37,530

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

371,365

 

 

 

 

 

 

371,365

 

Other

 

 

 

 

 

 

 

 

2,208

 

 

 

 

 

 

 

 

 

2,208

 

Net income attributable to Acadia Healthcare

  Company, Inc. stockholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

190,635

 

 

 

190,635

 

Balance at December 31, 2021

 

 

89,028

 

 

 

890

 

 

 

2,636,350

 

 

 

 

 

 

(119,751

)

 

 

2,517,489

 

Common stock issued under stock incentive plans

 

 

886

 

 

 

9

 

 

 

11,604

 

 

 

 

 

 

 

 

 

11,613

 

Repurchase of shares for payroll tax witholdings,

  net of proceeds from stock option exercises

 

 

 

 

 

 

 

 

(17,792

)

 

 

 

 

 

 

 

 

(17,792

)

Equity-based compensation expense

 

 

 

 

 

 

 

 

29,635

 

 

 

 

 

 

 

 

 

29,635

 

Other

 

 

 

 

 

 

 

 

(1,357

)

 

 

 

 

 

 

 

 

(1,357

)

Net income attributable to Acadia Healthcare

  Company, Inc. stockholders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

273,139

 

 

 

273,139

 

Balance at December 31, 2022

 

 

89,914

 

 

$

899

 

 

$

2,658,440

 

 

$

 

 

$

153,388

 

 

$

2,812,727

 

See accompanying notes.

F-9


Acadia Healthcare Company, Inc.

Consolidated StatementsTable of Cash FlowsContents

 

   Year Ended December 31, 
   2017  2016  2015 
   (In thousands) 

Operating activities:

    

Net income

  $199,589  $4,176  $111,476 

Adjustments to reconcile net income to net cash provided by continuing operating activities:

    

Depreciation and amortization

   143,010   135,103   63,550 

Amortization of debt issuance costs

   9,855   10,324   6,709 

Equity-based compensation expense

   23,467   28,345   20,472 

Deferred income tax expense

   31,372   28,647   43,613 

(Income) loss from discontinued operations, net of taxes

   —     —     (111

Debt extinguishment costs

   810   4,253   10,818 

Loss on divestiture

   —     178,809   —   

(Gain) loss on foreign currency derivatives

   —     (523  1,926 

Other

   11,412   4,715   1,615 

Change in operating assets and liabilities, net of effect of acquisitions:

    

Accounts receivable, net

   (28,570  (15,718  (24,954

Other current assets

   20,808   (20,648  (2,717

Other assets

   (3,176  (4,354  (8,021

Accounts payable and other accrued liabilities

   (10,113  22,693   6,868 

Accrued salaries and benefits

   (8,988  (8,572  1,658 

Other liabilities

   11,794   4,484   9,236 
  

 

 

  

 

 

  

 

 

 

Net cash provided by continuing operating activities

   401,270   371,734   242,138 

Net cash used in discontinued operating activities

   (1,693  (10,256  (1,735
  

 

 

  

 

 

  

 

 

 

Net cash provided by operating activities

   399,577   361,478   240,403 

Investing activities:

    

Cash paid for acquisitions, net of cash acquired

   (18,191  (683,455  (574,777

Cash paid for capital expenditures

   (274,177  (307,472  (276,047

Cash paid for real estate acquisitions

   (41,057  (40,757  (26,622

Settlement of foreign currency derivatives

   —     523   (1,926

Cash received on divestitures

   —     373,266   —   

Other

   (3,101  (2,470  (5,099
  

 

 

  

 

 

  

 

 

 

Net cash used in investing activities

   (336,526  (660,365  (884,471

Financing activities:

    

Borrowings on long-term debt

   —     1,480,000   1,150,000 

Borrowings on revolving credit facility

   —     179,000   468,000 

Principal payments on revolving credit facility

   —     (337,000  (310,000

Principal payments on long-term debt

   (34,805  (49,941  (31,965

Repayment of assumed debt

   —     (1,348,389  (904,467

Repayment of long-term debt

   (22,500  (200,594  (97,500

Payment of debt issuance costs

   —     (36,649  (26,421

Payment of premium on senior notes

   —     —     (7,480

Issuances of common stock, net

   —     685,097   331,308 

Common stock withheld for minimum statutory taxes, net

   (3,455  (8,846  (7,762

Excess tax benefit from equity awards

   —     —     309 

Other

   686   (3,837  (420
  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by financing activities

   (60,074  358,841   563,602 

Effect of exchange rate changes on cash

   7,250   (14,106  (2,359
  

 

 

  

 

 

  

 

 

 

Net increase (decrease) in cash and cash equivalents

   10,227   45,848   (82,825

Cash and cash equivalents at beginning of the period

   57,063   11,215   94,040 
  

 

 

  

 

 

  

 

 

 

Cash and cash equivalents at end of the period

  $67,290  $57,063  $11,215 
  

 

 

  

 

 

  

 

 

 

(continued on next page)

F-9


Acadia Healthcare Company, Inc.

Consolidated Statements of Cash Flows (continued)

 

 

Year Ended December 31,

 

  Year Ended December 31, 

 

2022

 

 

2021

 

 

2020

 

  2017 2016 2015 

 

(In thousands)

 

  (In thousands) 

Operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

280,033

 

 

$

195,562

 

 

$

(669,199

)

Adjustments to reconcile net income (loss) to net cash provided by continuing

operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

117,769

 

 

 

106,717

 

 

 

95,256

 

Amortization of debt issuance costs

 

 

3,261

 

 

 

4,071

 

 

 

12,636

 

Equity-based compensation expense

 

 

29,635

 

 

 

37,530

 

 

 

22,504

 

Deferred income taxes

 

 

16,545

 

 

 

11,772

 

 

 

53,108

 

Loss from discontinued operations, net of taxes

 

 

 

 

 

12,641

 

 

 

812,390

 

Debt extinguishment costs

 

 

 

 

 

24,650

 

 

 

7,233

 

Loss on impairment

 

 

 

 

 

24,293

 

 

 

4,751

 

Other

 

 

2,680

 

 

 

491

 

 

 

1,041

 

Change in operating assets and liabilities, net of effect of acquisitions:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(41,978

)

 

 

2,448

 

 

 

15,340

 

Other current assets

 

 

(17,626

)

 

 

1,968

 

 

 

9,675

 

Other assets

 

 

2,252

 

 

 

(10,770

)

 

 

1,519

 

Accounts payable and other accrued liabilities

 

 

5,174

 

 

 

6,164

 

 

 

41,910

 

Accrued salaries and benefits

 

 

6,804

 

 

 

9,755

 

 

 

(10,001

)

Other liabilities

 

 

15,090

 

 

 

(14,940

)

 

 

18,082

 

Government relief funds

 

 

(39,070

)

 

 

(38,128

)

 

 

86,599

 

Net cash provided by continuing operating activities

 

 

380,569

 

 

 

374,224

 

 

 

502,844

 

Net cash provided by discontinued operating activities

 

 

 

 

 

253

 

 

 

155,963

 

Net cash provided by operating activities

 

 

380,569

 

 

 

374,477

 

 

 

658,807

 

Investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for acquisitions, net of cash acquired

 

 

(9,507

)

 

 

(139,015

)

 

 

 

Cash paid for capital expenditures

 

 

(296,149

)

 

 

(244,811

)

 

 

(224,964

)

Proceeds from U.K. Sale

 

 

 

 

 

1,511,020

 

 

 

 

Settlement of foreign currency derivatives

 

 

 

 

 

(84,795

)

 

 

 

Proceeds from sale of property and equipment

 

 

7,074

 

 

 

3,493

 

 

 

92

 

Cash paid for purchase of finance lease

 

 

 

 

 

(31,401

)

 

 

 

Other

 

 

(7,248

)

 

 

(1,394

)

 

 

(13,365

)

Net cash (used in) provided by continuing investing activities

 

 

(305,830

)

 

 

1,013,097

 

 

 

(238,237

)

Net cash used in discontinued investing activities

 

 

 

 

 

 

 

 

(43,602

)

Net cash (used in) provided by investing activities

 

 

(305,830

)

 

 

1,013,097

 

 

 

(281,839

)

Financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Borrowings on long-term debt

 

 

 

 

 

425,000

 

 

 

925,000

 

Borrowings on revolving credit facility

 

 

 

 

 

500,000

 

 

 

100,000

 

Principal payments on revolving credit facility

 

 

(95,000

)

 

 

(330,000

)

 

 

(100,000

)

Principal payments on long-term debt

 

 

(18,594

)

 

 

(7,969

)

 

 

(41,291

)

Repayment of long-term debt

 

 

 

 

 

(2,227,935

)

 

 

(909,785

)

Payment of debt issuance costs

 

 

 

 

 

(7,964

)

 

 

(18,295

)

Repurchase of shares for payroll tax witholdings, net of proceeds from stock option exercises

 

 

(6,179

)

 

 

16,295

 

 

 

184

 

Contributions from noncontrolling partners in joint ventures

 

 

15,362

 

 

 

4,536

 

 

 

 

Distributions to noncontrolling partners in joint ventures

 

 

(1,004

)

 

 

(1,588

)

 

 

(916

)

Acquisition of ownership interests from noncontrolling partners

 

 

(5,540

)

 

 

 

 

 

 

Other

 

 

52

 

 

 

(6,900

)

 

 

(3,146

)

Net cash used in continuing financing activities

 

 

(110,903

)

 

 

(1,636,525

)

 

 

(48,249

)

Net cash used in discontinued financing activities

 

 

 

 

 

 

 

 

(3,250

)

Net cash used in financing activities

 

 

(110,903

)

 

 

(1,636,525

)

 

 

(51,499

)

Effect of exchange rate changes on cash

 

 

 

 

 

4,067

 

 

 

4,087

 

Net (decrease) increase in cash and cash equivalents, including cash classified within current assets

held for sale

 

 

(36,164

)

 

 

(244,884

)

 

 

329,556

 

Less: cash classified within current assets held for sale

 

 

 

 

 

 

 

 

(75,051

)

Net (decrease) increase in cash and cash equivalents

 

 

(36,164

)

 

 

(244,884

)

 

 

254,505

 

Cash and cash equivalents at beginning of the period

 

 

133,813

 

 

 

378,697

 

 

 

124,192

 

Cash and cash equivalents at end of the period

 

$

97,649

 

 

$

133,813

 

 

$

378,697

 

Supplemental Cash Flow Information:

    

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

  $159,098  $161,146  $87,034 

 

$

65,687

 

 

$

93,669

 

 

$

137,578

 

  

 

  

 

  

 

 

Cash paid for income taxes

  $10,291  $15,483  $6,911 
  

 

  

 

  

 

 

Cash paid (received) for income taxes

 

$

86,195

 

 

$

79,304

 

 

$

(16,486

)

Effect of acquisitions:

   

 

 

 

 

 

 

 

 

 

 

 

 

Assets acquired, excluding cash

  $19,649  $2,516,880  $1,988,634 

 

$

10,756

 

 

$

176,365

 

 

$

20,200

 

Liabilities assumed

   (1,458 (1,616,543 (1,024,515

 

 

(1,249

)

 

 

(37,350

)

 

 

(53

)

Issuance of common stock in connection with acquisition

   —    (216,882 (380,210

Redeemable noncontrolling interest resulting from acquisitions

   —     —    (9,132
  

 

  

 

  

 

 

Redeemable noncontrolling interest resulting from an acquisition

 

 

 

 

 

 

 

 

(20,147

)

Cash paid for acquisitions, net of cash acquired

  $18,191  $683,455  $574,777 

 

$

9,507

 

 

$

139,015

 

 

$

 

  

 

  

 

  

 

 

See accompanying notes.


F-10


Table of Contents

Acadia Healthcare Company, Inc.

Notes to Consolidated Financial Statements

December 31, 20172022

1. Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.(the “U.S.”) and Puerto Rico. At December 31, 2017,2022, the Company operated 582250 behavioral healthcare facilities with approximately 17,80011,000 beds in 39 states the U.K. and Puerto Rico.

On January 19, 2021, the Company completed the sale of its operations in the United Kingdom (the “U.K.”) to RemedcoUK Limited, a company organized under the laws of England and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allowed the Company to reduce its indebtedness and focus on its U.S. operations. As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. See Note 9 – U.K. Sale.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships andC-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its’its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The majority of the Company’s expenses are “cost of revenue” items. Costs that could be classified as general and administrative expenses include the Company’s corporate office costs, which were $76.4$124.3 million, $86.8$108.2 million and $68.3$97.8 million for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.

Certain reclassifications have been made to prior years to conform to the current year presentation.

2. Summary of Significant Accounting Policies

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, cash and cash equivalent balances may exceed federally insured limits. Management believes that the Company mitigates any risks by depositing cash and investing in cash equivalents with major financial institutions.

Insurance

The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides. A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary providing coverage for up to $10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. The Company has obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place. The reserve for professional and general liability risks was estimated based on historical claims, prior settlements and judgments, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The Company recorded an unfavorable adjustment of $5.9 million to its estimated liability for self-insured professional and general liability claims during the year ended December 31, 2022, relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period. The professional and general liability reserve was $103.6 million at December 31, 2022, of which $12.1 million was included in other accrued liabilities and $91.5 million was included in other long-term liabilities. The professional and general liability reserve was $87.8 million at

F-11


Table of Contents

December 31, 2021, of which $11.9 million was included in other accrued liabilities and $75.9 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $37.8 million at December 31, 2022, of which $10.2 million was included in other current assets and $27.6 million was included in other assets, and such receivable was $37.9 million at December 31, 2021, of which $10.8 million was included in other current assets and $27.1 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $24.2 million at December 31, 2022, of which $12.0 million was included in accrued salaries and benefits and $12.2 million was included in other long-term liabilities, and such liability was $23.6 million at December 31, 2021, of which $12.0 million was included in accrued salaries and benefits and $11.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $117.8 million, $106.7 million and $95.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful life, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

The Company performed an impairment review of long-lived assets in the fourth quarter of 2022 and 2021 and recorded no impairment. The impairment review of long-lived assets in the fourth quarter of 2020 indicated the carrying amounts of certain of the Company’s long-lived assets may not be recoverable. This created a non-cash impairment of $4.2 million for the year ended December 31, 2020, which was recorded in loss on impairment on the Company’s consolidated statements of operations.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable.

As of the Company’s annual impairment tests on October 1, 2022 and October 1, 2021, the Company had one reporting unit, behavioral health services. The fair value of the Company’s behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded.

During the second quarter of 2021, the Company sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, the Company sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition.  

As of the Company’s annual impairment test on October 1, 2020, the Company had two operating segments for segment reporting purposes, U.S. facilities and U.K. facilities, each of which represented a reporting unit for purposes of the Company’s goodwill impairment test.

The Company’s annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. facilities of $356.2 million. The non-cash loss on impairment is included in loss on sale within discontinued operations in the consolidated statements of operations. As of the Company’s impairment test on October 1, 2020, the fair value of the U.S. facilities reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded. Additionally, for the year ended December 31, 2020, the Company recorded a non-cash impairment charge of $0.6 million related to indefinite-lived assets related to closed facilities in the U.S., which is included in loss on impairment in the consolidated statements of operations.

F-12


Table of Contents

Other Current Assets

Other current assets consisted of the following (in thousands):

 

 

December 31,

 

 

 

2022

 

 

2021

 

Prepaid expenses

 

$

27,052

 

 

$

22,292

 

Other receivables

 

 

15,371

 

 

 

10,786

 

Workers’ compensation deposits – current portion

 

 

12,000

 

 

 

12,000

 

Insurance receivable – current portion

 

 

10,158

 

 

 

10,807

 

Assets held for sale

 

 

8,347

 

 

 

15,808

 

Income taxes receivable

 

 

5,767

 

 

 

1,523

 

Inventory

 

 

5,087

 

 

 

4,786

 

Other

 

 

2,255

 

 

 

1,884

 

Other current assets

 

$

86,037

 

 

$

79,886

 

Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

 

 

December 31,

 

 

 

2022

 

 

2021

 

Accrued expenses

 

$

26,699

 

 

$

26,791

 

Accrued interest

 

 

17,596

 

 

 

17,418

 

Cost report payable

 

 

13,738

 

 

 

6,487

 

Insurance liability – current portion

 

 

12,128

 

 

 

11,923

 

Accrued property taxes

 

 

9,009

 

 

 

8,375

 

Government relief funds

 

 

8,975

 

 

 

8,550

 

Contract liabilities

 

 

6,653

 

 

 

30,371

 

Income taxes payable

 

 

1,338

 

 

 

5,540

 

Finance lease liabilities

 

 

990

 

 

 

990

 

Other

 

 

13,466

 

 

 

10,054

 

Other accrued liabilities

 

$

110,592

 

 

$

126,499

 

Stock Compensation

The Company measures and recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 718, “ Compensation—Stock Compensation .” The Company uses the Black-Scholes valuation model to determine grant-date fair value for stock options and recognizes straight-line amortization of share-based compensation expense over the requisite service period of the respective awards. The fair values of restricted stock units are determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at their Monte-Carlo simulation value for units subject to market conditions.

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options and non-vested shares, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred

F-13


Table of Contents

taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Company established accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. The Company accrues for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Management believes that the positions taken on previously filed tax returns are reasonable and has not established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by the Company resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect the Company’s potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.

Recent Accounting Pronouncements

In November 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832)” (“ASU 2021-10”). ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. ASU 2021-10 applies to all business entities except for not-for-profit entities within the scope of Topic 958, Not-for-Profit Entities, and employee benefit plans within the scope of Topic 960, Plan Accounting— Defined Benefit Pension Plans, Topic 962, Plan Accounting—Defined Contribution Pension Plans, and Topic 965, Plan Accounting—Health and Welfare Benefit Plans that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance (for example, a grant model within IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or Subtopic 958-605, Not-For-Profit Entities—Revenue Recognition). ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company adopted the ASU for the year ended December 31, 2022. See Note 10 – The CARES Act for additional information on the Company’s accounting for government grants received.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and Accounts Receivableapplies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2024. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. There is no significant impact on the Company’s consolidated financial statements.

3. Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

Services ordered by a healthcare provider in an episode of care are not separately identifiable and therefore have been combined into a single performance obligation for each contract. The Company recognizes revenue as its performance obligations are completed. The performance obligation is satisfied over time as the customer simultaneously receives and consumes the benefits ofthe healthcare services provided. For inpatient services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being performed or the patient being discharged, and payments are due based on contract terms.

F-14


Table of Contents

As the Company’s performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as the Company’s patients typically are under no obligation to remain admitted in the Company’s facilities.

At December 31, 2022 and 2021, estimated implicit price concessions of $61.4 million and $49.7 million, respectively, had been recorded as reductions to the Company’s accounts receivable balances to enable the Company to record its revenues and accounts receivable at the estimated amounts the Company expected to collect.

The Company disaggregates revenue from contracts with customers by service type and by payor.

The Company’s facilities and services provided by the facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; comprehensive treatment centers (“CTCs”); and residential treatment centers.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities and eating disorder facilities. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Comprehensive treatment centers. CTCs specialize in providing medication-assisted treatment in an outpatient setting to individuals addicted to opioids such as opioid analgesics (prescription pain medications).

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

The table below presents total revenue from continuing operations attributed to each category (in thousands):

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Acute inpatient psychiatric facilities

 

$

1,330,757

 

 

$

1,126,872

 

 

$

984,609

 

Specialty treatment facilities

 

 

564,671

 

 

 

510,929

 

 

 

452,805

 

Comprehensive treatment centers

 

 

419,940

 

 

 

385,635

 

 

 

349,217

 

Residential treatment centers

 

 

295,031

 

 

 

283,169

 

 

 

281,158

 

Other

 

 

 

 

 

7,789

 

 

 

22,140

 

Revenue

 

$

2,610,399

 

 

$

2,314,394

 

 

$

2,089,929

 

The Company receives payments from the following sources for services rendered in ourits facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, Clinical Commissioning GroupsCenters for Medicare and Medicaid Services (“CCGs”CMS”) and local authorities in England, Scotland and Wales); and (v)(iv) individual patients and clients. Revenue is recorded in

The Company determines the period in which services are provided attransaction price based on established billing rates lessreduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on amounts reimbursable by Medicare or Medicaid under provisionscontractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.

The following table presents the percentageCompany’s facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue before provision for doubtful accounts generated by each payor type:

   Year Ended December 31, 
   2017  2016  2015 

Commercial

   19.8  18.7  23.1

Medicare

   9.8   9.4   11.7 

Medicaid

   27.7   25.4   33.3 

U.K. public funded sources

   32.6   35.8   19.5 

Self-Pay

   8.7   9.4   9.6 

Other

   1.4   1.3   2.8 
  

 

 

  

 

 

  

 

 

 

Revenue before provision for doubtful accounts

   100  100  100
  

 

 

  

 

 

  

 

 

 

Onwill occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a combined basis, revenue relatedpatient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the Medicare and Medicaid programs were 38%, 35% and 45%consolidated statements of all revenue before provision for doubtful accountsoperations. Bad debt expense for the years ended December 31, 2017, 20162022, 2021 and 2015, respectively. The Company’s concentration of credit risk from other payors is reduced by the large number of payors and their geographic dispersion. The Company generated approximately 36%, 38% and 20% of its revenue for the years ended December 31, 2017, 2016 and 2015, respectively, from facilities located in the U.K.

Allowance for Contractual Discounts2020 was not significant.

The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculatedestimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management

F-15


Table of Contents

estimates the allowance for contractual discountstransaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s cost report receivablespayables were $9.0$13.7 million and $7.4$6.5 million atas of December 31, 20172022 and 2016,2021, respectively, and were included in other current assets inliabilities on the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.sheet. The net adjustments to estimated cost report settlements resulted in increasesan increase to revenue of $0.2$0.1 million $0.7for the year ended December 31, 2022, compared to decreases to revenue of $5.4 million and $1.9$1.3 million for the years ended December 31, 2017, 20162021 and 2015,2020, respectively.

Management believes that we are in substantial compliance with all applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.

Allowance for Doubtful Accounts

The Company’s ability to collect outstanding patient receivables from third-party payors is critical to its operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. The Company estimates uncollectible accounts and establishes an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, historical collection experience, current economic conditions, and other relevant factors. Accounts receivable that are determined to be uncollectible based on the Company’s policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on the Company’s results of operations and cash flows.

A summary of activity in the Company’s allowance for doubtful accounts is as follows (in thousands):

   Balance at
Beginning of
Period
   Additions
Charged to Costs
and Expenses
   Accounts
Written Off, Net
of Recoveries
   Balance at
End of
Period
 

Year ended December 31, 2015

  $22,449   $35,127   $(28,244  $29,332 

Year ended December 31, 2016

   29,332    41,909    (32,325   38,916 

Year ended December 31, 2017

   38,916    40,918    (40,031   39,803 

Charity Care

The Company provides care without charge to patients who are financially unable to pay for the healthcare services they receive based on Company policies and federal and state poverty thresholds. Such amounts determined to qualify as charity care are not reported as revenue. The costscost of providing charity care services were $6.6$6.4 million, $7.1$3.8 million and $4.6$4.4 million for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively. The estimated cost of charity care services was determined using a ratio of cost to gross charges determined from ourthe Company’s most recently filed Medicare cost reports and applying that ratio to the gross charges associated with providing charity care for the period.

Insurance

The Company is subject to medical malpracticefollowing table presents revenue by payor type and other lawsuits due to the natureas a percentage of the services the Company provides. A portion of the Company’s professional liability risk is insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Companyrevenue for professional liability losses up to $78.0 million in the aggregate. The insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 million in excess of a retention level of $3.0 million. The reserve for professional and general liability risks was estimated based on historical claims, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. The professional and general liability reserve was $55.0 million as of December 31, 2017, of which $22.8 million was included in other accrued liabilities and $32.2 million was included in other long-term liabilities. The professional and general liability reserve was $52.3 million as of December 31, 2016, of which $11.7 million was included in other accrued liabilities and $40.6 million was included in other long-term liabilities. The Company estimates receivables for the portion of professional and general liability reserves that are recoverable under the Company’s insurance policies. Such receivable was $22.7 million as of December 31, 2017, of which $17.6 million was included in other current assets and $5.1 million was included in other assets, and such receivable was $25.9 million as of December 31, 2016, of which $6.5 million was included in other current assets and $19.4 million was included in other assets.

The Company’s statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $18.5 million as of December 31, 2017, of which $10.0 million was included in accrued salaries and benefits and $8.5 million was included in other long-term liabilities, and such liability was $16.6 million as of December 31, 2016, of which $10.0 million was included in accrued salaries and benefits and $6.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.

Property and Equipment and Other Long-Lived Assets

Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $143.0 million, $134.8 million and $63.0 millioncontinuing operations for the years ended December 31, 2017, 20162022, 2021 and 2015, respectively.

The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows.

Goodwill and Indefinite-Lived Intangible Assets

The Company’s goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. The Company has two operating segments, U.S. Facilities and U.K. Facilities, for segment reporting purposes, each of which represents a reporting unit for purposes of the Company’s goodwill impairment test. Potential impairment is noted for a reporting unit if its carrying value exceeds the fair value of the reporting unit. For a reporting unit with potential impairment of goodwill, the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, an impairment loss is recorded. The Company’s annual impairment tests of goodwill and other indefinite-lived intangibles in 2017, 2016 and 2015 resulted in no impairment charges.

Other Current Assets

Other current assets consisted of the following2020 (in thousands):

 

   As of December 31, 
   2017   2016 

Other receivables

  $30,455   $44,975 

Prepaid expenses

   27,320    27,455 

Insurance receivable – current portion

   17,588    6,472 

Income taxes receivable

   15,056    11,714 

Workers’ compensation deposits – current portion

   10,000    10,000 

Inventory

   4,787    4,633 

Other

   2,129    2,288 
  

 

 

   

 

 

 

Other current assets

  $107,335   $107,537 
  

 

 

   

 

 

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

 

Amount

 

 

%

 

Commercial

 

$

788,895

 

 

 

30.2

%

 

$

684,292

 

 

 

29.6

%

 

$

596,698

 

 

 

28.5

%

Medicare

 

 

394,227

 

 

 

15.1

%

 

 

364,598

 

 

 

15.8

%

 

 

330,070

 

 

 

15.8

%

Medicaid

 

 

1,319,600

 

 

 

50.6

%

 

 

1,147,884

 

 

 

49.6

%

 

 

1,037,852

 

 

 

49.7

%

Self-Pay

 

 

76,050

 

 

 

2.9

%

 

 

93,425

 

 

 

4.0

%

 

 

98,302

 

 

 

4.7

%

Other

 

 

31,627

 

 

 

1.2

%

 

 

24,195

 

 

 

1.0

%

 

 

27,007

 

 

 

1.3

%

Revenue

 

$

2,610,399

 

 

 

100.0

%

 

$

2,314,394

 

 

 

100.0

%

 

$

2,089,929

 

 

 

100.0

%

Other Accrued Liabilities

OtherContract liabilities primarily consisted of advances from payors and unearned revenue from CMS’ Accelerated and Advance Payment Program. In April 2020, the Company received approximately $45.2 million from CMS’ Accelerated and Advance Payment Program for Medicare providers. Of the $45.2 million of advance payments received in 2020, the Company repaid approximately $25.1 million of advance payments during 2021 and made additional payments of approximately $20.1 million during the year ended December 31, 2022. Contract liabilities of $6.7 million and $30.4 million are included in other accrued liabilities consistedat December 31, 2022 and 2021, respectively, on the consolidated balance sheet. A summary of the followingactivity in contract liabilities is as follows (in thousands):

 

   As of December 31, 
   2017   2016 

Accrued expenses

  $37,268   $37,323 

Accrued interest

   36,370    33,616 

Unearned income

   31,342    28,805 

Insurance liability – current portion

   22,788    11,672 

Accrued property taxes

   3,945    2,732 

Income taxes payable

   1,012    527 

Other

   8,488    8,283 
  

 

 

   

 

 

 

Other accrued liabilities

  $141,213   $122,958 
  

 

 

   

 

 

 

Balance at December 31, 2020

 

$

47,196

 

Payments received

 

 

11,739

 

Revenue recognized

 

 

(3,463

)

Medicare advance repayments

 

 

(25,101

)

Balance at December 31, 2021

 

$

30,371

 

Payments received

 

 

22,914

 

Revenue recognized

 

 

(26,497

)

Medicare advance repayments

 

 

(20,135

)

Balance at December 31, 2022

 

$

6,653

 

Stock Compensation

The Company measures and recognizes the cost

F-16


Table of employee services received in exchange for awards of equity instruments based on the grant-date fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “Compensation—Stock Compensation.” The Company uses the Black-Scholes valuation model to determine grant-date fair value for equity awards and uses straight-line amortization of share-based compensation expense over the requisite service period of the respective awards.Contents

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with FASB ASC 260, “Earnings Per Share,” based on the weighted-average number of shares outstanding in each period and dilutive stock options,non-vested shares and warrants, to the extent such securities have a dilutive effect on earnings per share.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.

The Company reviews its deferred tax assets for recoverability and establishes a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

The Tax Act was enacted on December 22, 2017. The Tax Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay aone-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. See additional disclosure described in Note 9 – Income Taxes. ASC 740 “Income Taxes” (“ASC 740”) requires the Company to recognize the effect of the tax law changes in the period of enactment. However, the Securities and Exchange Commission (the “SEC”) staff issued Staff Accounting Bulletin 118 (“SAB 118”) which will allow the Company to record provisional amounts during a measurement period similarly to the measurement period used when accounting for business combinations. The Company will continue to assess the impact of the recently enacted tax law on its business and consolidated financial statements.

Recent Accounting Pronouncements

In August 2017, the FASB issued Accounting Standards Update (“ASU”)2017-12,“Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU2017-12”). ASU2017-12 amends the hedge accounting model to enable entities to better portray the economics of their risk management activities in the financial statements and simplifies the application of hedge accounting in certain situations. ASU2017-12 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. Management is evaluating the impact of ASU2017-12 on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU2017-04,“Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU2017-04”). ASU2017-04 simplifies the measurement of goodwill by eliminating the requirement to calculate the implied fair value of goodwill (step 2 of the current impairment test) to measure the goodwill impairment charge. Instead, entities will record impairment charges based on the excess of a reporting unit’s carrying amount over its fair value. ASU2017-04 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. Management is evaluating the impact of ASU2017-04 on the Company’s consolidated financial statements.

In March 2016, the FASB issued ASU2016-09,“Improvements to Employee Share-Based Payment Accounting” (“ASU2016-09”). ASU2016-09 includes multiple provisions intended to simplify various aspects of the accounting for share-based payments. ASU2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company adopted ASU2016-09 as of January 1, 2017 as described in Note 9 – Income Taxes.

In March 2016, the FASB issued ASU2016-02,“Leases” (“ASU2016-02”). ASU2016-02’s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. ASU2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Additionally, ASU2016-02 would permit both public and nonpublic organizations to adopt the new standard early. Management believes the primary effect of adopting the new standard will be to recordright-of-use assets and obligations for current operating leases. Management is evaluating the impact ASU2016-02 will have on the Company’s consolidated financial statements, internal controls, policies and procedures.

In May 2014, the FASB and the International Accounting Standards Board issued ASU2014-09,“Revenue from Contracts with Customers (Topic 606)” (“ASU2014-09”). ASU2014-09’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASU2014-09 requires companies to exercise more judgment and recognize revenue in accordance with the standard’s core principle by applying the following five steps:

Step 1: Identify the contract with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

ASU2014-09 also includes a cohesive set of quantitative and qualitative disclosure requirements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from the entity’s contracts with customers.

ASU2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Additionally, ASU2014-09 would permit both public and nonpublic organizations to adopt the new revenue standard early, but not before the original public organization effective date (that is, annual periods beginning after December 15, 2016). ASU2014-09

requires retrospective application using either a full retrospective adoption or a modified retrospective adoption approach. Full retrospective adoption requires entities to apply the standard as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings at the date of initial application.

The Company will adopt ASU2014-09 using the modified retrospective method effective January 1, 2018 and will use a portfolio approach to group contracts with similar characteristics and analyze historical cash collections trends. The Company anticipates that, as a result of certain changes required by ASU2014-09, the majority of its provision for doubtful accounts will be recorded as a direct reduction to revenue instead of being presented as a separate line item. Management does not anticipate ASU2014-09 will have a significant impact on the Company’s consolidated financial statements.

3.4. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2017, 20162022, 2021 and 20152020 (in thousands, except per share amounts):

 

   Year Ended December 31, 
   2017   2016   2015 

Numerator:

      

Basic and diluted earnings per share attributable to Acadia Healthcare Company, Inc.:

      

Income from continuing operations

  $199,835   $6,143   $112,443 

Income from discontinued operations

   —      —      111 
  

 

 

   

 

 

   

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $199,835   $6,143   $112,554 
  

 

 

   

 

 

   

 

 

 

Denominator:

      

Weighted average shares outstanding for basic earnings per share

   86,948    85,701    68,085 

Effects of dilutive instruments

   112    271    306 
  

 

 

   

 

 

   

 

 

 

Shares used in computing diluted earnings per common share

   87,060    85,972    68,391 
  

 

 

   

 

 

   

 

 

 

Basic earnings per share attributable to Acadia Healthcare Company, Inc.:

      

Income from continuing operations

  $2.30   $0.07   $1.65 

Income from discontinued operations

   —      —      —   
  

 

 

   

 

 

   

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.:

  $2.30   $0.07   $1.65 
  

 

 

   

 

 

   

 

 

 

Diluted earnings per share attributable to Acadia Healthcare Company, Inc.:

      

Income from continuing operations

  $2.30   $0.07   $1.64 

Income from discontinued operations

   —      —      —   
  

 

 

   

 

 

   

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.:

  $2.30   $0.07   $1.64 
  

 

 

   

 

 

   

 

 

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations attributable to Acadia

    Healthcare Company, Inc.

 

$

273,139

 

 

$

203,276

 

 

$

140,258

 

Loss from discontinued operations

 

 

 

 

 

(12,641

)

 

 

(812,390

)

Net income (loss) attributable to Acadia Healthcare

    Company, Inc.

 

$

273,139

 

 

$

190,635

 

 

$

(672,132

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding for basic

   earnings per share

 

 

89,680

 

 

 

88,769

 

 

 

87,875

 

Effects of dilutive instruments

 

 

1,875

 

 

 

2,024

 

 

 

720

 

Shares used in computing diluted earnings per

   common share

 

 

91,555

 

 

 

90,793

 

 

 

88,595

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings (loss) per share attributable to Acadia

   Healthcare Company, Inc. stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations attributable to Acadia

    Healthcare Company, Inc.

 

$

3.05

 

 

$

2.29

 

 

$

1.60

 

Loss from discontinued operations

 

 

 

 

 

(0.14

)

 

 

(9.25

)

Net income (loss) attributable to Acadia Healthcare

    Company, Inc.

 

$

3.05

 

 

$

2.15

 

 

$

(7.65

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted earnings (loss) per share attributable to Acadia

   Healthcare Company, Inc. stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations attributable to Acadia

    Healthcare Company, Inc.

 

$

2.98

 

 

$

2.24

 

 

$

1.58

 

Loss from discontinued operations

 

 

 

 

 

(0.14

)

 

 

(9.17

)

Net income (loss) attributable to Acadia Healthcare

    Company, Inc.

 

$

2.98

 

 

$

2.10

 

 

$

(7.59

)

Approximately 1.40.1 million, 1.10.3 million and 0.81.9 million shares of common stock issuable upon exercise of outstanding stock options were excluded from the calculation of diluted earnings per share for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively, because their effect would have been anti-dilutive.

4.5. Acquisitions

2017 AcquisitionThe Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On November 13, 2017, we completed7, 2022, the acquisition of Aspire Scotland, an education facility with 36 bedsCompany acquired four CTCs located in Scotland,Georgia from Brand New Start Treatment Centers.

On December 31, 2021, the Company acquired the equity of CenterPointe Behavioral Health System, LLC and certain related entities (“CenterPointe”) for cash consideration of approximately $21.3$140 million.

2016 U.S. Acquisitions

On June 1, 2016, The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Company completedRevolving Facility. At the time of the acquisition, CenterPointe operated four acute inpatient hospitals with 306 beds and ten outpatient locations primarily in Missouri.

F-17


Table of Pocono Mountain Recovery Center (“Pocono Mountain”), an inpatient psychiatric facility with 108 beds located in Henryville, Pennsylvania, for cash consideration of approximately $25.4 million.Contents

On May 1, 2016, the Company completed the acquisition of TrustPoint Hospital (“TrustPoint”), an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.

On April 1, 2016, the Company completed the acquisition of Serenity Knolls (“Serenity Knolls”), an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.

Priory

On February 16, 2016, the Company completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of its common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K. operating 324 facilities with approximately 7,100 beds at February 16, 2016.

The Competition and Markets Authority (the “CMA”) in the U.K. reviewed the Company’s acquisition of Priory. On July 14, 2016, the CMA announced that the Company’s acquisition of Priory was referred for a phase 2 investigation unless the Company offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that the Company had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider the Company’s undertakings.

On October 18, 2016, the Company signed a definitive agreement with BC Partners (“BC Partners”) for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds (collectively, the “U.K. Disposal Group”). On November 10, 2016, the CMA accepted the Company’s undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concerns about the impact of the Company’s acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K. As a result of the CMA’s acceptance of the undertakings, the Company’s acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, the Company completed the sale of the U.K. Disposal Group to BC Partners for £320 million cash (the “U.K. Divestiture”).

In conjunction with the sale, the Company recorded a loss on divestiture of $175.0 million in the consolidated statements of income for the year ended December 31, 2016. The loss on divestiture consisted of an allocation of goodwill to the U.K. Disposal Group of $106.9 million, loss on the sale of properties of $42.0 million and estimated transaction-related expenses of $26.1 million. The allocation of goodwill was based on the fair value of the U.K. Disposal Group relative to the total fair value of the Company’s U.K. Facilities segment.

The consolidated statements of income for the year ended December 31, 2016 include revenue of $154.7 million and income from continuing operations before income taxes of $81.2 million related to the U.K. Disposal Group excluding the loss on divestiture. The consolidated statements of income for the year ended December 31, 2015 include revenue of $58.5 million and income from continuing operations before income taxes of $17.0 million related to the U.K. Disposal Group excluding the loss on divestiture.

Summary of Acquisitions

The Company selectively seeks opportunities to expand and diversify its base of operations by acquiring additional facilities. Approximately $31.4 million of the goodwill associated with domestic acquisitions completed in 2016 is deductible for federal income tax purposes. The fair values assigned to certainof assets acquired and liabilities assumed atin the date ofCenterPointe acquisition dates, during the year ended December 31, 2016 in connection with Priory, Serenity Knolls, Trustpoint and Pocono Mountain acquisitions (collectively the “2016 Acquisitions”) were as follows (in thousands):

 

  Priory   Other   Total 

Cash

  $10,253   $2,488   $12,741 

 

$

5,640

 

Accounts receivable

   57,832    4,264    62,096 

Prepaid expenses and other current assets

   7,921    103    8,024 

Accounts receivable, net

 

 

9,358

 

Other current assets

 

 

1,981

 

Property and equipment

   1,598,156    35,400    1,633,556 

 

 

35,227

 

Goodwill

   679,265    96,052    775,317 

 

 

105,883

 

Intangible assets

   23,200    338    23,538 

 

 

825

 

Other assets

   8,862    47    8,909 
  

 

   

 

   

 

 

Deferred tax assets

 

 

1,573

 

Operating lease right-of-use assets

 

 

29,245

 

Total assets acquired

   2,385,489    138,692    2,524,181 

 

 

189,732

 

Accounts payable

   24,203    749    24,952 

 

 

3,820

 

Accrued salaries and benefits

   39,588    918    40,506 

 

 

3,585

 

Other accrued expenses

   48,305    391    48,696 

Deferred tax liabilities – noncurrent

   56,462    269    56,731 

Debt

   1,348,389    —      1,348,389 

Other liabilities

   61,311    30,243    91,554 
  

 

   

 

   

 

 

Current portion of operating lease liabilities

 

 

2,820

 

Other accrued liabilities

 

 

4,326

 

Deferred tax liability

 

 

1,805

 

Operating lease liabilities

 

 

27,850

 

Total liabilities assumed

   1,578,258    32,570    1,610,828 

 

 

44,206

 

  

 

   

 

   

 

 

Net assets acquired

  $807,231   $106,122   $913,353 

 

$

145,526

 

  

 

   

 

   

 

 

Other

The qualitative factors comprising the goodwill acquired in the 2016 AcquisitionsCenterPointe acquisition include the value of the business and efficiencies derived through synergies expected by the elimination of certain redundant corporate functions and expenses, the ability to leverage call center referrals to a broader provider base, coordination of services provided across the combined network of facilities, achievement of operating efficiencies by benchmarking performance and applying best practices throughoutpractices.

Goodwill

The following table summarizes changes in goodwill for the combined companies.years ended December 31, 2022 and 2021 (in thousands):

Balance at January 1, 2021

 

$

2,105,264

 

Increase from acquisitions

 

 

97,122

 

2021 dispositions

 

 

(2,449

)

Balance at December 31, 2021

 

 

2,199,937

 

Increase from acquisitions

 

 

9,488

 

Adjustments related to 2021 acquisitions

 

 

8,761

 

Increase from contributions of redeemable noncontrolling interests

 

 

4,619

 

Balance at December 31, 2022

 

$

2,222,805

 

Of the increases to goodwill from acquisitions in 2022 and 2021, the Company expects $9.5 million and $56.1 million to be tax-deductible for the years ended December 31, 2022 and 2021, respectively.

Transaction-related expenses

Transaction-related expenses represent costs primarily related to legal, accounting, termination, restructuring, management transition, acquisition and other similar costs. Transaction-related expenses comprised the following costs for the years ended December 31, 2017, 20162022, 2021 and 20152020 (in thousands):

 

   Year Ended December 31, 
   2017   2016   2015 

Severance and contract termination costs

  $14,709   $12,415   $8,466 

Legal, accounting and other fees

   9,558    21,058    17,768 

Advisory and financing commitment fees

   —      14,850    10,337 
  

 

 

   

 

 

   

 

 

 
   $24,267   $48,323   $36,571 
  

 

 

   

 

 

   

 

 

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Management transition costs

 

$

11,575

 

 

$

 

 

$

 

Termination and restructuring costs

 

 

6,476

 

 

 

5,343

 

 

 

3,468

 

Legal, accounting and other acquisition-related costs

 

 

5,741

 

 

 

7,435

 

 

 

8,252

 

 

 

$

23,792

 

 

$

12,778

 

 

$

11,720

 

F-18


5.Table of Contents

6. Property and Equipment

Property and equipment consisted of the following at December 31, 2022 and 2021 (in thousands):

 

 

December 31,

 

 

 

2022

 

 

2021

 

Land

 

$

169,137

 

 

$

154,376

 

Building and improvements

 

 

1,797,809

 

 

 

1,683,560

 

Equipment

 

 

292,200

 

 

 

253,100

 

Construction in progress

 

 

349,473

 

 

 

221,249

 

 

 

 

2,608,619

 

 

 

2,312,285

 

Less: accumulated depreciation

 

 

(656,574

)

 

 

(541,126

)

Property and equipment, net

 

$

1,952,045

 

 

$

1,771,159

 

During the year ended December 31, 2021, the Company recorded non-cash impairment charges of $24.3 million related primarily to the closure of certain facilities. During the second quarter of 2021, the Company opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter 2021, the Company recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

The Company has recorded assets held for sale within other current assets on the consolidated balance sheets for closed properties actively marketed of $8.3 million and $15.8 million at December 31, 2022 and 2021, respectively.

7. Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following as ofat December 31, 20172022 and 20162021 (in thousands):

 

  Gross Carrying Amount   Accumulated Amortization 

 

Gross Carrying Amount

 

 

Accumulated Amortization

 

  December 31,
2017
   December 31,
2016
   December 31,
2017
   December 31,
2016
 

 

December 31, 2022

 

 

December 31, 2021

 

 

December 31, 2022

 

 

December 31, 2021

 

Intangible assets subject to amortization:

        

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contract intangible assets

  $2,100   $2,100   $(2,100  $(2,100

Non-compete agreements

   1,147    1,147    (1,147   (1,147

 

$

1,131

 

 

$

1,131

 

 

$

(1,131

)

 

$

(1,131

)

  

 

   

 

   

 

   

 

 
   3,247    3,247    (3,247   (3,247

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intangible assets not subject to amortization:

        

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Licenses and accreditations

   12,266    12,228    —      —   

 

 

11,512

 

 

 

11,600

 

 

 

 

 

 

 

Trade names

   60,586    57,538    —      —   

 

 

45,935

 

 

 

40,435

 

 

 

 

 

 

 

Certificates of need

   14,496    13,544    —      —   

 

 

18,594

 

 

 

18,110

 

 

 

 

 

 

 

  

 

   

 

   

 

   

 

 

 

 

76,041

 

 

 

70,145

 

 

 

 

 

 

 

   87,348    83,310    —      —   
  

 

   

 

   

 

   

 

 

Total

  $90,595   $86,557   $(3,247  $(3,247

 

$

77,172

 

 

$

71,276

 

 

$

(1,131

)

 

$

(1,131

)

  

 

   

 

   

 

   

 

 

Amortization expense related to definite-lived intangible assets was $0.4 million and $0.5 million for the years ended December 31, 2016 and 2015, respectively.

All the Company’s defined-liveddefinite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

6.During the second quarter of 2021, the Company sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, the Company sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition. These dispositions are reflected in other investing activities in the consolidated statement of cash flows.

8. Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

The Company elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as

F-19


Table of Contents

right-of-use assets and liabilities on the consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

Operating lease liabilities are recorded at the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore, incremental borrowing rates were calculated based on information available at the lease commencement date. The Company reviews service agreements for embedded leases and records right-of-use assets and liabilities as necessary.

Lease Position

The Company recorded the following at December 31, 2022 and 2021 on the consolidated balance sheets (in thousands):

Right-of-Use Assets

 

Balance Sheet Classification

 

December 31, 2022

 

 

December 31, 2021

 

Finance lease right-of-use assets

 

Property and equipment, net

 

$

8,250

 

 

$

8,627

 

Operating lease right-of-use assets

 

Operating lease right-of-use assets

 

 

135,238

 

 

 

133,761

 

Total

 

 

 

$

143,488

 

 

$

142,388

 

 

 

 

 

 

 

 

 

 

 

 

Lease Liabilities

 

Balance Sheet Classification

 

December 31, 2022

 

 

December 31, 2021

 

Current:

 

 

 

 

 

 

 

 

 

 

Finance lease liabilities

 

Other accrued liabilities

 

$

990

 

 

$

990

 

Operating lease liabilities

 

Current portion of operating lease liabilities

 

 

26,463

 

 

 

23,348

 

Noncurrent:

 

 

 

 

 

 

 

 

 

 

Finance lease liabilities

 

Other liabilities

 

 

10,858

 

 

 

10,807

 

Operating lease liabilities

 

Operating lease liabilities

 

 

116,429

 

 

 

116,841

 

Total

 

 

 

$

154,740

 

 

$

151,986

 

Weighted-average remaining lease terms and discount rates were as follows at December 31, 2022 and 2021:

 

 

December 31,

 

 

 

2022

 

 

2021

 

Weighted-average remaining lease term (in years):

 

 

 

 

 

 

 

 

Finance

 

 

21.9

 

 

22.9

 

Operating

 

 

8.4

 

 

9.1

 

 

 

 

 

 

 

 

 

 

Weighted-average discount rate:

 

 

 

 

 

 

 

 

Finance

 

 

5.1

%

 

 

5.1

%

Operating

 

 

5.0

%

 

 

5.1

%

F-20


Table of Contents

Lease Costs

The Company recorded the following lease costs for the years ended December 31, 2022, 2021 and 2020 (in thousands):

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Finance lease costs:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation of leased assets

 

 

378

 

 

 

378

 

 

 

868

 

Interest of lease liabilities

 

 

1,041

 

 

 

2,174

 

 

 

3,214

 

Total finance lease costs

 

$

1,419

 

 

$

2,552

 

 

$

4,082

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease costs

 

 

34,349

 

 

 

28,233

 

 

 

27,050

 

Variable lease costs

 

 

3,129

 

 

 

2,488

 

 

 

2,501

 

Short term lease costs

 

 

2,605

 

 

 

3,257

 

 

 

3,558

 

Other lease costs

 

 

5,379

 

 

 

4,541

 

 

 

4,253

 

Total rents and leases

 

$

45,462

 

 

$

38,519

 

 

$

37,362

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total lease costs

 

$

46,881

 

 

$

41,071

 

 

$

41,444

 

Other

Undiscounted future cash flows for finance and operating leases recorded on the consolidated balance sheet were as follows at December 31, 2022 (in thousands):

 

 

Finance Leases

 

 

Operating Leases

 

2023

 

$

990

 

 

$

32,818

 

2024

 

 

1,007

 

 

 

29,568

 

2025

 

 

1,089

 

 

 

25,146

 

2026

 

 

1,180

 

 

 

19,251

 

2027

 

 

1,089

 

 

 

12,380

 

Thereafter

 

 

21,821

 

 

 

62,653

 

Total minimum lease payments

 

 

27,176

 

 

 

181,816

 

Less: amount of lease payments representing interest

 

 

15,328

 

 

 

38,924

 

Present value of future minimum lease payments

 

 

11,848

 

 

 

142,892

 

Less: Current portion of lease liabilities

 

 

990

 

 

 

26,463

 

Noncurrent lease liabilities

 

$

10,858

 

 

$

116,429

 

Supplemental data for the years ended December 31, 2022, 2021 and 2020 were as follows (in thousands):

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows for operating leases

 

$

33,836

 

 

$

27,508

 

 

$

26,810

 

Operating cash flows for finance leases

 

$

1,041

 

 

$

2,174

 

 

$

3,214

 

Financing cash flows for finance leases

 

$

(51

)

 

$

31,136

 

 

$

551

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Right-of-use assets obtained in exchange for lease obligations:

 

 

 

 

 

 

 

 

 

 

 

 

Operating leases

 

$

31,294

 

 

$

63,279

 

 

$

21,285

 

Finance leases

 

$

 

 

$

 

 

$

 

F-21


Table of Contents

9. U.K. Sale

On January 19, 2021, the Company completed the U.K. Sale pursuant to a Share Purchase Agreement in which it sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of the Company’s U.K. operations.The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“GBP”) to U.S. Dollars (“USD”) exchange rate, cash retained by the buyer and transaction costs. The Company used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash on the balance sheet to reduce debt by $1,640 million during the first quarter of 2021 as described in Note 11 – Long-Term Debt.

As a result of the U.K. Sale, the Company reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements. In December 2020, the Company’s U.K. operations met the criteria to be classified as assets held for sale. The carrying value of the U.K. operations was written down to fair value less costs to sell in the consolidated balance sheet at December 31, 2020. This resulted in a loss on sale of $867.3 million, which includes approximately $356.2 million of non-cash goodwill impairment, recorded within discontinued operations in the consolidated statement of operations. During the first quarter of 2021, an additional $14.3 million was recorded as a loss on sale primarily resulting from an increase in the U.K. operations carrying value.

For the years ended December 31, 2021 and 2020, results of operations of the U.K. operations were as follows (in thousands):

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

Revenue

 

$

62,520

 

 

$

1,119,768

 

Salaries, wages and benefits

 

 

35,937

 

 

 

632,134

 

Professional fees

 

 

6,815

 

 

 

127,291

 

Supplies

 

 

2,217

 

 

 

38,285

 

Rents and leases

 

 

2,509

 

 

 

47,748

 

Other operating expenses

 

 

6,682

 

 

 

113,534

 

Depreciation and amortization

 

 

 

 

 

74,935

 

Interest expense, net

 

 

10

 

 

 

(417

)

Loss on sale

 

 

13,490

 

 

 

867,324

 

Loss on impairment

 

 

 

 

 

20,239

 

Transaction-related expenses

 

 

6,265

 

 

 

8,719

 

Total expenses

 

 

73,925

 

 

 

1,929,792

 

Loss from discontinued operations before income taxes

 

 

(11,405

)

 

 

(810,024

)

Provision for income taxes

 

 

1,236

 

 

 

2,366

 

Loss from discontinued operations

 

$

(12,641

)

 

$

(812,390

)

The consolidated cash flows for the year ended December 31, 2020 related to the discontinued U.K. operations includes cash paid for capital expenditures of $48.4 million.

10. The CARES Act

As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. On April 24, 2020, then President Trump signed into law the Paycheck Protection Program and Health Care Enhancement Act (the “PPP Act”). Among other things, the PPP Act allocates $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. The Company accounts for government grants by analogizing to the grant model in accordance with International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, and as such, has recognized income from grants in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. The Company recognizes grants once both of the following conditions are met: (i) the Company is able to comply with the relevant terms and conditions of the grant and (ii) the grant will be received.

During 2020, the Company participated in certain relief programs offered through the CARES Act, including receipt of approximately $34.9 million relating to the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund. During the fourth quarter of 2020, the Company recorded approximately $32.8 million of income from provider relief fund related to PHSSE Fund funds received in 2020.

F-22


Table of Contents

In 2021, the Company received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, the Company recorded $17.9 million of income from provider relief fund related to the funds received. During the year ended December 31, 2022, the Company received $7.7 million of additional funds from the PHSSE Fund and $14.2 million from the American Rescue Plan (“ARP”) Rural Payments for Hospitals. During the year ended December 31, 2022, the Company recorded $21.5 million of income from provider relief fund related to PHSSE Fund and ARP funds received. The remaining unrecognized funds of $9.0 million are included in other accrued liabilities on the consolidated balance sheet at December 31, 2022. The Company continues to evaluate its compliance with the terms and conditions to, and the financial impact of, the additional funds received, including potential repayment of the remaining balance.

Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund funds and agree to the terms and conditions of payment. Under the terms and conditions for receipt of the payment, the Company was allowed to use the funds to cover lost revenues and healthcare costs related to COVID-19, and the Company was required to properly and fully document the use of these funds to the U.S. Department of Health and Human Services (“HHS”). The reporting of the funds is subject to future audit for compliance with the terms and conditions. The Company recognized Provider Relief Fund funds to the extent it had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions. The grant income associated with the COVID-19 expenses and lost revenues incurred during the years ended December 31, 2022, 2021 and 2020 is reflected as income from provider relief fund in the Company’s consolidated statements of operations.

During 2020, the Company applied for and received approximately $45.2 million of payments from the CMS Accelerated and Advance Payment Program. Of the $45.2 million of advance payments received in 2020, the Company repaid approximately $25.1 million of advance payments during 2021 and made additional repayments of approximately $20.1 million during the year ended December 31, 2022.

In addition, the Company received a 2% increase in facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020, to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provides for certain federal income and other tax changes. The Company received a cash benefit of approximately $39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. The Company repaid half of the $39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter 2022 to eliminate the liability. The payroll tax deferral at December 31, 2021 was included in accrued salaries and benefits on the consolidated balance sheet.

11. Long-Term Debt

Long-term debt consisted of the following (in thousands):

 

   December 31, 2017   December 31, 2016 

Amended and Restated Senior Credit Facility:

    

Senior Secured Term A Loans

  $380,000   $400,000 

Senior Secured Term B Loans

   1,398,400    1,435,450 

Senior Secured Revolving Line of Credit

   —      —   

6.125% Senior Notes due 2021

   150,000    150,000 

5.125% Senior Notes due 2022

   300,000    300,000 

5.625% Senior Notes due 2023

   650,000    650,000 

6.500% Senior Notes due 2024

   390,000    390,000 

9.0% and 9.5% Revenue Bonds

   21,920    22,175 

Less: unamortized debt issuance costs, discount and premium

   (50,432   (59,816
  

 

 

   

 

 

 
   3,239,888    3,287,809 

Less: current portion

   (34,830   (34,805
  

 

 

   

 

 

 

Long-term debt

  $3,205,058   $3,253,004 
  

 

 

   

 

 

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Credit Facility:

 

 

 

 

 

 

 

 

Term Loan A

 

$

398,438

 

 

$

417,031

 

Revolving Line of Credit

 

 

75,000

 

 

 

170,000

 

5.500% Senior Notes due 2028

 

 

450,000

 

 

 

450,000

 

5.000% Senior Notes due 2029

 

 

475,000

 

 

 

475,000

 

Less: unamortized debt issuance costs, discount and

   premium

 

 

(12,647

)

 

 

(14,811

)

 

 

 

1,385,791

 

 

 

1,497,220

 

Less: current portion

 

 

(21,250

)

 

 

(18,594

)

Long-term debt

 

$

1,364,541

 

 

$

1,478,626

 

Amended and Restated Senior

New Credit Facility

The Company entered into a credit agreement establishing a new senior credit facility (the “New Credit Facility”) on March 17, 2021. The New Credit Facility provides for a $600.0 million senior secured revolving credit facility (the “Revolving Facility”) and a $425.0 million senior secured term loan facility (the “Term Loan Facility” and, together with the Revolving Facility, the “Senior Facilities”), each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which the Company may borrow up to $20.0 million.  

As a part of the closing of the New Credit Facility on March 17, 2021, the Company (i) refinanced and terminated the Company’s prior credit facilities under an amended and restated credit agreement, dated as of December 31, 2012 (the “Prior Credit

F-23


Table of Contents

Facility”) and (ii) financed the redemption of all of the Company’s outstanding 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”).

The Company had $521.6 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.4 million related to security for the payment of claims required by its workers’ compensation insurance program at December 31, 2022.

During the year ended December 31, 2022, the Company repaid $95.0 million of the balance outstanding on the Revolving Facility. During the third quarter of 2021, the Company repaid $60.0 million of the initial $160.0 million balance outstanding on the Revolving Facility. During the fourth quarter of 2021, the Company had a draw of $70.0 million on the Revolving Facility related to the CenterPointe acquisition.

The New Credit Facility requires quarterly principal repayments for the Term Loan Facility of $5.3 million for March 31, 2023 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.

The Company has the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of the Consolidated EBITDA (as defined in the New Credit Facility) of the Company and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.

Subject to certain exceptions, substantially all of the Company’s existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of the Company’s obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at the Company’s option, either (i) adjusted LIBOR plus 1.75% or (ii) an alternative base rate plus 0.75% (in each case, subject to adjustment based on the Company’s consolidated total net leverage ratio). An unused fee initially set at 0.25% per annum (subject to adjustment based on the Company’s consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.

The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At December 31, 2022, the Company was in compliance with such covenants.

Prior Credit Facility

The Company entered into a credit agreement establishing a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amendedamended and Restatedrestated credit agreement establishing the Prior Credit Agreement (the “Amended and Restated Credit Agreement”)Facility, which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”).Facility. The Company has amended the Amended and RestatedPrior Credit AgreementFacility from time to time as described in the Company’s prior filings with the SEC.

On January 25, 2016,April 21, 2020, the Company entered into the NinthThirteenth Amendment (the “Ninth“Thirteenth Amendment”) to the Amended and RestatedPrior Credit Agreement.Facility. The NinthThirteenth Amendment modified certain definitions and provided increased flexibilityamended the Consolidated Leverage Ratio in the prior covenant to increase such leverage ratio for the Company in termsrest of its financial covenants. The Company’s baskets for permitted investments were also increased to provide increased flexibility for it to

invest innon-wholly owned subsidiaries, joint ventures and foreign subsidiaries. The Company may now invest innon-wholly owned subsidiaries and joint ventures up to 10.0% of the Company and its subsidiaries’ total assets in any four consecutive fiscal quarter period, and up to 12.5% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The Company may also invest in foreign subsidiaries that are not loan parties up to 10% of the Company and its subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of the Company and its subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of the Company and its subsidiaries’ total assets in any fiscal year.2020.

On February 16, 2016,November 13, 2020, the Company entered into a Second Incremental Facilitythe Fourth Repricing Facilities Amendment (the “Second Incremental“Fourth Repricing Facilities Amendment”) to the AmendedPrior Credit Facility. The Fourth Repricing Facilities Amendment extended the maturity date of each of the prior revolving line of credit and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility TrancheB-2 (the “TrancheB-2 Facility”) and added $135.0 million to the Term Loan A facility (the “TLAFacility of the Prior Credit Facility (“TLA Facility”) from November 30, 2021 to November 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the Amendedrevolving line of credit in an aggregate committed amount of $500.0 million with an aggregate committed amount of approximately $459.0 million and Restated Senior Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-2 Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under(2) replaced the TLA Facility were usedaggregate outstanding principal amount of approximately $352.4 million with an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to pay downboth facilities remained unchanged from the majority of our $300.0 million revolving credit facility.

On May 26, 2016,prior facilities, and the Company entered into a TrancheB-1 Repricing Amendment (the “TrancheB-1 Repricing Amendment”)commitment fee applicable to the Amended and Restated Credit Agreement. The TrancheB-1 Repricing Amendment reducednew revolving line of credit also remained unchanged from the Applicable Rate with respect to the Term Loan B facility TrancheB-1 (the “TrancheB-1 Facility”) from 3.5% to 3.0% in the caseprior revolving line of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.

On September 21, 2016, the Company entered into a TrancheB-2 Repricing Amendment (the “TrancheB-2 Repricing Amendment”) to the Amended and Restated Credit Agreement. The TrancheB-2 Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-2 Facility from 3.75% to 3.0% in the case of Eurodollar Rate loans and 2.75% to 2.0% in the case of Base Rate Loans.credit. In connection with the TrancheB-2Fourth Repricing Facilities Amendment, the Company recorded a debt extinguishment charge

F-24


Table of $3.4Contents

of $1.0 million, including the write-off of discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of income.operations for the year ended December 31, 2020.

On November 22, 2016,January 5, 2021, the Company entered intomade a Tenth Amendment (the “Tenth Amendment”) tovoluntary payment of $105.0 million on the Amended and RestatedTerm Loan B Facility Tranche B-4 of the Prior Credit Agreement. The Tenth Amendment, among other things, (i) amended the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.

Facility (“Tranche B-4 Facility”). On November 30, 2016,January 19, 2021, the Company entered intoused a Refinancing Facilities Amendment (the “Refinancing Amendment”)portion of the net proceeds from the U.K. Sale to repay the Amended and Restated Credit Agreement. The Refinancing Amendment increasedoutstanding balances of $311.7 million of the Company’s line of credit on its revolving credit facility to $500.0 million from $300.0 million and reduced its TLA Facility to $400.0and $767.9 million from $600.6 million (together,of the “Refinancing Facilities”)Tranche B-4 Facility. In addition,As a part of the Refinancing Amendment extendedclosing of the maturity date forNew Credit Facility on March 17, 2021, the Refinancing Facilities to November 30,Company refinanced and terminated the Prior Credit Facility. At March 31, 2021, from February 13, 2019, and lowered the Company’s effective interest rate on the line of credit on its revolving credit facility and TLA Facility by 50 basis points. Inin connection with the Refinancing Amendment,termination of the Prior Credit Facility, the Company recorded a debt extinguishment charge of $0.8$10.9 million, including thewrite-off of deferred financing costs, which was recorded in debt extinguishment in the consolidated statements of income.

On May 10, 2017, the Company entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-1 Facility and the TrancheB-2 Facility from 3.0% to 2.75% in the case of Eurodollar Rate loans and from 2.0% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, the Company recorded a debt extinguishment charge of $0.8 million, including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of operations.

The Company had $493.4 million of availability under the revolving line of credit and had standby letters of credit outstanding of $6.6 million related to security for the payment of claims required by its workers’ compensation insurance program as of December 31, 2017. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $5.0 million for March 31, 2018 to December 31, 2019, $7.5 million for March 31, 2020 to December 31, 2020, and $10.0 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the TrancheB-1 Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-1 Facility due on February 11, 2022. The Company is required to repay the TrancheB-2 Facility in equal quarterly installments of approximately $2.4 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-2 Facility due on February 16, 2023. On December 29, 2017, the Company made an additional payment of $22.5 million, including $7.7 million on the TrancheB-1 Facility and $14.8 million on the TrancheB-2 Facility.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.75% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.75% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2017. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of December 31, 2017, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.75%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. As of December 31, 2017, the Company was in compliance with such covenants.

Senior Notes

6.125%5.500% Senior Notes due 20212028

On March 12, 2013,June 24, 2020, the Company issued $150.0$450.0 million of 6.125%5.500% Senior Notes due 20212028 (the “6.125%“5.500% Senior Notes”). The 6.125%5.500% Senior Notes mature on March 15, 2021July 1, 2028 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125%5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.year, commencing on January 1, 2021.

5.625%5.000% Senior Notes due 20232029

On February 11, 2015,October 14, 2020, the Company issued $375.0$475.0 million of 5.625%5.000% Senior Notes due 20232029 (the “5.625%“5.000% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625%5.000% Senior Notes mature on FebruaryApril 15, 20232029 and bear interest at a rate of 5.625%5.000% per annum, payable semi-annually in arrears on FebruaryApril 15 and AugustOctober 15 of each year.

6.500%year, commencing on April 15, 2021. The Company used the net proceeds of the 5.000% Senior Notes due 2024

On February 16, 2016,to prepay approximately $453.3 million of the outstanding borrowings on the Company’s Term Loan B Facility Tranche B-3 of the Prior Credit Facility (“Tranche B-3 Facility”) and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, the Company issued $390.0recorded a debt extinguishment charge of $2.9 million, including the write-off of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024discount and bear interest at a ratedeferred financing costs of 6.500% per annum, payable semi-annuallythe Tranche B-3 Facility, which was recorded in arrears on March 1 and September 1debt extinguishment costs in the consolidated statement of eachoperations for the year beginning on September 1, 2016.ended December 31, 2020.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625%5.500% Senior Notes and 6.500%the 5.000% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated SeniorNew Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

9.0% and 9.5% Revenue Bonds5.625% Senior Notes due 2023

On NovemberFebruary 11, 2012,2015, the Company issued $375.0 million of 5.625% Senior Notes. On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company had outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, the Company redeemed the 5.625% Senior Notes.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, the Company redeemed the 6.500% Senior Notes.

Redemption of 5.625% Senior Notes and 6.500% Senior Notes

On January 29, 2021, the Company issued conditional notices of full redemption providing for the redemption in full of $650 million of 5.625% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes.

F-25


Table of Contents

On March 1, 2021, the Company satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the acquisitionredemption of Park Royal,the 6.500% Senior Notes, the Company assumedrecorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.  

On March 17, 2021, the Company satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, the Company recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.  

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes were to mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. On June 24, 2020, the Company redeemed the 6.125% Senior Notes.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes were to mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. On June 24, 2020, the Company redeemed the 5.125% Senior Notes.

Redemption of 6.125% Senior Notes and 5.125% Senior Notes

On June 10, 2020, the Company issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and 5.125% Senior Notes on July 10, 2020 (the “Redemption Date”), in each case at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”). On June 24, 2020, the Company satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the Company recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statement of operations for the year ended December 31, 2020.

Other long-term debt

During the year ended December 31, 2021, the Company repaid other long-term debt of $23.0 million. The fair market value$3.3 million, which is reflected in repayment of thelong-term debt assumed was $25.6 million and resulted in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (“9.0% and 9.5% Revenue Bonds”), respectively. The 9.0% bondswithin financing activities in the amountconsolidated statement of $7.5 million have a maturity date of December 1, 2030 and require yearly principal payments beginning in 2013. The 9.5% bonds in the amount of $15.5 million have a maturity date of December 1, 2040 and require yearly principal payments beginning in 2031. The principal payments establish a bond sinking fund to be held with the trustee and shall be sufficient to redeem the principal amounts of the 9.0% and 9.5% Revenue Bonds on their respective maturity dates. As of December 30, 2017 and December 31, 2016, $2.3 million was recorded within other assets on the consolidated balance sheets related to the debt service reserve fund requirements. The yearly principal payments, which establish a bond sinking fund, will increase the debt service reserve fund requirements. The bond premium amount of $2.6 million is amortized as a reduction of interest expense over the life of the revenue bonds using the effective interest method.cash flows.

Debt Issuance Costs

Debt issuance costs are deferred and amortized to interest expense over the term of the related debt. Debt issuance costs at December 31, 20172022 were $46.5$12.6 million, net of accumulated amortization of $27.5$4.6 million. Debt issuance costs at December 31, 20162021 were $55.3$14.8 million, net of accumulated amortization of $18.9$2.4 million. Amortization expense related to debt issuance costs, which is included in interest expense on the consolidated statements of operations, was $8.6$2.2 million, $8.6$2.8 million and $5.1$9.8 million, respectively, for the years ended December 31, 2017, 20162022, 2021 and 2015.2020.

Other

The aggregate maturities of long-term debt as ofat December 31, 20172022 were as follows (in thousands):

 

2018

  $34,830 

2019

   34,855 

2020

   44,880 

2021

   474,910 

2022

   767,240 

Thereafter

   1,933,605 
  

 

 

 

Total

  $3,290,320 
  

 

 

 

2023

 

$

21,250

 

2024

 

 

29,219

 

2025

 

 

39,844

 

2026

 

 

383,125

 

2027

 

 

 

Thereafter

 

 

925,000

 

Total

 

$

1,398,438

 

7.

F-26


Table of Contents

12. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At December 31, 2022, the Company operated eight facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 86% of the equity interests of these entities and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions. The Company consolidates the operations of each facility based on its status as primary beneficiary, as further discussed in Note 13 – Variable Interest Entities. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2021

 

$

55,315

 

Contributions from noncontrolling partners in joint ventures

 

 

6,734

 

Net income attributable to noncontrolling interests

 

 

4,927

 

Distributions to noncontrolling partners in joint ventures

 

 

(1,588

)

Balance at December 31, 2021

 

 

65,388

 

Contributions from noncontrolling partners in joint ventures

 

 

21,162

 

Net income attributable to noncontrolling interests

 

 

6,894

 

Acquisition of ownership interests from noncontrolling partners

 

 

(4,183

)

Distributions to noncontrolling partners in joint ventures

 

 

(1,004

)

Balance at December 31, 2022

 

$

88,257

 

13. Variable Interest Entities

For legal entities where the Company has a financial relationship, the Company evaluates whether it has a variable interest and determines if the entity is considered a variable interest entity (“VIE”). If the Company concludes an entity is a VIE and the Company is the primary beneficiary, the entity is consolidated. The primary beneficiary analysis is a qualitative analysis based on power and benefits. A reporting entity has a controlling financial interest in a VIE and must consolidate the VIE if it has both power and benefits. It must have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE.

At December 31, 2022, the Company operated eight facilities through non-wholly owned subsidiaries. The Company owns between approximately 65% and 86% of the equity interests of these entities, and noncontrolling partners own the remaining equity interests. The Company manages each of these facilities, is responsible for the day to day operations and, therefore, has the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These activities include, but are not limited to, behavioral healthcare services, human resource and employment-related decisions, marketing and finance. The terms of the agreements governing each of the Company’s VIEs prohibit the Company from using the assets of each VIE to satisfy the obligations of other entities. Consolidated assets at December 31, 2022 and 2021 include total assets of variable interest entities of $434.2 million and $320.6 million, respectively, which cannot be used to settle the obligations of other entities. Consolidated liabilities at December 31, 2022 and 2021 include total liabilities of variable interest entities of $24.4 million and $24.1 million, respectively.

F-27


Table of Contents

The consolidated VIEs assets and liabilities in the Company’s consolidated balance sheets are shown below (in thousands):

 

 

December 31,

 

 

 

2022

 

 

2021

 

Cash and cash equivalents

 

$

32,478

 

 

$

26,360

 

Accounts receivable, net

 

 

23,789

 

 

 

20,144

 

Other current assets

 

 

2,561

 

 

 

1,304

 

Total current assets

 

 

58,828

 

 

 

47,808

 

Property and equipment, net

 

 

313,358

 

 

 

220,793

 

Goodwill

 

 

39,564

 

 

 

34,945

 

Intangible assets, net

 

 

16,139

 

 

 

10,490

 

Operating lease right-of-use assets

 

 

6,284

 

 

 

6,603

 

Total assets

 

$

434,173

 

 

$

320,639

 

Accounts payable

 

$

4,650

 

 

$

3,690

 

Accrued salaries and benefits

 

 

6,866

 

 

 

5,656

 

Current portion of operating lease liabilities

 

 

233

 

 

 

197

 

Other accrued liabilities

 

 

6,179

 

 

 

6,818

 

Total current liabilities

 

 

17,928

 

 

 

16,361

 

Operating lease liabilities

 

 

6,433

 

 

 

6,666

 

Other liabilities

 

 

 

 

 

1,083

 

Total liabilities

 

$

24,361

 

 

$

24,110

 

14. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

 

 

Foreign

Currency

Translation

Adjustments

 

 

Change in Fair

Value of

Derivative

Instruments

 

 

Pension

Plan

 

 

Total

 

Balance at January 1, 2020

 

$

(434,633

)

 

$

24,958

 

 

$

(5,209

)

 

$

(414,884

)

Foreign currency translation gain (loss)

 

 

61,532

 

 

 

 

 

 

(285

)

 

 

61,247

 

Loss on derivative instruments, net of tax

   of $(3.9) million

 

 

 

 

 

(11,272

)

 

 

 

 

 

(11,272

)

Pension liability adjustment, net of tax

   of $(0.8) million

 

 

 

 

 

 

 

 

(6,456

)

 

 

(6,456

)

Balance at December 31, 2020

 

 

(373,101

)

 

 

13,686

 

 

 

(11,950

)

 

 

(371,365

)

Foreign currency translation gain (loss)

 

 

(4,293

)

 

 

 

 

 

33

 

 

 

(4,260

)

Gain on derivative instruments, net of tax

   of $0.1 million

 

 

 

 

 

19

 

 

 

 

 

 

19

 

U.K. Sale

 

 

377,394

 

 

 

(13,705

)

 

 

11,917

 

 

 

375,606

 

Balance at December 31, 2021

 

$

 

 

$

 

 

$

 

 

$

 

15. Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation provides that up to 10,000,000 shares of preferred stock may be issued. The Boardboard of Directorsdirectors has the authority to issue preferred stock in one or more series and to fix for each series the voting powers (full, limited or none), and the designations, preferences and relative participating, optional or other special rights and qualifications, limitations or restrictions on the stock and the number of shares constituting any series and the designations of this series, without any further vote or action by the stockholders.

Common Stock

On March 3, 2016, the Company held a Special MeetingThe Company’s amended and restated certificate of Stockholders, where the Company’s stockholders approved an amendmentincorporation provides that up to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized180,000,000 shares of Common Stock from 90,000,000 to 180,000,000 (the “Amendment”). On March 3, 2016, the Company filed the Amendment with the Secretary of State of the State of Delaware.common stock may be issued. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters on which stockholders may vote. There are no preemptive, conversion, redemption or sinking fund provisions applicable to shares of

F-28


Table of Contents

the Company’s common stock. In the event of liquidation, dissolution or winding up, holders of the Company’s common stock are entitled to share ratably in the assets available for distribution, subject to any prior rights of any holders of preferred stock then outstanding. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Amended and Restated SeniorNew Credit Facility imposes restrictions on the Company’s ability to pay dividends.

Equity Offerings

On January 12, 2016, the Company completed the offering of 11,500,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that the Company granted to the underwriters as part of the offering) at a price of $61.00 per share. The net proceeds to the Company from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering-related costs of $0.7 million, were $685.0 million. The Company used the net offering proceeds to fund a portion of the purchase price for the acquisition of Priory.

On February 16, 2016, the Company completed the acquisition of Priory for a total purchase price of approximately $2.2 billion including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of common stock to shareholders of Priory.

8.16. Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees andnon-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). As ofAt December 31, 2017,2022, a maximum of 8,200,00012,700,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of which 4,498,6873,133,811 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $23.5$29.6 million, $28.3$37.5 million and $20.5$22.5 million in equity-based compensation expense for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively. Stock compensation expense for the yearyears ended December 31, 2017 included2022, 2021 and 2020 is impacted by forfeiture adjustments and restricted stock unit adjustments based on actual performance compared to vesting targets of $(5.7) million. As oftargets. At December 31, 2017,2022, there was $42.5$61.9 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.21.4 years.

As ofAt December 31, 2017,2022, there were no warrants outstanding and exercisable.outstanding. The Company recognized a deferred income tax benefit of $9.2$8.0 million, $9.6 million and $10.7$5.5 million for the years ended December 31, 20172022, 2021 and 2016,2020, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 20162020, 2021 and 20172022 was as follows (aggregate intrinsic value in thousands):

 

 

Number of

Options

 

 

Weighted

Average

Exercise Price

 

 

Weighted

Average

Remaining

Contractual

Term (in years)

 

 

Aggregate

Intrinsic

Value

 

  Number of
Options
   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Contractual
Term (in years)
   Aggregate
Intrinsic
Value
 

Options outstanding at January 1, 2016

   694,743   $42.87    7.70   $20,717 

Options outstanding at January 1, 2020

 

 

1,360,068

 

 

$

39.40

 

 

 

 

 

 

 

 

 

Options granted

   503,850    57.98    9.28    297 

 

 

507,600

 

 

 

33.13

 

 

 

 

 

 

 

 

 

Options exercised

   (57,397   31.92    N/A    1,530 

 

 

(68,700

)

 

 

29.15

 

 

 

 

 

 

 

 

 

Options cancelled

   (140,250   57.13    N/A    N/A 

 

 

(288,662

)

 

 

39.67

 

 

 

 

 

 

 

 

 

  

 

   

 

   

 

   

 

 

Options outstanding at December 31, 2016

   1,000,946    49.42    7.80    8,166 

Options outstanding at December 31, 2020

 

 

1,510,306

 

 

 

37.56

 

 

 

 

 

 

 

 

 

Options granted

   259,300    42.25    9.30    205 

 

 

324,320

 

 

 

57.53

 

 

 

 

 

 

 

 

 

Options exercised

   (87,367   25.92    N/A    1,636 

 

 

(558,322

)

 

 

39.45

 

 

 

 

 

 

 

 

 

Options cancelled

   (198,313   54.71    N/A    N/A 

 

 

(170,235

)

 

 

40.08

 

 

 

 

 

 

 

 

 

  

 

   

 

   

 

   

 

 

Options outstanding at December 31, 2017

   974,566   $47.89    7.46   $3,802 
  

 

   

 

   

 

   

 

 

Options exercisable at December 31, 2016

   288,959   $42.81    6.22   $6,111 
  

 

   

 

   

 

   

 

 

Options exercisable at December 31, 2017

   405,634   $41.20    6.05   $3,549 
  

 

   

 

   

 

   

 

 

Options outstanding at December 31, 2021

 

 

1,106,069

 

 

 

42.07

 

 

 

 

 

 

 

 

 

Options granted

 

 

334,260

 

 

 

55.73

 

 

 

 

 

 

 

 

 

Options exercised

 

 

(285,577

)

 

 

40.66

 

 

 

 

 

 

 

 

 

Options cancelled

 

 

(175,475

)

 

 

46.98

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2022

 

 

979,277

 

 

$

46.27

 

 

 

7.44

 

 

$

35,303

 

Options exercisable at December 31, 2022

 

 

301,827

 

 

$

41.43

 

 

 

5.69

 

 

$

12,341

 

Restricted stock activity during 2016 and 2017 was as follows:F-29


Table of Contents

 

   Number of
Shares
   Weighted
Average
Grant-Date
Fair Value
 

Unvested at January 1, 2016

   944,562   $52.74 

Granted

   387,347    55.38 

Cancelled

   (122,178   57.02 

Vested

   (365,312   47.18 
  

 

 

   

 

 

 

Unvested at December 31, 2016

   844,419   $55.76 

Granted

   404,224    42.38 

Cancelled

   (145,981   55.03 

Vested

   (292,794   53.07 
  

 

 

   

 

 

 

Unvested at December 31, 2017

   809,868   $50.19 
  

 

 

   

 

 

 

Restricted stock unit activity during 2016 and 2017 was as follows:

 

   Number of
Units
   Weighted
Average
Grant-Date
Fair Value
 

Unvested at January 1, 2016

   218,084   $56.97 

Granted

   230,750    56.95 

Cancelled

   —      —   

Vested

   (175,235   52.71 
  

 

 

   

 

 

 

Unvested at December 31, 2016

   273,599   $59.68 

Granted

   219,840    43.23 

Cancelled

   —      —   

Vested

   (132,530   58.67 
  

 

 

   

 

 

 

Unvested at December 31, 2017

   360,909   $50.04 
  

 

 

   

 

 

 

The grant-date fair value of the Company’s stock options isFair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the years ended December 31, 20172022, 2021 and 2016:2020:

 

 

Year Ended December 31,

 

  December 31, 2017 December 31, 2016 

 

2022

 

 

2021

 

 

2020

 

Weighted average grant-date fair value of options

  $14.39  $18.96 

 

$

20.72

 

 

$

20.64

 

 

$

12.37

 

Risk-free interest rate

   2.0 1.4

 

 

2.0

%

 

 

0.9

%

 

 

1.6

%

Expected volatility

   33 33

 

 

39

%

 

 

40

%

 

 

41

%

Expected life (in years)

   5.5  5.5 

 

 

5.0

 

 

 

5.0

 

 

 

5.0

 

The Company’s estimate of expected volatility for stock options is based upon the volatility of guideline companies givenits stock price over the lack of sufficient historical trading experienceexpected life of the Company’s common stock.award. The risk-free interest rate is the approximate yield on U.S.U. S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

9.Other Stock-Based Awards

Restricted stock activity during 2020, 2021 and 2022 was as follows:

 

 

Number of

Shares

 

 

Weighted

Average

Grant-Date

Fair Value

 

Unvested at January 1, 2020

 

 

805,136

 

 

$

34.14

 

Granted

 

 

637,312

 

 

 

25.82

 

Cancelled

 

 

(129,683

)

 

 

34.56

 

Vested

 

 

(289,769

)

 

 

35.88

 

Unvested at December 31, 2020

 

 

1,022,996

 

 

$

28.41

 

Granted

 

 

352,430

 

 

 

58.32

 

Cancelled

 

 

(82,751

)

 

 

39.63

 

Vested

 

 

(366,048

)

 

 

30.81

 

Unvested at December 31, 2021

 

 

926,627

 

 

$

37.84

 

Granted

 

 

650,396

 

 

 

64.65

 

Cancelled

 

 

(145,205

)

 

 

49.03

 

Vested

 

 

(386,616

)

 

 

32.64

 

Unvested at December 31, 2022

 

 

1,045,202

 

 

$

54.89

 

F-30


Table of Contents

Restricted stock unit activity during 2020, 2021 and 2022 was as follows:

 

 

Number of

Units

 

 

Weighted

Average

Grant-Date

Fair Value

 

Unvested at January 1, 2020

 

 

447,357

 

 

$

38.89

 

Granted

 

 

583,680

 

 

 

10.60

 

Performance adjustment

 

 

117,772

 

 

 

13.50

 

Cancelled

 

 

(63,056

)

 

 

43.35

 

Vested

 

 

(12,691

)

 

 

42.09

 

Unvested at December 31, 2020

 

 

1,073,062

 

 

$

20.15

 

Granted

 

 

149,416

 

 

 

61.52

 

Performance adjustment

 

 

465,993

 

 

 

25.49

 

Cancelled

 

 

 

 

 

 

Vested

 

 

(184,051

)

 

 

42.30

 

Unvested at December 31, 2021

 

 

1,504,420

 

 

$

23.20

 

Granted

 

 

105,311

 

 

 

73.96

 

Performance adjustment

 

 

182,543

 

 

 

33.05

 

Cancelled

 

 

 

 

 

 

Vested

 

 

(518,474

)

 

 

43.16

 

Unvested at December 31, 2022

 

 

1,273,800

 

 

$

20.69

 

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions.

17. Income Taxes

The Company adopted ASU2016-09 as of January 1, 2017, which changes how the Company accounts for share-based awards for tax purposes. Income tax effects of share-based awards are now recognized in the income statement, instead of through equity, when the awards vest.

Excess tax benefits/deficiencies are generated when the deduction for tax purposes is greater/less than the compensation cost for financial reporting purposes. Upon adoption of ASU2016-09, the Company no longer records excess tax benefits/deficiencies in additionalpaid-in capital as a component of equity. Instead, excess tax benefits/deficiencies are included in the provisionProvision for income taxes on the consolidated statements of operations. These changes are recorded prospectively as of January 1, 2017, which resulted in an increase in our income tax provision of $1.7 million, or an increase in the effective tax rate of 0.7%, for the year ended December 31, 2017. Prior periods have not been adjusted. An adjustment for prior period excess tax benefits of $8.6 million is recorded as a cumulative-effect adjustment in retained earnings at December 31, 2017 as the Company adopted ASU2016-09 using the modified retrospective transition method. Excess tax benefits were previously required to be included in financing activities on the consolidated statement of cash flows and are now required to be included in operating activities. The changes to the consolidated statement of cash flows are recorded prospectively as of January 1, 2017. Additionally, the Company has elected not to adjust its policy on accounting for forfeitures and will continue to estimate forfeiture rates.

Income tax expense (benefit) from continuing operations consists of the following for the periods presented (in thousands):

 

  Year Ended December 31, 

 

Year Ended December 31,

 

  2017   2016   2015 

 

2022

 

 

2021

 

 

2020

 

Current:

      

 

 

 

 

 

 

 

 

 

 

 

 

Federal

  $3,325   $572   $(218

 

$

63,041

 

 

$

48,292

 

 

$

(18,215

)

State

   680    (863   4,078 

 

 

13,769

 

 

 

6,715

 

 

 

4,981

 

Foreign

   1,832    423    5,915 

 

 

755

 

 

 

778

 

 

 

732

 

  

 

   

 

   

 

 

Total current

   5,837    132    9,775 

 

 

77,565

 

 

 

55,785

 

 

 

(12,502

)

Deferred:

      

 

 

 

 

 

 

 

 

 

 

 

 

Federal

   27,179    45,077    40,635 

 

 

9,808

 

 

 

13,339

 

 

 

46,442

 

State

   4,408    1,491    5,349 

 

 

6,377

 

 

 

(1,892

)

 

 

564

 

Foreign

   (215   (17,921   (2,371

 

 

360

 

 

 

325

 

 

 

6,102

 

  

 

   

 

   

 

 

Total deferred provision

   31,372    28,647    43,613 

 

 

16,545

 

 

 

11,772

 

 

 

53,108

 

  

 

   

 

   

 

 

Provision for income taxes

  $37,209   $28,779   $53,388 

 

$

94,110

 

 

$

67,557

 

 

$

40,606

 

  

 

   

 

   

 

 

F-31


Table of Contents

A reconciliation of the U.S. federal statutory rate from continuing operations, to the effective tax rate is as follows for the periods presented:

 

  Year Ended December 31, 

 

Year Ended December 31,

 

  2017 2016 2015 

 

2022

 

 

2021

 

 

2020

 

U.S. federal statutory rate on income before income taxes

   35.0 35.0 35.0

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

Impact of foreign operations

   (14.1 (13.5 (10.0

 

 

(0.1

)

 

 

1.7

 

 

 

(0.5

)

Impact of foreign divestiture

   —    39.2   —   

Effects of statutory rate change

   (8.5 (14.5  —   

 

 

 

 

 

 

 

 

3.2

 

State income taxes, net of federal tax effect

   2.1  7.5  4.8 

 

 

4.7

 

 

 

3.9

 

 

 

5.1

 

Permanent differences

   1.8  8.3  4.2 

 

 

0.1

 

 

 

1.7

 

 

 

1.5

 

Transaction related items

   —    25.9   —   

Change in valuation allowance

   1.6  2.8  1.2 

 

 

0.2

 

 

 

(2.8

)

 

 

127.4

 

Unrecognized tax benefit release

   (0.8 (7.2  —   

 

 

 

 

 

(0.9

)

 

 

(0.4

)

Federal tax credits

 

 

(0.6

)

 

 

(0.8

)

 

 

(1.0

)

Basis recognition related to foreign divestiture

 

 

 

 

 

 

 

 

(129.9

)

CARES Act impacts to net operating losses

 

 

 

 

 

 

 

 

(4.5

)

Other

   (1.4 3.8  (2.8

 

 

(0.1

)

 

 

0.7

 

 

 

0.2

 

  

 

  

 

  

 

 

Effective income tax rate

   15.7 87.3 32.4

 

 

25.2

%

 

 

24.5

%

 

 

22.1

%

  

 

  

 

  

 

 

For the year ended December 31, 2022, the provision for income taxes was $94.1 million, reflecting an effective tax rate of 25.2%, compared to $67.6 million, reflecting an effective tax rate of 24.5%, for the year ended December 31, 2021.

The domestic and foreign components of income (loss) from continuing operations before income taxes for continuing operations are as follows (in thousands):

 

  Year Ended December 31, 

 

Year Ended December 31,

 

  2017   2016   2015 

 

2022

 

 

2021

 

 

2020

 

Foreign

  $120,905   $(144,717  $28,316 

 

$

5,420

 

 

$

5,596

 

 

$

9,904

 

Domestic

   115,893    177,672    136,437 

 

 

368,723

 

 

 

270,164

 

 

 

173,893

 

  

 

   

 

   

 

 

Total

  $236,798   $32,955   $164,753 
  

 

   

 

   

 

 

Income from continuing operations before income taxes

 

$

374,143

 

 

$

275,760

 

 

$

183,797

 

F-32


Table of Contents

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities of the Company at December 31, 20172022 and December 31, 20162021 were as follows (in thousands):

 

  December 31, 

 

December 31,

 

  2017   2016 

 

2022

 

 

2021

 

Deferred tax assets:

    

 

 

 

 

 

 

 

 

Net operating losses and tax credit carryforwards – federal and state

  $29,409   $37,638 

 

$

7,333

 

 

$

9,354

 

Capital loss carryovers

 

 

215,745

 

 

 

215,367

 

Bad debt allowance

   827    15,381 

 

 

1,148

 

 

 

1,083

 

Accrued compensation and severance

   14,179    23,379 

 

 

18,784

 

 

 

18,241

 

Pension reserves

   1,494    697 

Insurance reserves

   13,483    17,468 

 

 

20,924

 

 

 

18,847

 

Leases

   5,332    2,926 

 

 

862

 

 

 

896

 

Accrued expenses

   3,114    —   

 

 

 

 

 

5,768

 

Interest carryforwards

   5,074    —   

 

 

2,639

 

 

 

3,396

 

Lease right-of-use liabilities

 

 

26,277

 

 

 

26,154

 

Fixed asset basis difference

 

 

2,128

 

 

 

 

Other assets

   1,747    2,038 

 

 

8,987

 

 

 

8,066

 

  

 

   

 

 

Total gross deferred tax assets

   74,659    99,527 

 

 

304,827

 

 

 

307,172

 

Less: valuation allowance

   (21,155   (16,031

 

 

(217,705

)

 

 

(217,325

)

  

 

   

 

 

Deferred tax assets

   53,504    83,496 

 

 

87,122

 

 

 

89,847

 

Deferred tax liabilities:

    

 

 

 

 

 

 

 

 

Fixed asset basis difference

   (54,214   (45,510

 

 

 

 

 

(2,456

)

Prepaid items

   (1,490   (1,324

 

 

(3,714

)

 

 

(2,882

)

Accrued expenses

 

 

(5,713

)

 

 

 

Intangible assets

   (70,820   (77,655

 

 

(139,843

)

 

 

(126,446

)

Accrued expenses

   —      (4,531

Other liabilities

   (3,582   (29,216
  

 

   

 

 

Lease right-of-use assets

 

 

(24,960

)

 

 

(24,660

)

Investment in foreign subsidiary

 

 

(2,530

)

 

 

(4,691

)

Total deferred tax liabilities

   (130,106   (158,236

 

 

(176,760

)

 

 

(161,135

)

  

 

   

 

 

Total net deferred tax liability

  $(76,602  $(74,740

 

$

(89,638

)

 

$

(71,288

)

  

 

   

 

 

The Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. As ofAt December 31, 20172022 and 2016,2021, the Company carried a valuation allowance against deferred tax assets of $21.2$217.7 million and $16.0$217.3 million, respectively. These amounts are primarily related to deferred tax assets related to the Company’s capital loss carryforward resulting from the U.K. Sale and certain state net operating losses. If the capital loss carryforward is not utilized, it will begin to expire in 2026.

The domesticAs of December 31, 2022 and 2021, the Company had no federal net operating loss carryforwards are approximately $28.4 million as of December 31, 2016. There are no domesticcarryforwards. The foreign net operating loss carryforwards at December 31, 2017. The foreign net operating loss carryforwards as of December 31, 20172022 and 20162021 are approximately $93.9$0.1 million and $92.2$0.1 million, respectively, and have no expiration.

The Company has state net operating loss carryforwards at December 31, 20172022 and 20162021 of approximately $256.9$191.5 million and $223.3$227.3 million, respectively. These net operating loss carryforwards, if not used to offset future taxable income, will expire from 20182023 to 2036. In addition, the Company has certain state tax credits of $0.9$0.2 million which will begin to expire in 20262030 if not utilized.

Income taxes receivable was $15.1$28.9 million and $11.7$24.6 million at December 31, 20172022 and 2016, respectively,2021, respectively. At December 31, 2022 and was2021, $23.1 million of income taxes receivable has been included in other assets due to anticipated delays in receipt of income tax refunds associated with amended tax return filings. The remaining $5.8 million and $1.5 million of income taxes receivable is included in other current assets in the December 31, 2022 and 2021 consolidated balance sheets.sheet, respectively. Income taxes payable of $1.0$1.3 million and $0.5$5.5 million at December 31, 20172022 and 20162021, respectively, was included in other accrued liabilities in the consolidated balance sheets.

F-33


Table of Contents

The Company has recorded income taxes payabledid not record any amounts related to unrecognized tax benefits of $6.4 million and $7.8 million at December 31, 20172022 or 2021. The Company’s accounting policy is to record any interest and 2016, respectively, in other liabilities in the consolidated balance sheets.penalties as a component of income tax expense, when applicable. A reconciliation of the beginning and ending amount of unrecognized income tax benefits, exclusive of any interest and penalties, net of the federal benefit, is as follows (in thousands):

 

   2017   2016   2015 

Balance at January 1

  $6,949   $4,511   $2,923 

Additions based on tax positions related to the current year

   5,488    —      1,516 

Additions for tax positions of prior years

   95    5,427    2,874 

Reductions as a result of the lapse of applicable statutes of limitations

   (6,428   (2,989   (2,802
  

 

 

   

 

 

   

 

 

 

Balance at December 31

  $6,104   $6,949   $4,511 
  

 

 

   

 

 

   

 

 

 

 

 

2021

 

Balance at January 1

 

$

2,060

 

Additions based on tax positions related to the

   current year

 

 

 

Reductions as a result of the lapse of applicable

   statutes of limitations and settlements with tax authorities

 

 

(2,060

)

Balance at December 31

 

$

 

The Company recognizes interest and penalties related to unrecognized tax benefits in its consolidated balance sheets. As of December 31, 2017 and 2016, the cumulative amounts recognized were $0.1 million and $0.9 million, respectively. It is possible the amount of unrecognized tax benefit could change in the next twelve months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, management does not anticipate the change will have a material impact on the Company’s consolidated financial statements.

The Company’s uncertain tax positions are related to tax years that remain subject to examination by the relevant taxing authorities. The Company and its subsidiaries file income tax returns in federal and in many state and local jurisdictions as well as foreign jurisdictions. The Company may be subject to examination by the Internal Revenue Service (“IRS”) for calendar year 2014years 2019 through 2016.2021. Additionally, any net operating losses that were generated in prior years and utilized in these years may also be subject to examination by the IRS. InWhile no foreign jurisdictions are presently under examination, the Company may be subject to examination for calendar years 20132018 through 2016.2021. Generally, for state tax purposes, the Company’s 20112017 through 20162021 tax years remain open for examination by the tax authorities. At the date of this report, there were no audits or inquires that had progressed sufficiently to predict their ultimate outcome.

One of the Company’s Puerto Rico subsidiaries was granted a tax exemption for which a tax credit of up to 15% of eligible payroll expenses is available to offset up to 50% of the income taxes attributed to that entity.

It is the Company’s intention to utilize its earnings in the foreign operations for an indefinite period of time. At December 31, 2017, there were no undistributed earnings of the foreign subsidiaries as the cumulative net loss of its foreign subsidiaries exceeds the cumulative earnings from its foreign subsidiaries. The cumulative net loss of the Company’s foreign subsidiaries includes a loss on divestiture of $175.0 million related to the U.K. Divestiture on November 30, 2016. If a deferred tax liability for undistributed foreign earnings becomes required, it would be significantly impacted by the Tax Act, the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes, foreign currency translation adjustment and the opportunity to use foreign tax credits.

U.S. Tax Reform

On December 22, 2017, Public Law115-97, informally referred to as The Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law. The Tax Act provides for significant changes to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21%, for U.S. taxable income. The Tax Act requires aone-time

remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. The Tax Act includes other changes, including, but not limited to, requiring aone-time transition tax on certain repatriated earnings of foreign subsidiaries that is payable over eight years, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, a new provision designed to tax global intangiblelow-taxed income, a limitation of the deduction for net operating losses, elimination of net operating loss carrybacks, immediate deductions for depreciation expense for certain qualified property, additional limitations on the deductibility of executive compensation and limitations on the deductibility of interest.

At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Tax Act; however, in certain cases, as described below, the Company has made a reasonable estimate of the effects on our existing deferred tax balances. In other cases, the Company has not been able to make a reasonable estimate and continues to account for those items based on its existing accounting under ASC 740 and the provisions of the tax laws that were in effect immediately prior to enactment of the Tax Act. For the items for which the Company was able to determine a reasonable estimate, the Company recognized a provisional amount of $20.2 million, which is included as a component of income tax expense from continuing operations.

ASC 740 requires the Company to recognize the effect of tax law changes in the period of enactment. However, the SEC staff issued SAB 118 which will allow the Company to record provisional amounts during a measurement period similarly to the measurement period used when accounting for business combinations. The Company will continue to assess the impact of the recently enacted tax law on its business and consolidated financial statements.

Provisional Amounts

Deferred Tax Assets and Liabilities

The Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. As a result of the reduction in the corporate income tax rate, the Company is required to revalue its net deferred tax assets and liabilities to account for the future impact of lower corporate tax rates on this deferred amount and record any change in the value of such asset or liability as aone-timenon-cash charge or benefit on its income statement. However, the Company is still analyzing certain aspects of the Tax Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts. The provisional amount recorded related to the remeasurement of our deferred tax balance was $20.2 million.

U.S. Tax on Foreign Earnings

Theone-time transition tax is based on total post-1986 earnings and profits that the Company previously deferred from U.S. income taxes. The Company has not made sufficient progress on the earnings and profits analysis for its foreign subsidiaries to reasonably estimate the effects of theone-time transition tax and, therefore, has not recorded provisional amounts. The Company continues to apply ASC 740 based on the provisions of the tax laws in effect immediately prior to the Tax Act being enacted. Since the Company had previously determined these amounts were indefinitely reinvested, no deferred taxes have been recorded at December 31, 2017.

The Company’s accounting for Global IntangibleLow-Taxed Income, Foreign-Derived Intangible Income, the Base Erosion and Anti-Abuse Tax and any remaining impacts of the foreign income provisions of the Tax Act is incomplete. The Company has not yet been able to make reasonable estimates of the effects of these items. Therefore, no provisional amounts have been recorded as of December 31, 2017.

10.18. Derivatives

The Company entered into foreign currency forward contracts during the yearsyear ended December 31, 2017 and 20162020 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between USU.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

The foreign currency contracts entered into duringIn August 2019, the year ended December 31, 2016 resulted in gains of $0.5 million which have been recorded in the consolidated statements of income.

In May 2016, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rateUSD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rateGBP-denominated debt of £449.3£538.1 million. The senior notes effectively converted include $150.0 million aggregate principal amount of 6.125% Senior Notes, $300.0 million aggregate principal amount of 5.125% Senior Notes and $200.0 million aggregate principal amount of 5.625% Senior Notes. During the term of the swap

agreements, the Company will receivereceived semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will makemade semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements resultresulted in £24.7£25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million (at a 1.45 exchange rate). The interest rates applicable tomillion.

In conjunction with the GBP interest payments are substantially the same as the interest ratesU.K. Sale in place for the existingUSD-denominated debt. At maturity,January 2021, the Company will repay the principal amounts listed above in GBP and receive the principal amount in USD.

The Company has designated thesettled its cross currency swap agreementsliability and certainoutstanding forward contracts entered into during 2016 and 2017 as qualifying hedging instruments and is accounting for these as net investment hedges. At December 31, 2017 and 2016, the fair value of these derivatives are $13.0 million and $73.5 million, respectively, and are recorded as an asset within derivative instrumentsshown in investing activities on the consolidated balance sheets. The gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive income as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swaps are included in operating activities in the consolidated statementsstatement of cash flows.

11.19. Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated SeniorNew Credit Facility, 6.125%5.500% Senior Notes 5.125%and 5.000% Senior Notes 5.625% Senior Notes, 6.500% Senior Notes, 9.0% and 9.5% Revenue Bonds, derivative instruments and contingent consideration liability as ofat December 31, 20172022 and 20162021 were as follows (in thousands):

 

   Carrying Amount   Fair Value 
   December 31,   December 31, 
   2017   2016   2017   2016 

Amended and Restated Senior Credit Facility

  $1,749,185   $1,799,993   $1,749,185   $1,799,993 

6.125% Senior Notes due 2021

  $148,098   $147,574   $150,134   $152,186 

5.125% Senior Notes due 2022

  $296,174   $295,442   $296,914   $293,595 

5.625% Senior Notes due 2023

  $641,891   $640,574   $651,519   $640,574 

6.500% Senior Notes due 2024

  $382,251   $381,268   $397,541   $389,847 

9.0% and 9.5% Revenue Bonds

  $22,289   $22,959   $22,289   $22,959 

Derivative instruments

  $12,997   $73,509   $12,997   $73,509 

Contingent consideration liabilities

  $—     $107   $—     $107 

 

 

Carrying Amount

 

 

Fair Value

 

 

 

December 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

New Credit Facility

 

$

471,489

 

 

$

584,418

 

 

$

471,489

 

 

$

584,418

 

5.500% Senior Notes due 2028

 

$

444,694

 

 

$

443,894

 

 

$

422,459

 

 

$

466,577

 

5.000% Senior Notes due 2029

 

$

469,609

 

 

$

468,907

 

 

$

433,214

 

 

$

481,802

 

The Company’s Amended and Restated SeniorNew Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500%5.500% Senior Notes and 9.0% and 9.5% Revenue Bonds5.000% Senior Notes were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair valuesF-34


Table of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

The fair value of the contingent consideration liabilities were categorized as Level 3 in the GAAP fair value hierarchy. The contingent consideration liabilities were valued using a probability-weighted discounted cash flow method. This analysis reflected the contractual terms of the purchase agreements and utilized assumptions with regard to future earnings, probabilities of achieving such future earnings and a discount rate.

12. Leases

The Company is obligated under certain operating leases to rent space for its facilities and other office space. The original terms of the leases typically range from five to 30 years, with optional renewal periods.

Aggregate minimum lease payments undernon-cancelable operating leases with original or remaining lease terms in excess of one year were as follows as of December 31, 2017 (in thousands):Contents

 

2018

  $69,613 

2019

   64,556 

2020

   60,156 

2021

   56,620 

2022

   51,071 

Thereafter

   835,369 
  

 

 

 

Total minimum rental obligations

  $1,137,385 
  

 

 

 

During the years ended December 31, 2017, 2016 and 2015, rent expense was $76.8 million, $73.3 million and $32.5 million, respectively.

13.20. Commitments and Contingencies

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, that arise in the ordinary course of the Company’s business, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. UnderCertain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties have the right to bringqui tam,or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of our individual facilities have received,Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and fromNovember 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. On September 30, 2022, the court entered an order certifying a class consisting of all persons who purchased or otherwise acquired the common stock of the Company between April 30, 2014 and November 15, 2018. At this time, to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. In the opinion of management, the Company is not currentlyable to quantify any potential liability in connection with this litigation because the case is in its early stages.  

On February 21, 2019, a party to any proceeding that would individually orpurported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the aggregate have a material adverse effect on the Company’s business, financial condition or results of operations.

14. Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners innon-wholly owned subsidiaries the Company controls. At December 31, 2017, certain of thesenon-wholly owned subsidiaries operated three facilities. The Company owns between 60% and 75% of the equity interests in the entity that owns each facility, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at January 1, 2016

  $8,055 

Acquisition of redeemable noncontrolling interests

   11,666 

Net loss attributable to noncontrolling interests

   (1,967
  

 

 

 

Balance at December 31, 2016

   17,754 

Acquisition of redeemable noncontrolling interests

   4,909 

Net loss attributable to noncontrolling interests

   (246
  

 

 

 

Balance at December 31, 2017

  $22,417 
  

 

 

 

15. Segment Information

The Company operates in one line of business,lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its facilitiespending in the United States (the “U.S. Facilities”District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated. On February 16, 2021, the court entered an order staying the case. On October 23, 2020, a purported stockholder filed a third related derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Pfenning v. Jacobs, et al., Case No. 2020-0915-JRS, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty. On February 17, 2021, the court entered an order staying the case. On February 24, 2021, a purported stockholder filed a fourth derivative action on behalf of the Company against former and current officers and directors in the lawsuit styled Solak v. Jacobs, et al., Case No. 2021-0163, which is pending in the Court of Chancery of the State of Delaware. The complaint alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, and insider selling. At this time, the Company is not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.  

In the fall of 2017, the Office of Inspector General (“OIG”) and itsissued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the United Kingdom (the “U.K. Facilities”) separatelydate of the demand. In April 2019, the OIG issued subpoenas relating to assess performancesix additional facilities requesting certain documents and makeinformation from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the Company’s operating segments include its U.S. Facilities and U.K. Facilities. At December 31, 2017, the U.S. Facilities included 209 behavioral healthcare facilitiesgovernment’s investigation but is not able to quantify any potential liability in connection with approximately 8,900 beds in 39 states and Puerto Rico, and the U.K. Facilities included 373 behavioral healthcare facilities with approximately 8,900 beds in the U.K.

these investigations.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income from continuing operations before income taxes (in thousands):

   Year Ended December 31, 
   2017   2016   2015 

Revenue:

      

U.S. Facilities

  $1,809,844   $1,698,525   $1,426,205 

U.K. Facilities

   1,026,472    1,110,361    360,698 

Corporate and Other

   —      2,028    7,589 
  

 

 

   

 

 

   

 

 

 
  $2,836,316   $2,810,914   $1,794,492 
  

 

 

   

 

 

   

 

 

 

Segment EBITDA(1):

      

U.S. Facilities

  $475,260   $443,341   $377,587 

U.K. Facilities

   198,566    245,046    90,035 

Corporate and Other

   (69,467   (79,797   (62,790
  

 

 

   

 

 

   

 

 

 
  $604,359   $608,590   $404,832 
  

 

 

   

 

 

   

 

 

 

   Year Ended December 31, 
   2017   2016   2015 

Segment EBITDA(1)

  $604,359   $608,590   $404,832 

Plus (less):

      

Equity-based compensation expense

   (23,467   (28,345   (20,472

Debt extinguishment costs

   (810   (4,253   (10,818

Loss on divestiture

   —      (178,809   —   

Gain (loss) on foreign currency derivatives

   —      523    (1,926

Transaction-related expenses

   (24,267   (48,323   (36,571

Interest expense, net

   (176,007   (181,325   (106,742

Depreciation and amortization

   (143,010   (135,103   (63,550
  

 

 

   

 

 

   

 

 

 

Income from continuing operations before income taxes

  $236,798   $32,955   $164,753 
  

 

 

   

 

 

   

 

 

 

   U.S. Facilities   U.K. Facilities   Corporate and
Other
   Consolidated 

Goodwill:

        

Balance at January 1, 2017

  $2,041,795   $639,393   $—     $2,681,188 

Increase from 2017 acquisition

   —      15,302    —      15,302 

Foreign currency translation

   —      60,770    —      60,770 

Purchase price allocation and other

   797    (6,883   —      (6,086
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2017

  $2,042,592   $708,582   $—     $2,751,174 
  

 

 

   

 

 

   

 

 

   

 

 

 

   December 31, 
   2017   2016 

Assets(2):

    

U.S. Facilities

  $3,567,126   $3,382,167 

U.K. Facilities

   2,647,150    2,441,018 

Corporate and Other

   210,226    201,541 
  

 

 

   

 

 

 
  $6,424,502   $6,024,726 
  

 

 

   

 

 

 

(1)Segment EBITDA is defined as income from continuing operations before provision for income taxes, equity-based compensation expense, debt extinguishment costs, gain on foreign currency derivatives, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.
(2)Assets include property and equipment for the U.S. Facilities of $1.2 billion, U.K. Facilities of $1.8 billion and corporate and other of $49.2 million at December 31, 2017. Assets include property and equipment for the U.S. Facilities of $1.0 billion, U.K. Facilities of $1.7 billion and corporate and other of $27.1 million at December 31, 2016.

16.21. Employee Benefit Plans

Defined Contribution Plan

The Company maintains a qualified defined contribution 401(k) plan covering substantially all of its employees in the U.S. The Company may, at its discretion, make contributions to the plan. The Company contributed $0.2recorded expense of $6.6 million, $0.1$2.8 million and $0.1$3.8 million related to the 401(k) plan for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.

Partnerships in Care Pension Plan

As part of the acquisition of Partnerships in Care on July 1, 2014, the Company assumed a frozen contributory defined benefit retirement plan (“Partnerships in Care Pension Plan”) covering substantially all of the employees of Partnerships in Care and its subsidiaries prior to May 1, 2005 at which time, the Partnerships in Care Plan was frozen to new participants. Effective May 2015, the active participants no longer accrue benefits. The benefits under the Partnerships in Care Pension Plan were primarily based on years of service and final average earnings.

The Company accounts for the Partnerships in Care Pension Plan in accordance with ASC715-30 “Compensation — Defined Benefit Plans”, (“ASC715-30”). In accordance with ASC715-30, the Company recognizes the unfunded liability of the Partnerships in Care Pension Plan on the Company’s consolidated balance sheet and unrecognized gains (losses) and prior service credits (costs) as changes in other comprehensive income (loss). The measurement date of the Partnerships in Care Pension Plan’s assets and liabilities coincides with the Company’syear-end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases, when applicable, expected long-term returns on plan assets and consider expected age of retirement and mortality. Expected return on plan assets is determined by using the specific asset distribution at the measurement date.

The following table summarizes the funded status (unfunded liability) of the Partnerships in Care Pension Plan based upon actuarial valuations prepared as of December 31, 2017 and 2016 (in thousands):

 

   2017   2016 

Projected benefit obligation

  $67,288   $64,162 

Fair value of plan assets

   58,493    53,462 
  

 

 

   

 

 

 

Unfunded liability

  $8,795   $10,700 
  

 

 

   

 

 

 

The following table summarizes changes in the Partnerships in Care Pension Plan net pension liability asF-35


Table of December 31, 2017 and 2016 (in thousands):Contents

 

   2017   2016 

Net pension liability at beginning of period

  $10,700   $2,821 

Employer contributions

   (809   (740

Net pension expense (benefit)

   426    339 

Pension liability adjustment

   (2,544   8,781 

Foreign currency translation gain (loss)

   1,022    (501
  

 

 

   

 

 

 

Net pension liability at end of period

  $8,795   $10,700 
  

 

 

   

 

 

 

A pension liability of $8.8 million and $10.7 million were recorded within other liabilities on the consolidated balance sheets as of December 31, 2017 and 2016. The following assumptions were used to determine the plan benefit obligation:

 

Discount rate

   2.5  2.7

Compensation increase rate

   2.3  2.4

Measurement date

   December 31, 2017   December 31, 2016 

A summary of the components of net pension plan expense for the year ended December 31, 2017 and 2016 is as follows (in thousands):

   2017   2016 

Interest cost on projected benefit obligation

  $1,738   $1,964 

Expected return on assets

   (1,312   (1,625
  

 

 

   

 

 

 

Total pension plan expense (benefit)

  $426   $339 

Assumptions used to determine the net periodic pension plan expense for the year ended December 31, 2017 and 2016 were as follows:

   2017  2016 

Discount rate

   2.5  2.7

Expected long-term rate of return on plan assets

   2.5  2.7

The Company recognizes changes in the funded status of the pension plan as a direct increase or decrease to stockholders’ equity through accumulated other comprehensive income. The accumulated other comprehensive income (loss) related to the Partnerships in Care Pension Plan for the years ended December 31, 2017, 2016 and 2015 was $(4.1) million ($(4.5) million net of taxes), $(7.4) million ($6.1 million net of taxes) and $2.6 million ($(1.7) million net of taxes), respectively.

The trustees of the Partnerships in Care Pension Plan are required to invest assets in the best interest of the Partnerships in Care Pension Plan’s members and also ensure liquid assets are available to make benefit payments as they become due. Performance of the Partnerships in Care Pension Plan’s assets are monitored quarterly, at a minimum, and asset allocations are adjusted as needed. The Partnerships in Care Pension Plan’s weighted-average asset allocations by asset category as of December 31, 2017 and 2016 were as follows:

   December 31, 2017  December 31, 2016 

Cash and cash equivalents

   0.7  1.5

U.K. government obligation

   19.0  14.5

Annuity contracts

   38.6  41.6

Equity securities

   29.4  26.3

Debt securities

   9.9  12.1

Other

   2.4  4.0

As of December 31, 2017 and 2016, the Partnerships in Care Pension Plan cash and cash equivalents were classified as Level 1 in the GAAP fair value hierarchy. Fair values were based on utilizing quoted prices (unadjusted) in active markets for identical assets. The U.K. government obligations, annuity contracts, equity securities, debt securities and other investments were classified as Level 2 in the GAAP fair value hierarchy. Fair values were based on data points that are observable, such as quoted prices, interest rates and yield curves.

17. Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

   Foreign Currency
Translation
Adjustments
   Change in Fair
Value of
Derivative
Instruments
   Pension Plan   Total 

Balance at January 1, 2015

  $(66,206  $—     $(2,164  $(68,370

Foreign currency translation loss

   (40,103   —      —      (40,103

Pension liability adjustment, net of tax of $0.9 million

   —      —      3,826    3,826 
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2015

   (106,309   —      1,662    (104,647

Foreign currency translation loss

   (477,772   —      —      (477,772

Gain on derivative instruments, net of tax of $29.1 million

   —      40,598    —      40,598 

Pension liability adjustment, net of tax of $(1.3) million

   —      —      (7,749   (7,749
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2016

   (584,081   40,598   (6,087   (549,570

Foreign currency translation gain

   207,341    —      —      207,341 

Loss on derivative instruments, net of tax of $(22.9) million

   —      (33,431   —      (33,431

Pension liability adjustment, net of tax of $0.4 million

   —      —      1,542    1,542 
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2017

  $(376,740  $7,167   $(4,545  $(374,118
  

 

 

   

 

 

   

 

 

   

 

 

 

18. Quarterly Information (Unaudited)

The tables below present summarized unaudited quarterly results of operations for the years ended December 31, 2017 and 2016. Management believes that all necessary adjustments have been included in the amounts stated below for a fair presentation of the results of operations for the periods presented when read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2017 and 2016. Results of operations for a particular quarter are not necessarily indicative of results of operations for an annual period and are not predictive of future periods.

   Quarter Ended 
   March 31,   June 30,   September 30,  December 31, 
   (In thousands except per share amounts) 

2017:

       

Revenue

  $679,194   $715,896   $716,714  $724,512 

Income from continuing operations before income taxes

  $48,484   $66,216   $61,459  $60,639 

Net income attributable to Acadia Healthcare Company, Inc. stockholders

  $34,958   $49,630   $45,618  $69,629(1) 

Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders

  $0.40   $0.57   $0.52  $0.80(1) 

Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders

  $0.40   $0.57   $0.52  $0.80(1) 

2016:

       

Revenue

  $616,813   $756,548   $734,665  $702,888 

Income from continuing operations before income taxes

  $32,479   $73,852   $(115,814)(2)  $42,438(3) 

Net income attributable to Acadia Healthcare Company, Inc. stockholders

  $25,688   $56,445   $(117,808)(2)  $41,818(3) 

Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders

  $0.31   $0.65   $(1.36)(2)  $0.48(3) 

Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders

  $0.31   $0.65   $(1.36)(2)  $0.48(3) 

(1)Includes aone-time tax benefit of $20.2 million on revaluation of deferred tax items pursuant to the enactment of the Tax Act.
(2)Includes loss on divestiture of $174.7 million and debt extinguishment costs of $3.4 million, or $142.0 million net of taxes, in connection with the U.K. Divestiture and the repricing of our TrancheB-2 Facility.
(3)Includes loss on divestiture of $4.0 million and debt extinguishment costs of $0.8 million, or $3.1 million net of taxes, in connection with the Company’s divestitures and the Refinancing Amendment.

19.22. Financial Information for the Company and ItsCombined Wholly-Owned Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625%5.500% Senior Notes and 6.500% senior notesthe 5.000% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated SeniorNew Credit Facility. Summarized financial information presented below is consistent with the consolidated financial statements of the Company, except transactions between combining entities have been eliminated. Financial information for the combined non-guarantor entities has been excluded. Presented below is condensed consolidating financial information for the Company and its subsidiaries as of December 31, 2017 and 2016, and for the years ended December 31, 2017, 2016 and 2015. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors the combinednon-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

at December 31, 2017

(In thousands)2022 and 2021, and for the year ended December 31, 2022. The summarized balance sheet information at December 31, 2021, has been adjusted to reclassify certain wholly-owned subsidiaries as non-guarantor entities.

 

   Parent   Combined
Subsidiary
Guarantors
   Combined
Non-
Guarantors
   Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Current assets:

         

Cash and cash equivalents

  $—     $46,860   $20,430   $—    $67,290 

Accounts receivable, net

   —      230,890    66,035    —     296,925 

Other current assets

   —      85,746    21,589    —     107,335 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total current assets

   —      363,496    108,054    —     471,550 

Property and equipment, net

   —      1,086,802    1,961,328    —     3,048,130 

Goodwill

   —      1,936,057    815,117    —     2,751,174 

Intangible assets, net

   —      57,628    29,720    —     87,348 

Deferred tax assets – noncurrent

   2,370    —      3,731    (2,370  3,731 

Derivative instruments

   12,997    —      —      —     12,997 

Investment in subsidiaries

   5,429,386    —      —      (5,429,386  —   

Other assets

   381,913    38,860    7,807    (379,008  49,572 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total assets

  $5,826,666   $3,482,843   $2,925,757   $(5,810,764 $6,424,502 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Current liabilities:

         

Current portion of long-term debt

  $34,550   $—     $280   $—    $34,830 

Accounts payable

   —      70,767    31,532    —     102,299 

Accrued salaries and benefits

   —      69,057    29,990    —     99,047 

Other accrued liabilities

   36,196    27,676    77,341    —     141,213 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total current liabilities

   70,746    167,500    139,143    —     377,389 

Long-term debt

   3,183,049    —      401,017    (379,008  3,205,058 

Deferred tax liabilities – noncurrent

   —      27,975    54,728    (2,370  80,333 

Other liabilities

   —      103,112    63,322    —     166,434 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total liabilities

   3,253,795    298,587    658,210    (381,378  3,829,214 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Redeemable noncontrolling interests

   —      —      22,417    —     22,417 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total equity

   2,572,871    3,184,256    2,245,130    (5,429,386  2,572,871 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total liabilities and equity

  $5,826,666   $3,482,843   $2,925,757   $(5,810,764 $6,424,502 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2016

(InSummarized balance sheet information (in thousands):

 

   Parent   Combined
Subsidiary
Guarantors
   Combined
Non-
Guarantors
   Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Current assets:

         

Cash and cash equivalents

  $—     $15,681   $41,382   $—    $57,063 

Accounts receivable, net

   —      209,124    54,203    —     263,327 

Other current assets

   —      61,724    45,813    —     107,537 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total current assets

   —      286,529    141,398    —     427,927 

Property and equipment, net

   —      940,880    1,762,815    —     2,703,695 

Goodwill

   —      1,935,260    745,928    —     2,681,188 

Intangible assets, net

   —      56,676    26,634    —     83,310 

Deferred tax assets – noncurrent

   13,522    —      4,606    (14,348  3,780 

Derivative instruments

   73,509    —      —      —     73,509 

Investment in subsidiaries

   4,885,865    —      —      (4,885,865  —   

Other assets

   493,294    40,480    7,189    (489,646  51,317 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total assets

  $5,466,190   $3,259,825   $2,688,570   $(5,389,859 $6,024,726 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Current liabilities:

         

Current portion of long-term debt

  $34,550   $—     $255   $—    $34,805 

Accounts payable

   —      49,205    30,829    —     80,034 

Accrued salaries and benefits

   —      72,835    32,233    —     105,068 

Other accrued liabilities

   33,616    24,375    64,967    —     122,958 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total current liabilities

   68,166    146,415    128,284    —     342,865 

Long-term debt

   3,230,300    —      512,350    (489,646  3,253,004 

Deferred tax liabilities – noncurrent

   —      40,574    52,294    (14,348  78,520 

Other liabilities

   —      101,938    62,921    —     164,859 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total liabilities

   3,298,466    288,927    755,849    (503,994  3,839,248 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Redeemable noncontrolling interests

   —      —      17,754    —     17,754 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total equity

   2,167,724    2,970,898    1,914,967    (4,885,865  2,167,724 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Total liabilities and equity

  $5,466,190   $3,259,825   $2,688,570   $(5,389,859 $6,024,726 
  

 

 

   

 

 

   

 

 

   

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2017

(In thousands)

 

 

December 31,

 

 

 

2022

 

 

2021

 

Current assets

 

$

396,553

 

 

$

349,250

 

Property and equipment, net

 

 

1,517,893

 

 

 

1,166,409

 

Goodwill

 

 

2,105,227

 

 

 

2,086,978

 

Total noncurrent assets

 

 

3,921,336

 

 

 

3,527,700

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

345,606

 

 

 

340,514

 

Long-term debt

 

 

1,364,541

 

 

 

1,478,626

 

Total noncurrent liabilities

 

 

1,629,750

 

 

 

1,688,326

 

Redeemable noncontrolling interests

 

 

 

 

 

 

Total equity

 

 

2,342,533

 

 

 

1,848,110

 

 

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Revenue before provision for doubtful accounts

  $—    $1,746,656  $1,130,578  $—    $2,877,234 

Provision for doubtful accounts

   —     (35,636  (5,282  —     (40,918
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Revenue

   —     1,711,020   1,125,296   —     2,836,316 

Salaries, wages and benefits

   23,467   902,180   610,513   —     1,536,160 

Professional fees

   —     93,991   102,232   —     196,223 

Supplies

   —     75,248   39,191   —     114,439 

Rents and leases

   —     33,365   43,410   —     76,775 

Other operating expenses

   —     217,900   113,927   —     331,827 

Depreciation and amortization

   —     66,482   76,528   —     143,010 

Interest expense, net

   61,872   81,274   32,861   —     176,007 

Debt extinguishment costs

   810   —     —     —     810 

Transaction-related expenses

   —     11,236   13,031   —     24,267 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total expenses

   86,149   1,481,676   1,031,693   —     2,599,518 

(Loss) income from continuing operations before income taxes

   (86,149  229,344   93,603   —     236,798 

Equity in earnings of subsidiaries

   259,282   —     —     (259,282  —   

(Benefit from) provision for income taxes

   (26,456  69,882   (6,217  —     37,209 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income (loss) from continuing operations

   199,589   159,462   99,820   (259,282  199,589 

Income from discontinued operations, net of income taxes

   —     —     —     —     —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income (loss)

   199,589   159,462   99,820   (259,282  199,589 

Net loss attributable to noncontrolling interests

   —     —     246   —     246 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $199,589  $159,462  $100,066  $(259,282 $199,835 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income:

      

Foreign currency translation gain

   —     —     207,341   —     207,341 

Loss on derivative instruments

   (33,431  —     —     —     (33,431

Pension liability adjustment, net

   —     —     1,542   —     1,542 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income

   (33,431  —     208,883   —     175,452 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Comprehensive income (loss)

  $166,158  $159,462  $308,949  $(259,282 $375,287 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2016

(InSummarized operating results information (in thousands)

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Revenue before provision for doubtful accounts

  $—    $1,662,734  $1,190,089  $—    $2,852,823 

Provision for doubtful accounts

   —     (38,349  (3,560  —     (41,909
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Revenue

   —     1,624,385   1,186,529   —     2,810,914 

Salaries, wages and benefits

   28,345   865,104   648,405   —     1,541,854 

Professional fees

   —     89,062   96,424   —     185,486 

Supplies

   —     76,246   41,179   —     117,425 

Rents and leases

   —     34,540   38,808   —     73,348 

Other operating expenses

   —     206,308   106,248   —     312,556 

Depreciation and amortization

   —     58,018   77,085   —     135,103 

Interest expense, net

   50,921   75,848   54,556   —     181,325 

Debt extinguishment costs

   4,253   —     —     —     4,253 

Loss on divestiture

   —     778   178,031   —     178,809 

Gain on foreign currency derivatives

   (523  —     —     —     (523

Transaction-related expenses

   —     32,173   16,150   —     48,323 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total expenses

   82,996   1,438,077   1,256,886   —     2,777,959 

(Loss) income from continuing operations before income taxes

   (82,996  186,308   (70,357  —     32,955 

Equity in earnings of subsidiaries

   65,560   —     —     (65,560  —   

(Benefit from) provision for income taxes

   (21,612  68,335   (17,944  —     28,779 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income (loss) from continuing operations

   4,176   117,973   (52,413  (65,560  4,176 

Income from discontinued operations, net of income taxes

   —     —     —     —     —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income (loss)

   4,176   117,973   (52,413  (65,560  4,176 

Net loss attributable to noncontrolling interests

   —     —     1,967   —     1,967 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $4,176  $117,973  $(50,446 $(65,560 $6,143 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income:

      

Foreign currency translation loss

   —     —     (477,772  —     (477,772

Gain on derivative instruments

   40,598   —     —     —     40,598 

Pension liability adjustment, net

   —     —     (7,749  —     (7,749
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income

   40,598   —     (485,521  —     (444,923
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Comprehensive income (loss)

  $44,774  $117,973  $(535,967 $(65,560 $(438,780
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income

Year Ended December 31, 2015

(In thousands)

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Revenue before provision for doubtful accounts

  $—    $1,415,016  $414,603  $—    $1,829,619 

Provision for doubtful accounts

   —     (32,614  (2,513  —     (35,127
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Revenue

   —     1,382,402   412,090   —     1,794,492 

Salaries, wages and benefits

   20,472   726,215   227,045   —     973,732 

Professional fees

   —     83,422   33,041   —     116,463 

Supplies

   —     65,077   15,586   —     80,663 

Rents and leases

   —     29,094   3,434   —     32,528 

Other operating expenses

   —     170,018   36,728   —     206,746 

Depreciation and amortization

   —     41,768   21,782   —     63,550 

Interest expense, net

   68,533   17,476   20,733   —     106,742 

Debt extinguishment costs

   10,818   —     —     —     10,818 

Loss on foreign currency derivatives

   1,926   —     —     —     1,926 

Transaction-related expenses

   —     24,914   11,657   —     36,571 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total expenses

   101,749   1,157,984   370,006   —     1,629,739 

(Loss) income from continuing operations before income taxes

   (101,749  224,418   42,084   —     164,753 

Equity in earnings of subsidiaries

   176,178   —     —     (176,178  —   

(Benefit from) provision for income taxes

   (37,047  85,765   4,670   —     53,388 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income (loss) from continuing operations

   111,476   138,653   37,414   (176,178  111,365 

Income from discontinued operations, net of income taxes

   —     111   —     —     111 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income (loss)

   111,476   138,764   37,414   (176,178  111,476 

Net loss attributable to noncontrolling interests

   —     —     1,078   —     1,078 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net income attributable to Acadia Healthcare Company, Inc.

  $111,476  $138,764  $38,492  $(176,178 $112,554 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income:

      

Foreign currency translation loss

   —     —     (40,103  —     (40,103

Pension liability adjustment, net

   —     —     3,826   —     3,826 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Other comprehensive income

   —     —     (36,277  —     (36,277
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Comprehensive income (loss)

  $111,476  $138,764  $2,215  $(176,178 $76,277 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2017

(In thousands)

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Operating activities:

     

Net income (loss)

  $199,589  $159,462  $99,820  $(259,282 $199,589 

Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:

     

Equity in earnings of subsidiaries

   (259,282  —     —     259,282   —   

Depreciation and amortization

   —     66,482   76,528   —     143,010 

Amortization of debt issuance costs

   10,270   —     (415  —     9,855 

Equity-based compensation expense

   23,467   —     —     —     23,467 

Deferred income tax expense

   1,236   28,882   1,254   —     31,372 

Debt extinguishment costs

   810   —     —     —     810 

Other

   4,189   2,498   4,725   —     11,412 

Change in operating assets and liabilities, net of effect of acquisitions:

     

Accounts receivable, net

   —     (21,791  (6,779  —     (28,570

Other current assets

   —     (6,429  27,237   —     20,808 

Other assets

   24,549   (3,277  101   (24,549  (3,176

Accounts payable and other accrued liabilities

   —     4,909   (15,022  —     (10,113

Accrued salaries and benefits

   —     (3,974  (5,014  —     (8,988

Other liabilities

   —     8,794   3,000   —     11,794 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash provided by (used in) continuing operating activities

   4,828   235,556   185,435   (24,549  401,270 

Net cash used in discontinued operating activities

   —     (1,693  —     —     (1,693
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash provided by (used in) operating activities

   4,828   233,863   185,435   (24,549  399,577 

Investing activities:

     

Cash paid for acquisitions, net of cash acquired

   —     —     (18,191  —     (18,191

Cash paid for capital expenditures

   —     (161,312  (112,865  —     (274,177

Cash paid for real estate acquisitions

   —     (37,047  (4,010  —     (41,057

Other

   —     (7,944  4,843   —     (3,101
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash used in investing activities

   —     (206,303  (130,223  —     (336,526

Financing activities:

     

Principal payments on long-term debt

   (34,550  (14,250  (10,554  24,549   (34,805

Repayment of long-term debt

   (22,500  —     —     —     (22,500

Common stock withheld for minimum statutory taxes, net

   (3,455  —     —     —     (3,455

Other

   (539  1,225   —     —     686 

Cash provided by (used in) intercompany activity

   56,216   16,644   (72,860  —     —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by financing activities

   (4,828  3,619   (83,414  24,549   (60,074
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Effect of exchange rate changes on cash

   —     —     7,250   —     7,250 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net increase in cash and cash equivalents

   —     31,179   (20,952  —     10,227 

Cash and cash equivalents at beginning of the period

   —     15,681   41,382   —     57,063 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Cash and cash equivalents at end of the period

  $—    $46,860  $20,430  $—    $67,290 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2016

(In thousands)

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Operating activities:

     

Net income (loss)

  $4,176  $117,973  $(52,413 $(65,560 $4,176 

Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:

     

Equity in earnings of subsidiaries

   (65,560  —     —     65,560   —   

Depreciation and amortization

   —     58,018   77,085   —     135,103 

Amortization of debt issuance costs

   10,751   —     (427  —     10,324 

Equity-based compensation expense

   28,345   —     —     —     28,345 

Deferred income tax (benefit) expense

   (2,172  50,611   (19,792  —     28,647 

Loss from discontinued operations, net of taxes

   —     —     —     —     —   

Debt extinguishment costs

   4,253   —     —     —     4,253 

Loss on divestiture

   —     778   178,031   —     178,809 

(Gain) loss on foreign currency derivatives

   (523  —     —     —     (523

Other

   —     4,022   693   —     4,715 

Change in operating assets and liabilities, net of effect of acquisitions:

     

Accounts receivable, net

   —     (24,017  8,299   —     (15,718

Other current assets

   —     (3,138  (17,510  —     (20,648

Other assets

   (3,109  (4,048  (306  3,109   (4,354

Accounts payable and other accrued liabilities

   —     (45,552  68,245   —     22,693 

Accrued salaries and benefits

   —     3,844   (12,416  —     (8,572

Other liabilities

   —     4,050   434   —     4,484 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by continuing operating activities

   (23,839  162,541   229,923   3,109   371,734 

Net cash used in discontinued operating activities

   —     (10,256  —     —     (10,256
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by operating activities

   (23,839  152,285   229,923   3,109   361,478 

Investing activities:

     

Cash paid for acquisitions, net of cash acquired

   —     (103,359  (580,096  —     (683,455

Cash paid for capital expenditures

   —     (177,593  (129,879  —     (307,472

Cash paid for real estate acquisitions

   —     (28,956  (11,801  —     (40,757

Settlement of foreign currency derivatives

   —     523   —     —     523 

Cash received for divestiture

   370,000   7,859   (4,593  —     373,266 

Other

   —     (1,573  (897  —     (2,470
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash used in investing activities

   370,000   (303,099  (727,266  —     (660,365

Financing activities:

     

Borrowings on long-term debt

   1,480,000   —     —     —     1,480,000 

Borrowings on revolving credit facility

   179,000   —     —     —     179,000 

Principal payments on revolving credit facility

   (337,000  —     —     —     (337,000

Principal payments on long-term debt

   (49,706  (293,000  (3,344  296,109   (49,941

Repayment of assumed debt

   (1,348,389  —     —     —     (1,348,389

Repayment of long-term debt

   (200,594  —     —     —     (200,594

Payment of debt issuance costs

   (36,649  —     —     —     (36,649

Issuance of common stock

   685,097   —     —     —     685,097 

Common stock withheld for minimum statutory taxes, net

   (8,846  —     —     —     (8,846

Other

   (1,149  (2,688  —     —     (3,837

Cash (used in) provided by intercompany activity

   (707,925  460,196   546,947   (299,218  —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash provided by (used in) financing activities

   (346,161  164,508   543,603   (3,109  358,841 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Effect of exchange rate changes on cash

   —     —     (14,106  —     (14,106
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net increase in cash and cash equivalents

   —     13,694   32,154   —     45,848 

Cash and cash equivalents at beginning of the period

   —     1,987   9,228   —     11,215 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Cash and cash equivalents at end of the period

  $—    $15,681  $41,382  $—    $57,063 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2015

(In thousands)

   Parent  Combined
Subsidiary
Guarantors
  Combined
Non-
Guarantors
  Consolidating
Adjustments
  Total
Consolidated
Amounts
 

Operating activities:

     

Net income (loss)

  $111,476  $138,764  $37,414  $(176,178 $111,476 

Adjustments to reconcile net income (loss) to net cash (used in) provided by continuing operating activities:

     

Equity in earnings of subsidiaries

   (176,178  —     —     176,178   —   

Depreciation and amortization

   —     41,768   21,782   —     63,550 

Amortization of debt issuance costs

   7,147   —     (438  —     6,709 

Equity-based compensation expense

   20,472   —     —     —     20,472 

Deferred income tax (benefit) expense

   617   42,246   750   —     43,613 

Loss from discontinued operations, net of taxes

   —     (111  —     —     (111

Debt extinguishment costs

   10,818   —     —     —     10,818 

Loss (gain) on foreign currency derivatives

   1,926   —     —     —     1,926 

Other

   —     1,582   33   —     1,615 

Change in operating assets and liabilities, net of effect of acquisitions:

     

Accounts receivable, net

   —     (18,632  (6,322  —     (24,954

Other current assets

   —     (1,152  (1,565  —     (2,717

Other assets

   (1,100  (8,567  546   1,100   (8,021

Accounts payable and other accrued liabilities

   —     (7,583  14,451   —     6,868 

Accrued salaries and benefits

   —     312   1,346   —     1,658 

Other liabilities

   —     9,350   (114  —     9,236 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by continuing operating activities

   (24,822  197,977   67,883   1,100   242,138 

Net cash provided by discontinued operating activities

   —     (1,735  —     —     (1,735
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash (used in) provided by operating activities

   (24,822  196,242   67,883   1,100   240,403 

Investing activities:

     

Cash paid for acquisitions, net of cash acquired

   —     (254,848  (319,929  —     (574,777

Cash paid for capital expenditures

   —     (172,329  (103,718  —     (276,047

Cash paid for real estate acquisitions

   —     (25,293  (1,329  —     (26,622

Settlement of foreign currency derivatives

   —     (1,926  —     —     (1,926

Other

   —     (5,099  —     —     (5,099
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash used in investing activities

   —     (459,495  (424,976  —     (884,471

Financing activities:

     

Borrowings on long-term debt

   1,150,000   —     —     —     1,150,000 

Borrowings on revolving credit facility

   468,000   —     —     —     468,000 

Principal payments on revolving credit facility

   (310,000  —     —     —     (310,000

Principal payments on long-term debt

   (31,965  —     (1,315  1,315   (31,965

Repayment of assumed debt

   (904,467  —     —     —     (904,467

Repayment of long-term debt

   (97,500  —     —     —     (97,500

Payment of debt issuance costs

   (26,421  —     —     —     (26,421

Payment of premium on senior notes

   (7,480  —     —     —     (7,480

Issuance of common stock, net

   331,308   —     —     —     331,308 

Common stock withheld for minimum statutory taxes, net

   (7,762  —     —     —     (7,762

Excess tax benefit from equity awards

   309   —     —     —     309 

Other

   —     (420  —     —     (420

Cash (used in) provided by intercompany activity

   (539,200  191,334   350,281   (2,415  —   
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net cash provided by (used in) financing activities

   24,822   190,914   348,966   (1,100  563,602 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Effect of exchange rate changes on cash

   —     (2,359  —     —     (2,359
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net (decrease) increase in cash and cash equivalents

   —     (74,698  (8,127  —     (82,825

Cash and cash equivalents at beginning of the period

   —     76,685   17,355   —     94,040 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Cash and cash equivalents at end of the period

  $—    $1,987  $9,228  $—    $11,215 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.:

 

For the Year Ended December 31, 2022

Revenue

$

2,299,562

Income from continuing operations before income taxes

325,309

Net income

244,148

Net income attributable to Acadia Healthcare Company, Inc.

By:

/s/ JOEY A. JACOBS244,148

Joey A. Jacobs

Chairman of the Board and Chief Executive Officer

Dated: February 27, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.F-36

Signature

Title

Date

/s/ JOEY A. JACOBS

Joey A. Jacobs

Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

February 27, 2018

/s/ DAVID M. DUCKWORTH

David M. Duckworth

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

February 27, 2018

/s/ E. PEROT BISSELL

E. Perot Bissell

Director

February 27, 2018

/s/ CHRISTOPHER R. GORDON

Christopher R. Gordon

Director

February 27, 2018

/s/ VICKY B. GREGG

Vicky B. Gregg

Director

February 27, 2018

/s/ WILLIAM F. GRIECO

William F. Grieco

Director

February 27, 2018

/s/ WADE D. MIQUELON

Wade D. Miquelon

Director

February 27, 2018

/s/ WILLIAM M. PETRIE

William M. Petrie

Director

February 27, 2018

/s/ HARTLEY R. ROGERS

Hartley R. Rogers

Director

February 27, 2018

/s/ REEVE B. WAUD

Reeve B. Waud

Director

February 27, 2018